resist
rate
rr
period
year
gener
better
report
total
icu
mean
mrsa
rr
sari
icu
wherea
studi
icu
end
durat
treatment
pneumonia
reduc
day
written
guidelin
empir
antibiot
treatment
prophylaxi
revis
respect
resist
situat
studi
icu
signific
decreas
total
antimicrobi
ad
studi
icu
result
mainli
reduc
consumpt
gener
cephalosporin
carbapenem
imidazol
ni
chang
significantli
time
compar
year
cost
antibiot
halv
correspond
respect
percentag
antibiot
total
icu
budget
pharmaceut
decreas
conclus
surveil
feedback
antibiot
use
resist
serv
valuabl
qualiti
control
instrument
impact
antibiot
treatment
antibiot
use
reduc
cost
antibioticspd
cut
two
third
icu
studi
without
increas
devic
associ
nosocomi
infect
rate
resist
situat
gener
better
sari
icu
show
heavi
fluctuat
similar
ill
burden
differ
antibiot
prescript
children
populationbas
studi
k
hedin
andr
n
rodh
lstad
c
petersson
falun
se
object
respiratori
tract
infect
common
reason
antibiot
prescript
sweden
countri
prescript
rate
vari
markedli
differ
countri
counti
municip
reason
variat
prescript
rate
obviou
aim
studi
find
possibl
explan
differ
antibiot
prescript
rate
children
therefor
prospect
popul
base
log
book
studi
conduct
four
municip
accord
offici
statist
high
three
municip
low
antibiot
prescript
rate
method
one
month
parent
record
infecti
symptom
physician
consult
antibiot
treatment
children
log
book
children
parent
also
answer
questionnair
socioeconom
factor
concern
infecti
ill
result
antibiot
prescrib
children
high
prescript
area
low
prescript
area
crude
multipl
logist
regress
analys
take
account
socioeconom
factor
concern
infecti
ill
number
symptom
day
physician
consult
differ
antibiot
prescript
rate
remain
adjust
ci
variabl
impact
antibiot
prescript
rate
although
relev
geograph
differ
high
level
concern
infecti
ill
famili
conclus
differ
antibiot
prescript
rate
could
explain
socioeconom
factor
concern
infecti
ill
number
symptom
day
physician
consult
differ
may
attribut
differ
prescript
custom
case
prescript
pattern
alway
ration
decreas
outpati
antibiot
prescrib
germani
germani
includ
newer
macrolid
fluoroquinolon
extendedspectrum
betalactam
wv
kern
k
de
k
nink
h
der
freiburg
bonn
de
object
esac
european
surveil
antibiot
consumpt
wwwuaacbeesac
project
shown
outpati
antibiot
prescrib
germani
compar
low
among
european
countri
assess
trend
time
region
variat
outpati
antibiot
use
germani
wonder
observ
decreas
trend
includ
drug
class
similar
extent
method
prescript
data
compulsori
health
insur
cover
popul
sampl
year
prescript
thereaft
analys
use
atcwho
methodolog
current
ddd
definit
specif
defin
follow
drug
group
basic
penicillin
bpen
oral
penicillin
aminopenicillin
extendedspectrum
betalactam
esbl
oral
cephalosporin
staphylococc
penicillin
aminopenicillinbetalactams
inhibitor
combin
parenter
cephalosporin
broadspectrum
betalactam
newer
macrolid
nml
roxithromycin
clarithromycin
azithromycin
versu
older
macrolid
oml
quinolon
fq
folat
synthesi
inhibitor
tss
tetracyclin
tet
also
assess
data
express
yearli
person
cover
insur
find
outpati
prescrib
correspond
day
decreas
year
decreas
trend
last
year
observ
region
decreas
signific
oml
tss
tet
bpen
decreas
use
esbl
increas
rate
prescrib
nml
fq
tet
bpen
howev
remain
prescrib
antibiot
region
variat
remain
larg
bpen
low
prescrib
rate
eastern
region
small
tss
nml
fq
conclus
decad
observ
decreas
outpati
antibiot
prescrib
includ
relev
antibiot
drug
class
except
esbl
nml
fq
rel
increas
signific
fq
sever
communityacquir
pneumonia
admit
intens
care
unit
impact
antibiot
therapi
delay
hospit
mortal
antibiot
therapi
enrol
studi
pt
divid
group
accord
time
treatment
h
gi
baselin
sever
score
apach
ii
sofa
psi
microbiolog
document
hospit
outcom
compar
group
result
pt
includ
studi
microbiolog
document
achiev
pt
posit
blood
cultur
pneumonia
mean
age
apach
ii
sofa
psi
mechan
ventil
vasopressor
use
overal
icu
hospit
allcaus
mortal
respect
baselin
sever
score
compar
group
respect
hospit
mortal
provid
tabl
conclus
sever
cap
treat
combin
therapi
time
treatment
seem
impact
hospit
allcaus
mortal
base
result
antibiot
treatment
initi
within
first
hour
hospit
admiss
period
ii
cefoperazon
sulbactam
g
day
monotherapi
use
empir
antibacteri
therapi
vap
rotat
cefepim
cefoperazonesulbactam
perform
due
previou
studi
demonstr
high
frequenc
esbl
produc
among
enterobacteriacea
sampl
lower
respiratori
tract
obtain
minib
sensit
microorgan
antibiot
studi
ceftazidim
cefepim
cefoperazonesulbactam
carbapenem
determin
disk
diffus
method
result
main
pathogen
vap
aureu
p
aeruginosa
enterobacteriacea
structur
chang
period
antibiot
sensit
p
aeruginosa
enterobacteriacea
k
pneumonia
e
coli
studi
separ
high
level
resist
enterobacteriacea
cefepim
explain
strain
prevail
given
icu
produc
extend
spectrum
betalactamas
ctxm
resist
enterobacteriacea
cefepim
period
ii
period
ceftazidim
meropenem
imipenem
cefoperazonesulbactam
respect
chang
cefepim
cefoperazonesulbactam
follow
decreas
enterobacteriacea
resist
level
cefepim
ii
period
resist
level
p
aeruginosa
cefepim
period
ii
period
ceftazidim
meropenem
imipenem
cefoperazon
sulbactam
respect
conclus
exclus
cefepim
month
nt
improv
sensit
enterobacteriacea
medic
level
resist
p
aeruginosa
enterobacteriacea
cefoperazonesulbactam
increas
despit
wide
use
antibiot
month
antibiot
consumpt
german
acut
care
hospit
steibbauert
k
de
e
meyer
p
straach
wv
kern
freiburg
frankfurt
de
object
outpati
antibiot
use
germani
differ
substanti
eastern
southern
part
countri
rel
low
use
western
part
rel
high
use
nationwid
estim
hospit
antibiot
use
geograph
variat
aim
present
studi
provid
estim
recent
hospit
antibiot
use
densiti
germani
identifi
basic
unithospit
characterist
associ
excess
use
method
data
hospit
consumpt
system
antibiot
anatom
therapeut
chemic
atc
class
obtain
conveni
sampl
acut
care
hospit
germani
particip
im
survey
year
complet
data
dispens
drug
patientday
per
year
least
one
nonpaediatr
nonpsychiatr
depart
ward
total
nonicu
surgic
departmentsward
nonicu
nonsurg
gener
medicin
oncologyhaematolog
neurologystrok
departmentsward
icu
cover
million
patientday
analys
data
express
ddd
whoatc
definit
version
prescribedrecommend
daili
dose
pdd
better
reflect
high
dosag
given
hospit
patient
per
patient
day
find
weight
mean
departmentsward
incl
icu
expect
icu
antibiot
use
densiti
much
higher
use
nonicu
area
use
haematologyoncolog
higher
nonsurg
departmentsward
univari
analys
bedsiz
categori
univers
affili
icu
surgic
ward
region
icu
surgic
nonsurg
ward
haematologyoncolog
specialti
nonsurg
ward
associ
use
densiti
associ
partli
confirm
multivari
logist
regress
analys
factor
associ
excess
use
densiti
show
univers
affili
haematologyoncolog
independ
associ
high
use
conclus
base
hospit
sampl
antibiot
use
german
hospit
show
littl
nonsignific
region
variat
appear
similar
describ
european
countri
adjust
data
least
univers
affili
haematologyoncolog
import
compar
analys
hospit
antibiot
consumpt
impact
formulari
chang
medic
intens
care
unit
outcom
infect
antimicrobi
resist
sought
evalu
formulari
chang
impact
infect
resist
method
prospect
patient
icu
follow
period
month
phase
patient
per
patient
day
collect
baselin
data
decreas
use
piperacillintazobactam
pt
substitut
cefepim
period
month
phase
ii
patient
per
patient
day
result
total
infect
phase
vs
phase
ii
lower
respiratori
tract
lrti
patient
vs
patient
urinari
tract
infect
uti
patient
vs
patient
sepsi
undetermin
aetiolog
patient
vs
patient
respect
signific
differ
death
vs
cure
improv
infect
vs
readmiss
unit
vs
hospit
risk
death
vs
mean
length
icu
stay
day
vs
day
rate
nosocomi
infect
vs
lrti
vs
uti
vs
soft
tissu
infect
vs
bacteremia
vs
per
patient
day
intraven
cathet
infect
phase
ii
respect
cost
antimicrobi
acquisit
phase
ii
per
patient
respect
p
mean
antimicrobi
treatment
cost
per
patient
pt
vs
cefepim
vs
phase
ii
respect
p
vitro
suscept
rate
infect
colon
escherichia
coli
unchang
studi
period
vs
staphylococcu
aureu
p
vs
methicillinresist
aureu
vs
enterococcu
faecium
vs
vancomycinresist
enterococci
phase
ii
respect
vs
pseudomona
aeruginosa
vs
klebsiella
pneumonia
extend
spectrum
beta
lactamas
phase
ii
respect
conclus
implement
formulari
substitut
pt
cefepim
medic
icu
result
decreas
use
pt
addit
decreas
cost
less
aureu
infect
without
advers
affect
outcom
infect
antimicrobi
resist
intraven
antibiot
use
scottish
hospit
evalu
glasgow
antimicrobi
audit
tool
ra
seaton
nathwani
p
burton
e
dougla
glasgow
dunde
uk
introduct
data
antibiot
prescrib
within
scottish
hospit
coordin
multisit
point
preval
survey
perform
concern
antimicrobi
overus
hospit
method
antibiot
use
acut
medic
surgic
unit
scottish
hospit
across
trust
investig
use
point
preval
survey
data
collect
pharmacist
appropri
iv
rout
administr
determin
review
data
infecti
diseas
physician
idp
compar
specif
design
computeris
algorithm
idp
also
judg
appropri
chosen
iv
agent
local
guidelin
patient
hospit
region
survey
singl
day
receiv
antibiot
intraven
receiv
oral
antibiot
receiv
iv
previous
median
durat
iv
therapi
day
iqr
day
time
iv
oral
switch
idp
judg
appropri
iv
rout
patient
compar
algorithm
sensit
algorithm
specif
posit
predict
valu
neg
predict
valu
idp
judg
iv
agent
chosen
administ
appropri
frequent
prescrib
iv
agent
gener
cephalosporin
coamoxiclav
metronidazol
glycopeptid
signific
region
differ
seen
antibiot
group
includ
site
vs
site
p
glycopeptid
site
vs
site
p
possibl
coordin
collect
compar
data
scottish
hospit
gaat
give
good
estim
appropri
iv
therapi
signific
differ
prescrib
pattern
similar
patient
group
across
differ
hospit
site
demonstr
data
may
use
inform
local
nation
audit
support
prescrib
initi
associ
continu
variabl
test
univari
analysi
spearman
correl
test
r
multipl
linear
regress
analysi
perform
backward
stepwis
approach
result
median
rate
total
hospit
glycopeptid
use
rang
ddd
per
pd
higher
consumpt
larg
public
hospit
consumpt
higher
intens
care
area
median
rang
surgeri
area
median
rang
medicin
median
rang
glycopeptid
use
correl
number
central
line
per
pd
r
p
size
variou
area
hospit
intens
care
r
medicin
area
r
surgeri
area
r
p
median
incid
mrsa
per
pd
incid
mrsa
explain
small
proport
variat
hospit
glycopeptid
consumpt
multivari
linear
regress
model
incid
mrsa
number
bed
surgeri
area
independ
predictor
total
glycopeptid
use
hospit
adjust
control
factor
number
centrallin
per
pd
associ
glycopeptid
use
conclus
hospit
total
glycopeptid
use
heavili
determin
incid
mrsa
although
glycopeptid
use
surgeri
area
highest
total
number
surgeri
bed
hospit
explain
larg
variat
total
hospit
glycopeptid
use
therefor
take
account
interpret
consumpt
decid
evalu
antibiot
manag
acut
lower
respiratori
tract
infect
among
dutch
elderli
patient
primari
care
j
bont
c
birkhoff
verheij
e
hak
behalf
esprit
object
acut
lower
respiratori
tract
infect
lrti
caus
variou
complic
lead
morbid
well
mortal
notabl
among
elderli
patient
antibiot
treatment
lrti
common
despit
dutch
clinic
guidelin
recommend
antibiot
case
pneumonia
high
risk
seriou
complic
assess
cours
ill
outcom
pneumonia
acut
bronchiti
exacerb
copd
asthma
among
dutch
elderli
patient
primari
care
assess
whether
gp
inclin
prescrib
antibiot
readili
patient
potenti
risk
factor
complic
acut
bronchiti
exacerb
copd
asthma
method
retrospect
analys
medic
data
episod
lrti
among
patient
year
age
present
primari
care
describ
cours
ill
outcom
relat
prescript
antibiot
patient
risk
factor
complic
cours
assess
mean
multivari
logist
regress
risk
factor
complic
cours
includ
heart
failur
histori
myocardi
infarct
angina
pectori
diabet
histori
stroke
dementia
malign
histori
pneumonia
hospitalis
preced
year
result
one
complic
aros
episod
lrti
among
suffer
pulmonari
complic
cardiovascular
complic
heart
failur
myocardi
infarct
etc
protract
cours
diabet
event
patient
complic
led
hospit
admiss
lrti
fatal
antibiot
readili
prescrib
patient
age
year
heart
failur
present
patient
diabet
signific
associ
observ
patient
comorbid
condit
patient
diagnos
exacerb
copd
acut
bronchiti
histori
pneumonia
hospitalis
preced
year
like
receiv
antibiot
conclus
consider
part
elderli
patient
lrti
suffer
sever
complic
cours
primari
care
although
gp
inclin
prescrib
readili
antibiot
old
heart
failur
diabet
potenti
risk
factor
taken
account
object
studi
aim
analys
infecti
diseas
id
traine
nightweekend
shift
consult
process
term
patient
consult
characterist
type
recommend
complianc
recommend
method
consult
perform
id
traine
night
shift
weekend
june
analys
term
consult
type
treatment
continu
tc
consult
surgic
antibiot
prophylaxi
pa
consult
without
request
specif
antibiot
other
appropri
recommend
assess
day
consult
infecti
diseas
specialist
id
adher
recommend
assess
day
consult
idss
recommend
includ
antibiot
consid
appropri
appropri
accord
nation
intern
guidelin
recommend
consid
compli
done
hour
consult
except
consult
emerg
medicin
consult
antibiot
start
counsel
idss
result
consult
tc
pa
other
clinic
id
consult
request
mostli
gener
surgeri
clinic
consult
traine
consult
specialist
overal
consult
sp
clinic
infecti
diseas
diagnos
clinic
infecti
diseas
diagnos
microbiolog
request
spesif
antibiot
pa
approv
consult
antibiot
recommend
consult
six
consult
pa
antibiot
chang
clinic
diagnos
infecti
diseas
one
consult
tc
antibiot
chang
due
lack
respons
given
antibiot
other
tc
approv
inappropri
antibiot
recommend
rate
inappropri
choic
inappropri
dosag
one
antibiot
unnecessari
overal
complianc
id
recommend
rate
complianc
antibiot
recommend
evalu
consult
found
higher
complianc
microbiolog
etc
recommend
chi
squar
p
conclus
methodolog
improv
complianc
nontreat
base
recommend
optim
antibiot
select
necessari
studi
influenc
onlin
practic
guidelin
appropri
antibiot
prescrib
universityaffili
psychiatr
hospit
jf
westphal
c
nonnenmach
gregoir
hitting
c
oulerich
f
jehl
brumath
strasbourg
fr
background
problem
dissemin
guidelin
frequent
cite
major
reason
failur
impact
practic
review
effect
variou
method
guidelin
dissemin
show
predict
impact
achiev
guidelin
made
access
computerbas
remind
integr
clinician
workflow
report
timeseri
prospect
investig
aim
compar
appropri
antibiot
ab
order
pneumonia
treatment
initi
level
vs
embed
current
ab
guidelin
pneumonia
computer
physician
drugord
entri
system
teach
psychiatr
hospit
compris
adult
bed
method
total
consecut
ab
order
pneumonia
evalu
pharmaci
depart
includ
order
order
implement
onlin
ab
guidelin
appropri
ab
order
rel
guidelin
assess
accord
criteria
choic
ab
respect
mode
acquisit
communityor
hospitalacquir
pneumonia
presenc
clinic
risk
factor
involv
gramneg
bacilli
daili
dosag
plan
durat
treatment
data
extract
computer
infect
declar
system
record
abrequir
infect
hospit
result
number
ab
order
least
criterion
inappropri
tend
decreas
yet
significantli
p
vs
implement
onlin
guidelin
respect
number
criteria
inappropri
rel
ab
order
pneumonia
significantli
lower
postimplement
period
vs
implement
differ
ci
p
trend
decreas
number
order
contain
criterion
inappropri
analyz
separ
number
inappropri
order
choic
ab
daili
dosag
plan
durat
treatment
decreas
yet
significantli
p
criterion
postv
preimplement
period
vs
respect
conclus
studi
moder
impact
ab
prescrib
practic
onlin
guidelin
avail
time
drug
order
show
addit
type
intervent
need
improv
qualiti
ab
prescrib
materi
pilot
hospit
median
capac
rang
bed
region
distribut
repres
popul
size
gener
hospit
teach
hospit
gener
hospit
teach
bed
result
am
internist
microbiologist
pharmacist
amt
includ
mean
member
met
everi
week
averag
hospit
irrespect
size
affili
undertaken
wide
rang
antibiot
manag
intervent
increas
includ
respect
major
review
formulari
hospit
develop
clinic
guidelin
topic
restrict
access
select
antibiot
carbapenem
glycopeptid
quinolon
new
drug
hospit
antibiot
consumpt
databas
establish
hospit
antibacteri
suscept
databas
hospit
crossanalysi
databas
perform
hospit
prescrib
assist
antibiot
stop
order
treatment
streamlin
ivpo
therapi
switch
implement
hospit
respect
hospit
report
better
use
target
antibiot
hospit
decreas
consumpt
restrict
antibiot
hospit
decreas
total
antibiot
consumpt
hospit
decreas
high
consum
depart
conclus
hospit
particip
amt
pilot
scheme
develop
multipl
antibiot
polici
intervent
establish
monitor
guidanc
antibiot
prescript
preliminari
data
hospit
indic
success
meet
selfdefin
target
appropri
use
reduc
consumpt
select
antimicrobi
agent
systemat
evalu
use
standard
quantit
qualit
indic
plan
antibiot
prescrib
practic
two
link
london
teach
hospit
comparison
differ
antibiot
consumpt
measur
method
larg
multidisciplinari
hospit
e
pujat
apin
u
dumpi
riga
lv
object
antibiot
select
pressur
determin
total
amount
antibiot
number
densiti
patient
treat
antibiot
particular
geograph
area
sever
antibiot
consumpt
detect
method
combin
hospit
set
object
evalu
efficaci
differ
approach
larg
multidisciplinari
hospit
method
point
preval
studi
repeat
annual
stradin
univers
hospit
bed
latvia
patient
receiv
antibiot
day
survey
identifi
medic
record
review
data
antibiot
dose
rout
administr
collect
addit
annual
data
antibiot
dispens
depart
collect
pharmaci
total
use
gram
antibiot
express
defin
daili
dose
dddwho
bed
day
bd
admiss
day
ad
use
denomin
result
tabl
total
use
antibiot
stradin
univers
hospit
hospit
commonli
use
antibiot
group
pharmaci
studi
gener
cephalosporin
bd
penicillin
extend
spectrum
follow
fluoroquinolon
metronidazol
signific
differ
distribut
differ
antibiot
preval
pharmaci
studi
calcul
ddd
contrast
distribut
antibiot
calcul
per
patient
preval
studi
quit
differ
gener
cephalosporin
respect
fluoroquinolon
smaller
proport
extend
spectrum
penicillin
metronidazol
conclus
differ
distribut
antibiot
calcul
ddd
per
bed
day
admiss
distribut
antibiot
annual
pharmaci
studi
point
preval
studi
calcul
ddd
also
similar
contrast
preval
data
express
proport
patient
select
antibiot
show
quit
differ
distribut
studi
use
ddd
may
overestim
use
certain
antibiot
group
set
ddd
significantli
differ
actual
pdd
use
studi
prescrib
pattern
error
antibiot
saudi
hospit
aljam
albarrak
riyadh
sa
background
term
prescrib
pattern
use
extens
studi
describ
differ
aspect
prescrib
process
antibiot
well
drug
prescrib
purpos
achiev
definit
therapeut
outcom
improv
patient
qualiti
life
minim
risk
clinic
literatur
incid
antibiot
prescrib
error
rang
object
studi
address
antibiot
prescrib
pattern
incid
prescrib
error
tertiari
hospit
potenti
relationship
method
prospect
studi
prescript
period
june
august
tertiari
hospit
analys
hospit
provid
primari
secondari
level
care
criteria
use
includ
frequenc
select
prescrib
drug
averag
number
item
per
prescript
complianc
hospit
formulari
frequenc
prescript
antibiot
gener
prescrib
diagnosi
prescrib
pattern
incid
prescrib
error
perform
result
total
number
prescript
studi
emerg
room
er
primari
care
highest
number
prescript
averag
number
item
per
prescript
prescrib
drug
primari
care
error
emerg
antibiot
medicin
ophthalmolog
gynaecolog
paediatr
prescript
error
primari
care
emerg
depart
discuss
conclus
prescript
includ
studi
incid
prescrib
error
averag
number
item
per
prescript
total
prescript
error
also
relat
frequenc
prescrib
antibiot
relat
prescrib
antibiot
prescrib
trade
name
p
complianc
hospit
formulari
p
sever
factor
influenc
prescrib
pattern
variat
prescrib
rate
identifi
includ
gener
physician
behavior
differ
morbid
mortal
pattern
social
percept
toward
ill
physician
clinic
skill
experi
qualif
well
physician
continu
educ
train
special
antibiot
prescrib
guidelin
restrict
target
primari
care
emerg
depart
physician
effect
polici
restrict
select
class
antibiot
antimicrobi
drug
cost
resist
nonrestrict
antibiot
logist
regress
model
perform
show
new
polici
independ
posit
effect
vitro
antimicrobi
suscept
pseudomona
aeruginosa
p
acinetobact
baumannii
escherichia
coli
isol
conclus
data
suggest
consider
limit
program
aim
reduc
consumpt
restrict
antibiot
approv
use
specialist
least
proport
set
educ
program
aim
involv
medic
staff
directli
respons
care
patient
voluntari
decis
regard
appropri
use
antimicrobi
agent
may
profound
sustain
success
thu
deserv
studi
estim
hospit
versu
ambulatori
care
consumpt
antibiot
southwestern
germani
k
de
steibbauert
h
der
k
nink
wv
kern
freiburg
bonn
de
object
preliminari
data
esac
european
surveil
antibiot
consumpt
wwwuaacbeesac
project
indic
proport
hospit
care
hc
antibiot
use
total
antibiot
use
sever
european
countri
rang
countri
howev
far
abl
report
repres
countrywid
inform
hc
ambulatori
care
hc
antibiot
consumpt
estim
ac
versu
hc
consumpt
antibiot
one
german
feder
state
locat
southwestern
part
countri
million
popul
method
data
hc
consumpt
atc
class
obtain
conveni
sampl
acut
care
gener
hospit
n
extrapol
statewid
consumpt
use
offici
statist
total
statewid
gener
plu
special
nonpsychiatricnonpaediatricnonradiotherapi
hospit
express
defin
daili
dose
per
inhabit
day
final
compar
ambulatori
care
antibiot
use
densiti
region
period
time
year
find
estim
statewid
hc
consumpt
antibiot
confid
interv
year
statewid
antibiot
consumpt
ac
set
time
total
consumpt
ac
consumpt
fluoroquinolon
macrolidesclindamycin
made
major
proport
total
use
drug
class
conclus
hospit
antibiot
use
southwestern
part
germani
estim
overal
antibiot
consumpt
gener
popul
antibiot
use
profil
tempor
trend
period
greek
univers
hospit
implic
antibiot
polici
chang
ei
kritsotaki
p
assithianaki
p
kanello
n
tzagaraki
mc
ioannid
gika
heraklion
gr
object
investig
profil
tempor
trend
inpati
antimicrobi
use
period
univers
hospit
heraklion
crete
greec
examin
way
frequenc
data
collect
stratif
differ
patientcar
area
provid
guidanc
antibiot
polici
chang
method
retrospect
monitor
antimicrobi
consumpt
carri
accord
anatom
therapeut
chemic
classif
atc
defin
daili
dose
ddd
measur
methodolog
pharmaci
record
use
obtain
aggreg
data
drug
deliveri
individu
ward
result
express
usag
densiti
rate
ddd
per
bedday
linear
regress
use
order
assess
statist
signific
tempor
trend
usag
densiti
result
hospitalwid
antimicrobi
use
atc
group
significantli
increas
annual
averag
increas
rate
stratif
clinic
servic
demonstr
differ
intens
profil
class
use
well
vari
tempor
trend
figur
pool
usag
rate
overal
percentag
increas
annual
averag
increas
rate
respect
medic
ward
icu
haematooncolog
ward
surgic
ward
fairli
constant
usag
rate
shift
toward
newer
broadspectrum
antibiot
detriment
older
penicillin
cephalosporin
note
hospit
area
conclus
surveil
aggreg
data
consumpt
antimicrobi
use
atcddd
system
provid
clear
pictur
profil
hospit
usag
monthli
data
suffici
surveil
period
allow
assess
tempor
trend
stratif
usag
rate
clinic
servic
allow
area
concern
specifi
thu
surveil
monthli
antimicrobi
consumpt
rate
stratifi
patientcar
area
provid
simpl
rapid
effici
tool
trigger
antibiot
polici
chang
hospit
target
detail
qualityofus
audit
appropri
use
aminoglycosid
impact
antibiot
control
team
c
rioux
p
lesprit
jr
zahar
hulin
berniercomb
c
brunbuisson
e
girou
pari
fr
object
mani
factor
involv
appropri
use
aminoglycosid
ag
modal
administr
serum
monitor
durat
treatment
assess
prospect
risk
factor
impact
antibiot
control
team
appropri
ag
prescript
method
set
restrict
deliveri
system
ag
hospit
first
perform
observ
audit
oa
assess
appropri
prescript
includ
justif
prescrib
adequaci
drug
choic
adequaci
administr
modal
modal
serum
monitor
durat
treatment
implement
specif
guidelin
hospit
wide
perform
intervent
audit
ia
antibiot
control
team
could
interfer
ag
prescript
consid
inappropri
appropri
ag
prescript
audit
compar
result
prescript
analys
ia
prescript
modifi
control
team
compar
oa
prescript
ia
significantli
appropri
regard
treatment
durat
vs
p
serum
monitor
vs
p
median
treatment
durat
shorter
ia
oa
p
logist
regress
model
show
risk
factor
appropri
treatment
durat
adjust
ci
p
valu
hospit
intens
care
unit
polymicrobi
infect
antibiot
control
team
intervent
tabl
conclus
despit
restrict
deliveri
system
ag
use
frequent
associ
excess
treatment
durat
error
monitor
modal
reinforc
practic
guidelin
direct
counsel
improv
appropri
prescript
hospit
antibiot
consumpt
southern
eastern
mediterranean
countri
preliminari
result
arm
project
p
zarb
borg
h
goossen
ferech
arm
particip
introduct
arm
intern
research
project
investig
antimicrobi
resist
consumpt
southern
eastern
mediterranean
countri
collect
compar
valid
antimicrobi
resist
data
well
inform
antibiot
consumpt
pattern
infect
control
initi
object
consumpt
part
studi
aim
collect
data
antimicrobi
use
within
particip
hospit
region
inform
current
unavail
method
data
collect
plan
period
use
anatom
therapeut
chemic
atc
classif
valid
methodolog
adopt
european
surveil
antimicrobi
consumpt
esac
wwwuaacbeesac
hospit
particip
cypru
hospit
egypt
jordan
malta
tunisia
turkey
result
express
bedday
result
data
first
year
data
collect
indic
turkish
hospit
seem
show
lowest
overal
consumpt
day
whilst
cypriot
hospit
show
highest
valu
ddd
day
common
antibiot
use
betalactam
especi
penicillin
although
jordan
turkey
cephalosporin
consumpt
close
penicillin
broadspectrum
penicillin
mostli
utilis
penicillin
cypru
jordan
tunisia
wherea
malta
turkey
combin
penicillin
wide
use
variabl
cephalosporin
consumpt
concern
cypru
utilis
mainli
first
gener
jordan
malta
second
gener
egypt
tunisia
turkey
signific
variabl
hospit
nevertheless
use
third
gener
cephalosporin
appear
signific
conclus
signific
variabl
evid
countri
like
multifactori
depend
antibiot
licens
countri
nation
andor
hospit
formulari
type
hospit
well
antibiot
donat
relev
studi
hospit
nevertheless
preliminari
result
suggest
trend
within
hospit
countri
tend
similar
furthermor
region
whole
seem
utilis
consider
quantiti
broadspectrum
antimicrobi
factor
high
preval
resist
alreadi
document
studi
russian
pharmacoepidemiolog
studi
antibiot
prescript
pregnanc
result
mean
age
patient
min
max
year
mean
gestat
age
admiss
hospit
week
often
infect
commun
acquir
nosocomi
patient
estim
origin
infect
preval
infect
pregnanc
russia
urinari
tract
infect
std
candidiasi
rti
therefor
interest
analys
antibiot
prescript
uti
pregnanc
tabl
case
use
topic
intravagin
antimicrobi
administr
often
topic
administr
antimicrobi
prescript
prescrib
combin
drug
includ
antibacteri
amtimycot
case
antimicrobi
prescrib
system
mostli
prescrib
antimicrobi
betalactam
outpati
inpati
ampicillin
prescrib
often
outpati
inpati
amoxicillin
clavulan
acid
prescrib
outpati
inpati
pregnant
women
uti
cephalosporin
prescrib
outpati
inpati
uti
mainli
iiiand
ist
gener
mitroimidazol
gener
metronidasol
nitrofuran
aminolglycosid
prescrib
quit
often
unjustifi
antimicrobi
fluoroquinolon
doxiciclin
antivir
drug
antifung
prescrib
rel
rare
despit
fact
prescrib
drug
class
b
fda
antimicrobi
prescrib
pregnanc
class
c
class
unclassifi
conclus
often
prescrib
antimicrobi
uti
preval
infect
pregnanc
russia
betalactam
combin
topic
antibacteri
case
prescrib
antimicrobi
class
c
unclassifi
fda
outpati
inpati
use
antibiot
low
vitro
activ
uropathogen
object
studi
dynam
antibiot
usag
children
orphanag
locat
differ
russian
citi
result
intervent
increas
use
activ
antimicrobi
restrict
use
least
activ
method
studi
perform
orphanag
citi
european
russia
moscow
saintpetersburg
smolensk
karachev
bryansk
use
antimicrobi
previou
month
analys
upon
review
medic
record
children
year
appropri
recommend
predomin
use
select
betalactam
eg
amoxicillinclavulan
amc
restrict
antimicrobi
class
eg
cotrimoxazol
sxt
made
applic
basi
expert
analysi
antibiot
usag
pneumococc
nasopharyng
resist
rate
repeat
antibiot
usag
analysi
perform
month
later
upon
review
medic
record
children
year
result
total
usag
antimicrobi
increas
increas
resist
pen
aminopenicillin
enhanc
use
cephalosporin
led
increas
resist
drug
spite
recommend
restrict
usag
amox
aminoglycosid
sxt
analysi
show
antimicrobi
still
account
prescript
respect
thu
dictat
need
enforc
measur
antibiot
consumpt
ambulatori
care
latvia
berzina
ferech
g
ozolin
h
goosen
riga
lv
antwerp
object
collect
data
antibiot
consumpt
ambulatori
care
ac
latvia
accord
esac
data
collect
protocol
esac
european
surveil
antimicrobi
consumpt
grant
dg
sanco
ec
intern
network
nation
surveil
system
aim
collect
reliabl
compar
data
antibiot
consumpt
europ
method
data
ac
antibiot
consumpt
collect
use
atcddd
classif
version
express
defin
daili
dose
per
inhabit
per
day
data
obtain
state
medicin
agencybas
report
wholesal
ac
result
overal
use
antibiot
ac
posit
latvia
countri
compar
low
antibiot
consumpt
europ
mostli
use
class
antibiot
ac
penicillin
extend
spectrum
mainli
amoxicillin
frequent
use
antibiot
tetracyclin
mainli
doxycyclin
repres
combin
penicillinswith
betalactamas
inhibitor
essenti
coamoxiclav
macrolid
mainli
clarithromycin
fluoroquinolon
essenti
ciprofloxacin
combin
sulphonamid
trimethroprim
inclderiv
frequent
use
antibiot
ac
latvia
amoxicillin
doxycyclin
coamoxiclav
conclus
valid
data
outpati
antibiot
use
latvia
first
time
collect
deliv
european
surveil
antimicrobi
consumpt
allow
intern
comparison
pattern
antibiot
consumpt
latvia
european
countri
trend
glycopeptid
antibiot
consumpt
period
gener
hospit
athen
greec
introduct
glycopeptid
use
restrict
hellen
hospit
sinc
late
aim
studi
record
trend
consumpt
last
year
hospit
fleme
gener
hospit
bed
correl
data
number
import
gram
strain
isol
hospit
time
period
method
measur
glycopeptid
use
period
use
data
pharmaci
comput
consumpt
express
patient
day
abc
calc
furthermor
correl
data
data
microbiolog
depart
concern
number
mrsa
mrse
enterococci
isol
period
result
glycopeptid
consumpt
patient
day
year
increas
time
cumul
number
mrsa
mrse
enterococci
isol
respect
increas
type
data
put
graph
glycopeptid
consumpt
correl
well
number
import
gram
strain
isol
figur
furthermor
vre
percentag
among
enterococci
studi
year
respect
worth
note
mrsa
strain
sensit
rifampin
clindamycin
cotrimoxazol
clindamycin
rifampin
cotrimoxazol
rifampin
linezolid
introduc
hospit
yet
conclus
despit
restrict
polici
tremend
increas
glycopeptid
use
record
hospit
studi
period
correl
number
import
gram
strain
isol
b
nevertheless
vre
signific
problem
hospit
yet
c
huge
increas
glycopeptid
use
could
avoid
least
part
sinc
older
simpler
antibiot
could
substitut
glycopeptid
mani
case
audit
linezolid
use
univers
teach
hospit
galway
ireland
object
audit
linezolid
use
sixmonth
period
among
inpati
popul
teach
hospit
includ
medic
surgic
specialti
except
nephrolog
rheumatolog
orthopaed
method
prospect
audit
carri
prescrib
linezolid
inpati
octob
april
ward
pharmacist
record
detail
patient
prescrib
linezolid
chart
review
perform
assess
profil
patient
prescrib
linezolid
clinic
microbiolog
indic
treatment
adher
treatment
guidelin
document
advers
event
result
period
cours
linezolid
prescrib
fifti
two
percent
patient
linezolid
prescrib
surgic
specialti
half
patient
care
one
surgeon
pneumonia
clinic
indic
use
case
soft
tissu
infect
case
microbiolog
indic
clear
case
mrsa
vre
isol
case
therapi
either
empir
signific
organ
isol
prior
prescript
linezolid
therapi
direct
organ
could
treat
altern
agent
durat
treatment
exceed
day
cours
advers
event
record
case
one
cours
linezolid
conclus
third
case
linezolid
use
prescrib
without
clear
justif
avoid
use
linezolid
associ
increas
cost
risk
acquir
resist
particip
prior
oral
interview
interview
fill
answer
result
total
cm
specialist
complet
inquiri
repres
approxim
nation
quorum
mean
age
year
interview
cm
specialist
work
fulltim
fulltim
employ
hospit
lab
hl
next
routin
microbiolog
activ
perform
cm
specialist
mainli
domain
clinic
biolog
hospit
hygien
lesser
extent
qualiti
control
lab
manag
almost
two
third
interview
cm
specialist
believ
train
nt
prepar
properli
task
perform
desir
chang
includ
emphasi
clinic
aspect
infecti
diseas
antibiot
treatment
counsel
cm
exist
separ
special
belgium
includ
clinic
biolog
special
train
major
respond
think
cm
becom
subspeci
still
part
clinic
biolog
specif
minim
train
need
defin
major
cm
specialist
also
believ
cm
share
lab
infrastructur
disciplin
essenti
aspect
cm
lie
predominantli
medic
expertis
conclus
cm
train
put
emphasi
clinic
aspect
infecti
diseas
antibiot
treatment
counsel
major
respond
feel
cm
becom
subspecialti
still
part
clinic
biolog
well
defin
train
curriculum
object
sinc
year
infecti
diseas
consult
record
computer
databas
epi
info
cdc
report
consult
fellow
conduct
year
compar
consult
conduct
two
veteran
boardcertifi
infecti
diseas
consult
period
method
analys
computer
consult
record
includ
demograph
detail
patient
refer
depart
initi
rout
purpos
consult
recommend
compar
differ
consult
result
larger
percentag
veteran
compar
fellow
consult
request
attend
physician
vs
p
followup
vs
p
laboratori
result
vs
p
prescript
restrict
antimicrobi
agent
vs
p
preval
fellow
consult
fellow
higher
rate
addit
consult
patient
seen
vs
p
perform
bedsid
consult
vs
p
consult
curb
side
discuss
vs
p
less
consult
telephon
vs
p
diagnosi
prophylaxi
often
purpos
veteran
consult
vs
p
vs
p
respect
also
offer
new
diagnos
frequent
p
veteran
consult
often
conduct
consult
communityacquir
infect
vs
p
often
start
antibiot
treatment
vs
p
conclus
signific
differ
detect
consult
conduct
first
year
fellow
compar
veteran
infecti
diseas
consult
differ
reflect
chang
demand
activ
consult
work
experi
knowledg
accumul
period
analysi
computer
data
consult
facilit
supervis
well
direct
consult
work
address
issu
antibiot
use
pattern
microbi
resist
bridg
gap
health
care
public
health
capac
build
infecti
diseas
control
object
recent
year
european
union
eu
develop
support
mani
activ
field
communic
diseas
activ
concern
surveil
network
specif
infecti
diseas
eg
enternet
salmonella
escherichia
coli
infect
ewgli
legionella
infect
eiss
influenza
infect
also
eu
train
programm
like
epiet
european
programm
intervent
epidemiolog
train
eu
communic
diseas
bulletin
even
recent
eu
initi
bichat
improv
prepared
respons
bioterror
develop
eu
cdc
moreov
major
part
new
programm
commun
action
field
public
health
ph
concern
id
commit
improv
inform
inform
exchang
particularli
strengthen
intern
rapid
respons
capacityal
illustr
import
idc
eu
agenda
method
european
public
health
associ
eupha
umbrella
organis
ph
associ
eu
eupha
creat
eupha
section
idc
bring
togeth
eupha
member
expertis
field
repres
variou
mention
eu
initi
order
promot
strengthen
research
field
idc
provid
platform
exchang
inform
experi
research
idc
bring
togeth
research
ph
practition
policymak
activ
idc
encourag
joint
activ
idc
improv
idc
train
result
section
member
differ
countri
section
repres
ecdc
advisori
forum
differ
section
activ
organis
workshop
breakfast
meet
preconfer
meet
time
idc
topic
eupha
confer
object
establish
crossbord
dutchgerman
network
wwwmrsanetorg
provid
userfriendli
knowledg
centr
hospit
public
health
author
gp
nurs
home
laboratori
primari
purpos
aid
reduct
mrsarat
limit
crossbord
transmiss
mrsa
guidelin
implement
play
signific
role
reach
aim
crossbord
ca
mrsa
guidelin
redesign
accord
intern
standard
sociocultur
differ
nation
method
base
qualiti
standard
safeti
healthcar
document
use
high
risk
chemic
organ
framework
systemat
content
analysi
nation
mrsaguidelin
develop
nation
guidelin
analys
basi
framework
result
content
analysi
current
nation
mrsaguidelin
show
five
domin
mrsaperspect
rule
expert
risk
demandand
communitydriven
german
guidelin
mainli
domin
ruleand
expertdriven
perspect
guidelin
liter
deriv
law
follow
infect
transmiss
rout
contrast
dutch
focu
demand
user
commun
address
public
health
accept
guidelin
user
conclus
analysi
show
fact
differ
guidelineperspect
result
enorm
confus
set
guidelin
manag
use
guidelin
becom
uncontrol
lead
illusori
organis
healthcar
worker
nt
act
accord
guidelin
start
appli
insight
might
lead
costincreas
contrast
situat
implement
guidelin
success
crossbord
situat
cultur
technic
synchronis
alongsid
integr
approach
differ
perspect
guidelin
necessari
inlin
current
diseas
manag
model
research
redesign
evalu
guidelin
practic
help
achiev
r
tsiklauri
tbilisi
ge
background
anim
bite
common
recogn
public
health
problem
estim
bite
year
georgia
base
averag
visit
postexposur
treatment
cost
list
per
year
despit
frequenc
expens
injuri
littl
inform
incid
anim
bite
lack
systemat
report
lack
measur
qualiti
complet
report
data
object
investig
anim
bite
rabi
report
case
reveal
unreport
case
analys
base
studi
result
find
effect
epidemiolog
measur
anim
bite
death
due
rabi
prevent
georgia
method
capturerecaptur
method
use
along
loglinear
model
sourc
use
identifi
victim
policlinicambulatori
report
hospit
report
anim
control
report
victim
report
result
year
dog
anim
bite
report
capturerecaptur
method
estim
unreport
bite
period
death
due
rabi
regist
georgia
case
among
regist
last
year
reason
fatal
case
untreat
uncomplet
treat
late
began
postexposur
treat
case
bite
mostli
dog
bite
bit
person
know
rabi
prevent
measur
incorrect
inform
prevent
knew
epidemiolog
clinic
aspect
diseas
physician
respons
qualiti
postexposur
treatment
adequ
knowledg
conclus
dog
anim
bite
common
prevent
injuri
improv
surveil
prevent
rabi
georgia
focu
educ
gener
public
seriou
consequ
anim
bite
injuri
develop
anim
vaccin
strategi
pharmacoeconom
electron
resourc
expect
econom
burden
methicillinresist
staphylococcu
aureu
complic
skin
skin
structur
infect
model
approach
kuznik
r
mallick
weber
collegevil
chapel
hill
us
object
model
expect
rate
clinic
failur
initi
empir
therapi
econom
burden
like
associ
increas
preval
methicillinresist
staphylococcu
aureu
mrsa
patient
hospitalis
complic
skin
skin
structur
infect
csssi
unit
state
method
use
publish
data
preval
mrsa
bacteri
pathogen
caus
csssi
us
invitro
suscept
rate
commonli
use
regimen
csssi
us
relat
pervas
pathogen
identifi
estim
cost
failur
initi
empir
treatment
recent
studi
larg
us
multihospit
databas
develop
model
predict
expect
clinic
econom
impact
increas
preval
mrsa
specif
clinic
failur
commonli
use
initi
regimen
csssi
model
term
invitro
suscept
rate
respect
mrsa
weight
mrsa
preval
vari
rate
mrsa
yield
project
clinic
failur
rate
cost
attribut
increas
level
methicillin
resist
time
result
given
current
preval
aureu
pathogen
csssi
half
methicillinresist
base
case
mrsa
model
project
overal
clinic
failur
rate
commonli
use
initi
regimen
expect
overal
treatment
cost
us
dollar
per
patient
rang
none
aureu
pathogen
resist
mrsa
clinic
failur
rate
project
treatment
cost
per
patient
differ
two
scenario
translat
expect
clinic
failur
rate
increment
cost
per
patient
patient
hospitalis
csssi
annual
us
expect
health
care
system
burden
million
attribut
mrsa
worstcas
scenario
mrsa
caus
pathogen
mrsa
csssi
clinic
failur
rate
project
treatment
cost
per
patient
expect
conclus
go
beyond
exist
estim
model
gener
substanti
expect
clinic
failur
rate
econom
impact
attribut
current
mrsa
level
well
simul
expect
impact
increas
mrsa
preval
time
vari
level
mrsa
across
region
choic
initi
empir
regimen
treatment
complic
skin
skin
structur
infect
us
expect
cost
differ
tigecyclin
vancomycinaztreonam
r
mallick
kuznik
weber
collegevil
chapel
hill
us
object
compar
tigecyclin
vancomycinaztreonam
term
treatmentrel
cost
patient
hospitalis
unit
state
complic
skin
skin
structur
infect
csssi
method
conduct
retrospect
analysi
pool
data
us
centr
two
random
doubleblind
clinic
studi
compar
tigecyclin
vancomycinaztreonam
treatment
csssi
use
regress
analysi
estim
effect
tigecyclin
treatment
hospit
length
stay
lo
control
signific
predictor
use
publish
estim
daili
hospitalis
cost
csssi
us
multihospit
audit
translat
estim
impact
lo
econom
term
analysi
repeat
subgroup
patient
primari
pathogen
methicillinresist
staphylococcu
aureu
mrsa
clinic
efficaci
tigecyclin
vancomycinaztreonam
p
similar
across
treatment
includ
model
paramet
result
retrospect
analysi
pool
clinic
data
us
centr
found
tigecyclin
associ
shorter
lo
day
p
compar
combin
vancomycinaztreonam
treatment
patient
csssi
mean
daili
hospitalis
cost
us
exclud
antibiot
cost
translat
expect
medic
cost
save
per
patient
tigecyclin
compar
vancomycinaztreonam
mrsa
subgroup
compris
clinic
studi
sampl
tigecyclin
associ
greater
reduct
lo
day
p
compar
vancomycin
aztreonam
translat
expect
medic
cost
save
per
patient
treat
tigecyclin
expect
medic
cost
save
offset
higher
averag
daili
drug
acquisit
cost
tigecyclin
rel
vancomycinaztreonam
combin
conclus
retrospect
analysi
pool
clinic
data
patient
csssi
treat
us
centr
tigecyclin
associ
significantli
reduc
length
hospit
stay
rel
vancomycinaztreonam
translat
substanti
cost
save
especi
subset
csssi
patient
mrsa
econom
impact
linezolid
treatment
skin
soft
tissu
mrsa
infect
itali
eandi
p
dale
sorensen
baker
procaccini
duttagupta
turin
london
uk
bethesda
us
rome
new
york
us
object
linezolid
shown
highli
effect
infect
caus
methicillinresist
staphylococcu
aureu
mrsa
patient
complic
skin
soft
tissu
infect
cssti
object
studi
evalu
clinic
econom
consequ
use
linezolid
empir
treatment
cssti
italian
hospit
perspect
method
decisionanalyt
model
develop
calcul
clinic
cost
outcom
empir
treatment
hospit
patient
cssti
itali
prescrib
linezolid
vancomycin
teicoplanin
efficaci
data
deriv
clinic
trial
cost
publish
sourc
appli
test
advers
event
day
intraven
oral
linezolid
treatment
hospit
ward
type
gener
intensivecar
resourc
use
util
pattern
obtain
combin
clinic
trial
data
expert
opinion
outcom
includ
total
cost
per
patient
cost
per
cure
cost
per
death
avoid
uncertainti
surround
ce
ratio
test
use
oneway
sensit
analysi
result
start
empir
treatment
linezolid
result
patient
cure
mrsa
compar
vancomycin
averag
cost
per
patient
treat
linezolid
versu
patient
treat
vancomycin
result
cost
per
cure
separ
analysi
patient
cure
use
linezolid
compar
teicoplanin
averag
total
cost
per
episod
linezolid
treat
patient
versu
teicoplanin
treat
patient
result
cost
per
cure
sensit
paramet
includ
hospit
lo
mrsa
resist
rate
conclus
treatment
cssti
due
suspect
mrsa
itali
empir
use
linezolid
costeffect
compar
vancomycin
teicoplanin
outpati
home
parenter
antimicrobi
therapi
treatment
cellul
evalu
efficaci
cost
h
ziglam
r
tilley
c
wootton
j
morrison
nathwani
dunde
uk
object
outpati
home
parenter
antibiot
therapi
ohpat
programm
effect
well
toler
econom
advantag
care
select
patient
popul
skin
soft
tissu
infect
repres
high
burden
diseas
amen
treatment
ophat
programm
retrospect
analys
outcom
registri
evalu
clinic
health
econom
impact
treat
cellul
set
method
review
patient
cellul
erysipela
treat
ohpat
patient
treatment
full
integr
care
pathway
icp
icp
document
microbiolog
outcom
drug
vascular
access
complic
rate
impact
drug
cost
inpati
bed
day
number
patient
treat
april
march
present
also
review
use
inpati
discharg
diagnosi
data
inform
statist
divis
scotland
isd
dunde
infecti
diseas
unit
didu
outcom
registri
databas
key
diagnosi
icd
code
group
consid
cellul
erysipela
eight
consecut
year
result
patient
receiv
intraven
antibiot
therapi
mean
durat
day
two
primari
agent
administ
oncedaili
ceftriaxon
patient
teicoplanin
patient
patient
cure
improv
worsen
requir
surgeri
tinea
pedi
found
patient
treat
cellul
econom
benefit
realiz
despit
use
expens
agent
data
dunde
outcom
registri
reveal
mean
reduct
length
hospit
day
reduct
compar
scottish
data
isd
show
chang
length
hospit
year
day
year
day
conclus
found
ohpat
clinic
effect
administ
safe
success
outpati
set
major
complic
minor
patient
cure
tinea
pedi
found
signific
risk
factor
acut
cellul
indic
improv
awar
manag
toe
web
intertrigo
might
reduc
incid
cellul
analysi
also
support
premis
adult
ohpat
programm
substanti
reduc
healthcar
resourc
use
european
healthcar
set
costeffect
analysi
intraven
moxifloxacin
compar
levofloxacin
hospitalis
elderli
patient
communityacquir
pneumonia
object
evalu
costeffect
moxifloxacin
compar
levofloxacin
hospitalis
patient
age
commun
acquir
pneumonia
cap
method
randomis
doubleblind
parallel
group
studi
conduct
us
hospit
patient
radiolog
evid
bacteri
pneumonia
confirm
least
sign
age
year
manag
inpati
initi
treatment
patient
initi
receiv
moxifloxacin
mg
iv
od
levofloxacin
mg
iv
od
stabilis
switch
oral
therapi
agent
effect
endpoint
econom
analysi
percentag
patient
success
treat
defin
patient
mark
improv
resolut
clinic
cure
test
cure
visit
day
therapi
experi
seriou
cardiac
advers
event
total
cost
estim
perspect
treat
hospit
includ
antibiot
drug
hospit
stay
hospit
readmiss
within
day
cost
manag
treatment
failur
result
patient
includ
analysi
randomis
moxifloxacin
levofloxacin
ci
moxifloxacin
levofloxacin
treat
patient
success
treat
resolut
clinic
cure
toc
seriou
drug
relat
ae
moxifloxacin
group
patient
report
mean
day
iv
antibiot
treatment
day
inpati
stay
day
iv
antibiot
treatment
day
inpati
stay
levofloxacin
group
mean
per
patient
drug
cost
moxifloxacin
group
levofloxacin
group
mean
total
cost
moxifloxacin
group
levofloxacin
group
find
consist
across
rang
patient
subgroup
cost
sensit
length
hospit
stay
conclus
patient
moxifloxacin
group
higher
rate
success
treatment
slightli
lower
averag
cost
levofloxacin
group
confirm
result
target
studi
moxifloxacin
show
superior
clinic
efficaci
comparison
coamoxiclav
without
clarithromycin
hospitalis
cap
patient
antibiot
cost
slightli
higher
moxifloxacin
group
levofloxacin
group
total
cost
slightli
lower
due
reduc
hospit
stay
econom
impact
invas
fungal
infect
icu
patient
tertiari
care
hospit
switzerland
imhof
w
zingg
r
laffer
c
ruef
zurich
ch
object
invas
fungal
infect
ifi
caus
signific
morbid
mortal
manag
invas
fungal
infect
current
undergo
import
chang
due
avail
new
therapeut
agent
improv
safeti
profil
acquisit
cost
new
agent
high
evalu
averag
overal
cost
manag
microbiolog
diagnosi
treatment
invas
fungal
infect
critic
ill
patient
larg
univers
hospit
method
retrospect
pairwisematch
cohort
studi
perform
surgic
icu
one
medic
icu
univers
hospit
icu
patient
document
ifi
n
match
control
subject
n
basi
diseas
sever
sex
age
year
clinic
outcom
princip
evalu
inhospit
mortal
econom
impact
microbiolog
studi
antibiot
treatment
assess
calcul
base
period
admiss
diagnosi
ifi
case
durat
hospit
stay
control
respect
result
median
length
hospit
icu
stay
differ
significantli
case
control
vs
day
vs
day
p
respect
ifi
occur
median
hospit
stay
rang
day
mortal
rate
patient
ifi
match
control
subject
respect
p
signific
differ
case
control
charlson
index
mccabe
sap
ii
score
median
number
antibiot
treatment
cours
case
control
p
median
durat
therapi
day
vs
day
p
respect
microbiolog
studi
mi
conduct
patientday
pd
case
pd
control
group
p
frequent
sampl
bloodcultur
group
swab
order
significantli
frequent
case
median
rang
vs
p
cost
mi
pd
case
vs
pd
control
cost
antifung
therapi
pd
vs
pd
respect
conclus
ifi
associ
excess
length
icu
hospit
stay
increas
use
antibiot
microbiolog
diagnost
microbiolog
studi
signific
econom
impact
treatment
ifi
costeffect
voriconazol
amphotericin
b
deoxychol
earli
late
treatment
invas
aspergillosi
r
green
j
mauskopf
c
robert
zyczynski
h
schlamm
boston
research
triangl
park
new
york
us
object
estim
costeffect
altern
initi
drug
treatment
invas
pulmonari
aspergillosi
ipa
suspect
earlier
later
lung
involv
base
presenc
absenc
halo
sign
thorac
comput
tomographi
ct
method
construct
decis
analysi
model
compar
treatment
outcom
subset
patient
enrol
clinic
trial
initi
treatment
ipa
amphotericin
b
dexoychol
ambd
vs
voriconazol
vor
patient
includ
suspect
lung
involv
underw
baselin
thorac
ct
subset
subdivid
two
group
base
presenc
absenc
characterist
ct
halo
sign
perimet
ground
glass
ct
opac
surround
solid
lung
nodul
cm
diamet
known
earli
indic
ipa
healthcar
resourc
use
surviv
data
obtain
directli
clinic
trial
us
unit
cost
drug
health
care
servic
appli
standard
data
sourc
cost
surviv
estim
without
halo
sign
baselin
increment
costeffect
ratio
compar
vor
ambd
calcul
patient
subgroup
sensit
result
uncertainti
health
care
use
cost
estim
test
result
patient
halo
subgroup
better
surviv
nohalo
subgroup
vs
lower
total
treatment
cost
vs
surviv
higher
vor
ambd
patient
subgroup
halo
vs
nohalo
vs
halo
subgroup
total
cost
lower
treat
vor
treat
ambd
vs
nohalo
subgroup
total
cost
per
patient
slightli
higher
treat
vor
vs
account
differ
surviv
increment
costeffect
ratio
vor
compar
ambd
per
addit
survivor
subgroup
conclus
earlier
identif
treatment
ipa
appear
result
better
surviv
potenti
lower
cost
later
treatment
initi
treatment
ipa
vor
improv
surviv
patient
earli
late
diseas
compar
ambd
cost
save
halo
subgroup
costeffect
nohalo
subgroup
within
constraint
analysi
object
describ
compar
nurs
labor
time
requir
prepar
administr
liposom
amphotericin
b
lamb
amphotericin
b
deoxychol
ambd
voriconazol
vor
method
activ
associ
nurs
prepar
administr
three
studi
drug
time
train
observ
five
hospit
one
itali
three
franc
one
unit
kingdom
target
task
classifi
like
affect
differ
drug
exclud
task
like
differ
sitespecif
factor
eg
travel
time
patient
room
differ
hospit
target
task
includ
obtain
suppli
medic
prepar
medic
educ
patient
administ
medic
monitor
advers
event
prepar
followup
medic
mean
time
administr
singl
day
studi
drug
summaris
compar
account
singl
daili
dose
lamb
ambd
daili
dose
vor
iv
oral
result
sixtynin
patient
observ
receiv
dose
studi
medic
five
hospit
time
administr
minut
per
day
lamb
ambd
vor
iv
vor
oral
respect
administr
time
significantli
lower
vor
iv
compar
lamb
p
vor
oral
compar
iv
regimen
p
task
prepar
medic
requir
time
iv
formul
longer
lamb
group
other
lamb
min
vs
ambd
min
vor
iv
min
ambd
requir
time
patient
monitor
administr
followup
drug
formul
ambd
min
vs
lamb
min
vor
iv
min
conclus
vor
iv
requir
significantli
less
time
prepar
administ
daili
basi
compar
lamb
measur
iv
antifung
versu
oral
vor
administr
suggest
opportun
save
minut
per
day
switch
oral
therapi
possibl
need
costeffect
investig
focus
diagnosi
manag
prevent
osteopenia
osteoporosi
set
hiv
diseas
treat
haart
act
act
patient
first
target
intervent
r
manfredi
l
calza
f
chiodo
bologna
background
osteopeniaosteoporosi
emerg
untoward
effect
hiv
infectionhaart
pathogenesi
multifactori
involv
class
antihiv
drug
although
proteas
inhibitor
use
overal
haart
durat
male
sex
seem
relat
greater
riskepidemiologicalclin
data
ongo
studi
centr
hivinfect
patient
p
follow
bone
miner
densiti
assess
lumbar
spinefemur
head
dual
energi
xray
absorptiometri
dexa
exam
estim
preval
osteopeniaosteoporosi
screen
p
frequenc
osteopenia
osteoporosi
base
lumbar
tscore
respect
increas
risk
found
p
treat
proteas
inhibitor
versu
receiv
nonnucleosid
revers
transcriptas
inhibitor
tripl
nucleosid
nucleotid
combin
discuss
futur
insight
prospect
studi
extens
p
sampl
need
elucid
epidemiolog
pathogenesi
clinic
issu
evolut
hivassoci
bone
metabol
anomali
plan
strategi
earli
diagnosi
prevent
manag
also
costeffect
issu
consid
sinc
pharmacoeconom
data
still
exist
set
although
sever
consequ
eg
patholog
fractur
prosthet
implant
expect
infrequ
consequ
term
length
intens
hospit
relat
cost
especi
sever
consequ
p
qualiti
life
play
notabl
role
anyway
reliabl
diagnost
procedur
dexa
afford
cost
around
eur
totalbodi
scan
also
offer
bodi
composit
assess
well
firstlin
drug
osteopenia
eg
supplement
calcium
eur
vitamin
eur
cost
compar
cost
standard
care
asymptomat
haarttreat
p
eur
immunolog
virolog
laboratori
clinic
control
made
least
quarterli
like
postmenopaus
osteopeniaosteoporosi
burden
greater
risk
bone
mass
anomali
also
hiv
diseas
investig
multipl
costeffect
point
view
establish
p
prefer
candid
dexa
screen
examin
use
hiv
diseas
cours
therapi
exam
repeat
interven
pharmacolog
prevent
seriou
potenti
invalid
complic
compar
studi
cost
new
drug
differ
therapeut
categori
falaga
k
fragouli
g
zouglaki
karydi
athen
gr
object
drug
treatment
becom
expens
due
increas
cost
introduct
new
drug
seem
uneven
distribut
medic
cost
differ
therapeut
categori
hypothes
cost
new
antimicrobi
agent
may
differ
therapeut
categori
may
play
role
stagnat
develop
new
antibiot
method
perform
pharmacoeconom
compar
analysi
drug
cost
treatment
new
agent
introduc
unit
state
drug
market
variou
therapeut
categori
calcul
drug
cost
us
dollar
usd
treatment
new
drug
approv
fda
period
januari
juli
accord
red
book
pharmaci
fundament
refer
result
new
antineoplast
agent
found
expens
drug
comparison
therapeut
categori
median
drugtreat
cost
usd
compar
median
drugtreat
cost
categori
rang
usd
tabl
hand
new
antimicrobi
drug
found
much
less
expens
median
drugtreat
cost
usd
antimicrobi
agent
antimicrobi
agent
exclud
antihiv
medic
respect
conclus
drugtreat
cost
new
medic
vari
consider
differ
therapeut
categori
fact
may
influenc
industri
decis
regard
develop
new
drug
may
play
role
shortag
new
antimicrobi
agent
fight
seriou
problem
antimicrobi
resist
usag
expenditur
tertiari
hospit
ta
peppa
k
maleng
n
zacho
voutsina
kosmopoul
n
galanaki
piraeu
athen
gr
object
aim
assess
usag
distribut
expenditur
year
object
analys
antiobiot
util
croatia
use
anatomicaltherapeuticchem
atc
drug
classif
system
number
defin
daili
dose
ddd
method
data
number
packag
purchas
price
collect
individu
drug
data
use
calcul
number
defin
daili
dose
ddd
ddd
per
inhabit
per
day
dddtid
data
obtain
pharmaci
hospit
extrapol
total
number
pharmaci
hospit
croatia
drug
util
segment
use
prescrib
qualiti
indic
result
overal
util
antibiot
croatia
amount
accord
drug
group
penicillin
show
highest
util
dddtid
predomin
subgroup
penicillin
combin
includ
betalactamas
inhibitor
ddd
tid
within
combin
amoxicillin
clavulan
acid
account
broadspectrum
penicillin
account
dddtid
total
penicillin
util
predomin
amoxicillin
dddtid
cephalosporin
rank
second
follow
macrolid
lincosamid
dddtid
predomin
macrolid
among
latter
azithromycin
show
highest
util
dddtid
account
total
macrolid
util
tetracyclin
rank
fourth
account
overal
antibiot
util
follow
quinolon
dddtid
antimicrobi
dddtid
aminoglycosid
sulfonamid
account
neglig
proport
overal
util
du
segment
includ
antibiot
regist
croatia
amoxicillin
clavulan
acid
lead
one
follow
cephalexin
cefuroxim
azithromycin
norfloxacin
nitrofurantoin
clarithromycin
hospit
util
account
overal
antibiot
util
express
dddtid
respect
financi
cost
predomin
aminoglycosid
lowest
proport
tetracyclin
respect
conclus
util
antibiot
croatia
among
highest
europ
mostli
due
overus
amoxicillin
clavulan
acid
ration
ground
profession
guidelin
object
object
research
analys
antibiot
prescrips
behavior
famili
doctor
specialist
treatment
prior
introduct
health
care
reform
poland
materi
method
prescript
first
six
month
compar
data
collect
two
randomli
chosen
pharmaci
citi
zabrz
suppli
citizen
silesian
agglomer
variou
social
background
take
account
valu
singl
antibiot
packag
price
patient
pay
averag
price
medic
prescrib
famili
specialist
doctor
calcul
result
total
prescript
analys
date
first
halfyear
percentag
prescript
antibiot
reach
averag
year
averag
first
halfyear
famili
doctor
mostli
prescrib
penicyllin
makrolid
cephalosporin
tetracyclin
chinolon
period
spcialist
doctor
prescrib
penicyllin
cephalosporin
makrolid
tetracyclin
lincozamid
chinolon
first
halfyear
famili
doctor
often
prescrib
penicyllin
makrolid
cephalosporin
tetracyclin
lincozamidsbas
treatment
specialist
doctor
hand
prescrib
penicllin
makrolid
cephalosporin
tetracyclin
lincozamid
chinolon
averag
price
prescrib
medic
year
respect
famili
doctorseu
specialist
doctor
eu
conclus
consider
increas
percentag
prescript
antibiot
tendenc
toward
prescrib
antibiot
specif
group
doctor
chang
significantli
year
prescript
antibiot
line
recommend
also
price
medic
prescrib
famili
doctor
risen
internet
guid
antimicrobi
resist
sosa
f
traub
valov
p
chea
boston
us
object
organ
plethora
inform
avail
provid
clinician
tool
easili
access
avail
onlin
resourc
includ
academ
institut
profession
societi
well
site
maintain
privat
individu
inform
clinician
new
advanc
epidemiolog
diagnosi
treatment
prevent
common
infect
inform
subject
clinic
trial
antimicrobi
resist
inform
specif
pathogen
infect
genom
resourc
cultur
collect
electron
imag
pathogen
antimicrobi
agent
antimicrobi
resist
lectur
teach
materi
environment
health
safeti
inform
list
websit
infecti
diseas
clinic
microbiolog
profession
societi
method
defin
four
inclus
criteria
extens
consult
apua
staff
scientif
advisori
member
recognizedreput
sourc
high
qualiti
inform
present
potenti
use
medic
profession
gener
public
eas
navig
ideal
paramet
determin
guid
scope
appropri
sourc
identifi
onlin
subsequ
review
set
broad
categori
establish
organ
topic
onlin
resourc
site
review
includ
maintain
feder
govern
academ
institut
nonprofit
organ
commerci
entiti
person
websit
includ
qualiti
associ
academ
institut
review
intend
introduct
amr
websit
result
use
popular
search
engin
googl
yahoo
altavista
initi
identifi
great
number
websit
use
broad
search
term
antibiot
resist
identifi
web
address
term
antimicrobi
resist
gener
hit
term
drug
resist
gener
hit
conclus
websit
found
classifi
follow
systemat
topic
structur
websit
list
describ
full
citat
resourc
authoreditor
titl
websit
date
public
last
revis
method
result
portal
free
use
requir
registr
regist
user
novemb
intrain
posit
hold
faculti
posit
infecti
diseas
id
microbiolog
hematooncolog
specialist
nonunivers
teach
set
remain
mix
group
primari
physician
special
doctor
pharmaceut
compani
worker
run
cost
portal
partial
cover
educ
grant
pharmaceut
sponsor
role
organ
site
name
acknowledg
articl
chosen
two
faculti
member
one
id
physician
one
haematologist
sent
regist
user
daili
email
post
select
toc
alert
variou
core
clinic
journal
well
known
educ
web
site
eg
cdc
medscap
short
turkish
summari
provid
reader
refer
abstract
avail
free
full
text
origin
articl
link
materi
includ
guidelin
free
slide
set
studi
protocol
updat
group
cme
activ
meet
announc
registr
may
also
use
site
expert
opinion
trial
period
site
visit
time
hit
approxim
gb
materi
download
frequenc
read
relat
time
highest
weekday
lowest
weekend
type
document
ie
educ
materi
guidelin
popular
news
eg
peak
epidem
avian
influenza
relat
news
articl
announc
page
frequent
visit
id
specialist
follow
clinic
microbiolog
haematolog
pharmaceut
compani
worker
respect
conclus
time
publish
medic
data
high
attract
rate
among
physician
result
also
indic
web
page
get
old
month
publish
emphas
import
welltim
announc
portal
materi
neli
nric
survey
inform
need
infecti
diseas
profession
p
kostkova
dsouza
g
madl
j
manisaada
wiseman
roy
j
weinberg
london
uk
healthcar
profession
increasingli
face
problem
inform
overflow
get
imposs
keep
uptod
latest
research
find
care
guidelin
pathway
govern
strategi
nation
local
polici
internet
enabl
instant
inform
dissemin
enabl
access
latest
result
time
well
inform
knowledg
exchang
use
chat
room
discuss
forum
howev
get
increasingli
difficult
busi
profession
find
reliabl
qualityassur
inform
internet
need
nation
internet
librari
uk
address
problem
umbrella
portal
nation
electron
librari
infect
neli
http
wwwneliorguk
provid
singl
access
portal
qualityassur
inform
treatment
diagnosi
prevent
manag
infect
diseas
nation
resourc
infect
control
nric
http
wwwnricorguk
singlestop
shop
polici
guidelin
research
around
infect
control
host
neli
better
meet
inform
need
internet
portal
access
uniqu
user
per
month
conduct
inform
need
studi
explor
clinic
question
user
need
diseas
prioriti
user
seek
answer
neli
nric
pilot
qualit
onlin
questionnairebas
studi
reveal
user
come
varieti
profession
clinic
scientist
consult
registrar
psychotherapist
lectur
gp
medic
librarian
inform
scientist
health
protect
question
mainli
around
hiv
tinea
molluscum
contagio
mening
cold
mrsa
lyme
toxoplasma
chicken
pox
influenza
diarrhoea
vomit
rash
staph
aureu
travel
infect
antibiot
resist
malaria
mmr
mening
viral
myocard
anthrax
smallpox
tb
line
quantit
weblogbas
evalu
commonli
access
topic
neli
nhsbase
user
antimicrobi
resist
hae
tb
mening
hiv
chlamydia
e
coli
staph
aureu
adenoviru
blood
born
infect
result
ongo
analysi
googl
search
keyword
brought
user
neli
nric
discuss
result
identifi
need
specif
infect
diseas
profess
discuss
relat
differ
nation
variat
inform
need
prioriti
train
infect
dsouza
p
kostkova
f
cook
holm
london
uk
specialist
today
requir
prompt
access
qualiti
inform
order
work
effect
divers
specialist
interest
field
infect
led
format
larg
number
profession
scientif
societi
play
increasingli
import
role
ensur
traine
effect
support
period
train
also
longerterm
person
develop
detail
relev
societi
confer
grant
etc
societi
websit
confin
either
societi
other
specialti
knowledg
numer
place
look
inform
necessari
find
latest
inform
train
infect
tii
wwwtrainingininfectionorguk
onlin
resourc
primarili
aim
infect
specialist
traine
use
throughout
career
path
bring
togeth
inform
one
central
access
point
user
infect
specialti
find
appropri
inform
specialti
quickli
easili
identifi
link
key
relev
resourc
cover
broad
rang
infect
relat
disciplin
dynam
databas
structur
inform
societi
confer
grant
journal
textbook
avail
site
put
togeth
creat
onestop
infect
train
portal
onlin
discuss
forum
implement
allow
traine
share
idea
make
combin
expertis
user
abl
receiv
alert
new
inform
specialti
well
remind
confer
deadlin
journal
submiss
deadlin
etc
abil
discuss
region
issu
onlin
within
specialti
also
aim
promot
greater
local
intern
collabor
train
infect
endors
nation
electron
librari
infect
neli
wwwneliorguk
establish
digit
librari
bring
togeth
best
avail
onlin
evidencebas
resourc
investig
treatment
prevent
control
infecti
diseas
research
design
statist
method
medic
abstract
kompoti
matsagoura
koutsovasili
koutsovasili
drimi
athen
gr
statist
method
use
biomed
research
articl
increasingli
scrutin
medic
journal
howev
strict
polici
gener
appli
abstract
present
medic
congress
object
studi
aim
assess
frequenc
research
design
statist
method
report
abstract
present
two
success
year
european
congress
clinic
microbiolog
infecti
diseas
eccmid
materi
method
review
abstract
includ
abstract
book
eccmid
pragu
pg
eccmid
copenhagen
cp
abstract
origin
research
studi
abstract
lectur
includ
studi
two
independ
investig
read
abstract
extract
inform
concern
origin
type
clinic
laboratori
anim
model
research
design
sampl
size
statist
method
use
studi
data
analysi
perform
logist
regress
pearson
chisquar
test
categor
variabl
student
ttest
continu
variabl
statist
signific
level
set
p
result
total
abstract
includ
analysi
accord
elig
criteria
pg
cp
laboratori
studi
prevail
follow
clinic
studi
experiment
studi
anim
model
major
studi
observ
retrospect
prospect
crosssect
concern
diagnost
accuraci
test
laboratori
method
pharmacolog
studi
random
control
trial
statist
evalu
clearli
describ
abstract
pg
cp
p
rest
abstract
includ
descript
statist
statist
proport
statist
method
report
vari
accord
type
studi
anim
model
studi
clinic
studi
laboratori
studi
p
multicentr
research
studi
report
statist
frequent
singlecent
studi
vs
respect
p
conclus
statist
analysi
insepar
part
origin
research
research
design
well
implement
statist
method
alway
report
adequ
manner
thu
improv
scientif
qualiti
abstract
antimicrobi
pkpd
streptogramin
phase
doubleblind
singl
escal
oral
dose
studi
evalu
safeti
toler
pharmacokinet
healthi
adult
male
volunt
rangaraju
j
rey
j
hodgson
romainvil
vitri
sur
sein
fr
background
nxl
formerli
xrp
novel
semisynthet
oral
streptogramin
consist
ww
ratio
associ
pristinamycin
ia
pi
deriv
pristinamycin
iib
pii
deriv
nxl
develop
treatment
respiratori
tract
skin
skin
structur
infect
method
healthi
male
subject
enrol
studi
subject
cohort
mg
mg
mg
mg
mg
mg
receiv
either
placebo
addit
cohort
subject
receiv
singl
dose
mg
fast
fed
condit
blood
urin
sampl
pk
analysi
collect
multipl
time
point
safeti
assess
via
advers
event
physic
examin
clinic
laboratori
data
ecg
cardiac
monitor
result
administ
mg
capsul
singl
dose
mg
mg
well
toler
safe
seriou
sever
advers
event
dosedepend
number
ae
sever
signific
variat
blood
pressur
heart
rate
abnorm
ecg
record
clinic
signific
chang
compar
baselin
laboratori
paramet
compon
rapidli
absorb
pi
slightli
rapidli
absorb
pii
cmax
auc
increas
approxim
proport
dose
proport
pi
pii
compon
estim
mean
exposur
valu
approxim
compar
administ
indic
rel
bioavail
pi
pii
simila
elimin
halflif
rang
hour
pi
hour
pii
food
increas
bioavail
pi
pii
approxim
conclus
safe
well
toler
exhibit
predict
pk
properti
healthi
volunt
dose
mg
administ
singl
dose
correl
vancomycin
daptomycin
suscept
staphylococcu
aureu
refer
accessori
gene
regul
polymorph
function
w
rose
rybak
b
tsuji
g
kaatz
g
sakoula
detroit
new
york
us
object
polymorph
accessori
gene
regul
agr
locu
aureu
sa
defin
group
iiv
agr
group
ii
sa
associ
glycopeptid
treatment
failur
patient
sa
loss
agr
function
appear
higher
tendenc
becom
vancomycin
v
resist
unknown
whether
associ
pertain
glycopeptid
examin
effect
vari
v
daptomycin
agr
agr
null
pair
vitro
pharmacodynam
model
ivpm
method
agr
group
ii
wildtyp
prototyp
knockout
tetm
agr
pair
evalu
mic
valu
determin
accord
clinic
laboratori
standard
institut
ivpm
glass
hollow
fibr
model
use
simul
dosag
aucmic
exposur
v
rang
g
q
h
faucmic
rang
mgl
h
mg
kgday
faucmic
rang
dosag
regimen
aucmic
breakpoint
produc
resist
evalu
hollow
fibr
ivpm
ivpm
simul
perform
duplic
h
resist
evalu
use
x
mic
screen
plate
h
result
preexposur
mic
valu
agr
agr
v
lgml
respect
vintermedi
resist
mic
mgl
detect
agr
ii
null
strain
simul
v
dosag
mg
q
aucmic
repres
mic
increas
fold
breakpoint
resist
verifi
hollow
fibr
model
although
signific
regrowth
note
suboptim
dose
resist
detect
screen
plate
daptomycin
regimen
evalu
conclus
exposur
sa
v
approxim
optim
serum
concentr
result
develop
heteroresist
agr
null
group
ii
loss
agr
function
correl
develop
resist
despit
suboptim
simul
exposur
result
implic
loss
agr
function
import
develop
glycopeptid
resist
loss
suscept
teicoplanin
effici
penetr
rabbit
infect
vitreou
may
enhanc
express
virul
factor
subinhibitori
concentr
e
foresti
f
jehl
c
gallion
r
andr
bronner
l
leining
g
strasbourg
fr
object
fluoroquinolon
antibiot
effici
penetr
insid
vitreou
howev
altern
treatment
endophtalm
may
requir
case
exampl
resist
bacteria
use
rabbit
experiment
model
endophtalm
evalu
penetr
teicoplanin
differ
condit
influenc
subinhibitori
concentr
teicoplanin
also
evalu
express
aureu
virul
factor
method
new
zealand
rabbit
kg
receiv
one
repeat
dose
intraven
iv
teicoplanin
mgkg
everi
hour
day
plu
one
dose
day
day
anoth
group
rabbit
infect
cfu
methicillin
resist
aureu
ib
cmi
mgl
produc
enterotoxin
pantonvalentin
leucocidin
lukelukd
administr
hour
later
mgkg
teicoplanin
singl
dose
reach
steadi
state
vitreou
sampl
new
inject
teicoplanin
indic
time
well
blood
min
teicoplanin
inject
teicoplanin
concentr
measur
hplc
bacteri
count
record
express
virul
factor
semiquantifi
dedic
competit
rtpcr
test
result
safe
eye
teicoplanin
penetr
remain
moder
reach
mgl
within
h
one
iv
inject
halflif
teicoplanin
rabbit
vitreou
hour
day
repeat
inject
intraocular
concentr
stabilis
around
mgl
residu
blood
concentr
compris
mgl
infect
eye
teicoplanin
repeatedli
administr
begin
clinic
sign
ie
h
postinfect
cfuml
reach
intravitr
concentr
mgl
h
postinfect
increas
mgl
h
postinfect
h
fourth
inject
howev
subinhibitori
concentr
mgl
may
respons
signific
increas
agr
gammahemolysin
hlga
luke
pantonvalentin
leucocidin
lukpv
express
ratio
rang
fold
conclus
preliminari
result
strongli
suggest
teicoplanin
iv
administr
constitut
interest
altern
therapi
endophtalm
provid
high
intraocular
concentr
rapidli
obtain
investig
concern
optimis
teicoplanin
dosag
regimen
pharmacokinet
temocillin
intens
care
patient
mont
carlo
simul
evalu
suscept
breakpoint
jw
mouton
r
dejongh
v
basma
p
tulken
carryn
nijmegen
nl
genk
brussel
background
temocillin
tmo
narrow
spectrum
penicillin
good
activ
gram
neg
microorgan
includ
esbl
ampc
produc
littl
pharmacokinet
data
avail
howev
perform
pharmacokinet
studi
icu
patient
receiv
tmo
paramet
estim
use
predict
concentr
continu
infus
coinf
compar
data
obtain
icu
patient
receiv
coinf
valid
model
model
use
perform
mont
carlo
simul
mc
determin
probabl
target
attain
pta
pharmacodynam
indic
pdi
order
evalu
suggest
clinic
breakpoint
method
blood
sampl
taken
icu
patient
prior
h
infus
g
tmo
n
h
coinf
h
n
cool
centrifug
store
analysi
hplc
protein
bind
determin
use
ultrafiltr
method
result
use
estim
popul
pharmacokinet
paramet
winnonmix
includ
covari
matrix
use
perform
simul
coinf
well
perform
mc
cycl
obtain
pta
unbound
fraction
includ
confid
interv
ci
target
concentr
ft
mic
chosen
pdi
pharmacodynam
properti
tmo
result
protein
bind
onecompart
model
best
fit
data
estim
se
vc
l
correspond
mean
halflif
h
use
estim
predict
unbound
concentr
coinf
mgl
mean
concentr
patient
mgl
bia
less
breakpoint
mic
mean
ft
mic
mgl
howev
mc
take
variat
popul
account
indic
pta
dose
obtain
mgl
ft
mic
respect
ci
ft
mic
indic
clinic
breakpoint
mgl
ci
rel
larg
expect
data
obtain
patient
rather
volunt
conclus
popul
pharmacokinet
estim
icu
patient
well
agreement
valid
studi
bia
mc
indic
suscept
breakpoint
temocillin
mgl
provid
administr
g
use
tissu
penetr
pharmacokinet
moxifloxacin
diabet
foot
infect
interim
analysi
j
majcherpeszynska
k
karrasch
r
mundkowski
gussmann
p
kujath
b
ruf
w
schareck
h
koch
b
drewelow
rostock
bad
saarow
lubeck
leipzig
beeskow
de
object
broad
spectrum
activ
gramposit
gramneg
anaerob
organ
moxifloxacin
cover
pathogen
mainli
polymicrobi
infect
associ
diabet
foot
inflammatori
fibrot
process
diabet
foot
infect
dfi
contribut
impair
tissu
penetr
antibiot
addit
diabet
patient
repres
pharmacolog
risk
popul
physiolog
chang
diabet
patient
may
alter
pharmacokinet
antibiot
studi
design
investig
penetr
moxifloxacin
perinecrot
tissu
patient
dfi
pharmacokinet
properti
moxifloxacin
diabet
patient
method
interim
analysi
open
multicentr
studi
includ
adult
hospit
male
femal
patient
mean
age
year
type
diabet
mellitu
dfi
pharmacokinet
paramet
moxifloxacin
penetr
dfi
tissu
steadi
state
day
follow
daili
administr
mg
iv
po
evalu
correl
penetr
moxifloxacin
clinic
laboratori
paramet
examin
result
patient
moxifloxacin
concentr
measur
infect
diabet
foot
wound
hour
administr
exceed
vitro
valu
suscept
staphylococci
mgl
moxifloxacin
concentr
achiev
dfi
tissu
correl
strongli
r
p
correspond
plasma
concentr
r
p
extent
system
inflamm
blood
glucos
level
take
account
predict
pkpd
paramet
moxifloxacin
base
vitro
valu
mgl
staphylococcu
aureu
therapeut
success
expect
cmaxmic
signific
differ
rout
administr
iv
vs
po
observ
tmax
p
p
clinic
relev
paramet
cmax
moxifloxacin
tissu
concentr
allow
sequenti
therapi
ivpo
indic
conclus
base
adequ
plasma
concentr
diabet
patient
suffici
penetr
dfi
tissu
possibl
sequenti
therapi
moxifloxacin
representsfrom
pharmacolog
point
view
valuabl
therapeut
option
treatment
diabet
foot
infect
caus
suscept
organ
fluoquinolon
effect
patient
lymphocyt
prolong
treatment
e
bertazzoni
minelli
benini
doria
p
franceschetti
fracass
verona
fluoroquinolon
fq
wide
use
clinic
practic
well
toler
common
advers
reaction
affect
gastrointestin
tract
phototox
allergi
aim
studi
evalu
possibl
cellular
damag
lymphocyt
patient
treat
differ
fq
accord
pharmacokinet
data
blood
sampl
obtain
thirtysix
patient
treat
ciprofloxacin
cpx
pt
levofloxacin
lvx
pt
moxifloxacin
mfx
pt
differ
dose
analys
patient
treat
cpx
lvx
therapi
drug
diuret
cardiovascular
drug
omeprazol
antiinflammatori
drug
etc
mxf
treat
patient
therapi
drug
sampl
collect
time
fq
administr
day
treatment
serum
level
fq
determin
microbiolog
method
hplc
comet
test
perform
lymphocyt
evalu
dna
damag
gsh
level
determin
effici
marker
metabol
process
detoxif
cpx
show
good
serum
concentr
level
increas
proport
administ
dose
mg
lvx
concentr
result
good
inhibitori
level
treatment
mg
per
os
iv
patient
oral
treat
mg
show
similar
serum
level
mgl
mfx
level
mgl
day
repeat
cpx
administr
induc
dosedepend
increas
dna
damag
paramet
statist
differ
treatment
mfx
mg
lvx
administr
nt
induc
dna
damag
day
intracellular
level
gsh
similar
treat
group
even
cpx
treat
patient
show
lowest
concentr
statist
correl
found
paramet
studi
data
indic
cpx
induc
dna
damag
lymphocyt
combin
reduc
effici
detoxif
system
effect
seem
depend
high
intersubject
variabl
fq
administ
dose
coadministr
drug
differ
age
patient
low
sampl
number
effect
singl
fq
molecul
seem
structurespecif
select
object
ertapenem
carbapenem
commonli
use
treat
intraabdomin
infect
antibacteri
spectrum
includ
major
caus
pathogen
clinic
trial
prove
excel
clinic
microbiolog
efficaci
periton
hand
inflammatori
pancreat
diseas
suffici
antibiot
concentr
inflammatori
tissu
vital
outcom
diseas
therefor
investig
ertapenem
concentr
pancreat
tissu
juic
comparison
plasma
level
measur
time
method
prospect
clinic
trial
ertapenem
given
dosag
g
iv
minut
prior
oper
patient
year
suffer
chronic
pancreat
pancrea
carcinoma
undergo
pancrea
resect
blood
sampl
collect
everi
minut
oper
moreov
collect
pancreat
tissu
pancreat
juic
shortli
resect
shortli
finalis
anastomosi
sampl
ertapenem
blood
juic
tissu
determin
hplc
result
patient
femal
male
mean
age
year
ertapenem
blood
concentr
determin
demonstr
intraop
high
concentr
mgl
valu
major
expect
pathogen
concomitantli
patient
ertapenem
concentr
determin
also
pancrea
tissu
pancrea
secret
patient
pancrea
secret
patient
suffici
high
ertapenem
level
detect
pancreat
tissu
patient
chronic
pancreat
accumul
seen
mean
pancrea
tissu
concentr
lgg
tissu
patient
pancrea
carcinoma
increas
ertapenem
level
pancrea
secret
patient
chronic
pancreat
conclus
patient
pancrea
carcinoma
ertapenem
level
measur
pancreat
tissu
well
pancreat
secret
penetr
seem
similar
imipenem
due
chronic
inflamm
possibl
alter
microcircul
one
half
one
third
chronic
pancreat
patient
ertapenem
level
detect
bacteri
strainindepend
pharmacodynam
linezoliddoxycyclin
combin
staphylococcu
aureu
simul
use
vitro
dynam
model
smirnova
alferova
lubenko
portnoy
zinner
firsov
moscow
ru
cambridg
us
object
delin
possibl
advantag
linezolid
l
doxycyclin
combin
monotherapi
pharmacodynam
l
ld
studi
aureu
method
aureu
atcc
clinic
isol
aureu
expos
twicedaili
l
halflif
h
oncedaili
halflif
h
alon
combin
ratio
base
aucmic
five
consecut
day
provid
simultan
monoexponenti
elimin
l
differ
halfliv
previous
describ
dynam
model
modifi
accord
blaser
zinner
mic
l
mgl
mic
mgl
aureu
atcc
aureu
respect
nine
dose
regimen
simul
organ
expos
differ
aucmic
hour
cumul
antimicrobi
effect
express
intens
ie
measur
start
treatment
time
last
antibiot
dose
number
antibioticexpos
bacteria
reach
least
cfuml
emerg
resist
monitor
daili
quantit
surviv
organ
agar
plate
contain
l
result
aureu
atcc
aureu
expos
l
ie
increas
increas
simul
auc
mic
ratio
although
significantli
higher
i
produc
treatment
rel
treatment
combin
treatment
ie
produc
much
greater
i
sum
l
i
observ
respect
monotreat
aureu
strain
base
popul
data
pronounc
select
aureu
resist
occur
monotreat
also
observ
lesser
extent
resist
l
observ
l
monoor
combin
treatment
conclus
data
predict
synergist
interact
l
aureu
antistaphylococc
effect
telavancin
vitro
dynam
model
impact
differ
halfliv
initi
concentr
simul
normal
nek
impair
elimin
kinet
iek
materi
method
glycopeptid
intermedi
suscept
strain
aureu
gisa
telavancin
mic
mgl
select
studi
nek
iek
simul
start
inoculum
log
cfuml
gisa
expos
differ
ratio
peak
concentr
cmax
mic
telavancin
singl
dose
ie
base
timekil
data
intens
antimicrobi
effect
ie
area
control
growth
timekil
curv
determin
time
zero
time
effect
longer
could
detect
ie
time
last
dose
number
antibioticexpos
bacteria
reach
log
cfuml
result
treatment
bacteri
regrowth
follow
gradual
reduct
start
inoculum
first
h
similar
nek
iek
simul
led
significantli
lower
minim
number
surviv
organ
iek
simul
compar
nek
simul
despit
similar
rate
initi
kill
time
regrowth
much
longer
iek
nek
simul
given
cmaxmic
ratio
i
observ
iek
greater
nek
simul
figur
conclus
find
demonstr
pharmacokineticdepend
pharmacodynam
telavancin
staphylococci
pharmacokinet
amoxicillin
pregnant
women
preterm
prematur
ruptur
membran
object
amoxicillin
wide
use
pregnanc
particular
treat
group
b
streptococcu
insuffici
knowledg
pharmacokinet
deliveri
could
pose
patient
preterm
prematur
ruptur
membran
pprom
seriou
risk
dose
investig
pharmacokinet
patient
pprom
critic
situat
method
seven
healthi
women
week
gestat
includ
receiv
g
first
dose
g
amoxicillin
pprom
accord
local
guidelin
patient
blood
sampl
taken
antibiot
serum
concentr
determin
valid
hplc
method
pharmacokinet
paramet
estim
popul
pk
model
use
nonmem
discrimin
variou
model
minimum
valu
object
function
mvof
use
reduct
mvof
consid
signific
result
threecompart
pharmacokinet
model
best
describ
time
cours
amoxicillin
clearanc
volum
distribut
central
compart
vc
estim
respect
lh
l
mean
se
estim
paramet
model
discrimin
improv
assum
size
third
compart
equal
first
compart
residu
error
found
proport
serum
concentr
interindividu
variabl
could
explain
variat
clearanc
mean
volum
distribut
steadi
state
vss
termin
halflif
l
h
respect
estim
valu
elimin
distribut
rate
constant
expect
due
small
popul
size
signific
relationship
observ
individu
posthoc
estim
clearanc
patient
characterist
conclus
describ
pharmacokinet
amoxicillin
pregnant
women
pprom
found
pharmacokinet
clearli
differ
nonpregn
individu
clearanc
vss
significantli
higher
termin
halflif
shorter
furthermor
model
found
describ
data
better
model
intrigu
question
whether
compart
uniqu
featur
associ
pregnanc
data
offer
theoret
basi
make
proper
doseadjust
particular
patient
group
critic
condit
penetr
piperacillin
tazobactam
sever
acut
pancreat
object
acut
necrot
pancreat
still
relat
extrem
high
mortal
rate
base
local
infecti
complic
particularli
necrot
area
limit
penetr
antimicrobi
drug
area
consid
major
caus
failur
therapi
sever
infect
combin
betalactamas
inhibitor
bli
betalactam
antibiot
like
broadspectrum
penicillin
bsp
antibacteri
activ
common
pathogen
sever
necrot
pancreat
coadministr
lead
increas
antibacteri
activ
due
inhibit
betalactamas
score
penetr
coadministr
pip
bli
inflam
necrot
pancreat
tissu
investig
yet
method
adress
penetr
capabl
bsp
bli
clinic
trial
design
investig
penetr
piperacillin
pip
tazobactam
taz
patient
sever
necrot
pancreat
undergo
pancrea
surgeri
sampl
n
taken
plasma
pl
necrot
area
pancreat
tissu
pn
peripancreat
fatti
tissu
pft
bursa
secret
bs
follow
intraven
administr
g
pip
g
taz
concentr
pip
taz
determin
hplc
uv
result
mean
plasma
concentr
h
applic
mgl
pip
mgl
taz
exceed
pl
bs
nearli
reach
pn
pft
concentr
pip
combin
taz
exceed
reach
pl
pn
bs
e
coli
kleb
spp
enterobact
proteu
spp
clostr
spp
pl
bs
even
pseudomona
bacteroid
conclus
given
combin
pip
taz
demonstr
reach
rapidli
effect
inhibitori
concentr
inflam
necrot
compart
pancreat
peripancreat
tissu
coadministr
piperacillin
tazobactam
may
potenti
clinic
benefit
prevent
treatment
local
infecti
complic
sever
necrot
pancreat
pkpd
challeng
vitro
timekil
curv
new
model
approach
schmidt
burkhardt
w
treyaprasert
h
derendorf
gainesvil
us
bangkok
th
object
vitro
pkpd
model
base
timekil
curv
data
becom
power
tool
predict
vivo
situat
date
sever
model
approach
undertaken
develop
suitabl
pkpd
model
fit
vitro
data
suffici
well
wide
use
simpl
sigmoid
emax
model
meet
criteria
partli
approach
undertaken
address
weak
point
current
use
model
appli
model
effect
ceftriaxon
escherichia
coli
method
constant
concentr
timekil
curv
perform
muellerhinton
broth
mhb
difco
without
bovin
serum
albumin
bsa
gl
use
concentr
ceftriaxon
rang
mic
mic
chang
number
bacteria
cfuml
versu
time
link
effect
escherichia
coli
atcc
employ
test
organ
sampl
taken
hour
data
model
simultan
use
modifi
sigmoid
emax
model
softwar
scientist
window
tm
result
differenti
equat
character
growth
rate
constant
time
start
number
n
bacteria
repres
simplest
case
barg
loggrowth
phase
stationari
phase
describ
addit
nmax
term
howev
bacteria
necessarili
start
grow
loggrowth
phase
delay
onset
growth
model
exponenti
term
character
factor
beta
b
time
describ
overal
chang
number
bacteria
growth
also
concentr
c
depend
kill
taken
account
certain
drug
specif
concentr
maximum
effect
reach
describ
maximum
kill
rate
constant
kmax
howev
may
necessari
model
delay
onset
kill
addit
exponenti
term
character
factor
alpha
time
final
hill
factorshap
factor
h
necessari
smooth
predict
curv
shown
figur
new
model
meet
vitro
timekil
curv
data
suffici
well
final
equat
includ
paramet
describ
conclus
propos
model
abl
describ
observ
data
much
better
simpl
emaxmodel
incorpor
two
addit
term
model
vitro
situat
could
describ
much
better
take
delay
onset
growth
kill
account
object
studi
describ
pharmacodynam
pd
profil
bpr
mg
iv
infus
mg
iv
infus
determin
overal
probabl
target
attain
pta
weight
expect
distribut
di
renal
function
rfx
popul
pop
interest
determin
organismspecif
pta
pathogen
encount
phase
ii
trial
method
subject
total
sampl
studi
phase
iii
subject
sampl
analys
use
bignpod
assess
impact
differ
degre
rfx
impair
pta
crcl
crclcockcroft
gault
method
employ
covari
pop
pk
analysi
mont
carlo
simul
mc
subject
perform
adapt
ii
overal
pta
calcul
ft
mic
weight
expect
di
rfx
pop
interest
accomplish
use
di
crcl
observ
previou
registr
studi
indic
cssti
np
di
mic
pathogen
suppli
sponsor
result
pop
pk
analysi
pop
mean
sd
valu
volum
clslope
clintercept
kcp
kpc
l
lhr
respect
obspr
plot
ob
x
pred
bayesian
step
mc
analysi
bpr
mg
iv
h
pta
achiev
ft
mic
ft
mic
exceed
mic
valu
mgl
mgl
respect
bpr
mg
iv
pta
achiev
ft
mic
exceed
mic
valu
mgl
organismspecif
analysi
pta
static
effect
ft
mic
exceed
mssa
mrsa
bpr
mg
iv
bpr
mg
iv
provid
pta
cidal
effect
ft
mic
mssa
mrsa
gnb
pta
bpr
mg
iv
achiev
cidal
effect
ft
mic
exceed
nonampcbear
gnb
ampcbear
gnb
pta
achiev
cidal
effect
conclus
extens
evalu
pd
bpr
perform
estim
overal
activ
bpr
target
pathogen
find
need
valid
clinic
trial
arena
investig
differ
levofloxacin
regimen
patient
acut
complic
urinari
tract
infect
p
tenk
r
benko
budapest
szege
hu
object
present
studi
aim
find
continu
intermitt
levofloxacin
mg
treatment
advantag
patient
acut
complic
urinari
tract
infect
uti
caus
urinari
obstruct
investig
levofloxacin
adsorb
surfac
foreign
bodi
insert
aim
temporari
resolut
ureter
obstruct
prevent
effect
levofloxacin
bacteri
biofilm
format
incrust
also
evalu
method
enrol
randomis
patient
acut
uti
caus
urinari
obstruct
obstruct
resolv
doubl
j
stent
dj
insert
percutan
nephrostomi
pcn
meanwhil
antibiot
treatment
start
patient
patient
group
antibiot
till
day
definit
cur
oper
foreign
bodi
remov
patient
group
antibiot
therapi
stop
day
dj
pcn
insert
short
term
antibiot
cours
advis
prevent
uti
invas
endoscop
treatmentwa
administ
group
day
oper
dj
pcn
remov
continu
remov
possibl
urinari
foreign
bodi
use
oper
group
patient
record
evalu
earli
late
clinic
microbiolog
recoveri
retriev
stent
section
laboratori
examin
adsorb
levofloxacin
condit
film
layer
stent
surfac
detect
hplc
rasterelectron
microscopi
rem
use
examin
biofilm
format
encrust
result
find
signific
differ
two
group
patient
neither
clinic
presenc
fever
back
pain
flank
pain
leukocyt
count
microbiolog
recoveri
statist
analysi
show
significantli
greater
amount
levofloxacin
adsorb
condit
film
stent
surfac
group
patient
vs
group
vs
group
viabl
adher
bacteria
recov
sonic
cultur
patient
biofilm
encrust
seen
rem
either
conclus
data
prove
hypothes
continu
antibiot
treatment
clinic
microbiolog
advantag
patient
indwel
ureter
stent
compar
intermitt
therapi
object
prophylaxi
bacteri
infect
cardiac
surgeri
wide
use
clinic
practic
staphylococcu
aureu
staphylococcu
epidermidi
enterococcu
spp
pathogen
frequent
involv
infect
complic
cardiopulmonari
bypass
cpb
surgeri
gener
agre
success
prophylaxi
depend
abil
reach
maintain
free
antibiot
concentr
tissu
higher
mic
common
pathogen
estim
tissu
concentr
linezolid
sternal
bone
patient
undergo
cpb
surgeri
method
six
patient
undergo
routin
cpb
surgeri
given
mg
linezolid
min
iv
infus
along
convent
prophylaxi
g
cefuroxim
immedi
surgeri
two
hour
end
infus
blood
sampl
sternal
bone
tissu
collect
local
medic
research
ethic
committe
approv
studi
patient
gave
written
inform
consent
sampl
assay
presenc
linezolid
highperform
liquid
chromatographi
hplc
method
result
follow
mg
infus
linezolid
mean
serum
concentr
six
patient
mgl
rang
mgl
hour
end
infus
concentr
linezolid
sternal
bone
mgl
rang
mg
l
hour
end
infus
penetr
linezolid
sternal
bone
conclus
penetr
linezolid
bone
simultan
blood
level
bone
sampl
concentr
linezolid
exceed
mic
suscept
pathogen
mgl
although
data
obtain
healthi
wellperfus
bone
valu
suggest
linezolid
may
use
agent
manag
multidrugresist
gramposit
bone
infect
antibacteri
effect
daptomycin
teicoplanin
vancomycin
aureu
studi
vitro
pharmacokinet
model
infect
noel
k
bowker
macgowan
bristol
uk
object
daptomycin
dap
first
cyclic
lipopeptid
antibiot
approv
parenter
use
gramposit
infect
yet
compar
pharmacodynam
studi
perform
use
dap
two
common
iv
therapi
teicoplanin
tei
vancomycin
van
use
pharmacokinet
pk
model
studi
antibacteri
effect
abe
agent
two
typic
mrsa
strain
hetero
vancomycin
intermedi
mrsa
hvisa
method
vitro
dilut
model
use
simul
free
drug
concentr
h
associ
dose
dap
mgkg
hrli
cmax
mgl
h
tei
mg
hrli
cmax
mgl
h
van
g
hrli
cmax
mgl
h
inoculum
cfuml
use
experi
perform
triplic
abe
assess
areaunderthebacterialkillcurv
h
logcfumlh
object
linezolid
first
oxazolidinon
activ
methicillin
resist
staphylococcu
aureu
effect
varieti
acut
infect
howev
longterm
administr
although
desir
bone
infect
caus
resist
gramposit
organ
hamper
occurr
anaemia
thrombocytopenia
administr
vitamin
report
prevent
myelosuppress
method
patient
attend
infecti
diseas
clinic
bone
infect
caus
resist
gramposit
bacteria
treat
linezolid
mg
bd
oral
receiv
vitamin
mg
od
oral
period
administr
linezolid
full
blood
count
followedup
weekli
linezolid
treatment
discontinu
haemoglobin
declin
mgdl
platelet
data
sixteen
patient
osteomyel
prosthet
joint
infect
evalu
comparison
perform
match
histor
control
receiv
linezolid
without
kaplanmey
curv
logrank
test
result
median
followup
patient
receiv
week
control
week
group
patient
discontinu
control
group
patient
discontinu
treatment
side
effect
p
ns
patient
receiv
discontinu
due
thrombocytopenia
due
anaemia
respect
percentag
control
group
p
ns
comparison
mean
time
occurr
thrombocytopenia
week
patient
receiv
week
control
patient
respect
time
occurr
anaemia
week
case
myelosuppress
revers
conclus
administr
fail
prevent
delay
thrombocytopenia
anaemia
patient
receiv
linezolid
method
investig
facilit
longer
administr
linezolid
group
patient
therapeut
drug
monitor
colistin
review
uk
clinic
antibiot
assay
servic
k
bowker
noel
tomaselli
macgowan
bristol
uk
object
last
year
increas
use
colistin
col
howev
littl
clinic
data
avail
therapeut
level
colistin
monitor
col
use
term
therapeut
level
avoid
toxic
patient
cystic
fibrosi
complic
gramneg
infect
previou
vitro
data
shown
col
bactericid
col
concentr
mgl
assess
col
data
collect
antibiot
assay
servic
last
seven
year
order
establish
level
obtain
method
col
level
determin
bioassay
data
retrospect
collect
hospit
inform
manag
system
data
assess
collect
stratifi
known
cystic
fibrosi
patient
sex
age
object
like
ceftriaxon
cfx
quinolon
moxifloxacin
mox
wide
use
treat
pneumococc
infect
studi
antibacteri
effect
abe
first
dose
exposur
free
drug
serum
concentr
iv
cfx
g
po
mox
mg
pneumonia
strain
typic
mic
low
high
inocula
method
hollow
fibr
vitro
model
use
simul
free
drug
concentr
h
cfx
g
h
iv
cmax
mgl
auc
mglaeh
h
mox
mg
mgl
mglaeh
h
cfx
mic
mgl
mic
cfx
mox
mic
mgl
auc
mic
initi
abe
measur
slope
log
viabl
count
h
total
abe
dose
interv
h
log
reduct
viabl
count
h
areaunderthebacterialkillcurv
inocula
cfuml
cfuml
use
result
initi
total
abe
low
high
inocula
given
pkpd
indic
model
drug
show
maxim
effect
clearanc
model
occur
h
inoculum
h
inoculum
signific
differ
speed
extent
abe
compar
cfx
mox
conclus
abe
iv
cfx
po
mox
pneumonia
similar
first
hr
drug
exposur
emerg
resist
e
coli
ent
cloaca
exposur
ceftriaxon
ertapenem
vitro
model
infect
k
bowker
noel
macgowan
bristol
uk
object
emerg
resist
eor
emerg
factor
therapeut
choic
studi
eor
ceftriaxon
cfx
ertapenem
ert
e
coli
ec
ent
cloaca
entclo
challeng
speci
within
induc
blactamas
method
vitro
dilut
model
use
simul
free
drug
concentr
associ
g
hrli
cfx
cmax
mgl
h
ert
cmax
mgl
h
h
two
inocula
cfuml
use
eor
assess
populationanalysisprofil
pap
area
pap
aucpap
use
measur
eor
ert
mic
mgl
ec
mgl
entclo
cfx
mic
mgl
ec
mgl
entclo
experi
perform
triplic
mean
valu
present
result
observ
h
similar
h
henc
data
h
given
cfuml
ec
viabl
count
reduc
fi
log
eor
entclo
inoculum
cfx
result
initi
log
drop
regrowth
ert
produc
log
reduct
eor
measur
mean
aucpap
n
entclo
shown
dose
cfx
result
eor
cfx
ert
high
low
inoculum
dose
ert
result
eor
inoculum
resist
emerg
cfx
ert
conclus
eor
depend
speci
entclo
ec
durat
exposur
long
short
agent
cfx
ert
ert
appear
induc
less
eor
cfx
cfx
ert
howev
initi
use
cfx
may
reduc
effect
ert
compar
serum
activ
telithromycin
azithromycin
amoxicillinclavulan
aerob
anaerob
respiratori
pathogen
object
purpos
investig
studi
clinic
potenti
telithromycin
new
ketolid
antibiot
treatment
mix
aerobicanaerob
respiratori
infect
studi
compar
pharmacodynam
durat
inhibitionkil
telithromycin
tel
azithromycin
azi
amoxicillinclavulan
ac
aerob
anaerob
pathogen
associ
mix
respiratori
infect
method
follow
written
inform
consent
ten
healthi
adult
subject
age
yr
receiv
singl
dose
tel
mg
azi
mg
ac
mg
one
week
apart
follow
fast
venou
blood
sampl
obtain
h
dose
store
inhibitori
bactericid
titr
determin
microdilut
pneumonia
h
influenza
agar
dilut
peptostrep
magnu
peptostrep
micro
prev
bivia
prev
melaninogenica
procedur
follow
clinic
laboratori
standard
institut
methodolog
bactericid
titr
serum
endpoint
determin
highest
dilut
serum
yield
kill
median
titr
time
point
calcul
durat
activ
use
comparison
agent
conclus
exvivo
studi
found
tel
provid
prolong
dose
interv
inhibitori
activ
serum
macrolideresist
strain
pneumonia
bl
po
neg
strain
h
influenza
common
respiratori
anaerob
pathogen
find
suggest
tel
could
clinic
util
treatment
communityacquir
mix
aerobicanaerob
respiratori
tract
infect
includ
sinus
bronchiti
pneumonia
object
increas
resist
isol
e
coli
p
aeruginosa
fluoroquinolon
fq
concern
sinc
antibiot
commonli
use
treatment
complic
urinari
tract
infect
uti
current
interpret
standard
exist
suscept
isol
urin
newer
fq
purpos
investig
evalu
activ
highdos
levofloxacin
fqresist
urinari
pathogen
method
studi
determin
serum
urin
level
high
dose
mg
levofloxacin
l
well
bactericid
activ
urin
uba
lresist
isol
e
coli
mic
lgml
p
aeruginosa
mic
lgml
follow
written
inform
consent
blood
urin
sampl
collect
healthi
adult
age
yo
fast
subject
f
prior
hour
singl
mg
dose
l
serum
urin
concentr
measur
valid
hplc
assay
cv
test
methodolog
uba
similar
microdilut
assay
use
serum
bactericid
test
clsi
except
antibioticfre
urin
use
dilut
sampl
median
titr
time
point
subject
use
determin
uba
result
mean
serum
pharmacokinet
paramet
similar
previous
publish
valu
cmax
lgml
auc
mgaehl
h
mean
urin
concentr
rang
lgml
h
lgml
h
uba
titr
maintain
least
hour
subject
e
coli
isol
mic
lg
ml
e
coli
strain
mic
lgml
subject
exhibit
uba
h
subject
exhibit
uba
h
similar
result
observ
p
aeruginosa
isol
conclus
result
exvivo
pharmacodynam
studi
healthi
volunt
found
mg
l
provid
prolong
least
half
dose
interv
uba
lresist
strain
e
coli
p
aeruginosa
lgml
suggest
separ
urinari
suscept
breakpoint
indic
urin
isol
treat
mg
dose
l
object
exposur
methicillinresist
aureu
mrsa
acid
ph
restor
suscept
betalactam
sabath
al
aac
macrophag
aureu
mainli
confin
within
phagolysosom
ph
acid
show
meropenem
mem
display
similar
intracellular
activ
mrsa
atcc
mssa
atcc
macrophag
present
studi
investig
intraphagocyt
activ
mem
cloxacillin
clx
mrsa
clinic
isol
includ
one
visa
strain
comparison
refer
mrsa
atcc
mssa
atcc
strain
method
mic
determin
mhb
plu
nacl
microdilut
method
meca
express
examin
neutral
acid
ph
semiquantit
rtpcr
rrna
housekeep
gene
intracellular
activ
assess
human
macrophag
expos
extracellular
concentr
equival
human
cmax
total
drug
mem
mgl
clx
mgl
examin
decreas
cellassoci
cfu
h
origin
postphagocytosi
inoculum
control
antibiot
approx
log
cfu
increas
result
tabl
show
mic
broth
neutral
acid
ph
intracellular
activ
strain
studi
atcc
meca
express
similar
bacteria
maintain
broth
ph
conclus
intracellular
environ
markedli
enhanc
activ
betalactam
mrsa
probabl
exposur
acid
ph
although
latter
affect
meca
express
compar
activ
dalbavancin
european
gramposit
isol
morrissey
c
dencer
jwt
dallow
j
childer
brook
j
cowan
london
uk
object
dalbavancin
dal
new
semisynthet
lipoglycopeptid
halflif
day
enabl
onceweekli
dose
studi
compar
activ
dal
agent
gramposit
isol
europ
method
isol
belgium
czech
republ
denmark
finland
franc
germani
hungari
itali
netherland
poland
spain
sweden
uk
includ
clsi
broth
microdilut
method
use
determin
mic
use
dri
microtitr
plate
follow
antimicrobi
agent
evalu
dal
vancomycin
van
teicoplanin
tei
daptomycin
dap
linezolid
lzd
dalfopristinquinupristin
syn
erythromycin
eri
levofloxacin
lev
tetracyclin
tet
result
select
data
shown
object
dalbavancin
dal
next
gener
lipoglycopeptid
antibiot
develop
treatment
complic
skin
skin
structur
infect
csssi
popul
pharmacokinet
pk
analysi
perform
estim
patient
paramet
determin
signific
covari
incorpor
pk
model
pharmacodynam
pd
paramet
simul
support
effect
weekli
dosag
method
pk
analysi
includ
dal
concentr
patient
across
clinic
trial
patient
receiv
mg
day
mg
day
possibl
covari
examin
includ
demographi
concomit
medic
includ
medic
consid
inhibitor
induc
substrat
cytochrom
enzym
pkpd
analysi
employ
mont
carlo
simul
timedepend
concentrationdepend
paramet
distribut
mic
obtain
directli
clinic
studi
also
simul
explor
effect
higher
mic
result
dal
pk
fit
model
interpati
variabl
ipv
paramet
typic
valu
ipv
cv
clearanc
cl
lh
influenc
bodi
surfac
area
bsa
creatinin
clearanc
clcr
volum
distribut
l
influenc
bsa
intercompartment
clearanc
peripher
volum
lh
l
respect
free
drug
concentr
simul
use
dal
protein
bind
weekli
regimen
free
dal
remain
mgl
major
patient
day
use
previous
describ
area
curv
auc
mic
target
staphylococcu
aureu
propos
mic
least
mgl
associ
greater
probabl
target
attain
conclus
dal
pk
predict
demonstr
low
ipv
bsa
clcr
sourc
variabl
describ
less
ipv
pd
simul
support
use
dalbavancin
weekli
regimen
object
methicillinresist
staphylococcu
joint
infect
due
periop
contamin
complic
arthroplasti
object
studi
assess
distribut
radioact
bone
relat
structur
use
quantit
autoradiographi
administr
dalbavancin
rabbit
method
new
zealand
white
male
rabbit
given
singl
intraven
iv
bolu
dose
mgkg
dalbavancin
n
control
vehicl
n
plasma
cerebrospin
fluid
csf
bone
bone
marrow
nucleu
pulposu
collect
h
postdos
necropsi
homogen
combust
analys
total
drugderiv
radioact
use
liquid
scintil
count
lsc
addit
left
hindlimb
rabbittim
point
flashfrozen
cryosect
quantit
autoradioluminographi
result
dalbavancinderiv
radioact
rapidli
wide
distribut
bone
bone
marrow
lesser
extent
csf
nucleu
pulposu
autoradioluminographi
data
indic
concentr
radioact
highest
bone
marrow
whole
blood
articul
cartilag
ligament
epiphys
plate
periostium
meniscu
h
postdos
dalbavancinderiv
radioact
measur
tissu
remain
rel
high
concentr
bone
marrow
lg
equivg
epiphys
plate
lg
equivg
periostium
lg
equivg
articular
cartilag
lg
equivg
homogen
bone
use
lsc
mean
concentr
hour
lg
equivg
conclus
dalbavancinderiv
radioact
rapidli
penetr
knee
joint
tissu
persist
rel
high
concentr
least
h
singl
iv
dose
rabbit
object
telavancin
tlv
bactericid
lipoglycopeptid
multipl
mechan
action
phase
trial
treatment
hospitalacquir
pneumonia
hap
focu
infect
due
methicillinresist
aureu
tlv
primarili
elimin
kidney
requir
dosag
adjust
renal
dysfunct
tlv
highli
protein
bound
healthi
subject
would
suggest
would
remov
dialysi
small
volum
distribut
lkg
mean
may
remov
cvvh
cvvh
wide
use
manag
critic
ill
patient
object
studi
determin
cvvh
telavancin
transmembran
clearanc
cl
commonli
use
hemofilt
polysulfon
convent
ultrafiltr
flow
rate
method
tlv
cl
assess
vitro
cvvh
model
use
citrat
anticoagul
bovin
blood
b
braun
diapact
machin
experi
run
use
gambro
polysulfon
freseniu
hemofilt
ultrafiltr
uf
flow
lhr
suffici
blood
flow
qb
mlmin
maintain
uf
rate
blood
sampl
collect
prefilt
line
uf
sampl
postfilt
uf
port
concentr
tlv
plasma
uf
sampl
assay
use
valid
lcmsm
method
tlv
cl
determin
use
follow
formula
cl
uf
flow
rate
tlv
uf
tlv
arteri
cl
differ
filter
type
compar
use
twotail
unpair
ttest
conclus
tlv
substanti
clear
cvvh
cl
increas
significantli
increas
uf
rate
cl
differ
hemofilt
type
cvvh
cl
higher
uf
flow
exce
total
cl
report
patient
normal
renal
function
tlv
like
requir
dose
adjust
patient
receiv
cvvh
object
telavancin
tlv
bactericid
lipoglycopeptid
multipl
mechan
action
phase
trial
treatment
hospitalacquir
pneumonia
hap
focu
infect
due
methicillinresist
aureu
tlv
primarili
elimin
kidney
requir
dosag
adjust
renal
dysfunct
tlv
highli
protein
bound
healthi
subject
would
suggest
would
remov
dialysi
small
volum
distribut
lkg
mean
may
remov
cvvhd
cvvhd
use
manag
critic
ill
patient
object
studi
determin
cvvhd
tlv
transmembran
clearanc
cl
commonli
use
hemodialyz
convent
cvvhd
dialys
flow
rate
method
tlv
cl
assess
vitro
cvvhd
model
use
citrat
anticoagul
bovin
blood
b
braun
diapact
machin
experi
run
time
use
gambro
polysulfon
freseniu
hemodialyz
dialys
flow
lhr
suffici
blood
flow
qb
mlmin
maintain
appropri
transmembran
pressur
blood
sampl
collect
prefilt
port
postfilt
port
v
spent
dialys
sampl
postfilt
port
plasma
tlv
concentr
arteri
venou
dialys
sampl
assay
use
valid
lcmsm
method
tlv
cl
determin
use
follow
formula
cl
flow
rate
tlv
tlv
arteri
tlv
venou
dialyt
cl
filter
type
compar
use
twotail
unpair
ttest
conclus
tlv
effect
clear
cvvhd
higher
permeabl
polysulfon
dialyz
associ
significantli
increas
cl
vs
dialyz
dialys
flow
increas
degre
tlv
cl
seen
cvvhd
suggest
dose
adjust
necessari
patient
receiv
cvvhd
object
still
subject
controversi
free
unbound
drug
respons
antibacteri
activ
antibiot
provid
proof
free
drug
contribut
antimicrobi
efficaci
compar
doserang
timekil
curv
studi
perform
exclud
influenc
factor
result
differ
mechan
action
done
within
antibiot
class
carbapenem
use
compound
differ
serum
protein
bind
method
constant
concentr
timekil
curv
perform
serum
slightli
serum
protein
bound
meropenem
imipenem
well
highli
serum
protein
bound
ertapenem
faropenem
rang
mic
mic
chang
number
bacteria
cfuml
versu
time
link
effect
escherichia
coli
atcc
klebsiella
pneumonia
bay
staphylococcu
aureu
bay
streptococcu
pneumonia
atcc
use
test
organ
sampl
taken
hour
data
model
simultan
use
softwar
scientist
window
tm
modifi
sigmoid
emax
model
character
growth
rate
constant
maximum
kill
rate
kmax
concentr
half
maximum
effect
result
four
bacteri
strain
investig
dramat
increas
highli
serum
protein
bound
carbapenem
ertapenem
faropenem
presenc
serum
protein
fig
substanc
signific
differ
kmax
determin
contrast
imipenem
meropenem
show
minor
differ
presenc
absenc
serum
conclus
free
unbound
drug
respons
antimicrobi
activ
analysi
timekil
curv
clearli
show
antibacteri
efficaci
significantli
decreas
presenc
serum
highli
bound
ertapenem
faropenem
unalt
slightli
bound
meropenem
imipenem
object
numer
vitro
experi
shown
protein
bind
pb
import
factor
antimicrobi
activ
especi
highli
bound
antibiot
howev
experiment
condit
simul
vivo
situat
best
still
subject
controversi
therefor
vitro
microdialysi
experi
perform
evalu
variou
influenc
factor
pb
highli
bound
betalactam
ceftriaxon
pb
method
compar
doserang
vitro
microdialysi
studi
conduct
determin
free
unbound
ceftriaxon
concentr
lactat
ringer
solut
todd
hewitt
broth
thb
without
bovin
serum
albumin
bsa
sigma
st
loui
gl
human
plasma
furthermor
vitro
constant
concentr
timekil
curv
perform
use
escherichia
coli
atcc
streptococcu
pneumonia
atcc
streptococcu
pneumonia
atcc
test
organ
data
analys
use
appropri
pkpd
model
character
growth
rate
constant
maximum
kill
rate
kmax
concentr
half
maximum
effect
correl
free
ceftriaxon
thb
concentr
determin
hplcuv
result
minor
differ
unbound
drug
concentr
antiinfect
activ
bsa
g
l
ad
either
lactat
ringer
pb
without
bsa
respect
thb
pb
without
bsa
respect
signific
chang
kmax
observ
howev
use
human
plasma
unbound
concentr
pb
alter
dramat
conclus
free
unbound
drug
respons
antimicrobi
activ
howev
one
reli
bind
commerci
purchas
bsa
consist
report
protein
bind
valu
unbound
concentr
measur
respect
experiment
condit
abl
correctli
interpret
experiment
result
vitro
postantibiot
effect
faropenem
penicillinresist
streptococcu
pneumonia
betalactamaseproduc
haemophilu
influenza
cl
young
ia
critchley
ua
ochsner
n
janjic
louisvil
us
object
faropenem
far
oral
penem
potent
activ
respiratori
pathogen
penicillin
pn
resist
streptococcu
pneumonia
sp
betalactamas
bla
produc
haemophilu
infleunza
hi
postantibiot
effect
pae
pharmacodynam
pd
paramet
monitor
suppress
bacteri
growth
follow
short
exposur
remov
drug
pae
clinic
import
agent
far
short
halfliv
h
aim
studi
determin
pae
far
resist
phenotyp
sp
hi
method
nine
clinic
isol
sp
pn
pni
pnr
six
clinic
isol
hi
blaneg
blaposit
test
pae
studi
pae
determin
cationadjust
muellerhinton
broth
lyse
hors
blood
sp
haemophilu
test
medium
hi
exponenti
cultur
cfuml
expos
far
x
mic
far
remov
serial
wash
dilut
prior
transfer
fresh
media
control
cultur
treat
way
bacteria
incub
shake
viabl
cfu
determin
h
count
cfu
plot
time
pae
defin
differ
time
requir
count
test
cultur
control
untreat
cultur
increas
count
observ
immedi
remov
result
signific
pae
h
observ
strain
sp
x
mic
howev
pae
prolong
pnr
strain
mean
pae
h
x
mic
among
hi
littl
pae
observ
blaneg
strain
signific
pae
observ
blaposit
isol
mean
pae
h
h
x
mic
respect
conclus
far
demonstr
prolong
pae
key
resist
phenotyp
sp
pnr
hi
blaposit
compar
suscept
strain
observ
pae
blaposit
hi
uniqu
class
betalactam
far
exhibit
vitro
pd
properti
may
contribut
clinic
efficaci
pnr
sp
blaposit
hi
telavancin
efficaci
vancomycin
murin
model
bacteraem
periton
induc
methicillinresist
staphylococcu
aureu
hegd
n
rey
b
benton
r
skinner
south
san
francisco
us
object
telavancin
tlv
novel
lipoglycopeptid
oper
multipl
mechan
produc
potent
rapid
bactericid
activ
clinic
relev
gramposit
bacteria
includ
methicillinresist
staphylococcu
aureu
mrsa
present
studi
evalu
vivo
efficaci
tlv
vs
vancomycin
van
model
mrsa
induc
periton
neutropen
mice
method
femal
nsa
immunocompromis
mice
inocul
intraperiton
atcc
mrsa
treat
begin
h
postinfect
subcutan
dose
q
vehicl
veh
test
compound
mous
pharmacokinet
data
gener
use
choos
dose
tlv
mgkg
van
mgkg
order
equat
clinic
exposur
auc
free
drug
lghrml
respect
surviv
studi
death
record
postinfect
surviv
curv
compar
use
logrank
test
bacteri
titer
determin
studi
design
group
control
drugtreat
surviv
anim
human
euthan
variou
time
posttreat
blood
spleen
harvest
determin
bacteri
titer
result
mic
tlv
van
lgml
respect
mortal
anim
treat
veh
van
mortal
tlvtreat
anim
p
vs
veh
van
pretreat
bacteri
titr
log
cfuml
log
cfug
blood
spleen
respect
analysi
time
kill
curv
blood
spleen
reveal
tlv
exhibit
significantli
greater
kill
activ
van
p
twoway
anova
hr
first
dose
titer
blood
reduc
greater
extent
tlv
log
cfuml
compar
van
log
cfuml
hr
second
dose
splenic
titer
reduc
greater
extent
tlv
log
cfug
compar
van
log
cfug
conclus
data
describ
demonstr
tlv
vivo
bactericid
activ
superior
van
mrsa
result
success
infect
resolut
consequ
improv
surviv
murin
periton
model
proper
use
carbapenem
bloodderiv
clinic
isol
pseudomona
aeruginosa
kobayashi
tokyo
jp
method
regimen
carbapenem
given
healthi
adult
subject
chang
blood
concentr
carbapenem
compar
use
pharmacokinet
paramet
twocompart
model
analysi
meropenem
mepm
imipenem
ipm
panipenem
papm
appli
lognorm
distribut
probabl
distribut
distribut
volum
plasma
halflif
mont
carlo
simul
mc
base
data
distribut
minim
inhibitori
concentr
mic
variou
carbapenem
bloodderiv
clinic
isol
pseudomona
aeruginosa
isolatedidentifi
keio
univers
hospit
octob
octob
mepm
mcgml
ipm
mcgml
papm
mcgml
mic
subject
obtain
mc
chang
blood
concentr
mic
subject
probabl
achiev
mic
calcul
carbapenem
regimen
use
formula
report
kuti
et
al
mic
ln
dosevd
mic
ln
natur
logarithm
dose
dose
mg
vd
distribut
volum
l
plasma
halflif
h
di
dose
interv
h
base
craig
data
maximum
bactericid
effect
gram
neg
bacilli
attain
mic
approxim
focus
inform
analys
data
result
probabl
achiev
mepm
mg
bid
follow
ipm
mg
bid
papm
mg
bid
dose
increas
mg
mg
mepm
mg
bid
follow
ipm
mg
bid
papm
mg
bid
dose
remain
mg
dose
frequenc
increas
three
time
daili
mepm
mg
tid
follow
ipm
mg
tid
papm
mg
tid
regard
mepm
mg
gid
mg
tid
show
higher
probabl
discuss
sever
sepsi
caus
pseudomona
aeruginosa
remark
higher
achiev
carbapenem
mg
tid
although
daili
dose
mg
lower
compar
mg
bid
carbapenem
low
mic
distribut
ie
superior
antibacteri
activ
show
higher
probabl
achiev
mic
therefor
optim
treatment
sepsi
mepm
mg
tid
mepm
mg
qid
appear
provid
compar
therapeut
effect
mg
tid
usual
dose
foreign
countri
penetr
moxifloxacin
normal
infect
subcutan
tissu
patient
spinal
cord
injuri
measur
microdialysi
background
skin
breakdown
also
term
decubitu
ulcer
pressur
sore
major
complic
associ
spinal
cord
injuri
result
infect
tissu
death
moxifloxacin
mfx
approv
treatment
sssi
object
construct
popul
pk
model
mfx
disposit
plasma
normal
infect
subcutan
tissu
spinal
cord
injur
patient
infect
decubitu
ulcer
method
patient
receiv
mg
mfx
oral
daili
enrol
studi
blood
saliva
interstiti
tissu
fluid
sampl
microdialysi
normal
infect
tissu
collect
time
period
hr
mfx
concentr
measur
valid
hplc
concentrationtim
data
obtain
present
studi
pool
previous
publish
mfx
data
n
popul
pk
model
perform
nonmem
result
concentr
mfx
achiev
plasma
saliva
normal
subcutan
tissu
infect
decubitu
ulcer
show
parallel
profil
versu
time
pk
best
describ
model
link
interstiti
tissu
fluid
popul
pk
paramet
follow
given
estim
percent
interindividu
variabl
parenthes
cl
lh
central
vd
l
intercompartment
cl
lh
peripher
vd
l
elimin
rate
constant
interstiti
tissu
fluid
h
conserv
mgl
peakmic
ratio
higher
ratio
higher
plasma
saliva
interstiti
tissu
fluid
conclus
studi
show
good
diffus
mfx
subcutan
tissu
spinal
cord
injur
patient
decubitu
ulcer
interstiti
tissu
fluid
reach
bactericid
level
common
bacteria
found
infect
skin
lesion
object
investig
pharmacodynam
paramet
postantibiot
effect
postantibiot
subminimum
inhibitori
concentr
effect
employ
design
dose
schedul
antimicrobi
agent
studi
compar
postantibiot
effect
postantibiot
subminimum
inhibitori
concentr
effect
ciprofloxacin
levofloxacin
moxifloxacin
clinic
isol
methicillin
suscept
staphylococcu
aureu
methicillin
resist
staphylococcu
aureu
pseudomona
aureginosa
method
follow
strain
test
studi
methicillinesuscept
staphylococcu
aureu
methicillin
resist
staphylococcu
aureu
pseudomona
aeruginosa
pae
determin
viabl
plate
count
method
use
mueller
hinton
broth
tube
contain
ml
broth
antibiot
test
mic
inocul
approxim
cfuml
growth
control
inoculum
antibiot
includ
experi
result
postantibiot
effect
ciprofloxacin
levofloxacin
moxifloxacin
increas
increas
concentr
drug
longest
postantibiot
effect
observ
moxifloxacin
moxifloxacin
show
postantibiot
effect
one
p
aureginosa
concentr
post
antibiot
effect
anoth
p
aureginosa
mic
studi
longest
postantibiot
subminimum
inhibitori
concentr
effect
mssa
determin
moxifloxacin
similarli
moxifloxacin
induc
longest
effect
mrsa
howev
time
frame
shorter
mssa
conclus
three
antibiot
show
longer
postantibiot
subminimum
inhibitori
concentr
effect
submic
concentr
immeasur
within
studi
period
ie
hour
lack
horizont
transmiss
fluoroquinolon
resist
miti
pneumonia
object
fluoroquinolon
fq
resist
aris
pneumonia
acquisit
dna
miti
subsequ
homolog
recombin
frequenc
occur
unknown
like
rare
event
increas
fq
resist
among
miti
may
increas
rate
horizont
transmiss
occur
sought
determin
frequenc
fq
resist
could
transfer
miti
pneumonia
pneumonia
miti
method
miti
either
fqr
tetracyclin
tet
fqr
penicillin
pen
fq
penr
pneumonia
either
fq
tetr
fq
penr
fqr
pen
grown
cocultur
use
pharmacodynam
model
presenc
either
moxifloxacin
mxf
levofloxacin
lfx
salivari
drug
concentr
incub
aliquot
plate
onto
either
tet
pen
contain
sba
plate
select
recipi
strain
fq
suscept
perform
use
microbroth
dilut
entir
parc
gyra
gene
amplifi
sequenc
determin
horizont
transmiss
occur
result
initi
experi
tet
use
select
agent
howev
tet
resist
transfer
therefor
penr
use
select
marker
increas
lfx
mic
observ
pneumonia
miti
strain
sequenc
parc
gene
reveal
select
mutat
pneumonia
miti
consist
fq
resist
sequenc
entir
gene
fail
uncov
evid
horizont
transmiss
mutat
detect
gyra
select
step
parc
clinic
microbiolog
infect
volum
supplement
mutat
occur
exposur
lfx
mxf
erad
miti
pneumonia
fail
either
select
resist
support
horizont
transmiss
conclus
although
step
parc
mutat
select
strain
pneumonia
miti
fail
find
evid
horizont
transmiss
pneumonia
miti
laboratori
condit
phenomenon
horizont
transfer
result
fq
resist
describ
howev
base
result
must
specul
extrem
rare
event
like
major
driver
fq
resist
interest
parc
mutat
select
select
pressur
lfx
mxf
complet
erad
pneumonia
miti
select
develop
fqr
mutat
object
aim
present
studi
assess
kill
activ
ertapenem
ert
metronidazol
mtr
four
select
bacteroid
fragili
strain
differ
mic
valu
vitro
pharmacokineticpharmacodynam
pkpd
model
sinc
anaerob
often
present
mix
infect
kill
kinet
also
establish
mix
inocula
employ
b
fragili
strain
togeth
four
select
escherichia
coli
strain
kill
activ
analys
kinet
concentr
antimicrobi
agent
simul
human
serum
kinet
method
pkpd
vitro
model
establish
ad
appropri
amount
broth
everi
half
hour
time
interv
sampl
obtain
plate
incub
coloni
form
unit
count
human
serum
concentr
simul
cmax
mgl
hour
ert
cmax
mgl
hour
mtr
mann
trend
test
use
statist
analysi
result
expect
e
coli
strain
kill
mtr
pure
well
mix
cultur
wherea
suscept
e
coli
strain
effect
kill
ert
pure
cultur
b
fragili
strain
effect
kill
mtr
growth
suscept
b
fragili
strain
reduc
ert
two
four
log
howev
mix
cultur
kill
activ
mtr
b
fragili
strain
significantli
reduc
conclus
part
moder
vitro
activ
ert
b
fragili
strain
reduc
activ
metronidazol
mix
cultur
b
fragili
strain
may
explain
difficulti
treat
mix
aerob
anaerob
infect
penetr
ciprofloxacin
human
cerebrospin
fluid
brain
tissu
tsona
metallidi
e
koumentaki
j
nikolaidi
p
kollara
g
lazaraki
p
nikolaidi
thessaloniki
gr
object
aim
present
studi
determin
penetr
ciprofloxacin
cerebrospin
fluid
csf
brain
tissu
human
method
total
patient
undergo
brain
tumor
excis
evalu
patient
receiv
singl
intraven
dose
mg
ciprofloxacin
sampl
blood
cerebrospin
fluid
brain
brainadjac
tumour
tissu
collect
surgeri
h
drug
administr
ciprofloxacin
concentr
serum
cerebrospin
fluid
brain
homogen
analys
mean
valid
hplc
method
result
ciprofloxacin
concentr
plasma
mcgml
cerebrospin
fluid
mcgml
tissu
homogen
mcgg
respect
h
rang
mcgml
mcg
ml
mcgg
csftoserum
ratio
rang
tissuetoserum
ratio
rang
mean
csfserum
concentr
ratio
brain
tissueserum
concentr
ratio
respect
conclus
find
suggest
valuabl
inform
brain
tissu
penetr
obtain
brain
materi
data
csf
penetr
extrapol
brain
sinc
blood
sf
barrier
differ
blood
brain
barrier
concentr
ciprofloxacin
cerebrospin
fluid
lower
serum
contrast
brain
tissu
concentr
exceed
serum
concentr
achiev
concentr
brain
tissu
gener
common
pathogen
central
nervou
system
infect
h
influenz
n
meningitidi
pneumonia
l
monocytogen
escherichia
coli
aerob
gramneg
bacilli
group
b
streptococci
mssa
cerebrospin
fluid
concentr
exceed
mic
neisseria
meningitidi
gramneg
aerob
bacilli
find
suggest
ciprofloxacin
may
accept
altern
treatment
mening
due
suscept
gramneg
aerob
organ
treatment
brain
abscess
object
model
perform
imipenem
imi
meropenem
mem
ertapenem
etm
esbl
produc
e
coli
klebsiella
spp
order
identifi
possibl
pd
differ
among
compound
method
minim
inhibitori
concentr
mic
gener
randomli
select
esbl
produc
isol
ec
n
kl
n
collect
brazilian
hospit
part
mystic
program
mic
test
imi
mem
etm
ceftazidim
ctz
cefotaxim
ctx
done
etest
methodolog
esbl
confirm
via
ctzclavulan
ctxclavulan
etest
pd
exposur
measur
percent
time
mic
free
drug
ft
mic
model
via
subject
mont
carlo
simul
follow
infus
imi
gram
everi
hour
mem
gram
everi
hour
etm
gram
everi
hour
use
pharmacokinet
healthi
volunt
bactericid
cumul
fraction
respons
cfr
calcul
regimen
popul
ec
kl
esbl
isol
togeth
bactericid
cfr
defin
ft
mic
agent
result
report
cfr
confid
interv
result
isol
suscept
imi
mem
mic
rang
mgl
respect
etm
mic
rang
mgl
conclus
find
support
data
although
etm
like
effect
empir
agent
esbl
produc
ec
kl
abil
achiev
high
bactericid
pd
exposur
depend
presenc
less
suscept
organ
popul
imi
mem
remain
first
line
esbl
infect
object
studi
analys
erad
resist
select
streptococcu
pneumonia
moxifloxacin
levofloxacin
azithromycin
use
parent
serotyp
infect
strain
subsequ
resist
stepmut
isol
b
c
select
vivo
patient
pneumonia
method
moxifloxacin
levofloxacin
azithromycin
mic
lgml
parent
strain
lg
ml
isol
b
lgml
isol
c
respect
pharmacokinet
computer
devic
use
simul
serum
epitheli
line
fluid
elf
concentr
initi
inocula
approx
cfuml
popul
analysi
profil
perform
use
plate
increas
antimicrobi
concentr
mic
basi
result
serum
moxifloxacin
erad
parent
isol
isol
hmic
valu
serum
hmic
valu
levofloxacin
azithromycin
respect
abl
erad
isol
elf
moxifloxacin
show
bactericid
pattern
isol
minor
approx
cfuml
surviv
popul
isol
b
c
grow
plate
moxifloxacin
concentr
higher
obtain
elf
levofloxacin
azithromycin
show
bactericid
pattern
isol
whole
popul
isol
b
c
grow
plate
levofloxacin
concentr
higher
lgml
obtain
elf
plate
azithromycin
concentr
high
lgml
isol
c
elf
moxifloxacin
hmic
valu
isol
isol
b
c
levofloxacin
hmic
valu
isol
isol
b
c
azithromycin
hmic
valu
isol
isol
b
isol
c
conclus
prevent
resist
depend
erad
possibl
emerg
mutant
pulmonari
tissu
parent
suscept
strain
moxifloxacin
concentr
elf
may
provid
advantag
previou
quinolon
macrolid
prevent
clinic
failur
object
explor
antimicrobi
pressur
influenc
evolut
streptococcu
pneumonia
popul
share
ecolog
nich
method
vitro
computer
pharmacodynam
model
simul
physiolog
concentr
obtain
h
mg
od
levofloxacin
mg
bid
ciprofloxacin
mg
od
azithromycin
use
investig
effect
mix
cultur
five
pneumonia
serotyp
approach
ecolog
popul
dynam
resist
pattern
suscept
studi
drug
lowlevel
macrolideresist
efflux
phenotyp
highlevel
macrolideresist
erm
genotyp
lowlevel
quinoloneresist
highlevel
quinoloneresist
initi
mix
inocula
time
includ
similar
percentag
serotyp
result
mean
coloni
count
antibioticfre
plate
whole
pneumococc
popul
increas
h
drugfre
simul
control
levofloxacin
simul
ciprofloxacin
simul
azithromycin
simul
h
control
drugfre
experi
domin
strain
margin
popul
azithromycin
select
much
higher
extent
strain
lowlevel
resist
macrolid
strain
highlevel
resist
account
vs
total
popul
h
ciprofloxacin
select
higher
extent
lowlevel
highlevel
quinolon
resist
vs
levofloxacin
decreas
proport
predomin
control
intermediateresist
strain
mic
lgml
unmask
highlevel
resist
strain
mic
lgml
conclus
strain
distribut
antibioticfre
environ
depend
bacteri
fit
monoand
multistrain
nich
select
pressur
antimicrobi
regimen
erad
popul
unmask
minor
popul
thu
redistribut
whole
popul
select
potenti
resist
phenotyp
low
preval
highlevel
quinolon
resist
commun
prefer
select
preval
resist
phenotyp
reevalu
role
broadspectrum
cephalosporin
staphylococci
appli
contemporari
vitro
result
pharmacokineticpharmacodynam
princip
h
sader
sm
bhavnani
pg
ambros
r
jone
north
liberti
us
object
reevalu
current
vitro
activ
assess
pkpd
target
attain
cefepim
cpm
ceftriaxon
cro
ceftazidim
caz
staphylococcu
spp
method
potenc
cpm
cro
caz
staphylococci
access
sentri
antimicrobi
surveil
program
databas
worldwid
period
aureu
sa
oxacillin
oxa
suscept
coagulaseneg
staphylococci
con
oxa
test
cpm
cro
caz
numer
compar
clsi
broth
microdilut
method
use
volunt
pk
data
linear
intermitt
intraven
infus
model
animalderiv
pkpd
target
time
mic
expect
probabl
target
attain
pta
cephem
evalu
use
mont
carlo
simul
pta
determin
follow
dose
regimen
cpm
hour
caz
gm
hour
cro
gm
hour
repres
common
dose
pattern
appli
clinic
cephem
suscept
calcul
base
current
clsi
breakpoint
bkp
also
bkp
deriv
pta
result
oxa
sa
valu
mgl
cpm
cro
caz
respect
oxa
con
valu
mgl
cpm
cro
caz
respect
calcul
cephem
summar
tabl
twenti
yearold
clsi
bkp
would
rank
test
agent
cpm
cro
caz
pkpd
pta
cpm
caz
cro
cpm
potenc
advantag
caz
superior
usual
dose
cro
oxa
staphylococci
caz
pk
overcom
byweight
activ
disadvantag
low
proport
activ
freedrug
penal
cro
pta
calcul
pta
remain
bkp
mgl
cpm
gm
caz
bkp
mgl
cro
conclus
regardless
appli
bkp
clsi
pkpd
cpm
widest
potent
antistaphylococc
activ
among
commonli
use
thirdor
fourthgener
cephem
use
dose
gmday
cpm
assur
maxim
coverag
oxa
staphylococci
whether
use
exist
clsi
modifi
pkpd
bkp
cro
use
caution
method
mic
strain
determin
serial
twofold
macrodilut
vitro
kinet
model
use
investig
antibacteri
efficaci
constant
drug
concentr
hour
select
dose
azithromycin
test
bacteri
strain
base
mic
valu
bacteri
count
determin
appropri
agar
plate
use
adapt
dropplat
method
twelv
differ
pkpd
model
fit
compar
timekil
data
use
nonlinear
regress
result
simpl
pkpd
model
suffici
describ
pharmacodynam
effect
four
bacteri
strain
appropri
model
gave
good
curv
fit
includ
satur
term
number
bacteria
nmax
delay
term
initi
bacteri
growth
phase
andor
onset
antiinfect
activ
well
hill
factor
h
captur
steep
concentrationrespons
relationship
azithromycin
high
potenc
pneumonia
strain
catarrhali
potenc
azithromycin
h
influenza
poor
conclus
develop
pkpd
model
suitabl
describ
pharmacodynam
azithromycin
applic
pkpd
model
eventu
provid
tool
ration
antibiot
dose
decis
object
optim
antimicrobi
dosag
regimen
aim
achiev
success
clinic
outcom
without
drug
toxic
emerg
bacteri
resist
concentr
depend
antibiot
fluoroquinolon
human
cmax
mic
ratio
consid
import
efficaci
reduc
select
resist
prolong
antibiot
concentr
mic
fluoroquinolon
resist
zoonot
bacteria
matter
public
health
concern
fluoroquinolon
treatment
poultri
rapidli
select
bacteria
reduc
fluoroquinolon
suscept
studi
compar
basic
pharmacokinet
paramet
recommend
dose
baytril
enrofloxacin
oral
solut
poultri
dose
bird
dose
continu
water
standard
compar
puls
water
treatment
dose
gavagemethod
puls
versu
continu
water
treatment
group
chicken
receiv
baytril
oral
solut
recommend
ppm
continu
water
recommend
mgkg
puls
water
group
three
bird
kill
hour
start
antibiot
treatment
caecal
content
liver
lung
sera
taken
concentr
fluoroquinolon
determin
fluoresc
hplc
gavag
treatment
dose
mgkg
crop
intub
four
bird
kill
group
hour
gavag
caecal
content
liver
sera
taken
analys
basic
pharmacokinet
paramet
determin
use
pk
solut
softwar
result
mean
fluoroquinolon
cmax
caecal
content
sera
gavag
puls
water
continu
water
treatment
respect
mgml
recommend
dose
mgml
recommend
dose
cmax
antibiot
liver
lung
increas
modifi
regimen
similar
proport
puls
water
gavag
treatment
result
higher
cmax
valu
also
faster
rate
fluoroquinolon
clearanc
continu
water
treatment
figur
dose
gavag
practic
thousand
chicken
howev
puls
dose
recommend
dose
increas
cmax
valu
fourfold
could
improv
efficaci
reduc
select
resist
compar
current
recommend
treatment
regim
object
nephrotox
major
concern
aris
use
intraven
colistimeth
sodium
method
prospect
cohort
studi
perform
henri
dunant
hospit
tertiari
care
center
athen
greec
patient
receiv
intraven
colistin
least
day
treatment
multidrug
resist
gramneg
bacteri
infect
includ
studi
develop
nephrotox
evalu
serum
creatinin
blood
urea
serum
electrolyt
urinalysi
creatinin
sodium
urin
collect
intraven
colistin
therapi
primari
end
point
studi
result
twentysix
patient
includ
studi
receiv
colistimeth
sodium
cm
least
day
evalu
mean
sd
median
daili
dose
cumul
dose
durat
treatment
intraven
cm
million
iu
million
iu
day
rang
day
respect
three
evalu
patient
develop
nephrotox
intraven
treatment
cm
cumul
dose
administ
cm
statist
correl
differ
end
start
cm
treatment
valu
serum
creatinin
r
p
spearman
test
statist
clinic
signific
decreas
mean
baselin
serum
sodium
concentr
observ
start
end
treatment
mean
mmoll
p
toxic
event
note
intraven
administr
colistimeth
sodium
conclus
although
evalu
small
number
patient
prospect
studi
show
nephrotox
commonli
observ
group
patient
receiv
intraven
colistimeth
sodium
howev
caution
taken
avoid
prolong
administr
antibiot
object
object
present
work
quantit
structureact
relationship
qsar
analysi
antimicrobi
activ
deriv
consequ
comput
design
new
antimicrobi
method
achiev
formul
object
qsar
investig
carri
use
comput
chemistri
approach
base
simplex
represent
molecular
structur
sirm
framework
sirm
possibl
develop
molecular
design
new
effect
antimicrobi
result
systemat
research
relationship
antimicrobi
activ
staphylococcu
aureu
methicillinsensit
mssa
strain
pseudomona
aeruginosa
r
strain
klebsiella
pneumonia
candida
albican
itrobact
freundii
structur
one
hundr
fifti
compound
deriv
analog
elucid
structureact
relat
allow
predict
biolog
properti
compound
execut
direct
synthesi
receiv
indispens
inform
research
mechan
biolog
effect
complet
adequ
statist
partial
least
squar
model
obtain
studi
cultur
base
first
one
molecular
fragment
promot
interf
given
antimicrobi
activ
determin
give
possibl
realiz
comput
high
throughput
screen
molecular
design
activ
compound
result
prognosi
verifi
experiment
investig
also
influenc
heterocycl
system
evolut
antimicrobi
activ
reveal
conclus
qsar
analysi
antimicrobi
activ
deriv
allow
us
discov
presenc
naphthalenesubstitut
fragment
independ
locat
molecul
distinctli
neg
influenc
antimicrobi
action
requir
molecular
design
formul
exampl
high
activ
compound
must
includ
fragment
comput
design
new
antimicrobi
base
substitut
crown
ether
activ
row
substitut
crown
ether
consequ
molecular
design
new
antimicrobi
method
wellknown
hierarch
system
qsar
model
base
simplex
represent
molecular
structur
use
solut
formul
problem
within
framework
one
possibl
develop
molecular
design
new
effect
antimicrobi
agent
result
tri
conduct
systemat
research
relationship
antimicrobi
activ
planococcu
citreu
streptococcu
lacti
micrococcu
lysodeikti
staphylococcu
aureu
streptococcu
faecali
bacillu
subtillum
two
hundr
fifti
crown
ether
includ
aromat
cyclic
heterocycl
etc
fragment
structur
molecul
particular
macro
cycl
size
dentaci
lipophili
natur
substitu
factor
elucid
similar
relat
allow
predict
biolog
properti
crown
compound
execut
direct
synthesi
receiv
indispens
inform
research
mechan
biolog
effect
kind
compound
complet
adequ
qsar
model
obtain
use
partial
least
squar
method
studi
cultur
base
first
one
molecular
fragment
posit
neg
influenc
explor
properti
determin
give
possibl
realiz
virtual
screen
molecular
design
compound
high
level
target
activ
result
prognosi
verifi
experiment
investig
conclus
qsar
analysi
antimicrobi
activ
crown
ether
allow
us
suppos
presenc
two
differ
mechan
antimicrobi
action
discov
presenc
diphenyloxid
tertbutyl
fragment
promot
diphenylsulphid
diaminobiphenyl
prevent
antimicrobi
action
shown
hexadenth
crown
ether
contain
aromat
fragment
tertbutyl
group
perspect
antimicrobi
object
methionyl
trna
synthetas
mr
catalys
coval
attach
methionin
cognat
trna
synthet
inhibitor
mr
potent
antibacteri
activ
staphylococcu
aureu
includ
clinicallyrelev
resist
strain
equal
lgml
determin
biochem
potenc
mechan
action
relat
compound
respect
aureu
mr
enzymat
activ
also
evalu
enzym
kinet
properti
mutat
form
aureu
mr
method
met
gene
aureu
express
e
coli
mr
purifi
near
homogen
ammonium
sulfat
fraction
anion
exchang
chromatographi
aminoacyl
trnamet
measur
use
scintil
proxim
assay
spa
kinet
atp
ppi
exchang
determin
use
thin
layer
chromatographi
tlc
mutant
aureu
mr
select
serial
passag
spontan
resist
presenc
result
exhibit
strong
inhibit
aureu
mr
aminoacyl
reaction
limit
enzym
concentr
order
estim
true
inhibit
constant
ki
util
atp
ppi
exchang
assay
show
potent
inhibit
aureu
mr
ki
pm
relat
inhibitor
analys
correl
observ
ki
mr
mic
aureu
found
competit
methionin
bind
uncompetit
atp
bind
ie
increas
atp
concentr
result
tighter
bind
major
analog
exhibit
compar
mechan
action
alter
mechan
action
observ
subset
analog
mutat
aureu
mr
variant
deriv
strain
elev
mic
show
substanti
weaker
bind
mutat
enzym
exhibit
impair
trna
aminoacyl
activ
defect
rang
reduc
turnov
rate
weaker
affin
one
substrat
conclus
potent
inhibitor
aureu
mr
enzymat
potenc
class
inhibitor
correl
microbiolog
potenc
mutat
confer
resist
result
function
impair
mr
encompass
wide
varieti
enzymat
phenotyp
report
antibacteri
antifung
activ
newli
synthes
physicochem
characteris
thioureid
benzoic
acid
new
compound
prepar
three
stage
firstli
benzoic
acid
prepar
treat
phtalid
pchlorophenol
potassium
salt
xylen
second
stage
synthesi
benzoyl
chlorid
treat
correspond
acid
thionyl
chlorid
use
anhydr
solvent
follow
third
stage
treatment
abovement
chlorid
ammonium
thiocyan
benzoyl
isothiocyan
result
reflux
reaction
mixtur
dri
aceton
new
compound
prepar
reflux
isothiocyan
primari
aromat
amin
dri
aceton
obtain
compound
character
physic
properti
chemic
structur
confirm
use
spectral
analysi
aim
studi
also
evalu
vitro
antimicrobi
activ
new
compound
vitro
antimicrobi
test
perform
binari
microdilut
method
multiwel
plate
order
establish
minim
inhibitori
concentr
mic
gramposit
listeria
l
monocytogen
staphylococcu
aureu
bacillu
b
subtili
gramneg
psedomona
p
aeruginosa
escherichia
e
coli
salmonella
enteritidi
well
candida
sp
use
refer
clinic
multidrug
resist
strain
result
show
test
compound
exhibit
specif
antimicrobi
activ
depend
natur
substitu
posit
benzen
ring
concern
microbi
spectrum
mic
valu
mic
valu
wide
rang
mcgml
mcgml
activ
prove
n
benzoyl
n
thiourea
n
benzoyl
n
thiourea
show
larg
spectrum
antimicrobi
activ
enterobacteri
strain
e
coli
enteritidi
l
monocytogen
aureu
candida
sp
test
compound
highli
activ
aureu
mic
mcgml
four
test
compound
exhibit
antifung
activ
mic
mcgml
p
aeruginosa
well
b
subtili
resist
test
compound
vitro
antimicrobi
activ
novel
dianthraquinon
produc
marin
streptomyc
sp
clinic
staphylococcu
aureu
enterococcu
faecium
isol
kl
laplant
k
lor
socha
dc
rowley
provid
north
kingston
us
object
escal
antibiot
resist
among
gramposit
pathogen
present
increas
treatment
challeng
requir
develop
new
therapeut
agent
recent
discov
new
class
dianthraquinon
antibiot
produc
marin
streptomycet
inhibitori
bactericid
activ
four
dianthraquinon
secondari
metabolit
four
semisynthet
deriv
measur
clinic
strain
vancomycin
resist
e
faecium
vre
methicillin
suscept
methicillin
resist
aureu
mssa
mrsa
respect
two
compound
test
expand
panel
pathogen
method
thirtytwo
clinic
strain
vre
n
mssa
n
mrsa
n
obtain
patient
veteran
affair
medic
center
provid
ri
mic
perform
use
methodolog
describ
clsi
control
isol
bactericid
activ
antimicrobi
agent
evalu
timekil
experi
use
randomli
select
mssa
n
mrsa
n
vre
n
isol
test
time
respect
mic
conclus
potent
activ
unusu
structur
dianthraquinon
test
suggest
may
provid
new
molecular
scaffold
develop
novel
antimicrobi
agent
biolog
test
warrant
fulli
explor
clinic
potenti
antibiot
efficaci
novel
antimicrobi
peptid
plectasin
staphylococci
object
purpos
investig
investig
vitro
efficaci
kill
kinet
plectasin
staphylococcu
aureu
plectasin
newli
discov
defensintyp
antimicrobi
peptid
found
fungu
pseudoplectania
nigrella
show
activ
sever
gramposit
bacteria
includ
drug
resist
strain
mygind
ph
et
al
plectasin
peptid
antibiot
therapeut
potenti
saprophyt
fungu
natur
method
experi
determin
accord
clsi
nccl
guidelin
bactericid
activ
character
time
kill
experi
time
mic
staphylococcu
aureu
aureu
use
test
organ
vancomycin
use
comparison
kill
kinet
post
antibiot
effect
pae
evalu
cfu
determin
inoculum
size
rang
cell
use
test
inoculum
effect
cell
employ
determin
mutant
prevent
concentr
mpc
frequenc
spontan
resist
result
plectasin
bactericid
evidenc
kill
kinet
show
log
reduct
cfuml
hour
incub
reduct
log
cfuml
hour
superior
compar
activ
vancomycin
inoculum
effect
observ
employ
rang
cell
observ
pae
durat
hour
minut
spontan
resist
mutat
observ
among
cell
staphylococci
mpc
determin
time
mic
conclus
plectasin
novel
antimicrobi
peptid
show
potent
antimicrobi
activ
gramposit
bacteria
includ
drugresist
organ
potent
excel
bactericid
activ
vitro
lack
crossresist
clinic
use
antibiot
low
spontan
resist
mutat
frequenc
good
pae
properti
suggest
plectasin
may
potenti
therapeut
agent
staphylococci
vitro
antimicrobi
activ
novel
polymer
guanidin
akacid
plu
c
kratzer
tobud
w
graning
buxbaum
georgopoulo
vienna
object
cation
antimicrobi
wide
use
disinfect
within
clinic
set
present
studi
bactericid
fungicid
activ
akacid
plu
novel
polymer
compound
cation
famili
disinfect
evalu
qualiti
control
strain
staphylococcu
aureu
enterococcu
hira
escherichia
coli
pseudomona
aeruginosa
candida
albican
aspergillu
niger
comparison
chlorhexidin
diglucon
method
vitro
activ
akacid
plu
chlorhexidin
determin
quantit
suspens
test
accord
european
committe
standard
concentr
bacteri
strain
c
albican
concentr
niger
exposur
min
presenc
absenc
bovin
albumin
dilut
distil
hard
water
result
basic
quantit
suspens
test
akacid
plu
destroy
bacteri
pathogen
concentr
min
contact
time
chlorhexidin
also
highli
activ
aureu
e
coli
p
aeruginosa
fail
elimin
e
hira
within
min
high
organ
burden
bactericid
activ
disinfect
slightli
reduc
akacid
plu
show
fungicid
activ
c
albican
within
min
elimin
niger
concentr
min
contact
time
chlorhexidin
fungicid
c
albican
achiev
biocid
activ
niger
conclus
novel
polymer
guanidin
akacid
plu
compar
chlorhexidin
diglucon
show
similar
bactericid
activ
aureu
e
coli
p
aeruginosa
superior
biocid
activ
e
hira
niger
investig
emerg
bacteri
resist
novel
antibacteri
photodynam
agent
novel
light
activ
antibacteri
agent
activ
gramposit
bacteria
greater
potenc
antibiot
emerg
resist
investig
method
mgl
ad
cellsml
mrsa
minut
incub
dark
unbound
remov
cultur
illumin
jcm
light
nm
cfu
analysi
undertaken
determin
number
viabl
cell
remain
surviv
clone
treatment
cultur
subject
treatment
cycl
undertaken
determin
whether
number
surviv
cell
increas
suggest
resist
build
result
surviv
methicillinresist
staphylococcu
aureu
mrsa
atcc
express
log
n
cfu
untreat
treat
suspens
respect
result
demonstr
detect
resist
build
activ
seen
success
treatment
low
propens
emerg
resist
valuabl
attribut
new
antibacteri
agent
might
effect
employ
clinic
set
prophylact
use
decolonis
skin
nare
therapeut
use
treat
infect
woundsulc
object
xf
drug
novel
light
activ
antibacteri
agent
activ
gramposit
bacteria
superior
potenc
antibiot
possess
low
propens
induc
resist
bacteri
strain
emerg
novel
exvivo
porcin
skin
model
develop
test
antibacteri
activ
surfac
skin
method
cell
methicillinresist
staphylococcu
aureu
mrsa
inocul
onto
cm
area
exvivo
porcin
skin
sampl
immobilis
agar
dri
solut
appli
minut
sampl
illumin
minut
blue
light
nm
variou
total
light
dose
use
lumacar
tm
lamp
cfu
analysi
undertaken
determin
number
viabl
cell
remain
treatment
control
drug
alon
light
alon
includ
result
use
mgl
cfu
analysi
demonstr
total
light
dose
jcm
kill
bacteria
jcm
kill
bacteria
jcm
jcm
total
light
dose
j
cm
found
kill
concentr
mgl
concentr
mgl
kill
kill
significantli
increas
mgl
conclus
result
demonstr
except
activ
low
concentr
mrsa
surfac
porcin
skin
light
nontox
skin
therapeut
concentr
work
progress
clinic
evalu
effect
compound
erad
staphylococc
nasal
carriag
object
rise
epidem
methicillinresist
staphylococcu
aureu
emrsa
emerg
mupirocin
resist
mean
essenti
develop
new
therapi
readili
overcom
microorgan
xf
seri
novel
light
activ
antibacteri
agent
activ
gramposit
bacteria
address
issu
superior
level
activ
antibiot
less
likelihood
resist
emerg
antibacteri
activ
xf
drug
emrsa
investig
method
mic
mbc
assay
use
investig
antibacteri
activ
novel
antimicrobi
photodynam
agent
rang
staphylococcu
aureu
strain
concentr
rang
mgl
investig
minut
nm
light
activ
jcm
appli
light
alon
effect
result
conclus
result
demonstr
except
low
mic
mbc
valu
aureu
strain
test
result
also
demonstr
equal
effect
mrsa
methicillinsensit
staphylococcu
aureu
mssa
indic
mode
action
independ
antibiot
resist
may
therefor
use
prevent
treatment
emrsa
nontox
skin
prophylactictherapeut
concentr
potenti
treatment
skin
sepsi
erad
nasal
skin
mrsa
carriag
work
progress
evalu
effect
compound
erad
staphylococc
nasal
carriag
object
novel
antibacteri
current
preclin
develop
mechan
action
direct
topoisomeras
spectrum
activ
exclus
gram
posit
organ
goal
studi
characteris
activ
timekil
kinet
common
aerob
cocci
comparison
current
market
molecul
linezolid
lin
vancomycin
van
quinupristindalfopristin
qd
moxifloxacin
mox
method
vitro
suscept
test
strain
use
cultur
collect
novexel
clinic
origin
mic
determin
agar
dilut
techniqu
mueller
hinton
agar
medium
use
supplement
hors
blood
group
streptococci
ga
group
b
streptococci
pneumonia
overnight
cultur
dilut
obtain
final
inoculum
cfuspot
mic
lowest
concentr
inhibit
visual
growth
less
coloni
ignor
ii
timekil
kinet
experi
perform
strain
aureu
n
pneumonia
n
ml
volum
appropri
growth
medium
initi
inoculum
around
cfuml
logarithm
grow
cultur
time
sampl
hour
period
enumer
use
spiral
plate
method
compar
linezolid
vancomycin
concentr
test
speci
result
versu
compar
shown
tabl
ii
time
kill
experi
show
bactericid
aureu
includ
methicillin
resist
strain
reduct
within
hour
compar
slowli
bactericid
effect
vancomycin
hour
vancomycin
bactericid
pneumonia
within
hour
linezolid
bacteriostat
strain
test
conclus
exhibit
bactericid
activ
common
gram
posit
cocci
includ
strain
exhibit
resist
methicillin
vancomycin
fluoroquinolon
warrant
investig
object
aim
studi
identifi
bacteri
protein
target
endogen
antisept
nchlorotaurin
nct
promis
microbicid
agent
topic
treatment
infect
addit
combin
nct
ammonium
chlorid
enhanc
microbicid
activ
significantli
investig
method
escherichia
coli
staphylococcu
aureu
treat
nct
nct
plu
ammonium
chlorid
differ
incub
time
min
period
kill
take
place
find
protein
chang
bacteri
protein
follow
mass
spectrometri
perform
result
incub
nct
reveal
chang
charg
separ
numer
protein
seri
spot
differ
isoelectr
point
moreov
e
coli
heat
shock
protein
appear
ribosom
releas
factor
dribos
periplasm
bind
protein
malonylcoa
transacylas
spot
decreas
aureu
enolas
translat
elong
factor
decreas
chang
appear
rapidli
presenc
ammonium
chlorid
explain
format
lipophil
microbicid
monochloramin
molecular
mechan
attack
compris
mainli
oxid
thio
amino
group
confirm
model
peptid
conclus
result
fit
well
previou
preclin
clinic
find
indic
surfac
attack
penetr
oxid
capac
bacteria
destruct
essenti
protein
nct
nct
plu
ammonium
chlorid
respect
object
ceftobiprol
new
extendedspectrum
cephalosporin
activ
methicillinsuscept
methicillinresist
staphylococci
well
enterobacteriacea
studi
antistaphylococc
activ
ceftobiprol
report
set
isol
recent
clinic
trial
method
consecut
clinic
isol
staphylococci
patient
enrol
multicentr
clinic
trial
involv
complic
skin
infect
examin
suscept
ceftobiprol
select
antigramposit
agent
mic
determin
use
clsi
methodolog
result
among
isol
staphylococcu
aureu
coagulaseneg
staphylococci
con
identifi
percentag
methicillinresist
strain
aureu
con
strain
except
one
con
linezolid
mic
mgl
suscept
vancomycin
linezolid
mic
mglagainst
methicillinsuscept
aureu
ceftobiprol
valu
mgl
respect
methicillinresist
aureu
ceftobiprol
valu
mgl
respect
ceftobiprol
mic
rang
mgl
methicillinsusceptiblecon
mscon
method
consecut
nondupl
bacteri
isol
strain
acquir
patient
bloodstream
respiratori
skin
skin
structur
infect
nosocomi
commun
acquir
submit
medic
centr
europ
america
asiapacif
region
isol
test
use
clsinccl
broth
microdilut
method
grn
current
market
fluoroquinolon
fq
includ
cipro
levofloxacin
levo
gatifloxacin
gati
repres
compar
agent
oxaand
cipro
r
subset
includ
grn
breakpoint
mgl
appli
compar
purpos
base
upon
mic
popul
distribut
strain
includ
quinoloneresist
determin
region
qrdr
mutat
result
potenc
grn
compar
fq
test
sa
see
tabl
key
resist
pattern
among
sa
collect
includ
oxa
cipro
erythromycin
clindamycin
tetracyclin
trimethoprim
sulfamethoxazol
grampositivetarget
compar
includ
vancomycin
linezolid
daptomycin
quinupristindalfopristin
remain
compar
current
market
fq
test
sa
grn
activ
vs
mg
l
oxa
r
sa
grn
display
markedli
enhanc
potenc
compar
cipro
levo
gati
among
cipror
isol
grn
also
maintain
greater
potenc
vs
mgl
although
overal
fq
compar
fq
agent
test
sa
grn
potent
agent
maintain
broadest
coverag
oxaand
cipror
strain
even
appli
conserv
epidemiolog
breakpoint
fq
indic
staphylococc
coverag
desf
quinolon
may
repres
superior
altern
among
fq
class
agent
minim
select
resist
object
assess
garenoxacin
grn
potenc
vast
number
intern
respiratori
tract
infect
rti
pathogen
especi
versu
phenotyp
high
mic
genotyp
sequenc
chang
qrdr
mutant
total
isol
contin
analys
tabl
conclus
grn
maintain
clinic
usabl
activ
mic
mgl
import
communityacquir
rti
pathogen
r
present
market
fluoroquinolon
isol
document
qrdr
mutat
continu
develop
novel
desf
quinolon
agent
appear
desir
vitro
activ
garenoxacin
test
ciprofloxacinsuscept
resist
enterobacteriacea
acinetobact
spp
strain
collect
worldwid
sentri
antimicrobi
surveil
program
h
sader
fritsch
p
strabala
r
jone
north
liberti
us
object
evalu
contemporari
activ
garenoxacin
grn
ciprofloxacin
cipro
suscept
ciproresist
r
enterobacteriacea
ent
acinetobact
spp
asp
unlik
recent
market
fluoroquinolon
fq
grn
desf
quinolon
lack
fluorin
method
total
isol
ent
asp
consecut
collect
medic
centr
bloodstream
respiratori
urinari
skin
soft
tissu
infect
test
refer
broth
microdilut
method
accord
clsinccl
method
interpret
criteria
grn
breakpoint
mgl
appli
comparison
purpos
result
result
major
organ
group
test
see
tabl
grn
show
excel
activ
larg
collect
ent
mgl
isol
inhibit
mgl
object
garenoxacin
grn
novel
broadspectrum
desf
quinolon
activ
gramneg
gramposit
aerob
anaerob
includ
quinoloneresist
staphylococcu
aureu
object
analysi
compar
microbiolog
efficaci
grn
compar
common
pathogen
involv
complic
skin
skin
structur
infect
csssi
method
two
multin
doubleblind
random
studi
conduct
first
studi
subject
receiv
grn
mg
iv
po
qd
piperacillintazobactam
g
iv
transit
po
amoxicillinclavulan
mg
po
second
studi
subject
receiv
grn
mg
po
qd
ciprofloxacinmetronidazol
mg
mg
antimicrobi
administ
day
subject
adult
newli
hospit
ambulatori
outpati
evid
csssi
underli
osteomyel
microbiolog
efficaci
determin
day
posttherapi
result
total
subject
microbiolog
evalu
grn
n
compar
n
diseas
diagnosi
similar
grn
compar
includ
infect
pressur
sore
vs
infect
diabet
foot
ulcer
vs
major
abscess
vs
postsurg
wound
infect
vs
major
common
skin
pathogen
erad
grn
background
acut
bacteri
sinus
ab
common
infect
worldwid
mani
patient
associ
allerg
componenthistori
howev
role
antibacteri
patient
pt
examin
fluoroquinolon
fq
invitro
immunomodulatori
effect
ie
clinic
efficaci
gem
compar
agent
ab
pt
without
allerg
rhiniti
ar
method
phase
clinic
trial
pool
pt
allerg
rhiniti
identifi
pt
compar
pt
report
ar
pt
clinic
respons
success
failur
end
therapi
eot
followup
fu
approx
week
treatment
studi
compar
cmp
cefuroxim
cef
trovafloxacin
tro
result
success
base
clinic
outcom
eot
fu
ar
non
ar
pt
shown
tabl
treatment
eot
success
high
non
ar
pt
fu
reduc
especi
fq
contrast
gem
retain
high
clinic
success
rate
pt
ar
unlik
cef
tro
conclus
gem
shown
efficaci
sub
group
problemat
ab
pt
advantag
may
due
high
antibacteri
activ
gem
vs
key
ab
pathogen
andor
stimulatori
ie
import
pt
decreas
local
immun
defenc
data
also
show
fluoroquinolon
immunostimulatori
properti
garenoxacin
efficaci
multidrugresist
streptococcu
pneumonia
retrospect
analysi
communityacquir
pneumonia
isol
obtain
nine
phase
ii
iii
clinic
studi
black
h
waskin
r
hare
kenilworth
us
object
garenoxacin
grn
novel
desf
quinolon
excel
activ
pneumonia
one
common
pathogen
caus
communityacquir
pneumonia
cap
incid
infect
caus
antibioticresist
isol
streptococcu
pneumonia
increas
therefor
inform
regard
activ
new
antiinfect
drug
popul
pneumonia
multidrug
resist
mdr
critic
mdr
pneumonia
mdrsp
includ
isol
previous
known
prsp
penicillinresist
pneumonia
well
strain
resist
two
follow
antibiot
secondgener
cephalosporin
macrolid
tetracyclin
trimethoprim
sulfamethoxazol
method
pretreat
sputum
blood
isol
collect
worldwid
grn
phase
clinic
cap
trial
retrospect
analys
mdrsp
phenotyp
pneumonia
isol
origin
identifi
subject
subject
secondari
mdr
suscept
test
central
laboratori
confirm
mdrsp
isol
match
individu
subject
assess
clinic
microbiolog
outcom
mdrspinfect
treat
grn
result
expand
suscept
test
identifi
mdrsp
isol
uniqu
subject
lowest
valu
mdrsp
isol
test
panel
repres
drug
observ
grn
tabl
lg
ml
lgml
respect
incid
resist
five
class
drug
penicillin
gener
cep
macrolid
tetracyclin
trisulf
respect
isol
resist
grn
use
propos
suscept
breakpoint
valu
lgml
thirtyf
percent
isol
resist
drug
class
respect
worldwid
incid
mdrsp
equival
geograph
distribut
among
north
america
europ
rest
world
overal
grn
provid
clinic
bacteriolog
success
cap
evalu
subject
mdr
infect
similar
clinic
success
evalu
subject
nonmdrsp
cap
infect
conclus
data
demonstr
abil
grn
success
erad
mdrsp
associ
cap
per
cent
success
shown
tabl
ab
antibiot
copd
chronic
bronchiti
obstruct
lung
diseas
hd
heart
diseas
result
although
gemifloxacin
show
lower
success
compar
cap
patient
defin
risk
factor
gemifloxacin
consider
success
compar
patient
associ
risk
factor
especi
diabet
patient
compar
success
low
advantag
often
promin
fu
eot
patient
comorbid
renal
failur
malign
recruit
suffici
number
analysi
conclus
data
support
use
gemifloxacin
treatment
cap
especi
patient
recognis
idsa
risk
factor
microbiolog
efficaci
garenoxacin
vs
compar
common
pathogen
associ
communityacquir
pneumonia
object
garenoxacin
grn
novel
broadspectrum
desf
quinolon
activ
mani
clinic
import
respiratori
pathogen
includ
penicillinresist
strain
streptococcu
pneumonia
grn
dual
site
inhibit
dna
gyras
topoisomeras
iv
may
less
like
promot
resist
object
analysi
compar
microbiolog
efficaci
grn
compar
common
pathogen
involv
communityacquir
pneumonia
cap
method
two
multin
doubleblind
random
studi
conduct
first
studi
subject
receiv
grn
mg
po
qd
amoxicillinclavulan
ac
mg
po
second
studi
subject
receiv
grn
mg
po
qd
levofloxacin
lev
mg
po
qd
adult
year
age
older
enrol
clinic
radiolog
evid
cap
new
infiltr
chest
radiograph
fever
leukocytosi
cough
chest
pain
auscultatori
find
sputum
product
major
subject
fine
class
iii
studi
bacteriolog
erad
assess
day
post
therapi
result
total
treat
subject
pretreat
pathogen
grn
n
compar
n
overal
erad
rate
treat
subject
grn
compar
erad
rate
pneumonia
garenoxacin
compar
erad
pneumonia
ac
lev
respect
strain
reduc
suscept
penicillin
erad
rate
vs
favour
grn
erad
rate
h
influenza
grn
compar
respect
lev
erad
h
influenza
isol
ac
erad
strain
isol
isol
moraxella
catarrhali
studi
studi
grn
effect
strain
catarrhali
ac
effect
strain
isol
grn
erad
staphylococcu
aureu
isol
vs
compar
conclus
grn
highli
activ
pathogen
commonli
associ
cap
includ
drugresist
strain
pneumonia
repres
effect
therapeut
option
patient
popul
object
garenoxacin
grn
novel
broadspectrum
desf
quinolon
activ
mani
clinic
import
respiratori
pathogen
includ
penicillinresist
strain
streptococcu
pneumonia
grow
problem
resist
strain
pneumonia
multidrugresist
pneumonia
mdrsp
becom
increasingli
common
object
studi
evalu
clinic
microbiolog
efficaci
grn
treatment
communityacquir
pneumonia
cap
caus
mdrsp
method
multin
openlabel
noncompar
studi
subject
adult
clinic
clinic
sign
sputum
product
radiolog
new
infiltr
chest
radiograph
microbiolog
predomin
gramposit
cocci
pair
sputum
gramstain
posit
blood
cultur
pneumonia
evid
cap
caus
pneumonia
subject
receiv
grn
mg
po
qd
grn
mg
iv
transit
mg
po
qd
day
clinic
microbiolog
respons
determin
testofcur
visit
day
posttherapi
result
total
subject
enrol
po
iv
po
clinic
microbiolog
evalu
clinic
microbiolog
success
rate
respect
clinic
success
rate
po
iv
po
respect
document
pneumonia
bacteremia
present
n
subject
clinic
success
rate
among
evalu
subject
resist
rate
pneumonia
penicillin
secondgener
cephalosporin
macrolid
tetracyclin
trimethoprim
sulfamethoxazol
twelv
evalu
subject
pneumonia
caus
mdrsp
clinic
success
rate
subject
mdrsp
nonmdrsp
subject
clinic
success
grn
strain
resist
antimicrobi
drug
class
respect
microbiolog
success
mdrsp
nonmdrsp
suscept
resist
class
strain
respect
grn
gener
well
toler
drugrel
advers
event
ae
report
po
iv
po
subject
conclus
grn
po
iv
po
effect
treatment
cap
caus
mdrsp
nonmdrsp
grn
well
toler
vitro
bactericid
activ
daptomycin
staphylococcu
aureu
enterococcu
spp
comparison
vancomycin
teicoplanin
linezolid
h
drugeon
juvin
nant
fr
object
aim
studi
evalu
bactericid
activ
kill
kinet
daptomycin
dap
staphylococcu
aureu
sa
clinic
isol
differ
teicoplanin
mic
enterococcu
faecali
efl
e
faecium
efm
differ
mechan
glycopeptid
resist
dap
compar
teicoplanin
tei
vancomycin
van
linezolid
lin
method
sa
strain
mssa
mrsa
tei
mic
distribut
mgl
enterococcu
efl
efm
glycopeptid
phenotyp
rvana
rvanb
studi
use
kill
curv
method
antibiot
concentr
use
mgl
mgl
two
fold
dilut
surviv
bacteria
count
hour
use
agar
plate
inhibitor
prevent
antibiot
carryov
antibiot
test
daptomycin
dap
teicoplanin
tei
vancomycin
van
linezolid
lin
result
sa
isol
suscept
dap
mic
mgl
lin
mic
mgl
van
mic
mgl
regardless
suscept
methicillin
dap
show
strong
concentr
depend
bactericid
activ
mssa
mrsa
bactericid
activ
ba
decreas
cfuml
observ
mgl
dap
hour
mgl
dap
suffici
hour
ba
obtain
mgl
dap
antibiot
show
time
depend
bactericid
activ
ba
observ
long
exposur
hour
high
concentr
enterococcu
isol
suscept
dap
mic
mg
l
lin
mic
mgl
regardless
resist
glycopeptid
ba
dap
also
concentr
depend
ba
obtain
mgl
hour
contact
mgl
hour
contact
efl
ba
observ
mgl
hour
contact
mgl
hour
contact
efm
antibiot
time
depend
activ
nt
show
bactericid
activ
concentr
mgl
conclus
bactericid
activ
daptomycin
strong
concentr
depend
influenc
level
mechan
glycopeptid
resist
bactericid
activ
linezolid
time
depend
observ
highest
concentr
bactericid
activ
vancomycin
teicoplanin
time
depend
influenc
mechan
glycopeptid
resist
object
telavancin
tlv
bactericid
lipoglycopeptid
multipl
mechan
action
phase
clinic
trial
treatment
complic
skin
skin
structur
infect
hospitalacquir
pneumonia
focu
infect
due
methicillinresist
staphylococcu
aureu
mrsa
studi
evalu
compar
antibacteri
activ
tlv
antibacteri
agent
recent
gramposit
clinic
isol
germani
method
total
aerob
gramposit
bacteri
strain
recent
collect
includ
antibiot
test
tlv
vancomycin
van
teicoplanin
penicillin
oxacillin
ampicillin
cefuroxim
ceftriaxon
daptomycin
dap
linezolid
lzd
quinupristindalfopristin
clindamycin
ciprofloxacin
levofloxacin
gentamicin
streptomycin
erythromycin
telithromycin
cotrimoxazol
tetracyclin
mic
determin
broth
microdilut
procedur
accord
guidelin
clsi
result
tlv
exhibit
potent
activ
gramposit
bacteria
includ
resist
isol
mrsa
vanresist
enterococci
pneumococci
includ
multipl
resist
strain
variou
antibiot
resist
phenotyp
streptococc
speci
tlv
show
excel
vitro
activ
speci
irrespect
antibiot
phenotyp
test
methicillinsuscept
aureu
mssa
n
mrsa
n
tlv
phenotyp
mgl
coagulaseneg
staphylococci
n
incl
msse
mrse
mssh
mrsh
other
mgl
tlv
enterococcu
faecali
n
e
faecium
n
mgl
respect
vanresist
strain
e
faecali
n
e
faecium
n
mic
tlv
rang
mgl
streptococcu
pneumonia
n
tlv
mic
rang
mgl
streptococcu
pyogen
streptococcu
agalactia
viridan
group
streptococci
n
mic
mgl
conclus
base
tlv
potent
van
dap
lzd
staphylococci
streptococci
e
faecali
superior
dap
lzd
e
faecium
least
activ
dap
lzd
vanresist
enterococci
tlv
appear
promis
new
antimicrobi
agent
treatment
infect
caus
gramposit
organ
includ
multipli
resist
isol
extent
protein
bind
pb
dap
still
investig
data
avail
far
indic
pb
either
therefor
test
two
fsc
correspond
pb
correspond
pb
activ
dap
determin
muellerhinton
broth
supplement
mgl
calcium
viabil
count
perform
h
one
methicillinsuscept
staphylococcu
aureu
mssa
two
methicillinresist
aureu
mrsa
one
vancomycinsuscept
van
one
vanresist
vanr
enterococcu
faecali
one
van
one
vanr
enterococcu
faecium
test
bactericid
activ
defin
kill
incub
result
dap
bactericid
concentr
mgl
mgl
seven
strain
concentr
mgl
bactericid
two
mrsa
van
e
faecium
four
strain
maximum
reduct
initi
inoculum
rang
cfuml
six
strain
bactericid
effect
mgl
mgl
dap
respect
occur
minut
h
h
van
e
faecali
van
mgl
mgl
bactericid
two
strain
h
mssa
mrsa
five
strain
van
bacteriostat
maximum
reduct
initi
inoculum
cfuml
mgl
h
respect
tpl
lzd
consist
bacteriostat
test
strain
conclus
dap
psc
mgl
well
fsc
mgl
show
pronounc
bactericid
effect
within
h
strain
van
bactericid
strain
h
compar
van
bacteri
kill
dap
rapid
tpl
lzd
bacteriostat
effect
human
serum
bactericid
activ
daptomycin
compar
staphylococcu
aureu
enterococcu
spp
background
daptomycin
new
cyclic
lipopeptid
antibiot
show
rapid
bactericid
activ
high
protein
bind
assess
standard
methodolog
studi
investig
bactericid
activ
daptomycin
effect
protein
bind
addit
human
serum
hs
method
exponentiallygrow
methicillinsuscept
andresist
aureu
mssa
mrsa
vancomycinsuscept
enterococcu
faecium
vse
resist
enterococcu
faecium
vre
ca
cfuml
expos
daptomycin
dap
vancomycin
van
teicoplanin
tei
piperacillintazobactam
ptz
linezolid
lzd
peak
p
trough
serum
concentr
mueller
hinton
broth
supplement
mgl
without
hs
viabl
count
determin
h
plot
made
log
reduct
viabl
count
time
areaunderthecurv
measur
calcul
bactericid
indic
bi
plot
j
antimicrob
chemoth
result
daptomycin
reduc
viabl
count
mssa
mrsa
approx
log
within
h
vse
vre
within
h
p
agent
either
achiev
requir
h
shown
bi
data
shown
repres
kill
beyond
limit
detect
hs
littl
effect
dap
kill
except
vre
nevertheless
dap
vre
bactericid
antibacteri
except
dap
p
conclus
dap
bactericid
agent
test
measur
either
bi
rate
kill
dap
p
reduc
mssa
mrsa
detect
within
min
effect
hs
minim
suggest
protein
bind
either
weak
highli
revers
data
support
use
dap
treatment
infect
caus
organ
daptomycin
activ
multiresist
staphylococcu
haemolyticu
bloodstream
isol
sever
infect
object
daptomycin
new
cyclic
lipopeptid
activ
multidrugresist
gramposit
pathogen
includ
mrsa
approv
use
cssst
infect
usfda
review
emea
approv
eu
member
countri
rapid
bactericid
activ
daptomycin
due
uniqu
mechan
action
make
attract
antibiot
seriou
gramposit
infect
studi
perform
evalu
activ
daptomycin
drug
multiresist
clinic
relev
staphylococcu
haemolyticu
mrsh
isol
bloodstream
infect
variou
hospit
itali
ii
determin
epidemiolog
genet
correl
among
strain
iii
character
sccmec
dna
strain
method
mrsh
strain
test
panel
antimicrobi
agent
broth
microdilut
method
perform
accord
clsi
clinic
laboratori
standard
institut
guidelin
includ
supplement
mgl
calcium
daptomycin
moreov
phenotyp
test
antibiot
suscept
profil
carri
result
compar
molecular
type
analysi
use
smaipfg
fingerprint
pcr
character
meccomplex
result
isol
resist
erythromycin
gentamicin
ciprofloxacin
strain
show
reduc
suscept
vancomycin
mic
mgl
strain
resist
cotrimoxazol
strain
clindamycin
strain
chloramphenicol
strain
tetracyclin
almost
isol
inhibit
mgl
daptomycin
four
strain
exhibit
mic
valu
mgl
pfge
analys
show
exist
least
two
multiresist
haemolyticu
clone
widespread
differ
hospit
methicillinresist
correl
presenc
meca
preliminari
result
regard
genet
element
carri
gene
show
organ
meccomplex
class
class
c
conclus
result
suggest
daptomycin
excel
activ
multiresist
mr
haemolyticu
isol
repres
seriou
threat
catheterrel
bloodstream
infect
furthermor
emerg
haemolyticu
exhibit
reduc
suscept
vancomycin
particular
concern
probabl
due
common
use
vancomycin
initi
therapi
infect
moreov
use
addit
molecular
techniqu
fingerprint
isol
make
studi
clinic
import
con
accur
object
ceftobiprol
new
cephalosporin
broad
spectrum
action
includ
methicillinresist
staphylococci
mr
well
mani
gramposit
gramneg
pathogen
bacteria
studi
investig
structur
basi
good
activ
mr
method
primari
betalactam
resist
determin
mr
penicillinbind
protein
pbp
clone
express
solubl
form
aminotermin
residu
form
membraneanchor
delet
solubl
form
crystal
structur
complex
form
soak
crystal
solut
contain
ceftobiprol
determin
angstrom
resolut
addit
data
structur
complex
form
solut
obtain
use
spectroscop
method
uvcircular
dichroism
result
ceftobiprol
react
rapidli
form
stabl
acylenzym
complex
ceftobiprol
moieti
posit
deep
within
activ
site
acylenzym
complex
form
form
sever
hydrogen
bond
hydrophob
interact
particular
side
chain
ceftobiprol
sit
deepli
within
sidechain
bind
pocket
pbp
side
chain
nitrocefin
previous
determin
complex
structur
addit
interact
probabl
add
enhanc
stabil
acylenzym
complex
form
ceftobiprol
compar
complex
form
betalactam
inact
mr
signific
structur
rearrang
apoenzym
acylenzym
evid
crystal
structur
solut
conclus
ceftobiprol
readili
form
stabl
inhibitori
acylenzym
complex
pbp
betalactam
resist
determin
mr
togeth
potent
inhibit
normal
complement
betalactam
sensit
penicillinbind
protein
account
excel
activ
staphylococci
probabl
account
low
rate
resist
develop
observ
experiment
condit
incid
staphylococcu
aureu
reduc
suscept
glycopeptid
french
hospit
novemb
april
c
morat
charron
c
bebear
j
maugein
bordeaux
fr
staphylococcu
aureu
major
caus
nosocomi
infect
around
world
glycopeptid
remain
drug
choic
sever
infect
caus
mrsa
howev
emerg
vancomycin
resist
enterococcu
coagulas
neg
staphylococcu
strain
staphylococcu
aureu
reduc
suscept
glycopeptid
gisa
report
differ
countri
like
japan
franc
spain
uk
unit
state
aim
studi
determin
proport
vancomycin
resist
clinic
aureu
isol
french
univers
hospit
novemb
april
want
defin
epidem
clone
studi
clinic
impact
gisa
strain
protocol
detect
first
screen
test
bhi
agar
contain
mgl
teicoplanin
vancomycin
teicoplanin
mic
determin
method
etest
inoculum
mcf
select
strain
final
isol
mic
teicoplanin
mg
l
mic
vancomycin
mgl
mic
teicoplanin
mgl
mic
vancomycin
mgl
studi
popul
analysi
pulsedfield
gel
electrophoresi
pfge
perform
differ
isol
pulsotyp
compar
novemb
april
aureu
isol
collect
patient
screen
glycopeptid
resist
initi
agar
screen
test
contain
mgl
teicoplanin
teicoplanin
mic
mgl
isol
patient
strain
select
determin
mic
macromethod
etest
techniqu
strain
select
studi
popul
analysi
profil
compar
refer
strain
profil
procedur
detect
isol
patient
heterogen
reduc
suscept
glycopeptid
hgisa
incid
staphylococcu
aureu
reduc
suscept
glycopeptid
hospit
found
four
strain
resist
methicillin
also
resist
gentamicin
divers
strain
confirm
pfge
epidem
clone
hospit
clinic
histori
show
patient
receiv
prior
treatment
vancomycin
patient
failur
treatment
cystic
fibrosi
object
enterococcu
faecali
preval
organ
involv
enterococc
infect
tehran
hospit
follow
e
faecium
due
widespread
expans
aminoglycosid
modifiy
enzym
agm
gene
rate
resist
high
level
concentr
aminoglycosid
increas
year
rate
high
level
gentamicin
resist
isol
enterococci
hlgr
high
iran
aim
studi
determin
gene
encod
resist
aminoglycosid
among
enterococci
iran
method
disk
contain
lg
gentamicin
use
detect
hlgr
isol
primer
specif
aac
aph
aph
iiia
gene
use
pcr
possibl
detect
acetyltransferas
phosphotransfera
common
agm
among
isol
enetrococci
these
isol
resist
differ
concentr
gentamicin
result
bp
region
aac
aph
gene
amplifi
pcr
hlgr
isol
well
low
level
getamicin
resist
isol
llgr
moreov
gene
aph
iiia
detect
isol
hlgr
llgr
respect
differ
isol
e
faecali
e
faecium
found
term
preval
aph
iiia
gene
conclus
bifunct
enzym
aac
aph
main
caus
resist
high
concentr
aminoglycosid
collect
enterococci
enzym
confer
resist
clinic
use
aminoglycosid
except
streptomycin
absenc
aac
aph
gentamicin
could
use
combin
therapi
preval
genet
analysi
methicillinresist
staphylococcu
aureu
express
highlevel
lowlevel
mupirocin
resist
kural
us
akgun
eskisehir
tr
object
investig
genet
locat
mupa
gene
encod
mupirocin
resist
character
mupirocinresist
methicillin
resist
staphylococcu
aureu
mrsa
isol
patient
turkish
univers
hospit
polymeras
chain
reaction
pcr
plasmid
analysi
method
methicillin
mupirocin
resist
detect
disk
diffus
oxoid
uk
etest
ab
biodisk
sweden
perform
determin
mupirocin
minimum
inhibitori
concentr
mic
presenc
mupa
meca
detect
pcr
use
specif
primer
plasmid
analysi
use
studi
genet
locat
mupa
gene
result
total
mrsa
strain
identifi
disk
diffus
aureu
clinic
isol
wound
blood
cathet
lower
respir
tract
bronchoalveolar
lavag
pleural
fluid
transtrach
aspir
sputum
urin
serebrospin
fluid
parasynthesi
fluid
periton
fluid
bone
marrow
clinic
sampl
among
mrsa
isol
mupirocin
resist
detect
strain
disk
diffus
etest
mupirosinresist
isol
express
highlevel
muh
express
lowlevel
mul
mupirocin
resist
isol
vancomycin
teicoplannin
suscept
chloramphenicol
resist
disk
diffus
isol
highlevel
low
level
mupirocin
resist
due
mupa
gene
also
detect
pcr
plasmid
detect
isol
howev
muh
isol
contain
kb
plasmid
encod
highlevel
resist
isol
contain
kb
plasmid
resist
chloramphenicol
conclus
result
indic
mrsa
clone
detect
hospit
acquir
highlevel
mupirocin
resist
plasmid
past
observ
recent
studi
suggest
number
strian
increas
follow
extens
topic
use
mupirocin
usag
mupirocin
hospit
yet
systemat
implement
frequent
prescrib
treatment
staphylococc
skin
infect
less
elimin
nasal
carriag
mrsa
hospit
awar
possibl
emerg
increas
mupirocin
highli
resist
mrsa
strain
futur
consid
use
mupirocin
control
spread
mrsa
hospit
emerg
spread
acquir
fusid
acid
resist
staphylococcu
aureu
object
major
rout
fusid
acid
resist
fusr
aureu
involv
acquisit
fusb
resist
determin
first
clinic
microbiolog
infect
volum
supplement
identifi
plasmid
show
two
currentlycircul
major
clone
fusr
aureu
identifi
date
acquir
fusb
ancestr
sourc
ii
fusb
one
least
three
lineag
protein
appear
evolv
sinc
recruit
origin
ancestr
fusb
staphylococci
method
plasmid
purif
dna
sequenc
pcr
amplif
clone
aureu
use
shuttlevector
perform
use
establish
method
antibiot
suscept
test
perform
agar
dilut
result
epidem
european
fusid
acidresist
impetigo
clone
eefic
communityacquir
mrsa
strain
shown
carri
chromosom
plasmidencod
fusb
respect
dna
sequenc
fusb
surround
region
background
reveal
ident
sequenc
howev
acquir
fusr
alway
result
acquisit
prototyp
fusb
gene
gene
encod
fusb
homologu
recent
identifi
sequenc
aureu
strain
identifi
addit
homologu
encod
genom
saprophyticu
strain
product
gene
homolog
fusb
clone
pcr
amplicon
correspond
gene
upstream
express
signal
aureu
establish
confer
resist
fu
sinc
function
homologu
close
relat
gramposit
organ
highli
like
evolv
ancestr
fusb
recruit
staphylococci
conclus
three
member
staphylococc
famili
fusb
protein
appear
evolv
ancestr
protein
base
low
level
sequenc
homolog
fusb
gene
nucleotid
level
clearli
occur
well
introduct
fu
clinic
three
fusb
protein
encod
far
success
geneplasmid
repres
sourc
share
sourc
major
fusr
strain
lineag
telithromycin
activ
reduc
efflux
streptococcu
pneumonia
c
benvenuti
r
koncan
g
bahar
mazzariol
g
cornaglia
verona
ankara
tr
object
telithromycin
show
excel
activ
mtype
erythromycinresist
streptococcu
pneumonia
thu
commonli
regard
capabl
overcom
efflux
resist
mechan
nevertheless
telithromycin
mic
valu
strain
appear
distinctli
higher
erythromycinsuscept
one
possibl
telithromycin
act
actual
efflux
substrat
alreadi
demonstr
streptococcu
pyogen
seem
worth
investig
method
telithromycin
mic
distribut
analys
collect
italian
pneumonia
strain
origin
multicentr
studi
effect
efflux
mechan
investig
use
telithromycin
result
telithromycin
mic
rang
mgl
mgl
mgl
erythromycinsuscept
strain
lack
mef
erm
gene
mgl
mgl
mgl
strain
endow
phenotyp
distinct
telithromycin
efflux
detect
strain
express
mef
gene
express
erm
b
gene
suscept
strain
lack
mef
erm
gene
efflux
revers
addit
inhibit
compound
sodium
arsen
demonstr
msrlike
sequenc
also
found
strain
efflux
telithromycin
other
conclus
first
time
telithromycin
shown
efflux
pyogen
isol
efflux
relat
presenc
mef
msrlike
gene
clearli
demonstr
owe
increasingli
evid
complex
pneumonia
efflux
system
gene
might
also
contribut
efflux
unusu
phenotyp
enterococcu
faecali
greec
express
lowlevel
resist
clindamycin
dalfopristin
suscept
quinupristindalfopristin
maniati
f
konto
p
liako
e
petinaki
spiliopoul
maniati
larissa
patra
gr
object
investig
resist
mechan
new
describ
phenotyp
among
enterococcu
faecali
express
lowlevel
resist
clindamycin
dalfopristin
suscept
quinupristindalfopristin
qd
method
greec
three
enterococcu
faecali
isol
express
unusu
phenotyp
recov
urin
sampl
isol
studi
pcr
lsagen
pfge
nucleotid
sequenc
analysi
lsa
bp
upstream
region
perform
isol
also
test
rtpcr
express
lsagen
result
isol
belong
three
distinct
clone
carri
lsagen
stop
codon
found
strain
point
mutat
lsagen
detect
compar
lsa
mrna
product
unusu
strain
obtain
fulli
qd
resist
one
quantit
differ
found
conclus
find
present
studi
clearli
show
resist
mechan
quinupristindalfopristin
correl
presenc
express
lsagen
mutat
detect
lsa
gene
probabl
respons
product
lsa
protein
decreas
activ
result
qd
suscept
presenc
erm
tr
gene
respons
macrolideresist
streptococcu
agalactia
object
investig
mechan
resist
macrolid
strain
streptococcu
agalactia
area
thessalia
greec
period
method
subject
studi
strain
agalactia
collect
clinic
specimen
vagin
swab
pregnant
non
pregnant
women
strain
identifi
gram
stain
lancefield
b
antigen
api
strep
system
biomerieux
franc
suscept
macrolid
lincosamid
streptogrammin
b
studi
disk
diffus
method
mic
also
measur
use
etest
differenti
mlsb
induc
type
test
doubl
disk
synergi
test
ddst
detect
gene
mef
erm
tr
erm
b
perform
polymeras
chain
reaction
pcr
clonal
resist
strain
studi
pulsefield
gel
electrophoresi
result
strain
resist
erythromycin
lincosamid
streptogrammin
b
none
found
resist
erythromycin
mphenopyp
strain
mlsb
constitut
phenotyp
mlsb
induc
strain
found
carri
erm
tr
gene
one
strain
found
carri
erm
tr
erm
b
gene
pfge
analysi
reveal
emerg
multipl
resist
clone
conclus
resist
agalactia
mlsb
antibiot
relat
presenc
erm
tr
gene
central
greec
emerg
novel
clindamycin
resist
phenotyp
among
invas
streptococcu
pyogen
isol
sweden
jasir
b
luca
c
schalen
lund
se
object
recent
throat
group
streptococci
ga
isol
diagnost
laboratori
total
resist
clindamycin
suscept
erythromycin
well
macrolid
found
isol
suscept
macrolid
streptogramin
b
atyp
strain
thu
agre
previous
known
ml
resist
phenotyp
main
object
character
these
resist
phenotyp
genotyp
method
result
isol
examin
resist
gene
pcr
strain
one
harbour
erma
gene
gene
sequenc
show
mutat
regulatori
part
local
transposon
strain
neg
erm
gene
also
test
rrna
mutat
neg
outcom
strain
tand
emm
type
show
belong
differ
type
conclus
ga
account
common
human
infect
acut
pharyngotonsil
impetigo
untreat
may
follow
nonsuppur
complic
rheumat
fever
acut
poststreptococc
glomerulonephr
ga
may
also
give
rise
invas
often
lifethreaten
acut
diseas
scarlatina
erysipela
endometr
necrotis
fasciiti
sepsi
often
accompani
toxic
shock
without
known
except
ga
fulli
suscept
betalactam
firstchoic
drug
treatment
case
allergi
intoler
penicillin
macrolid
use
possibl
consequ
signific
resist
develop
agent
evolv
mani
part
world
though
role
clindamycin
treatment
streptococc
diseas
limit
drug
shown
particularli
effect
erad
streptococci
penicillin
treatment
failur
pharyngotonsil
clindamycin
often
supplement
betalactam
also
may
lifesav
effect
treatment
fulmin
streptococc
infect
due
import
role
treatment
invas
streptococc
diseas
resist
develop
clindamycin
ga
consid
highli
undesir
alarm
find
possibl
new
phenotyp
select
clindamycin
resist
ga
motiv
thorough
analysi
phenotyp
well
identif
resist
determin
allahham
van
der
linden
rr
reinert
aachen
de
object
telithromycin
novel
ketolid
antibiot
signific
invitro
activ
streptococcu
pneumonia
aim
studi
character
resist
mechan
clinic
isol
pneumonia
reduc
suscept
telithromycin
mgl
perform
timekil
kinet
telithromycin
method
determin
mic
perform
microbroth
dilut
method
accord
clsi
serotyp
neufeld
quellung
reaction
multilocu
sequenc
type
sequenc
rrna
sequenc
gene
encod
ribosom
protein
ermb
perform
accord
standard
method
four
isol
select
timekil
two
telithromycin
mic
mgl
two
strain
telithromycin
mic
mgl
result
two
nationwid
studi
one
european
surveil
studi
n
perform
nation
refer
center
streptococci
nrc
germani
reduc
suscept
telithromycin
mgl
detect
isol
mgl
strain
antibiot
follow
telithromycin
penicillin
g
cefuroxim
erythromycin
clindamycin
tetracyclin
gatifloxacin
two
major
serotyp
observ
serotyp
serotyp
isol
possess
cmlsb
phenotyp
ermb
posit
isol
show
wide
rang
combin
resist
determin
includ
multipl
alter
rrna
alter
ribosom
protein
n
alter
erm
b
gene
n
predomin
clone
serotyp
sequenc
type
isol
seen
franc
n
germani
n
telithromycinresist
also
spread
clone
st
n
serotyp
variant
vitro
timekil
show
minim
kill
hour
regrowth
bactericid
activ
achiev
time
mic
strain
conclus
although
incid
telithromycin
resist
remain
rare
worldwid
spread
telithromycin
resist
multidrug
resist
clone
worldwid
distribut
worrisom
gb
obtain
nonpregn
women
erythromycin
resistantgb
identifi
phenotyp
analys
screen
pcr
mre
gene
erythromycin
resist
gene
erm
b
erm
tr
mef
mef
e
serotyp
type
specif
antisera
serotyp
ia
ib
ii
iii
iv
v
result
among
total
gb
erythromycinresist
erythromycinresist
gb
isol
vagin
swab
pregnant
women
nonpregn
women
frequenc
serotyp
erythromycinresist
gb
test
distribut
resist
gene
distribut
serotyp
among
differ
genotyp
illustr
tabl
nt
nontyp
mre
gene
found
gb
strain
test
mic
erythromycin
erythromycinresist
gb
mgl
rang
mgl
gb
harbour
erm
b
erm
b
erm
tr
mgl
mgl
respect
rang
mgl
gb
harbour
erm
tr
conclus
erm
b
erythromycinresist
gene
preval
among
gb
isol
isol
show
highest
mic
erythromycin
commonest
serotyp
among
erythromycinresist
gb
isol
iii
ii
show
genotyp
variabl
harbour
either
two
preval
gene
erm
b
orand
erm
tr
method
studi
rate
resist
tetracyclin
minocyclin
among
erythromycinresist
gb
strain
isol
univers
hospit
lozano
blesa
zaragoza
spain
isol
subsequ
phenotyp
analys
mean
disk
diffus
method
screen
pcr
erythromycin
tetracyclin
resist
gene
erm
b
erm
tr
mef
ae
tet
tet
suscept
erythromycin
josamycin
tetracyclin
minocyclin
test
agar
dilut
method
accord
nccl
strain
serotyp
type
specif
antisera
serotyp
ia
ib
ii
iii
iv
v
result
among
total
isol
macrolideresist
gb
collect
may
april
hospit
total
sgb
isol
tetracyclineresist
distribut
tet
tet
among
erythromycinresist
gb
harbour
erm
b
repect
harbour
erm
tr
distribut
tetracyclin
resist
gene
serotyp
among
differ
genotyp
gb
illustr
tabl
nt
non
typabl
isol
carri
tet
tet
tet
present
follow
mic
tetracyclin
rang
mgl
minocyclin
rang
mgl
isol
carri
tet
present
follow
mic
tetracyclin
rang
mgl
minocyclin
rang
mgl
conclus
major
tetracyclineresist
gb
harbour
tet
alon
combin
tet
preval
serotyp
among
total
tetracyclineresist
gb
serotyp
iii
serotyp
ii
serotyp
iii
preval
among
gb
harbour
tet
gene
serotyp
ii
preval
among
gb
harbour
tet
gene
object
know
preval
resist
macrolid
viridan
streptococci
mechan
genet
element
involv
method
studi
viridan
streptococcu
pharyng
isol
differ
patient
mic
macrolid
determin
agar
dilut
method
presenc
mef
erma
ermb
ermtr
gene
presenc
mega
macrolid
efflux
genet
assembl
resist
mef
isol
determin
pcr
specif
primer
similar
mef
gene
first
describ
pneumococci
mefe
streptococcu
pyogen
mefa
determin
sequenc
result
viridan
streptococci
isol
resist
macrolid
resist
isol
harbour
mef
gene
one
harbour
ermb
isol
harbour
mef
ermb
gene
isol
harbour
erma
ermtr
gene
studi
genet
element
harbour
mef
gene
streptococci
mef
isol
found
mega
insert
element
isol
harbour
mefe
isol
found
mefa
harbour
mega
conclus
phenotyp
frequent
viridan
streptococci
harbour
mef
gene
mlsb
phenotyp
viridan
streptococci
harbour
erm
gene
alon
combin
erm
mef
gene
isol
contain
mef
sequenc
correspond
mefe
genet
element
mega
usual
describ
pneumococci
harbour
gene
one
isol
contain
sequenc
correspond
mefa
genet
element
usual
describ
pyogen
increas
presenc
macrolideresist
pneumococci
harbour
mega
element
might
relat
wide
presenc
viridan
streptococci
acquisit
mega
pneumococci
viridan
streptococci
transform
studi
object
princip
mechan
macrolid
resist
streptococcu
pneumonia
itali
target
site
modif
mediat
erm
b
erm
gene
common
streptococcu
pyogen
rare
pneumonia
even
recent
studi
demonstr
increas
detect
resist
determin
recent
clinic
pneumonia
isol
carri
erm
obtain
patient
mening
itali
aim
studi
molecular
character
isol
method
antimicrobi
suscept
test
determin
etest
presenc
erythromycin
resist
determin
detect
pcr
assay
genotyp
perform
pfge
mlst
flank
region
erm
analys
sequenc
fragment
amplifi
invers
pcr
transform
conjug
experi
carri
transform
analys
pfge
hybrid
erm
probe
result
isol
belong
serotyp
st
resist
erythromycin
induc
resist
clindamycin
suscept
penicillin
tetracyclin
pcr
macrolid
resist
determin
detect
erm
pfge
analysi
reveal
genet
correl
strain
st
pneumonia
italian
isol
mlst
confirm
data
sinc
isol
belong
singleallel
variant
common
st
among
italian
st
isol
bp
dna
fragment
obtain
invers
pcr
contain
erm
gene
sequenc
fragment
contain
orf
upstream
erm
gene
erm
ident
describ
pyogen
orf
downstream
erm
one
homolog
hypothet
kinas
two
transposas
gramposit
speci
transform
experi
gene
erm
transfer
erythromycin
suscept
recipi
hybrid
analysi
one
transform
reveal
size
transfer
dna
fragment
approxim
kb
transconjug
obtain
mate
experi
conclus
first
italian
report
pneumonia
isol
carri
erm
erm
appear
contain
genet
element
includ
two
transposas
although
gene
transfer
conjug
object
treatment
first
oxazolidinon
antibiot
linezolid
infect
caus
staphylococci
prove
effect
case
present
studi
present
first
three
case
linezolid
resist
staphylococci
hospit
method
examin
three
coagulas
neg
staphylococcu
strain
isol
blood
cultur
bactec
becton
dickinson
identif
suscept
test
perform
vitek
ii
autom
system
biomerieux
result
confirm
api
system
biomerieux
etest
ab
biodisk
solna
sweden
accord
nccl
guidelin
result
three
linezolid
resist
staphylococci
isol
blood
cultur
identif
show
three
isol
staphylococcu
cohnii
subsp
urealitycum
mic
valu
lgml
n
lgml
n
much
higher
valu
lgml
character
sensit
strain
isol
deriv
three
patient
differ
ward
hospit
first
two
isol
recov
two
icu
patient
april
august
last
staphylococcu
cohnii
isol
patient
neurosurgeri
ward
still
hospit
patient
receiv
prolong
treatment
linezolid
conclus
although
six
linezolid
resist
clinic
isol
aureu
previous
report
literatur
three
isol
first
coagulas
neg
staphylococcu
isol
resist
linezolid
imper
screen
resist
linezolid
staphylococci
take
necessari
precaus
order
prevent
spread
linezolid
resist
strain
ward
hospit
correl
mic
number
mutat
rrna
gene
oxazolidinoneresist
staphylococcu
aureu
object
determin
number
mutat
rdna
allel
present
clinic
laboratorygener
linezolidresist
staphylococcu
aureu
isol
method
linezolidresist
isol
test
clinic
isol
mic
mgl
mutant
select
invitro
mic
mgl
mutant
rais
repeat
passag
increas
linezolid
concentr
parentag
verifi
pfge
mic
determin
agar
dilut
genom
dna
digest
ecori
hybrid
bp
probe
correspond
domain
v
gene
encod
rrna
determin
gene
copi
number
pyrosequenc
use
quantifi
proport
wildtyp
mutat
allel
present
assay
design
detect
presenc
mutat
confer
oxazolidinon
resist
pyrosequenc
hybrid
data
combin
determin
number
mutat
allel
present
result
resist
select
invitro
prove
less
stabl
clinic
isol
pyrosequenc
show
clinic
isol
mutat
invitro
select
mutant
rdna
copi
number
oxazolidinoneresist
clinic
isol
vari
laboratorygener
mutant
laboratoryselect
mutant
chang
copi
number
compar
parent
strain
chang
fragment
size
number
number
mutat
copi
linresist
isol
rang
laboratoryselect
mutant
clinic
isol
increas
number
mutat
gene
correl
increas
linezolid
mic
conclus
combin
pyrosequenc
hybrid
success
determin
number
mutat
rdna
allel
exposur
linezolid
select
chang
rrna
gene
copi
number
well
sequenc
invitro
select
mutant
posit
correl
number
proport
mutat
rdna
copi
mic
previous
unproven
staphylococci
object
linezolid
lzd
import
antibiot
treatment
enterococc
infect
especi
correspond
strain
possess
multiresist
includ
resist
vancomycin
van
report
emerg
lzd
resist
clonal
relat
vansuscept
vanresist
enterococcu
faecium
isol
origin
icu
patient
day
initi
linezolid
therapi
patient
method
vanresist
e
faecium
repeatedli
isol
intraabdomin
cultur
femal
icupati
infect
necrot
pancreat
pancreaticoduodenectomi
procedur
antibiot
suscept
test
bacteria
perform
etest
vana
gene
detect
pcr
possibl
lzd
resist
mechan
mutat
rdna
one
six
rrna
allel
e
faecium
examin
pcrbase
method
molecular
type
strain
perform
smai
macrorestict
analysi
result
vanresist
lzdsensit
e
faecium
vrlse
initi
detect
intraabdomin
cultur
howev
alreadi
twelv
day
init
lzd
therapi
vanand
lzdresist
e
faecium
vrlre
strain
detect
resist
lzd
confirm
mic
rang
mgl
e
faecium
isol
show
ident
close
relat
pfge
pattern
throughout
icu
period
vanand
lzdsuscept
e
faecium
vslse
strain
repeatedli
detect
specimen
vrlse
vrlre
isol
addit
vansuscept
e
faecium
isol
resist
lzd
vslre
detect
mutat
rdna
three
six
allel
led
lzd
resist
e
faecium
isol
examin
two
week
termin
lzd
therapi
lzdresist
strain
could
detect
followup
swab
conclus
resist
lzd
e
faecium
occur
alreadi
shortli
initi
lzd
therapi
assess
antibiot
suscept
isol
start
therapi
regularli
therapi
advis
especi
therapi
sever
infect
epidemiolog
clinic
repercuss
resist
lzd
among
enterococci
predict
time
attent
proper
dose
prompt
remov
infect
devic
feasibl
could
limit
occurr
spread
lzdresist
e
faecium
object
investig
mechan
resist
tetracyclin
shigella
spp
method
one
hundr
eleven
tetracyclineresist
shigella
spp
strain
sonnei
flexneri
isol
caus
enter
geograph
area
remain
recov
patient
travel
diarrhoea
antimicrobi
suscept
tetracyclin
determin
kirbybau
method
presenc
teta
tetb
tetg
gene
establish
pcr
sequenc
amplifi
product
use
corrobor
reliabl
pcr
result
maentel
haenszel
test
use
establish
statist
signific
result
statist
analysi
show
teta
gene
frequent
sonnei
p
tetb
usual
flexneri
p
although
without
statist
signific
presenc
nondetermin
mechan
tetracyclineresist
seem
frequent
among
sonnei
conclus
speciesspecif
differ
distribuit
teta
tetb
gene
shown
moreov
analys
strain
show
analys
determin
tetracyclineresist
concomit
presenc
one
analys
gene
rare
event
distribut
genet
determin
tetracyclin
resist
laribact
hongkongensi
isol
human
fish
object
studi
distribut
tetracyclin
resist
clone
character
tetracyclin
resist
determin
laribact
hongkongensi
recent
discov
bacteri
genu
speci
associ
communityacquir
gastroenter
method
twentyfour
l
hongkongensi
strain
isol
patient
communityacquir
gastroenter
l
hongkongensi
strain
isol
freshwat
fish
hong
kong
use
studi
genet
determin
tetracyclin
resist
look
screen
genom
dna
librari
l
hongkongensi
preval
teta
gene
strain
l
hongkongensi
studi
pcr
use
laboratorydesign
primer
presenc
tetracyclin
resist
determin
plasmid
examin
southern
blot
analysi
result
among
human
fish
isol
test
human
fish
isol
tetracyclineresist
gene
cluster
consist
put
transposas
tetr
teta
gene
clone
insert
restrict
fragment
genom
dna
resist
strain
pbkcmv
teta
tetr
gene
share
signific
nucleotid
sequenc
homolog
known
teta
tetr
gene
flank
region
end
teta
ident
correspond
region
tetc
island
chlamydia
sui
teta
almost
ident
transposon
plasmid
found
mani
gramneg
bacteria
suggest
illegitim
recombin
may
occur
produc
present
tetracyclin
resist
determin
southern
hybrid
suggest
teta
gene
plasmidencod
tetracyclin
resist
l
hongkongensi
associ
teta
pcr
amplif
teta
gene
isol
l
hongkongensi
includ
show
presenc
teta
four
tetracyclin
resist
isol
none
tetracyclin
suscept
one
contrast
strain
teta
two
strain
ident
strain
close
relat
gramneg
bacteria
plasmid
conclus
result
indic
horizont
transfer
gene
especi
relat
plasmid
l
hongkongensi
gramneg
bacteria
probabl
frequent
event
import
mechan
acquisit
dissemin
tetracyclin
resist
l
hongkongensi
succes
treatment
infect
endocard
linezolid
hryniewiecki
u
lopaciuk
j
stepinska
warsaw
pl
object
increas
proport
resist
strain
caus
infect
endocard
recent
year
chang
approach
choic
antibiot
therapi
linezolid
zyvoxid
new
bacteriostat
antibiot
wide
spectrum
activ
gramposit
organ
good
efficaci
experiment
anim
model
endocard
unfortun
clinic
experi
linezolid
treatment
endocard
limit
aim
studi
observ
efficaci
linezolid
treatment
infect
endocard
method
studi
group
consist
patient
hospitalis
institut
cardiolog
warsaw
warsaw
due
clinic
resist
infect
endocard
diagnosi
endocard
establish
accord
duke
criteria
clinic
examin
echocardiographi
laboratori
investig
posit
blood
cultur
vancomycin
mic
estim
pt
patient
treat
surgic
valv
replac
artifici
materi
remov
conjunct
differ
convent
antibiot
afterward
mg
linezolid
everi
hour
intraven
result
infect
endocard
diagnos
caus
mrcn
pt
mssa
pt
enterococcu
faecali
pt
staphylococcu
epidermidi
mr
pt
vancomycin
mic
vari
mgl
pt
cultureneg
endocard
diagnos
patient
treat
linezolid
intraven
week
averag
clinic
respons
erad
bacteremia
achiev
patient
leukopenia
nad
thrombocytopenia
advers
reaction
occur
patient
conclus
linezolid
effect
patient
gramposit
endocard
linezolid
could
also
effect
patient
cultureneg
endocard
linezolid
may
provid
altern
treatment
infect
endocard
due
multiresist
bacteria
patient
resist
cours
advers
reaction
convent
antibiot
object
evalu
safeti
efficaci
lzd
chines
popul
method
random
doubleblind
multicentr
studi
conduct
china
obtain
written
inform
consent
patient
year
age
pneumonia
pneu
skin
soft
tissu
infect
ssti
known
suspect
caus
gramposit
pathogen
random
receiv
either
lzd
mg
vancomycin
van
g
given
iv
patient
treat
day
outcom
assess
endoftreat
eot
followup
fu
visit
result
one
hundr
fortytwo
patient
enrol
receiv
studi
medic
pneu
ssti
clinic
assess
effect
cure
plu
mark
improv
patient
fulli
evalu
popul
summar
tabl
frequent
isol
pathogen
staphylococcu
aureu
isol
suscept
studi
drug
erad
rate
pathogen
evalu
patient
fu
evalu
lzdtreat
patient
vantreat
patient
p
patient
receiv
studi
drug
evalu
safeti
drugrel
advers
event
ae
report
lzdtreat
vantreat
patient
commonli
report
drugrel
ae
lzdtreat
patient
mild
abnorm
liver
function
test
leucopenia
rash
commonli
report
ae
vantreat
patient
seven
lzdtreat
vantreat
patient
discontinu
studi
drug
ae
conclus
linezolid
effect
drug
treatment
infect
caus
gramposit
pathogen
welltoler
erad
one
patient
rifamycinlinezolid
methicillinresist
staphylococcu
aureu
produc
pantonvalentin
leukocidin
respons
relaps
month
decolonis
famili
mupirocin
object
report
case
mother
experienc
relaps
period
method
pvlmrsa
isol
routin
mrsa
agar
biorad
antibiotyp
studi
disk
diffus
method
genet
pulsotyp
studi
french
centr
nation
de
de
staphylocoqu
lyon
cnr
result
mr
kym
child
octob
hospit
healthi
present
risk
factor
deliveri
three
week
later
address
surgic
treatment
abscess
buttock
cultur
yield
special
antibiotyp
methicillinr
kanamycinr
tobramycin
pvlmrsa
current
spread
across
europ
maghreb
cnr
found
lukspv
lukfpvgenesthrough
march
relaps
time
treat
pyostacin
total
week
two
children
address
abscess
buttock
thumb
yield
bacteria
march
mr
kym
address
infecti
diseas
ward
nasal
furonculosi
sampl
yield
pvlmrsa
mlsb
phenotyp
treatment
rifamycinlinezolid
initi
whole
famili
screen
father
boy
infect
thumb
month
earlier
carrier
girl
abscess
buttock
month
earlier
april
whole
famili
accept
attempt
decolonis
nasal
mupirocin
cure
decolonis
confirm
nare
cutan
fold
sampl
may
june
miss
addit
appoint
begin
term
phone
call
social
worker
confirm
none
relaps
cnr
studi
strain
mr
kym
children
abscess
boy
father
nare
confirm
ident
along
period
across
famili
conclus
short
treatment
linezolidrifamycin
relaps
case
associ
famili
decolonis
nasal
mupirocin
effect
strategi
stop
timeprolong
famili
outbreak
pvlmrsa
infect
multipl
brain
abscess
purul
mening
listeria
monocytogen
otherwis
healthi
man
favour
linezolid
respons
hamper
suspect
earli
drug
myelotox
introduct
l
monocytogen
cn
infect
immunocompet
adult
remain
rare
mening
common
cn
manifest
brain
abscess
overal
episod
anecdot
episod
cn
l
monocytogen
infect
report
immunocompet
patient
diagnosi
treatment
may
hamper
low
clinic
suspicion
frequent
nonspecif
present
survey
conduct
dalla
us
case
nonneonat
l
monocytogen
mening
found
estim
incid
rate
case
report
male
neglig
histori
obviou
exposur
l
monocytogen
hospit
owe
dizzi
brain
ct
scan
show
small
late
ischem
lesion
day
later
hyperpyrexia
headach
vomit
alter
mentat
occur
csf
studi
detect
elev
albumin
content
mgdl
low
glucos
mgdl
wbc
count
cellsll
neutrophil
ceftriaxonechloramphenicol
immedi
start
clinicalneurolog
condit
deterior
l
monocytogen
cultur
csf
treatment
chang
toward
highdos
ampicillingentamicin
persist
sever
clinicalneurolog
condit
alter
csf
assay
prompt
introduct
rifampicincotrimoxazol
day
day
later
focal
neurolog
deficit
appear
mri
show
small
hyperintens
focal
lesion
involv
medulla
oblongata
interpret
multipl
abscess
introduct
linezolidmeropenem
despit
anemia
requir
rbc
transfus
day
led
progress
clinicalcsf
improv
patient
recov
complet
control
mri
carri
month
discharg
confim
complet
disappear
multipl
brain
listeria
abscess
discuss
l
monocytogen
mening
multipl
subtentori
abscess
includ
rare
local
cerebellum
bulb
pon
varolii
evolv
cumbersom
present
despit
vitro
activ
broad
spectrum
agent
multipl
therapeut
chang
becam
necessari
last
linezolidmeropenem
combin
prove
effect
although
affect
relaps
anemia
probabl
attribut
linezolid
linezolid
due
elev
csfbrain
penetr
activ
broad
spectrum
cn
pathogen
includ
intracellular
l
monocytogen
expect
becom
key
antimicrobi
compound
wait
rct
discrep
favour
vitro
microbiolog
data
sever
clinic
cours
staphylococc
knee
soft
tissu
infect
respons
oxazolidinon
linezolid
failur
therapeut
attempt
introduct
offer
therapeut
altern
emerg
multiresist
seriou
gramposit
infect
novel
molecul
quinupristindalfopristin
linezolid
daptomycin
introduc
made
avail
multiresist
gramposit
cocci
document
suscept
avail
drug
includ
glycopeptid
howev
inezolid
encompass
uniqu
tissu
penetr
diffus
featur
regard
soft
tissu
lung
joint
central
nervou
system
make
last
drug
extrem
promis
circumst
penetr
rate
infecti
foci
becom
critic
clinic
experi
intrigu
case
report
sever
staphylococc
knee
arthtiri
associ
extens
local
cellulitisfasci
haematogen
dissemin
occur
surgic
curettag
character
complet
lack
respons
prolong
vancomycinteicoplanin
plu
rifampicin
therapi
base
appar
favour
vitro
sensit
assay
methicllinresist
staphylococci
rapidli
respond
iv
follow
oral
linezolid
administr
complet
lack
clinic
activ
glycopeptiderifampicin
administr
explain
vitro
measur
valu
isol
pathogen
show
complet
sensit
staphylococcu
aureu
vancomycinateicoplanin
rifampicin
suscept
concurr
hematogen
epidermidi
strain
glycopeptidesrifampicin
sinc
abscess
format
underli
osteomyel
care
exclud
adequ
instrument
examin
theoret
point
view
activ
glycopeptiderifampicin
molecul
provid
appropri
cure
hand
strictli
clinic
issu
administr
iv
linezolid
follow
one
week
oral
linezolid
allow
obtain
complet
clinicalbacteriolog
cure
complet
function
recoveri
without
sequela
followup
conclus
manag
sever
multiresist
gramposit
infect
concern
vitro
activ
singl
drug
therapeut
class
care
evalu
relat
expect
penetr
diffus
rate
drug
relev
organ
tissu
involv
ongo
infecti
local
otherwis
appar
unexplain
failur
may
occur
also
vitro
studi
point
complet
activ
test
compound
epidemiolog
resist
antibiot
ii
contemporari
preval
bro
betalactamas
catarrhali
report
sentri
antimicrobi
surveil
program
usa
l
deshpand
h
sader
r
jone
north
liberti
us
object
evalu
preval
among
blactamas
bl
produc
catarrhali
mcat
usa
although
blmediat
penicillin
pen
resist
r
mcat
stabl
occurr
determin
usa
isol
sinc
rate
report
method
communityacquir
mcat
isol
sentri
program
test
clsi
broth
microdilut
method
includ
worldwid
north
america
na
detect
pcr
method
levi
walker
compar
epidemiolog
test
mic
valu
blactamaseposit
bl
mcat
sampl
per
year
usa
site
canada
ca
site
test
oddnumb
year
result
rate
respect
rate
ca
isol
usa
sever
agent
remain
activ
amoxicillinclavulan
mgl
ceftriaxon
ctri
cefuroxim
erythromycin
levofloxacin
tetracyclin
trimethoprimsulfamethoxazol
tmp
smx
pen
mic
distribut
trimod
mgl
ctri
bimod
yet
miczon
distribut
overlap
best
discrimin
methicillin
mean
zone
vs
mm
pen
vs
disk
possibl
epidem
cluster
could
exclud
due
common
ribotyp
centr
ca
site
usa
conclus
enzym
na
preval
updat
mcat
isol
show
stabil
respect
phenotyp
test
zone
mic
easili
distinguish
blactamas
type
necessit
use
molecular
applic
object
although
resist
penicillin
beta
haemolyt
streptococci
report
yet
increas
resist
rate
altern
drug
erythromycin
clindamycin
tetracyclin
emerg
concern
bring
necess
care
monitor
penicillin
suscept
materi
method
order
detect
chang
penicillin
mic
perform
antimicrobi
suscept
test
isol
beta
haemolyt
streptococci
hospit
januari
novemb
identif
serogroup
level
done
use
commerci
latex
agglutin
kit
avipath
strep
omega
diagnost
ltd
scotland
unit
kingdom
result
total
isol
identifi
distribut
group
serogroup
b
c
g
correspondingli
penicillin
suscept
determin
use
etest
ab
biodisk
solna
sweden
strip
accord
manufactur
instruct
result
evalu
period
increas
mgml
group
mgml
group
b
mgml
group
c
mgml
group
g
tabl
conclus
even
though
highest
valu
found
group
b
mgml
result
indic
steadi
increas
penicillin
mic
serogroup
three
group
six
group
b
isol
penicillin
mic
mgml
reach
suscept
breakpoint
concentr
accord
clsi
also
highli
elev
concentr
group
b
streptococci
may
messeng
possibl
forthcom
resist
strain
object
studi
trend
macrolid
resist
rate
among
pneumonia
isol
children
age
month
attend
daycar
centr
franc
follow
implement
prudent
antibiot
use
campaign
alp
maritim
franc
pneumococc
conjug
vaccin
pcv
method
nasopharyng
aspir
obtain
random
cluster
sampl
children
attend
daycar
centr
nord
n
alp
maritim
area
consecut
survey
januari
march
march
march
suscept
erythromycin
clindamycin
resist
phenotyp
analys
disk
diffus
method
serotyp
determin
use
quell
reaction
pneumococc
immun
statu
antibiot
prescript
previou
month
record
result
sp
isol
children
respect
p
resist
macrolid
declin
overal
strain
p
among
erythromycinresist
er
isol
percentag
ermb
phenotyp
increas
p
proport
penicillin
nonsuscept
strain
declin
sp
isol
p
erythromycin
resist
remain
stabl
among
strain
overal
proport
treat
children
fell
p
reduct
observ
p
n
occur
p
percentag
macrolid
among
prescript
fell
v
trend
p
serotyp
distribut
show
er
isol
reduct
serotyp
observ
n
immunis
pcv
concern
least
children
conclus
macrolid
resist
follow
parallel
declin
penicillin
resist
result
antibioticprescript
reduc
campaign
pneumococc
immun
preval
macrolideresist
serotyp
object
evalu
preval
resist
invas
strain
pneumonia
erythromycin
declin
macrolid
consumpt
method
number
packag
antibiot
obtain
institut
public
health
slovenia
period
data
outpati
antibiot
consumpt
collect
use
atcddd
classif
version
result
express
inhabit
per
day
invas
strain
pneumonia
isol
steril
bodi
fluid
slovenian
hospit
includ
studi
suscept
test
perform
use
nccl
approv
disk
diffus
test
result
total
use
antibacteri
slovenia
decreas
consumpt
macrolid
constitut
total
use
antibacteri
decreas
shortact
erythromycin
miocamycin
intermediateact
midecamycin
roxithromycin
clarithromycin
longact
azithromycin
decreas
respect
year
use
intermediateact
macrolid
prescrib
subclass
macrolid
correspond
follow
longact
shortact
resist
pneumonia
strain
erythromycin
increas
children
adult
respect
rate
isol
resist
erythromycin
least
follow
agent
penicillin
tetracyclin
tmpsmx
chloramphenicol
increas
children
adult
respect
conclus
despit
reduct
macrolid
consumpt
outpati
resist
invas
strain
pneumonia
increas
observ
period
especi
children
multipl
drug
resist
explain
best
chang
pneumonia
resist
tenyear
surveil
studi
belgium
object
belgium
locat
countri
high
low
antibiot
resist
rate
model
resist
chang
time
place
belgium
provid
insight
correl
pneumonia
resist
popul
level
method
surveil
data
consist
pneumonia
invas
isol
identifi
postal
code
well
clinic
demograph
inform
antimicrobi
consumpt
im
health
servic
express
defin
daili
dose
ddd
per
inhabit
per
day
chang
resist
month
postal
code
evalu
use
mix
effect
model
repeat
measur
use
mathemat
model
transmiss
curv
shape
take
account
season
resist
penicillin
erythromycin
tetracyclin
ofloxacin
consid
analysi
result
resist
penicillin
macrolid
tetracyclin
peak
year
level
respect
shape
curv
similar
antibiot
studi
steep
rise
plateau
thereaft
resist
two
antibiot
class
correspond
resist
isol
multivari
model
explain
variabl
time
place
antibiot
studi
resist
one
antibiot
decreas
resist
two
increas
time
ci
p
isol
year
later
nine
ten
isol
macrolid
tetracyclin
resist
also
multipli
resist
mr
mr
increas
ddd
overal
cumul
antimicrobi
consumpt
antibiot
class
macrolid
broadspectrum
penicillin
associ
resist
conclus
resist
two
antibiot
import
factor
understand
chang
time
studi
antibiot
class
belgium
cumul
impact
antimicrobi
exposur
separ
antibiot
class
popul
level
facilit
surviv
transmiss
isol
resist
two
antibiot
class
method
isol
identifi
biochem
test
specif
serotyp
antimicrobi
suscept
ampicilllin
amp
amoxicillin
plu
clavulan
acid
auc
cloramphenicol
cm
gentamicin
gm
cotrimoxazol
sxt
acid
nal
tetracyclin
tc
establish
method
kirbi
bauer
presenc
betalactamas
encod
gene
tem
carb
well
teta
tetb
tetc
tetg
cmla
flor
gene
integron
type
establish
pcr
presenc
plasmidmedi
dhfr
determin
pcrrflp
cat
activ
colorimetr
assay
result
seven
differ
resist
pattern
identifi
suscept
strain
ii
amp
sxt
gm
ac
iii
amp
tc
cm
iv
amp
tc
sxt
cm
v
amp
ac
vi
amp
sxt
ac
vii
sxt
isol
resist
nalidix
acid
detect
resist
betalactam
agent
due
presenc
betalactamas
type
temlik
pattern
v
iii
temlik
plu
ii
v
vi
meanwhil
resist
cloranphenicol
tetracyclin
associ
cat
activ
iii
iv
flor
iii
tetb
iv
tetg
iii
respect
mechan
cotrimoxazol
resist
detect
isol
pattern
ii
vi
vii
detect
isol
group
iv
resist
gm
associ
presenc
gene
aadb
detect
analysi
integron
type
type
integron
detect
isol
belong
toi
pattern
ii
bp
aadb
bp
iii
bp
iv
bp
v
vi
bp
conclus
great
divers
resist
mechan
detect
mechan
might
spread
among
microorgan
result
seriou
health
problem
due
limit
number
antibiot
treatment
avail
area
small
outbreak
esbl
produc
acinetobact
baumannii
belgian
nurs
home
hospit
crossbord
transfer
patient
northern
franc
method
belgian
acut
hospit
invit
report
case
nosocomi
infectionscolonis
due
mdr
ab
isol
present
resist
profil
similar
french
epidem
strain
resist
agent
except
carbapenem
colistin
send
isol
refer
laboratori
phenotyp
confirm
genotyp
character
pcr
class
integron
pfge
type
guidelin
detect
epidem
strain
screen
carriag
patient
transfer
hospit
nurs
home
nh
close
french
border
well
infect
control
measur
sent
hospit
result
overal
ab
strain
hospit
sent
refer
laboratori
fulfil
phenotyp
resist
pattern
definit
confirm
ab
pfge
pattern
ident
french
epidem
clone
two
minioutbreak
cluster
involv
case
document
hospit
two
citi
tournai
chimay
close
french
border
two
patient
die
infect
first
outbreak
patient
resid
live
nh
two
french
citizen
hospitalis
differ
acut
care
hospit
north
franc
within
last
year
second
outbreak
index
case
also
previous
hospitalis
french
hospit
secondari
transmiss
two
hospitalis
patient
occur
outbreak
conclus
despit
larg
extens
ab
outbreak
franc
similar
problem
occur
belgium
howev
nation
alert
allow
detect
two
small
outbreak
belgian
institut
locat
close
french
border
outbreak
epidem
strain
import
franc
patient
circuit
studi
illustr
transfer
acut
care
hospit
nh
may
explain
crossbord
spread
multiresist
epidem
strain
type
extendedspectrum
betalactamas
salmonella
spp
decreas
suscept
fluoroquinolon
object
aim
studi
determin
rate
esbl
product
clinic
isol
salmonella
spp
detect
decreas
suscept
fluoroquinolon
esbl
posit
isol
turkey
method
total
salmonella
spp
isol
clinic
sampl
thirteen
centr
includ
studi
vitro
suscept
ampicillin
amoxicillinclavulan
acid
cefotaxim
gentamicin
chloramphenicol
tetracyclin
trimethoprimsulfamethoxazol
ciprofloxacin
determin
use
agar
dilut
method
muellerhinton
agar
follow
clinic
laboratori
standard
institut
clsi
guidelin
decreas
suscept
ciprofloxacin
defin
mic
mgl
salmonella
isol
screen
esbl
product
doubl
disk
synergi
method
use
amoxicillinclavulan
acid
cefotaxim
ceftazidim
disk
type
esbl
enzym
analys
pcr
tem
ctxm
shv
gene
result
salmonella
spp
highest
level
resist
observ
ampicillin
follow
chloramphenicol
tetracyclin
amoxicillin
clavulan
acid
trimethoprimsulfamethoxazol
gentamicin
cefotaxim
ciprofloxacin
resist
observ
one
isol
among
salmonella
isol
shown
produc
esbl
doubl
disk
synergi
test
isol
salmonella
typhimurium
n
serogroup
n
salmonella
enteritidi
n
three
isol
fecal
sampl
two
urin
one
blood
one
esbl
produc
isol
suscept
cefotaxim
vitro
two
isol
show
decreas
suscept
ciprofloxacin
esbl
produc
resist
ampicillin
amoxicillin
clavulan
acid
chloramphenicol
harbor
ctxm
type
enzym
three
isol
temtyp
enzym
also
present
conclus
albeit
rare
esbl
product
import
resist
factor
among
salmonella
spp
order
prevent
treatment
failur
decreas
suscept
fluoroquinolon
investig
routin
invas
isol
well
esbl
product
incid
faecal
carriag
esblproduc
enterobacteriacea
hospit
commun
patient
two
nonoutbreak
period
time
ident
esblproduc
isol
recov
e
coli
n
k
pneumonia
n
p
vulgari
n
e
cloaca
n
isol
recov
e
coli
n
k
pneumonia
n
k
oxytoca
n
p
vulgari
n
p
mirabili
n
e
cloaca
n
e
aerogen
n
conclus
dramat
signific
increas
frequenc
faecal
carriag
esblproduc
isol
demonstr
among
hospit
ambulatori
patient
result
reveal
preval
faecal
carriag
among
ambulatori
patient
hospit
patient
significantli
differ
period
time
outpati
came
commun
carri
enterobacteria
harbour
esbl
intestin
tract
suggest
commun
could
reservoir
microorgan
enzym
method
total
k
pneumonia
k
oxytoca
e
coli
c
freundii
marcescen
e
cloaca
univers
hospit
isol
blood
wound
urin
sputum
clinic
signific
specimen
proven
produc
esbl
antimicrobi
suscept
determin
accord
clsi
conjug
solid
medium
perform
isoelectr
focus
follow
bioassay
pcr
betalactamas
groupspecif
oligonucleotid
appli
follow
nucleotid
sequenc
rapd
eric
primer
perform
result
mic
ceftazidim
vari
mgl
mic
cefotaxim
mgl
addit
sulbactam
reduc
mic
transconjug
exhibit
resist
extendedspectrum
cephalosporin
aminoglycosid
strain
accord
pi
two
cluster
betalactamas
produc
could
describ
first
one
esbl
focuss
pi
second
pi
result
pcr
confirm
presenc
two
group
esbl
tem
shv
sequenc
repres
strain
show
presenc
two
particip
hospit
one
strain
e
cloaca
like
enzym
found
centr
clonal
dissemin
object
treatment
select
decontamin
digest
tract
sdd
four
strain
multidrugresist
mdr
gramneg
bacteria
three
escherichia
coli
strain
one
klebsiella
pneumonia
isol
intens
care
unit
icu
academ
medic
center
amc
amsterdam
isol
extend
spectrum
betalactamas
esbl
posit
investig
whether
due
interspeci
transfer
resist
gene
method
strain
type
amplifi
fragment
length
polymorph
analysi
plasmid
strain
character
restrict
fragment
length
polymorph
resist
gene
mdrstrain
character
pcr
sequenc
analysi
result
aflp
analysi
confirm
three
mdr
e
coli
isol
repres
three
differ
strain
mdrstrain
shown
harbour
plasmid
ident
extendedspectrum
esbl
gene
conclus
identif
emerg
mdr
gramneg
bacteria
recognit
resist
plasmid
transfer
sdd
treatment
crucial
optim
applic
regimen
icu
use
third
gener
cephalosporin
sdd
may
associ
emerg
increas
preval
esbl
therefor
optim
screen
resist
cephalosporin
icu
screen
esbl
includ
object
carbapenem
drug
choic
treatment
seriou
infect
caus
esblproduc
enterobacteriacea
emerg
carbapenem
resist
rare
document
investig
pair
carbapenemsuscept
resist
k
pneumonia
isol
three
patient
collect
therapi
carbapenem
method
preand
posttherapi
pair
esblproduc
k
pneumonia
isol
three
patient
urinari
catheterassoci
infect
treat
ertapenem
erp
case
meropenem
mem
one
case
district
gener
hospit
low
incid
esblproduc
organ
bed
day
meropenem
use
dddyear
isol
compar
pfge
xbaidigest
genom
dna
mic
determin
interpret
british
societi
antimicrobi
chemotherapi
methodolog
blactxm
allel
sought
multiplex
pcr
outer
membran
protein
omp
extract
analys
sdspage
result
three
patient
relaps
follow
erp
mem
therapi
posttherapi
isol
repeat
urin
sampl
resist
tabl
mic
erp
mem
ipm
six
isol
three
patient
belong
pfge
strain
transmiss
resist
variant
unlik
patient
geograph
tempor
unrel
separ
select
resist
individu
patient
seem
like
isol
group
ctxm
esbl
resist
isol
pair
lost
major
omp
consist
porin
compar
suscept
parent
three
patient
success
treat
amikacin
emerg
carbapenem
resist
ctxmproduc
k
pneumonia
follow
therapi
sever
limit
treatment
option
whilst
unusu
gener
select
occur
repeatedli
strain
wide
geograph
spread
divers
acquir
ampc
betalactamas
escherichia
coli
klebsiella
spp
uk
ireland
object
determin
distribut
gene
encod
acquir
ampc
betalactamas
cephalosporinresist
isol
e
coli
klebsiella
spp
submit
uk
nation
refer
laboratori
method
mic
determin
agar
dilut
interpret
accord
breakpoint
british
societi
antimicrobi
chemotherapi
isol
e
coli
klebsiella
spp
resist
cefotaxim
ceftazidim
irrespect
addit
clavulan
acid
infer
possibl
ampcmedi
resist
gene
encod
six
phylogenet
group
acquir
ampc
enzym
sought
multiplex
pcr
assay
perezperez
hanson
j
clin
microbiol
select
isol
compar
pfge
select
blaampc
amplicon
sequenc
result
e
coli
isol
klebsiella
spp
separ
patient
yield
pcr
amplicon
indic
presenc
gene
encod
acquir
ampc
enzym
forti
e
coli
isol
hospit
produc
cittyp
enzym
irish
hospit
produc
acc
type
dha
type
klebsiella
spp
produc
acc
isol
irish
hospit
fox
isol
welsh
hospit
dha
irish
isol
enzym
gene
encod
ebcentand
moxtyp
enzym
detect
twelv
e
coli
isol
one
hospit
produc
cittyp
enzym
isol
belong
epidem
uk
strain
design
strain
isol
also
contain
link
upstream
copi
characterist
strain
isol
lack
sequenc
repres
blaampc
amplicon
indic
product
novel
variant
isol
conclus
divers
acquir
ampc
enzym
present
e
coli
klebsiella
spp
uk
ireland
cittyp
common
acc
type
link
ireland
broad
resist
profil
ampc
enzym
compromis
patient
manag
henc
acquisit
enzym
epidem
e
coli
strain
suggest
acquir
ampc
enzym
pois
becom
import
public
health
issu
uk
object
character
spectrum
activ
potenc
dor
formerli
compar
agent
contemporari
wildtyp
bacteri
isol
medic
centr
europ
middl
east
dor
novel
parenter
carbapenem
late
stage
clinic
develop
whose
molecular
structur
confer
stabil
blactamas
resist
r
renal
dehydropeptidas
method
collect
includ
nondupl
consecut
clinic
isol
patient
medic
centr
europ
turkey
israel
submit
dor
surveil
program
identif
confirm
suscept
test
mic
valu
antimicrobi
determin
use
nccl
broth
microdilut
method
tent
dor
suscept
breakpoint
mgl
mgl
pneumonia
use
compar
purpos
clsi
criteria
use
test
agent
result
antimicrobi
activ
dor
carbapenem
vs
select
isol
dor
consist
display
activ
staphylococci
streptococci
mgl
similar
imipenem
e
coli
klebsiella
spp
mgl
respect
includ
strain
met
esbl
screen
criteria
similar
meropenem
enterobact
spp
isol
includ
ceftazidim
indic
ampc
product
also
highli
dor
carbapenem
r
dor
also
provid
slightli
enhanc
coverag
p
aeruginosa
acinetobact
spp
compar
carbapenem
carbapenem
r
among
latter
strain
howev
particularli
worrisom
develop
conclus
dor
new
carbapenem
competit
profil
incorpor
potent
gramneg
gramposit
activ
enhanc
activ
commonli
occur
nonfer
gramneg
bacilli
carbapenem
assum
greater
therapeut
role
mani
nation
multidrug
resist
includ
emerg
ambler
class
c
blactamas
spread
necessit
acceler
develop
phenotyp
genet
characteris
enterococc
isol
tehran
sewag
emphasi
detect
vana
vanb
gene
object
enterococci
member
normal
gut
flora
anim
human
thu
releas
environ
directli
via
sewag
outlet
surviv
long
time
period
last
decad
concern
focus
enterococci
resist
glycopeptid
antibiot
vancomycin
vancomycinresist
enterococci
vre
aim
studi
detect
analys
biochem
divers
entrococci
strain
tehran
sewag
determin
genet
character
vre
method
total
isol
enterococci
select
agar
medium
isol
identifi
speci
level
common
biochem
test
drug
suscept
test
isol
done
disk
diffus
method
antibiot
vancomycin
erythromycin
gentamicin
tetracyclin
chloramphenicol
ciprofloxacin
mic
also
done
macrobroth
dilut
assay
analysi
plasmid
profil
pcr
test
vana
vanb
gene
done
method
studi
vre
isol
collect
north
center
portug
portug
clinic
isol
hospit
differ
citi
ii
faecal
sampl
healthi
volunt
iii
river
water
sampl
iv
sampl
collect
downstream
hospit
sewag
water
v
sampl
urban
sewag
water
vi
swine
faec
vii
poultri
food
sampl
human
consumpt
identif
character
vancomycin
resist
gene
vana
vanb
determin
multiplex
pcr
backbon
structur
character
pcr
overlap
assay
overlap
fragment
sequenc
conclus
betalactamas
product
among
hi
strain
declin
significantli
sinc
among
children
attend
daycar
centr
antibiot
prescript
fell
among
popul
result
mic
distribut
show
strain
n
mic
mgl
mic
mgl
indic
resist
still
rel
rare
increas
compar
lognorm
distribut
amc
strain
r
extend
mgl
show
tail
mgl
may
indic
hidden
less
suscept
strain
could
equal
well
explain
test
circumst
sinc
left
part
mic
distribut
show
compar
tail
strain
suscept
moxifloxacin
levofloxacin
cefotaxim
lognorm
distribut
sxt
extend
mgl
strain
show
higher
valu
doxycyclin
resist
less
strain
resist
clarithromycin
azithromycin
mgl
conclus
resist
hi
common
antimicrobi
netherland
still
low
increas
object
pneumonia
sp
h
influenza
hi
two
common
pathogen
associ
communityacquir
pneumonia
chang
preval
resist
multidrug
resist
mdr
among
pathogen
import
therapeut
ramif
global
surveil
initi
longitudin
studi
benchmark
antibacteri
resist
among
respiratori
pathogen
method
sp
hi
isol
patient
specimen
collect
hospit
laboratori
franc
fr
germani
ger
itali
spain
spa
unit
kingdom
uk
isol
central
test
broth
microdilut
lev
penicillin
pen
sp
azithromycin
azi
erythromycin
eri
clindamycin
cli
ceftriaxon
ctx
cefuroxim
cfx
trimethoprimsulfamethoxazol
tmpsmx
nccl
data
analys
accord
pen
resist
mdr
blactamas
statu
mdr
defin
concurr
resist
follow
agent
ctx
cfx
eri
lev
pen
tmpsmx
result
sp
pen
r
ger
uk
spa
fr
azi
r
uk
ger
spa
fr
overal
lev
r
rare
mgl
countri
isol
suscept
drug
test
common
phenotyp
encount
preval
mdr
among
sp
rang
uk
fr
resist
pen
eri
cfx
tmpsmx
preval
mdr
phenotyp
found
europ
overal
mdr
sp
suscept
lev
hi
blactamas
rate
vari
countri
fr
base
lev
ctx
activ
agent
test
hi
regardless
blactamas
statu
conclus
lev
show
potent
activ
sp
hi
sp
lev
activ
independ
resist
pen
mdr
phenotyp
lev
maintain
consist
activ
sp
base
regardless
countri
studi
antimicrobi
surveil
data
studi
global
offer
guidanc
physician
empir
prescrib
sxt
obtain
sxt
obtain
conclus
result
suggest
betalactamas
product
constitut
threat
hi
therapi
sinc
valu
almost
constant
although
unregul
fluctuat
arnblp
percentag
seem
mechan
gain
import
relat
betalactamas
product
thu
conclud
need
awar
arnblp
strain
difficult
detect
use
nccl
breakpoint
molecular
studi
resist
gene
respons
resist
mechan
need
resist
betalactamas
produc
strain
antibiot
decreas
period
studi
due
diminish
use
antibiot
studi
show
import
monitor
antibiot
resist
hi
order
detect
emerg
mechan
antimicrobi
suscept
respiratori
haemophilu
influenza
strain
northern
greec
k
koraki
p
karapavlid
sofian
thessaloniki
gr
object
investig
antimicrobi
suscept
haemophilu
influenza
one
frequent
bacteri
pathogen
respiratori
tract
infect
treatment
infect
often
empir
consider
geograph
resist
variat
report
method
eighti
h
influenza
strain
collect
respiratori
tract
specimen
sputum
bronchoalveolar
lavag
endotrach
secret
period
identif
made
coloni
morpholog
gram
stain
characterist
xand
vfactor
requir
api
nh
biomerieux
franc
antibiot
select
reflect
repres
current
treatment
option
suscept
determin
kirbybau
disc
diffus
method
haemophilu
test
medium
accord
nccl
guidelin
result
h
influenza
strain
isol
children
adult
isol
came
children
admit
intens
care
unit
cystic
fibrosi
patient
season
trend
report
infect
sinc
isol
collect
springtim
autumn
month
overal
ampicillin
resist
resist
strain
isol
exclus
children
ampicillin
resist
doubl
among
cystic
fibrosi
patient
isol
suscept
amoxicillinclavulan
chloramphenicol
ciprofloxacin
imipenem
rank
order
cephalosporin
activ
cefotaxim
ceftriaxon
follow
cefuroxim
cefaclor
respect
trimethoprim
sulfomethoxazol
activ
isol
erythromycin
least
potent
antimicrobi
agent
isol
suscept
multiresist
phenotyp
detect
conclus
result
demonstr
ampicillin
resist
among
h
influenza
area
still
rel
low
overal
antibacteri
suscept
rate
high
knowledg
antimicrobi
resist
among
pathogen
imper
physician
choos
appropri
therapeut
agent
result
nosocomi
gramneg
uropathogen
studi
common
uropathogen
p
aeruginosa
e
coli
k
pneumonia
follow
baumannii
enterobact
spp
marcescen
proteu
spp
gramneg
rod
resist
rate
ir
among
p
aeruginosa
gentamicin
levofloxacin
ciprofloxacin
cefoperazon
cefoperazonesulbactam
cefepim
piperacillin
amikacin
ceftazidim
imipenem
meropenem
piperacillintazobactam
polymyxin
b
resist
rate
ir
among
e
coli
piperacillin
ticarcillinclavulan
acid
amoxicillinclavulan
acid
ciprofloxacin
gentamicin
moxifloxacin
levofloxacin
cefoperazon
ceftriaxon
cefepim
ceftazidim
cefoperazonesulbactam
piperacillintazobactam
amikacin
strain
suscept
ertapenem
imipenem
meropenem
resist
rate
ir
among
k
pneumonia
follow
piperacillin
cefoperazon
ceftriaxon
gentamicin
amoxicillinclavulan
acid
cefepim
ceftazidim
ciprofloxacin
piperacillin
tazobactam
moxifloxacin
cefoperazonesulbactam
levofloxacin
amikacin
ertapenem
imipenem
meropenem
activ
isol
conclus
p
aeruginosa
e
coli
k
pneumonia
main
gramneg
uropathogen
russian
icu
patient
imipenem
meropenem
ertapenem
show
promin
activ
e
coli
k
pneumonia
cefoperazonesulbactam
piperacillintazobactam
amikacin
exhibit
consider
activ
versu
e
coli
k
pneumonia
resist
p
aeruginosa
highli
resist
test
antimicrobi
except
polymyxin
b
thu
leav
virtual
choic
therapi
term
accept
patient
safeti
result
overal
gramneg
anaerob
bacteria
patient
studi
isol
site
repres
intraabdomin
soft
tissu
prostat
fluid
bone
dental
infect
suscept
prevotella
spp
bacteroid
spp
predominantli
b
fragili
group
strain
fusobacterium
spp
porphyromona
spp
veillonella
spp
ampicillin
clindamycin
metronidazol
imipenem
ertapenem
amoxicillinclavulan
acid
cefoperazonesulbactam
determin
speci
suscept
carbapenem
prevotella
spp
strain
resist
ampicillin
clindamycin
strain
intermedi
resist
metronidazol
among
bacteroid
spp
strain
resist
ampicillin
clindamycin
resist
metronidazol
detect
bacteroid
spp
object
object
studi
analys
current
blood
cultur
practic
describ
frequenc
occurr
antimicrobi
suscept
bloodstream
infect
bsi
isol
determin
contamin
rate
method
perform
prospect
survey
posit
blood
cultur
receiv
depart
microbiolog
tartu
univers
hospit
bed
blood
cultur
system
use
bactec
duplic
within
one
week
exclud
isol
identifi
use
convent
microbiolog
method
suscept
test
recommend
nccl
determin
extend
spectrum
betalactamas
esbl
produc
etest
cefepim
cefepim
combin
clavulan
acid
use
nosocomi
infect
defin
accord
cdc
criteria
result
studi
period
blood
cultur
bottl
receiv
compris
blood
cultur
set
set
per
patientday
result
posit
blood
cultur
consid
contamin
contamin
rate
total
bsi
episod
involv
patient
identifi
nosocomi
incid
nosocomi
bsi
nbsi
communityacquir
bsi
cabsi
per
patientday
respect
polymicrobi
bsi
detect
patient
among
nbsi
domin
coagulaseneg
staphylococci
staphylococcu
aureu
klebsiella
spp
escherichia
coli
frequent
pathogen
cabsi
e
coli
aureu
haemophilu
influenza
streptococcu
pneumonia
suscept
oxacillin
aureu
con
respect
pneumonia
isol
suscept
penicillin
e
coli
strain
suscept
ciprofloxacin
ampicillin
gentamicin
suscept
klebsiella
spp
ciprofloxacin
gentamicin
ampicillin
klebsiella
spp
none
e
coli
isol
esblproduc
suscept
pattern
nbsi
cabsi
pathogen
similar
conclus
compar
west
north
european
countri
number
blood
cultur
set
per
patientday
low
may
explain
rel
low
incid
bsi
intervent
reduc
contamin
rate
need
implement
suscept
among
bsi
isol
high
recent
outbreak
c
difficil
associ
diarrhoea
cdad
report
north
america
unit
kingdom
netherland
emphas
import
ongo
surveil
cdad
aim
present
studi
determin
epidemiolog
cdad
past
year
rate
nosocomi
transmiss
acut
care
hospit
materi
method
case
cdad
diagnos
januari
decemb
retrospect
review
cdad
case
defin
diarrhoea
hospitalis
patient
posit
result
c
difficil
cytotoxin
posit
toxigen
cultur
cdad
consid
sever
patient
fulfil
least
follow
criteria
fever
abdomin
pain
leukocyt
count
patient
endoscop
proven
pseudomembran
coliti
complic
toxic
megacolon
cdad
consid
commun
acquir
diarrhoea
occur
patient
within
h
admiss
patient
histori
hospitalis
previou
month
otherwis
cdad
consid
nosocomi
strain
serogroup
character
toxinotyp
pcrribotyp
detect
toxin
toxin
b
binari
toxin
perform
pcr
result
case
cdad
diagnos
clinic
chart
could
review
strain
studi
global
incid
cdad
per
thousand
discharg
higher
rate
diarrhoea
commun
acquir
patient
patient
nosocomi
cdad
transmiss
strain
patient
patient
ie
strain
serogroup
pcrribotyp
strain
anoth
patient
hospitalis
ward
previou
month
demonstr
case
binari
toxin
posit
strain
binari
toxin
associ
sever
diarrhoea
p
higher
case
fatal
p
specif
clone
account
strain
serogroup
h
pcrribotyp
clone
found
nosocomi
commun
case
three
strain
belong
toxinotyp
iii
investig
need
know
whether
strain
correspond
hypervirul
strain
involv
recent
outbreak
conclus
incid
cdad
low
hospit
cross
infect
limit
result
also
suggest
strain
binari
toxin
might
virul
develop
applic
new
exact
type
method
clostridium
difficil
multilocu
variabl
number
tandem
repeat
analysi
object
studi
epidemiolog
clostridium
difficil
type
method
higher
discriminatori
power
typeabl
reproduc
current
avail
method
requir
multilocu
variabl
number
tandem
repeat
analysi
mlva
new
candid
techniqu
alreadi
test
success
number
bacteri
fungal
speci
use
whole
genom
sequenc
develop
mlva
c
difficil
compar
method
standard
pcrribotyp
addit
mlva
test
collect
new
emerg
hypervirul
pcrribotyp
strain
method
short
tandem
repeat
loci
bp
identifi
use
tandem
repeat
finder
genom
c
difficil
strain
amplif
repeat
perform
use
singl
pcrprotocol
pcrfragment
analys
use
multicolour
capillari
electrophoresi
intern
marker
sampl
number
repeat
per
fragment
subsequ
determinedth
discriminatori
power
mlva
test
refer
strain
repres
serogroup
toxinotyp
abil
subtyp
specif
pcrribotyp
investig
subtyp
pcrribotyp
reppcr
type
tcdatcdb
strain
pcrribotyp
strain
belong
pcrribotyp
type
strain
isol
outbreak
endem
case
result
total
region
short
tandem
repeat
identifi
mlva
discrimin
refer
strain
known
refer
strain
pcrribotyp
reppcr
two
mlvatyp
recogn
among
tcdatcdb
strain
differ
present
one
repeatregion
pcrribotyp
strain
outbreakrel
strain
ident
interestingli
two
endem
type
strain
differ
strain
region
conclus
mlva
highli
discriminatori
genotyp
method
c
difficil
capabl
subtyp
variou
crribotyp
mlva
also
import
new
tool
studi
epidemiolog
emerg
pcrribotyp
strain
compar
studi
clostridium
difficil
diarrhoea
elderli
patient
treat
moxifloxacin
versu
amoxycillin
lower
respiratori
tract
infect
l
mooney
wilcox
leed
uk
fourth
gener
fluoroquinolon
moxifloxacin
improv
antianaerob
activ
consequ
new
agent
could
induc
c
difficil
infect
cdi
inhibit
protect
anaerob
flora
recent
report
suggest
associ
howev
studi
warrant
determin
risk
cdi
elderli
inpati
treat
agent
notabl
exposur
cd
measur
control
method
prospect
investig
propens
moxifloxacin
mox
amoxycillinmacrolid
amlmac
induc
cdi
use
treat
lower
respiratori
tract
infect
lrti
elderli
inpati
use
crossov
design
month
total
patient
prescrib
mox
amlmac
monitor
gastrointestin
symptom
diarrhoea
assess
due
cd
viral
caus
relev
clinic
data
collect
concurr
epidemiolog
surveil
also
perform
determin
environment
exposur
cd
result
patient
studi
receiv
mox
amlmac
univari
analysi
indic
signific
differ
mox
amlmac
patient
gender
age
vs
mean
year
respect
durat
hospitalis
total
prior
post
diarrhoea
durat
antibiot
therapi
differ
significantli
mox
compar
patient
either
total
day
day
diarrhoea
onset
signific
associ
mox
overal
risk
diarrhoea
howev
signific
mox
treatment
cd
viral
caus
diarrhoea
risk
factor
analysi
inform
possibl
confound
perform
initi
epidemiolog
survey
result
indic
chang
environment
exposur
level
cd
hospit
ward
molecular
type
clinic
environment
isol
cd
ongo
conclus
although
recent
report
highlight
risk
cdi
associ
fluoroquinolon
increas
age
none
specif
studi
hospitalis
elderli
popul
prospect
control
exposur
cd
diarrhoea
occur
rel
frequent
antibiot
therapi
elderli
mox
associ
increas
rate
diarrhoeal
symptom
caus
cdi
explain
associ
mox
treatment
significantli
associ
cdi
compar
amoxmac
treatment
lrti
elderli
inpati
preval
associ
macrolidelincosamidestreptogramin
b
resist
resist
moxifloxacin
clostridium
difficil
strain
isol
symptomat
adult
children
hospitalis
two
univers
hospit
warsaw
h
pituch
wultanska
g
nurzynska
p
obuchwoszczatynski
f
meiselmikolajczyk
luczak
warsaw
pl
object
clostridium
difficil
main
aetiolog
agent
nosocomi
diarhoea
clindamycin
penicillin
cephalosporin
associ
cdad
howev
sever
case
report
fluoroquinoloneassoci
c
difficil
diarrhea
publish
c
difficil
strain
usual
exhibit
suscept
metronidazol
vancomycin
describ
preval
associ
macrolidelincosamidestreptogramin
b
mlsb
type
resist
resist
moxifloxacin
c
difficil
strain
isol
adult
children
method
eightythre
c
difficil
strain
recov
adult
children
hospitalis
two
univers
hospit
investig
hospit
adult
n
children
n
hospit
adult
n
toxin
type
determin
commerci
test
toxin
cytotox
test
toxin
b
tcda
tcdb
detect
pcr
mic
erythromycin
clindamycin
moxifloxacin
vancomycin
metronidazol
determin
etest
ab
biodisk
sweden
ermb
gene
detect
pcr
result
sixtyseven
c
difficil
strain
toxigen
among
ab
ab
strain
suscept
vancomycin
metronidazol
high
level
resist
erythromycin
clindamycin
moxifloxacin
found
test
strain
respect
twentyon
c
difficil
strain
harbour
high
level
resist
erythromycin
clindamycin
moxifloxacin
simultan
among
ab
isol
adult
twentyon
macrolidelincosamidestreptogramin
b
mlsb
resist
ab
strain
carri
erythromycin
resist
methylas
gene
ermb
conclus
resist
clindamycin
erythromycin
moxifloxacin
among
polish
ab
c
difficil
strain
frequent
fluoroquinolon
resist
associ
resist
mlsb
antimicrobi
suggest
increas
use
fluoroquinolon
select
pressur
clonal
dissemin
ab
c
difficil
strain
fluoroquinolon
use
strong
risk
factor
cdad
hospit
acknowledg
work
support
ministri
scientif
research
inform
technolog
grant
nation
surveil
incid
clostridium
difficileassoci
diarrhoea
netherland
paltans
r
guseinova
r
van
den
berg
c
visser
e
van
der
vorm
ej
kuijper
leiden
amsterdam
nl
object
recent
outbreak
clostridium
difficileassoci
diarrhoea
cdad
due
new
emerg
pcrribotyp
toxinotyp
iii
strain
renew
interest
cdad
import
nosocomi
infect
determin
incid
cdad
netherland
conduct
prospect
surveil
studi
hospit
netherland
clinic
microbiolog
infect
volum
supplement
method
may
juli
particip
hospit
regist
patient
diagnos
cdad
standard
questionnair
devis
obtain
patient
inform
faec
sampl
isol
strain
sent
refer
laboratori
lumc
cultur
presenc
gene
toxin
b
tcda
tcdb
pcrribotyp
perform
accord
method
bidet
toxinotyp
describ
rupnik
et
al
result
routin
method
diagnos
cdad
laboratori
includ
combin
cytotox
test
enzymeimmunoassay
cultur
toxinogen
strain
total
patient
cdad
report
overal
incid
median
cdad
patient
admiss
vari
patient
cdad
commun
acquir
median
age
patient
nosocomi
acquir
cdad
year
patient
cdad
die
studi
period
least
differ
pcrribotyp
could
recogn
among
strain
type
identifi
patient
hospit
toxinotyp
reveal
presenc
least
differ
type
strain
tcdatcdb
tcdatcdband
tcdatcdb
conclus
incid
cdad
netherland
lower
report
usa
canada
vari
consider
per
hospit
new
emerg
type
found
patient
hospit
high
incid
cdad
per
admiss
outbreak
clostridium
difficil
pcrribotyp
toxinotyp
iii
harderwijk
netherland
object
sinc
sever
epidem
clostridium
difficileassoci
diarrhoea
cdad
caus
c
difficil
pcrribotyp
toxinotyp
iii
occur
usa
canada
uk
april
first
outbreak
encompass
patient
observ
medium
larg
hospit
bed
netherland
isol
strain
complet
resist
erythromycin
ciprofloxacin
patient
characterist
predispos
factor
outcom
cdad
studi
method
casecontrol
studi
perform
patient
random
select
control
without
diarrhoea
stay
depart
patient
diagnosi
cdad
made
standard
questionnair
design
collect
data
patient
record
surviv
patient
interview
month
diagnosi
faec
sampl
cultur
presenc
c
difficil
isol
type
result
incid
cdad
increas
per
patient
admiss
per
admiss
april
septemb
patient
cdad
due
type
identifi
patient
die
direct
result
cdad
eleven
patient
experienc
one
relaps
averag
age
case
yr
patient
male
multivari
analysi
antibiot
use
p
durat
hospit
stay
case
day
control
day
p
tube
feed
p
found
significantli
associ
cdad
particular
use
ciprofloxacin
p
cephalosporin
p
associ
associ
found
use
protonpump
inhibitor
risk
cdad
use
erytromycin
significantli
higher
case
control
univari
analysi
p
relat
signific
multivari
analysi
conclus
antibiot
use
especi
ciprofloxacin
cephalosporin
durat
hospit
stay
tube
feed
significantli
associ
cdad
caus
c
difficil
type
toxinotyp
iii
netherland
could
confirm
previous
describ
relat
use
protonpump
inhibitor
risk
cdad
clostridium
difficil
pcr
ribotyp
toxinotyp
iii
netherland
object
method
shortli
report
june
clostridium
difficil
pcr
ribotyp
toxinotyp
iii
england
virul
type
also
detect
netherland
respons
dutch
centr
infecti
diseas
control
undertaken
measur
monitor
control
outbreak
c
difficil
guidelin
infect
control
treatment
formul
separ
hospit
nurs
home
leiden
univers
medic
centr
serv
refer
centr
diagnost
type
c
difficil
laboratori
encourag
send
sampl
type
case
clear
rise
incid
c
difficil
rapid
spread
sever
clinic
suspect
casesorganisationbas
surveil
set
questionnair
sent
monthli
institut
c
difficil
associ
diarrhoea
cdad
outbreak
obtain
inform
incid
c
difficil
test
strategi
antibiot
use
control
measur
takenmeasur
taken
hospit
deal
outbreak
type
includ
treatment
cdad
vancomycin
stead
metronidazol
emphasi
frequent
thorough
clean
disinfect
isol
patient
diarrhoea
test
neg
c
difficil
toxin
cohort
isol
cdadcas
individu
isol
capac
exceed
strong
restrict
certain
antibiot
includ
fluorochinolon
result
novemb
sampl
institut
sent
type
result
type
posit
epidem
spread
type
detect
hospit
one
nurs
home
furthermor
retrospect
studi
four
hospit
isol
case
type
detect
becam
clear
one
region
three
hospit
cdad
incid
alreadi
risen
respect
unfortun
sampl
period
avail
type
hospit
epidem
spread
type
wide
rang
monthli
incid
cdad
observ
per
admiss
outbreak
incid
preepidem
period
vari
see
figur
conclus
outbreak
hospit
difficult
control
hospit
continu
new
case
long
period
although
incid
decreas
sever
hospit
fortun
c
difficil
outbreak
hospit
recognis
spread
hospit
observ
object
c
difficil
major
caus
antibiot
associ
diarrhoea
aad
coliti
c
aim
studi
determin
incid
infect
hospit
bed
period
month
marchoctob
method
number
liquid
stool
equal
adult
patient
mean
age
f
receiv
broad
spectrum
antibiot
especi
cephalosporin
plate
ccfa
oxoid
anaerob
brucella
agar
ba
alcohol
shock
procedur
cultur
posit
immunochromatograph
test
perform
toxin
colorpactm
toxin
bd
usa
last
test
neg
rapid
enzym
immunoassay
perform
toxin
ab
immunocard
meridian
bioscienc
inc
cincinatti
ohio
result
c
difficil
isol
sampl
seventeen
men
patholog
p
pneumolog
pn
surgic
urolog
u
outpati
respectivli
women
harbor
c
difficil
intestin
twelv
strain
produc
toxin
remain
produc
toxin
b
eleven
patient
sever
diarrhoea
day
one
patient
got
endoscop
examin
confirm
coliti
find
two
outpati
receiv
oral
cefuroxim
preced
week
posit
cultur
conlus
incid
c
difficil
infect
studi
among
report
intern
bibliographi
sinc
toxigen
b
c
difficil
strain
demonstr
half
case
use
test
detect
toxin
b
clinic
laboratori
recommend
molecular
technic
applic
eg
pfge
ribotyp
offer
better
knowledg
c
difficil
spread
hospit
assay
cytotox
stool
sampl
cell
tissu
cultur
commonli
consid
gold
standard
detect
c
difficil
toxin
howev
method
slow
therefor
use
result
delay
patient
treatment
implement
infect
control
measur
undertook
comparison
two
microtitr
platebas
elisa
kit
techlab
c
difficil
tox
ab
ii
meridian
premier
toxin
b
three
rapid
immunoassay
card
kit
remel
xpect
clostridium
difficil
toxin
ab
meridian
immunocard
toxin
b
techlab
tox
ab
quik
chek
inhous
cytotoxin
assay
sampl
test
refer
routin
microbiolog
examin
toxin
test
done
unform
sampl
adult
hospit
inpati
bone
marrow
transplant
recipi
sampl
c
difficil
toxin
test
request
refer
clinician
kit
use
accord
manufactur
instruct
three
hundr
thirti
three
specimen
test
use
five
kit
cytotoxin
assay
sensit
specif
calcul
assum
cytotoxin
assay
gold
standard
univers
correct
test
b
take
concensu
view
sampl
least
two
test
posit
truli
posit
data
shown
tabl
overal
microtitr
platebas
elisa
kit
sensit
rapid
immunoassay
card
kit
cytotoxin
assay
neg
seven
sampl
posit
least
two
test
thu
platebas
elisa
kit
also
sensit
less
specif
cytotoxin
assay
consensu
data
use
judg
true
posit
conclud
immunoassay
kit
offer
accept
altern
cytotoxin
assay
detect
c
difficil
toxin
allow
rapid
diagnosi
locat
enterotoxin
gene
strain
clostridium
perfringen
associ
gastroenter
object
clostridium
perfringen
type
common
caus
food
poison
also
associ
nonfood
born
gastroenter
includ
antibiot
associ
infecti
sporad
diarrhoea
diseas
symptom
due
enterotoxin
produc
organ
sporul
human
small
intestin
c
perfringen
entertoxin
gene
cpe
shown
locat
either
chromosom
one
two
larg
plasmid
gener
accept
c
perfringen
strain
associ
food
poison
chromosom
cpe
gene
whilst
strain
isol
nonfood
born
diarrhoea
plasmid
encod
cpe
gene
spore
strain
possess
chromosom
cpe
gene
found
far
heat
resist
spore
strain
plasmid
encod
cpe
gene
heat
resist
spore
abl
surviv
cook
process
go
caus
food
poison
thu
explain
food
poison
strain
found
chromosom
locat
cpe
gene
purpos
studi
determin
locat
cpe
gene
rang
c
perfringen
strain
uk
includ
food
born
nonfood
born
ill
method
multiplex
pcr
assay
describ
miyamoto
et
al
use
determin
locat
cpe
gene
strain
c
perfringen
isol
associ
food
born
ill
strain
associ
nonfood
born
ill
result
multiplex
pcr
assay
c
perfringen
strain
associ
food
born
outbreak
uk
found
plasmid
encod
cpe
gene
find
describ
strain
associ
nonfood
born
ill
cpe
gene
locat
one
two
plasmid
anticip
conclus
signific
number
food
born
outbreak
c
perfringen
food
poison
found
caus
strain
c
perfringen
carri
plasmid
encod
cpe
gene
sinc
strain
c
perfringen
chromosom
cpe
plasmid
cpe
gene
differ
physiolog
characterist
may
profound
impact
mode
transmiss
refer
miyamoto
k
wen
q
mcclane
b
multiplex
pcr
genotyp
assay
distinguish
isol
clostridium
perfringen
type
carri
chromosom
enterotoxin
gene
cpe
locu
plasmid
cpe
locu
sequenc
plasmid
cpe
locu
sequenc
journal
clinic
microbiolog
novel
multiplexpcr
method
simultan
detect
clostridium
difficil
toxin
toxin
b
binari
toxin
cdtacdtb
gene
appli
danish
cohort
kep
olsen
persson
copenhagen
dk
object
new
multiplex
pcr
method
develop
detect
clostridium
difficil
toxin
gene
tcda
tcdb
cdta
cdtb
method
appli
clostridium
difficil
strain
isol
danish
hospitalis
patient
diarrhoea
period
april
octob
order
investig
present
toxin
profil
correl
sex
age
method
multiplex
pcr
method
develop
simultan
amplif
four
clostridium
difficil
toxin
gene
tcda
tcdb
cdta
cdtb
rdna
intern
posit
control
templat
dna
prepar
plate
grown
bacteri
coloni
simpl
boil
procedur
amplicon
visual
standard
gel
electrophoresi
result
three
differ
toxin
profil
detect
danish
cohort
tcda
tcdb
cdtacdtb
tcda
tcdb
cdtacdtband
nontoxigen
tcda
tcdb
cdta
cdtb
preval
binari
toxin
gene
studi
clinic
isolatesmor
half
strain
isol
elderli
part
popul
year
strain
display
tcda
tcdb
cdtacdtb
profil
nontoxigen
strain
patient
femal
one
fourth
strain
isol
children
year
age
nontoxigen
four
patient
two
differ
toxin
profil
obtain
independ
faecal
sampl
conclus
method
offer
onestep
rapid
specif
identif
clostridium
difficil
toxin
gene
specif
toxin
profil
allow
evalu
pathogen
potenti
isol
clostridium
difficil
surveil
emerg
toxin
profil
studi
isol
toxigen
clostridium
difficil
strain
includ
gene
delet
analys
tcda
tcdc
toxin
regul
gene
independ
observ
caus
enhanc
pathogen
preval
clostridium
difficileassoci
diarrhoea
hospitalis
patient
nosocomi
diarrhoea
univers
medic
scienc
hospit
tehran
iran
object
studi
aim
determin
preval
clostridium
difficil
associ
diarrhoea
hospit
patient
nosocomi
diarrhoea
three
univers
hospit
tehran
decemb
august
method
studi
period
stool
sampl
hospit
patient
nosocomi
diarrhoea
cultur
test
stool
cytotoxin
assay
toxigen
cultur
also
sampl
examin
enzym
immunoassay
result
sampl
c
difficil
grew
stool
sampl
preval
toxin
posit
stool
cytotoxin
assay
enzym
immunoassay
toxigen
cultur
signific
relationship
c
difficileassoci
diarrhoea
sex
age
patient
result
present
studi
show
among
request
sampl
highest
percentag
c
difficileassoci
diarrhoea
observ
transplant
depart
follow
icu
paediatr
section
object
preval
toxigen
clostridium
difficil
c
difficil
report
korea
toxin
toxin
b
variant
c
difficil
strain
also
import
nosocomi
c
difficil
infect
howev
character
clostridi
toxin
toxin
toxin
b
studi
method
use
pcr
toxin
toxin
b
gene
c
difficil
isol
patient
admit
three
tertiari
hospit
januari
decemb
primer
toxin
gene
toxin
b
gene
result
toxin
toxin
b
posit
rate
use
concord
rang
hospit
proport
nontoxigen
strain
howev
could
differenti
toxin
toxin
b
variant
use
primer
proport
toxin
toxin
b
c
difficil
variant
hospit
respect
object
administr
antibiot
drug
long
known
caus
alter
gut
ecosystem
patient
alter
may
creat
nich
allow
overgrowth
pathogen
clostridium
difficil
main
caus
agent
nosocomi
infecti
diarrhoea
predict
tool
assess
risk
develop
clostridium
difficil
would
utmost
clinic
relev
remain
determin
whether
specif
pattern
preexist
gut
microbiota
predict
risk
onset
clostridium
difficil
upon
initi
antibiot
treatment
use
sampl
subject
enrol
previous
publish
clinic
studi
antibioticassoci
diarrhoea
aad
investig
potenti
relationship
domin
faecal
microbiota
subsequ
develop
clostridium
difficil
subject
receiv
antibiot
method
tempor
temperatur
gradient
gel
electrophoresi
ttge
use
assess
domin
speci
distribut
gut
microbiota
electrophoregram
digitis
migrat
distanc
regress
model
partial
least
squarediscrimin
analysi
pl
built
investig
correl
pretreat
domin
faecal
microbiota
acquisit
clostridium
difficil
antimicrobi
chemotherapi
result
pl
model
could
explain
subsequ
onset
clostridium
difficil
result
support
concept
permiss
flora
preliminari
data
focus
clostridium
coccoidesphylogenet
group
conclus
knowledg
first
time
domin
faecal
microbiota
found
heighten
suscept
subsequ
onset
clostridium
difficil
upon
initi
antibiot
treatment
find
insinu
strategi
reinforc
control
domin
faecal
microbiota
homeostasi
would
clinic
relev
studi
partial
financ
biocodex
laboratori
object
select
therapi
c
difficil
diarrhea
cdd
requir
reduct
pathogen
count
colon
spare
normal
flora
determin
par
select
cdd
serial
stool
sampl
collect
studi
entri
day
weekli
conduct
phase
studi
cdd
treatment
method
patient
n
random
receiv
mg
twice
daili
par
day
prior
therapi
given
patient
receiv
dose
standard
therapi
treatment
control
addit
patient
treat
vancomycin
mg
qid
day
five
well
person
donat
stool
normal
flora
control
fresh
stool
sampl
cultur
c
difficil
veget
spore
form
faecal
filtrat
test
cytotoxin
b
cell
assay
strain
character
tcdab
ermb
cdtab
pcr
ribotyp
studi
entri
day
aerob
anaerob
faecal
flora
cultur
dilut
examin
major
floral
shift
sinc
bacteroid
group
organ
ubiquit
present
cultiv
genera
select
indic
integr
microbi
flora
result
studi
entri
mean
log
cfu
sd
veget
count
c
difficil
par
patient
rang
day
except
one
patient
receiv
mg
patient
c
difficil
quantit
count
reduc
faec
vancomycin
similarli
effect
studi
entri
bacteroid
group
count
cfugm
patient
normal
stool
show
complex
multigenera
high
count
bacteroid
group
speci
cfug
mean
sd
cfu
bacteroid
group
countsg
fece
wet
weight
studi
entri
day
mgday
n
p
wilcoxon
match
pair
signedrank
test
tail
mgday
n
p
mgday
n
p
vancomycin
n
p
conclus
patient
cdd
variabl
impair
normal
flora
par
effect
dosag
erad
c
difficil
dosedepend
reduct
bacteroid
count
observ
vancomycin
significantli
reduc
bacteroid
count
cdd
treatment
par
effect
c
difficil
invivo
rel
spare
normal
flora
result
three
rt
pcr
assay
abl
detect
enteroviru
strain
cell
cultur
supernat
howev
detect
limit
mgb
rt
pcr
sensit
dilut
assay
vc
supernat
compar
rab
ver
rt
pcr
ver
mgb
neg
csf
vc
neg
thirtytwo
csf
specimen
patient
suspect
viral
mening
posit
rt
pcr
wherea
found
posit
vc
rab
rt
pcr
fail
detect
csf
confirm
posit
vc
echo
non
typabl
ev
among
sampl
posit
rt
pcr
sensit
ver
mgb
rab
respect
conclus
laboratori
mgb
rt
pcr
good
correl
ver
rt
pcr
wherea
rab
rt
pcr
less
sensit
especi
detect
echoviru
mgb
rt
pcr
seem
sensit
rt
pcr
studi
includ
ev
strain
help
precis
sensit
assay
dalwai
ahmad
e
hussein
pacsa
w
alnakib
kuwait
kw
object
enterovirus
gener
share
tissu
tropism
present
overlap
diseas
spectrum
howev
certain
enterovirus
may
repres
certain
diseas
other
coxsackieviru
though
report
caus
sever
diseas
febril
ill
herpangina
asept
mening
acut
flaccid
paralysi
frequenc
low
studi
aim
determin
preval
enterovirus
caus
nonspecif
febril
ill
asept
mening
enceph
neonat
diseas
myositi
kuwait
also
aim
studi
associ
certain
enteroviru
particular
diseas
sever
method
diagnosi
enterovir
infect
base
detect
enterovir
rna
seminest
rtpcr
portion
enterovir
genom
follow
southern
hybrid
enteroviru
specif
probe
confirm
result
enteroviru
genotyp
sequenc
portion
encod
region
sequenc
analys
blast
analysi
clustalw
align
phylip
phylogenet
analysi
packag
result
enterovirus
etiolog
agent
detect
diseas
case
investig
coxsackieviru
identifi
second
predomin
enteroviru
case
genotyp
associ
diseas
echoviru
although
identifi
diseas
investig
coxsackieviru
occur
less
frequent
cn
diseas
case
febril
ill
case
preliminari
studi
also
predominantli
detect
myositi
case
viru
show
homolog
coxsackieviru
prototyp
strain
parker
strain
wherea
adjoin
region
show
greater
homolog
human
enteroviru
b
genotyp
sequenc
conclus
coxsackieviru
determin
emerg
enteroviru
associ
differ
diseas
kuwait
frequent
repres
mild
febril
ill
myositi
case
cn
diseas
suggest
isol
might
less
neurovirul
molecular
analysi
suggest
isol
might
emerg
due
recombin
code
noncod
segment
coxsackieviru
human
enteroviru
b
group
genom
acknowledg
support
research
administr
project
grant
mi
ym
colleg
graduat
studi
kuwait
univers
new
propos
enteroviru
type
caus
mening
spain
introduct
sever
new
propos
enterovirus
ev
recent
describ
includ
name
total
isol
serotyp
identifi
america
africa
asia
associ
mainli
acut
flaccid
paralysi
unspecifi
diseas
object
determin
new
serotyp
circul
spain
type
diseas
produc
method
total
ev
isol
come
spanish
enteroviru
refer
laboratori
studi
micro
neutral
assay
type
pcr
isol
suspect
mention
method
complet
gene
amplifi
sequenc
specif
design
primer
result
four
isol
two
differ
region
spain
identifi
homolog
publish
sequenc
three
correspond
asept
mening
children
isol
csf
discuss
present
work
demonstr
new
propos
viru
circul
also
europ
associ
asept
mening
till
moment
seem
repres
minor
proport
studi
howev
possibl
spread
viral
infect
consid
ev
may
behav
way
previous
demonstr
object
rotaviru
import
caus
sever
gastroenter
infant
young
children
world
respons
death
annual
mostli
develop
countri
therefor
develop
rotaviru
vaccin
high
prioriti
rotaviru
strain
type
account
major
diarrhoea
episod
recent
monoval
attenu
rotaviru
vaccin
licens
mexico
view
hypothet
introduct
vaccin
europ
investig
variabl
time
antigen
gene
rotaviru
strain
area
method
fifti
strain
select
total
strain
obtain
children
less
year
age
hospitalis
acut
gastroenter
g
di
cristina
children
hospit
palermo
period
select
strain
genotyp
rtpcr
submit
gene
sequenc
analysi
result
one
strain
genotyp
sequenc
distribut
lineag
ii
lineag
includ
strain
differ
year
rang
lineag
ii
includ
strain
differ
year
rang
degre
similar
among
nucleotid
sequenc
italian
strain
lineag
compris
align
deduc
amino
acid
sequenc
show
major
lineag
specif
amino
acid
chang
variabl
antigen
region
respect
refer
wa
strain
conclus
sequenc
analysi
indic
palermo
cocircul
strain
belong
two
differ
lineag
overal
strain
show
high
degre
similar
insid
lineag
share
specif
amino
acid
modif
antigen
differ
circul
strain
might
permit
escap
neutral
persist
infantil
popul
result
suggest
rotaviru
strain
belong
two
lineag
includ
rotaviru
vaccin
prepar
epidem
spread
recombin
norovirus
four
capsid
type
hungari
object
norovirus
winter
vomit
diseas
predomin
etiolog
agent
hungari
common
pathogen
worldwid
outbreak
gastroenter
human
norovirus
genet
divers
group
virus
multipl
genogroup
gg
genotyp
recent
natur
occur
recombin
norovirus
identifi
virus
distinct
polymeras
gene
sequenc
design
ggiibhilversum
dissemin
waterborn
foodborn
transmiss
europ
aim
character
emerg
recombin
norovirus
caus
outbreak
gastroenter
hungari
method
stool
rna
sampl
noroviru
outbreak
januari
may
contain
ggiib
hilversum
polymeras
ggiibpol
select
analysi
viral
capsid
region
revers
transcriptionpolymeras
chain
reaction
rtpcr
follow
sequenceand
phylogenet
analysi
result
forti
confirm
noroviru
outbreak
caus
newvari
lineag
ggiibpol
viral
capsid
region
success
character
ggiibpol
outbreak
four
differ
recombin
detect
capsid
n
hu
n
n
n
interestingli
outbreak
caus
recombin
ggiibpol
strain
mostli
associ
outbreak
among
children
nonwint
season
conclus
epidem
spread
emerg
multipl
recombin
noroviru
strain
ggiibpol
detect
hungari
becam
second
common
noroviru
variant
next
endem
viru
caus
epidem
gastroenter
last
year
respiratori
infect
common
diseas
world
origin
great
morbid
mortal
especi
infant
elderli
human
metapneumoviru
hmpv
first
describ
dutch
children
acut
respiratori
tract
infect
arti
june
limit
studi
data
avail
tropic
develop
countri
sought
determin
role
hmpv
upper
lower
respiratori
tract
infect
cuban
patient
correl
presenc
viru
clinic
characterist
diseas
octob
septemb
clinic
sampl
receiv
nation
surveil
program
arti
nation
refer
laboratori
respiratori
virus
virolog
studi
use
detect
hmpv
rtnest
pcr
amplifi
conserv
fragment
nucleotid
polymeras
gene
found
rna
hmpv
sampl
patient
arti
individu
test
posit
hmpv
month
age
patient
evid
hmpv
symptom
consist
either
upper
lower
respiratori
tract
diseas
hmpv
posit
individu
detect
augustoctob
result
preliminari
studi
show
hmpv
present
among
cuban
patient
arti
constitut
first
report
frequenc
hmpv
infect
nonpreselect
group
cuban
patient
age
rang
month
year
old
note
first
report
hmpv
infect
central
america
caribbean
region
confirm
worldwid
distribut
viru
detect
human
metapneumoviru
paediatr
nasopharyng
aspir
taqman
minor
groov
binder
probe
assay
oneyear
prospect
studi
belgium
w
verstrepen
p
bruynseel
de
smet
merten
antwerp
object
human
metapneumoviru
hmpv
rel
high
incid
acut
respiratori
infect
children
difficult
isol
cultur
aim
studi
decreas
number
undiagnos
viral
respiratori
infect
hospit
mean
taqman
minor
groov
binder
mgb
probe
assay
method
octob
septemb
total
nasopharyng
aspir
children
present
paediatr
facil
analys
rna
extract
specimen
neg
rsv
parainfluenzaviru
influenzaviru
direct
immunofluoresc
assay
ifa
subject
taqman
mgb
probe
assay
parallel
previous
publish
taqman
assay
result
specimen
posit
ifa
either
rsv
parainfluenzaviru
influenzaviru
influenzaviru
b
hmpv
detect
remain
specimen
subject
newli
develop
pcr
patient
posit
hmpv
assay
present
respiratori
symptom
posit
specimen
children
less
year
compar
children
older
year
viral
load
highest
children
less
year
promin
season
variat
note
sinc
half
posit
specimen
occur
month
march
april
signific
differ
proport
viral
load
posit
specimen
ambulatori
patient
patient
admit
gener
ward
patient
requir
intens
care
compar
publish
taqman
assay
diagnost
sensit
specif
respect
wherea
ppv
npv
method
comparison
nccl
guidelin
fail
demonstr
signific
differ
assay
threshold
cycl
ct
strongli
posit
specimen
ct
associ
lower
ct
use
publish
taqman
assay
howev
new
taqman
mgb
probe
assay
appear
sensit
weakli
posit
specimen
ct
conclus
number
viral
respiratori
infect
confirm
hospit
substanti
increas
mean
hmpv
taqman
mgb
probe
assay
new
assay
reliabl
altern
previous
publish
taqman
assay
detect
hmpv
nasopharyng
aspir
nucleic
acid
sequenc
base
amplif
molecular
beacon
detect
realtim
identif
respiratori
syncyti
viru
paediatr
respiratori
specimen
r
manji
f
zhang
c
ginocchio
lake
success
us
background
respiratori
syncyti
viru
rsv
lead
caus
lower
respiratori
tract
infect
infant
young
children
bronchiol
pneumonia
major
clinic
manifest
rapid
diagnosi
rsv
infect
central
import
individu
patient
manag
ration
use
antibiot
antivir
agent
hospit
infect
control
monitor
epidemiolog
diseas
pattern
studi
includ
technic
valid
retrospect
clinic
evalu
real
time
nasba
assay
detect
rsv
rsv
b
paediatr
respiratori
sampl
method
sampl
test
includ
dilut
panel
vitro
transcrib
rna
local
rsv
isol
isol
common
respiratori
pathogen
frozen
respiratori
specimen
nasopharyng
aspir
wash
swab
children
age
rang
yr
evalu
paediatr
emerg
depart
respiratori
diseas
nucleic
acid
na
isol
amplif
detect
perform
use
nuclisen
easyq
basic
kit
nuclisen
easyq
rsv
ab
reagent
specimen
na
rsv
specif
intern
rna
control
ic
coextract
use
nuclisen
magnet
extract
reagent
nuclisen
minimag
instrument
coamplifi
use
singl
rsv
specif
primer
pair
includ
reaction
rsv
specif
molecular
beacon
ic
specif
molecular
beacon
target
amplif
continu
monitor
emit
fluoresc
perform
use
nuclisen
easyq
analyz
result
compar
direct
immunofluoresc
dfa
andor
viral
cultur
use
rmix
cell
diagnost
hybrid
oh
result
limit
detect
rsv
rna
copiesrxn
detect
rate
copiesrxn
assay
specif
rsv
cross
reactiv
respiratori
pathogen
nasba
assay
detect
posit
specimen
dfa
posit
sampl
vc
npv
assay
nasba
dfa
vc
nuclisen
easyq
rsv
assay
demonstr
superior
sensit
dfa
viral
cultur
detect
rsv
b
respiratori
specimen
assay
easi
use
requir
minim
hand
time
hr
faster
time
result
compar
rapid
cultur
hr
vs
hr
respiratori
syncyti
viru
rsv
major
caus
acut
lower
respiratori
tract
infect
infant
young
children
previous
shown
hrsv
isol
divid
two
antigen
group
b
g
protein
diverg
within
two
subgroup
appear
accumul
amino
acid
chang
time
suggest
evolut
select
pressur
knowledg
molecular
epidemiolog
rsv
far
base
mainli
studi
done
develop
world
e
temper
climat
limit
epidemiolog
data
avail
tropic
develop
countri
rsv
infect
may
follow
differ
pattern
report
examin
molecular
epidemiolog
evolutionari
pattern
g
protein
subgroup
b
rsv
consecut
epidem
cuba
sixthli
four
nasopharyng
swab
collect
children
year
age
respiratori
diseas
differ
hospit
cuba
examin
molecular
epidemiolog
evolutionari
pattern
g
protein
rsv
sampl
collect
rsv
subgroup
howev
subgroup
cocircul
cuban
isol
show
great
homogen
resembl
ancient
strain
long
five
nucleotid
differ
also
occur
two
strain
furthermor
detect
differ
size
g
protein
rsv
rsv
b
due
chang
stop
codon
use
genet
homogen
cuban
isol
resembl
ancient
strain
long
unusu
find
countri
subgroup
observ
predomin
strain
almost
similar
sequenc
phylogenet
analysi
subgroup
strain
show
strain
cluster
differ
genotyp
viru
isol
differ
geograph
region
subgroup
cocircul
cluster
whit
south
african
strain
circul
time
point
mutat
respiratori
syncyti
viru
detect
lightcycl
pcr
melt
curv
analysi
u
germer
l
nielsen
k
boy
h
westh
copenhagen
dk
object
object
analys
rsv
realtim
pcrposit
isol
clinic
sampl
appear
belong
three
differ
group
accord
melt
temperatur
tm
amplicon
analysi
done
accord
genotyp
phenotyp
differ
relat
geograph
distribut
materi
method
nasopharyng
aspir
collect
children
respiratori
distress
citi
copenhagen
viral
rna
extract
use
magnapur
lc
autom
extract
system
amplifi
realtim
rtpcr
previous
describ
five
sampl
three
group
differ
tm
select
bidirect
dna
sequenc
use
rsv
primer
sequenc
analys
use
chroma
lite
version
result
total
clinic
sampl
analys
sampl
posit
neg
rsv
three
distinct
group
differ
tm
could
identifi
melt
curv
analysi
group
n
tm
median
group
n
n
lower
tm
median
tm
respect
sequenc
analysi
amplicon
show
differ
tm
due
differ
genotyp
three
group
genotyp
close
relat
differ
two
nucleic
acid
posit
c
silent
mutat
posit
target
probe
genotyp
blast
complet
genom
sequenc
respiratori
syncyti
viru
subgroup
genbank
highest
ident
score
genotyp
genotyp
sequenc
blast
human
respiratori
syncyti
viru
mutant
subgroup
b
genbank
geograph
analysi
show
higher
preval
mutant
strain
genotyp
northern
area
greater
copenhagen
area
compar
central
southern
western
area
p
conclus
found
three
genotyp
rsv
accord
tm
pcr
product
two
genotyp
close
relat
two
point
mutat
phenotyp
genotyp
mainli
found
clinic
isol
northern
part
copenhagen
suggest
local
epidem
spread
object
biomerieux
develop
realtim
nasba
assay
detect
influenza
b
rna
differ
kind
respiratori
clinic
sampl
use
nuclisen
easyq
basic
kit
combin
specif
primer
molecular
beacon
method
nasalthroat
swab
transport
medium
hospitalis
children
yr
edouard
herriot
hospit
lyon
franc
use
evalu
influenza
rna
isol
use
nuclisen
minimag
extract
intern
control
ad
sampl
prior
nucleic
acid
extract
assay
design
detect
singl
tube
use
threelabel
approach
intern
control
influenza
influenza
b
rna
amplif
reaction
perform
nuclisen
easyq
analys
allow
realtim
detect
result
clinic
sampl
compar
cell
cultur
result
result
among
swab
test
realtim
nasba
detect
sampl
influenza
sampl
influenza
b
compar
cell
cultur
sampl
identifi
influenza
non
influenza
b
interestingli
influenza
posit
sampl
identifi
cell
cultur
found
neg
realtim
nasba
conclus
data
show
nuclisen
easyq
influenza
ab
assay
detect
influenza
viru
cell
cultur
method
moreov
realtim
nasba
detect
influenza
posit
sampl
detect
cell
cultur
assay
qualit
detect
influenza
influenza
b
virus
singl
reaction
done
within
hour
provid
valuabl
altern
cell
cultur
method
clinic
manag
patient
influenza
infect
result
patient
develop
mump
mening
patient
diagnos
mump
meningoenceph
age
limit
year
sex
ratio
mf
manifest
involv
fever
stiff
neck
nausea
vomit
headach
photophobia
neurolog
manifest
equilibrium
disord
drowsi
convuls
cerebellum
syndrom
mening
symptom
occur
shortli
parotid
case
parotid
case
case
evolv
without
parotid
swell
local
mump
infect
parotid
pancreat
submaxil
orchiti
lumbar
punctur
yield
csf
contain
predomin
cell
usual
lymphocyt
patient
polymorphonuclear
leukocyt
predomin
first
punctur
protein
level
normal
mildli
elev
case
hypoglycorrachia
found
patient
therapi
mump
mening
symptombas
analges
antipyret
case
glucocorticoid
therapi
case
conclus
neurolog
involv
mump
occur
case
men
afflict
two
time
often
women
age
distribut
uncompl
mump
mump
mening
local
mump
infect
case
mump
acut
gener
infect
occur
primarili
schoolag
children
adolesc
promin
manifest
mump
swell
tender
salivari
gland
especi
parotid
gland
uveiti
rare
manifest
mump
present
mump
case
complic
uveiti
year
old
paediatr
nurs
admit
emerg
depart
headach
malais
physic
examin
bilater
parotid
enlarg
notic
opthalmolog
consulat
reveal
anterior
uveiti
local
prednisolon
cyclopenthol
treatment
prescrib
lumbar
punctur
reveal
lymphocyt
pleocytosi
without
hypoglychorachea
elev
protein
level
mump
igm
found
posit
differenti
diagnosi
made
viral
infect
sarcoidosi
headach
diminish
day
hospitalis
uveiti
respond
well
local
therapi
patient
got
well
week
clinic
epidemiolog
aspect
measl
epidem
bucharest
romania
result
case
sex
ratio
mainli
affect
age
group
month
follow
year
year
year
year
case
hospitalacquir
mostli
paediatr
clinic
communityacquir
case
sourc
unknown
common
clinic
featur
fever
rash
conjunctiv
hiperemia
cough
micropoliadenopatia
diarrhoea
pulmonari
complic
describ
case
bacteri
pneumonia
viral
pneumonia
case
diagnos
acut
stomat
bacteri
conjunct
case
otiti
case
pharing
one
case
urinari
tract
infect
patient
previous
diagnos
treat
pulmonari
tb
case
confirm
serolog
detect
specif
igm
antibodi
patient
sever
clinic
form
measel
evolut
good
case
conclus
year
southeast
part
countri
evolv
measel
epidem
differ
featur
compar
previou
one
investig
recombin
protein
np
hn
develop
new
antigen
use
properti
appli
elisa
test
system
method
signific
antigen
epitop
nucleoprotein
np
haemagglutinin
hn
measl
viru
strain
edmonston
gener
comput
analysi
use
standard
geneengin
techniqu
evalu
two
fusion
peptid
np
hn
consist
linear
tcell
antigen
determin
virusneutr
activ
hyperimmun
serum
recombin
protein
determin
plaqu
reduct
neutral
test
prn
level
specif
igg
serum
genotyp
measl
viru
determin
enzymelink
immunosorb
assay
elisa
use
recombin
protein
np
hn
antigen
elisa
result
hyperimmun
serum
collect
mice
immun
np
hn
recombin
protein
level
neutral
activ
measur
prn
assay
strain
edmonston
titr
reach
np
hn
recombin
protein
respect
interestingli
hyperimmun
serum
recombin
protein
np
elisa
react
np
titr
hn
titr
turn
serum
recombin
protein
hn
react
hn
titr
estim
immunolog
properti
protein
use
panel
serum
sampl
collect
patient
diagnosi
measl
infect
confirm
laboratori
rtpcr
nucleotid
sequenc
rtpcr
product
use
genotyp
mv
select
interact
antibodi
elisa
recombin
protein
relat
variou
genotyp
reveal
interact
genotyp
express
high
level
correl
wherea
genotyp
serum
react
authent
control
use
recombin
protein
n
sar
viru
conclus
shown
neutral
antibodi
form
hot
superfici
protein
hn
f
sh
also
core
protein
np
data
demonstr
recombin
protein
np
hn
could
costeffect
altern
current
whole
viru
base
elisa
surveil
immun
measl
could
effici
detect
suscept
measl
relat
genotyp
episod
pregnant
woman
thirtyeight
week
gestat
hospit
obstetr
clinic
complaint
fever
malais
sever
vagin
bleed
admiss
white
blood
cell
count
haemoglobin
gl
platelet
count
level
ast
iu
alt
iu
lactat
dehydrogenas
iu
creatinin
phosphokinas
iu
babi
deliv
cesarean
section
serum
cchf
igm
posit
elisa
per
oral
ribavirin
administ
deliveri
first
day
deliveri
clinic
laboratori
find
babi
found
normal
howev
day
die
massiv
bleed
cchf
igm
found
neg
episod
pregnant
woman
week
gestat
admit
hospit
complaint
fever
malais
headach
myalgia
nausea
vomit
diarrhoea
subconjuntiv
bleed
laboratori
investig
white
blood
cell
count
haemoglobin
level
gl
platelet
count
level
ast
iu
alt
iu
ldh
iu
serolog
analysi
cchf
igm
cchf
viru
pcr
found
posit
twenti
six
week
gestat
obstetr
ultrasound
fetal
intraabdomin
fluid
visual
amniocentesi
perform
serolog
analysi
amniot
fluid
cchfvpcr
found
neg
intraabdomin
fluid
increas
scrotal
edema
visual
thirti
eighth
week
gestat
vagin
deliveri
babi
sever
ill
oper
diagnosi
necrot
enterocol
laboratori
find
normal
except
high
white
blood
cell
count
fifth
day
thrombocytopenia
occur
die
massiv
bleed
cchf
igm
pcr
neg
conclus
knowledg
first
episod
intrauterin
cchf
infect
episod
show
cchfv
transmit
placenta
obstetrician
endem
countri
consid
cchf
infect
among
patient
massiv
bleed
thrombocytopenia
object
detect
asymptomat
crimean
congo
hemorrhag
fever
viru
cchfv
infect
endem
area
calcul
attack
infect
rate
method
studi
perform
cchf
endem
region
household
member
index
case
screen
cchfv
igg
igm
elisa
data
relat
risk
exposur
obtain
structur
form
result
eleven
index
case
admit
clinic
household
member
case
screen
index
patient
posit
igm
pcr
cchfv
among
household
member
three
individu
igg
posit
one
patient
igm
posit
none
screen
individu
symptom
mean
age
sd
subject
femal
tick
bite
detect
risk
factor
p
cchv
infect
wherea
patient
care
contact
bodi
fluid
patient
p
eighteen
patient
histori
tick
bite
becam
infect
five
becam
ill
among
infect
eight
individu
five
becam
ill
conclus
although
consid
patient
notic
tick
bite
still
suggest
infect
rate
viru
rather
high
compar
similar
diseas
tick
bite
major
risk
factor
comparison
exposur
blood
bodi
fluid
infect
case
result
children
includ
studi
distribut
accord
sex
femal
male
median
age
year
iqr
followup
studi
record
year
number
case
increas
distribut
case
among
studi
proport
paediatr
patient
also
vari
panama
citi
record
infant
detect
increas
number
patient
rain
season
may
till
novemb
mean
day
onset
symptom
first
blood
sampl
day
ds
second
sampl
obtain
infant
averag
time
day
ds
frequenc
classic
symptom
relat
dengu
viru
infect
fever
sever
headach
chill
rash
myalgia
retroorbit
pain
arthralgia
gastrointestin
symptom
inflam
pharynx
cough
mild
respiratori
symptom
diarrhoea
infant
symptom
detect
first
fever
sever
headach
chill
myalgia
retroorbit
pain
arthralgia
mild
respiratori
symptom
cough
inflam
pharynx
observ
differ
clinic
featur
girl
boy
howev
detect
detect
signif
differ
among
symptom
compar
infant
year
old
older
p
four
patient
die
dengu
hemorrhag
fever
conclus
dengu
endem
panama
tropic
countri
one
world
major
emerg
infecti
diseas
data
ill
need
elabor
sanitari
programm
contribut
control
infect
diagnosi
dengu
infect
enzymelink
immunosorb
assay
revers
transcriptionpolymeras
chain
reaction
oral
specimen
dengu
salivari
elisa
shown
variou
investig
use
dengu
diagnosi
sought
perform
pilot
evalu
diagnost
valu
elisa
pcr
oral
brush
saliva
dengu
diagnosi
adult
method
adult
acut
fever
suspect
dengu
infect
admit
univers
hospit
enrol
dengu
diagnosi
made
standard
elisa
use
serum
plasma
patient
neg
elisa
serv
control
buccal
mucos
cell
collect
rtpcr
saliva
rtpcr
elisa
least
twice
day
apart
elisa
criteria
saliva
singl
igm
unit
singl
igg
unit
increas
igg
titr
second
titr
unit
secondari
dengu
infect
criteria
primari
dengu
infect
secondari
infect
plu
igm
igg
ratio
result
case
control
enrol
countri
endem
dengu
thu
primari
dengu
adult
case
studi
studi
perform
hospit
patient
first
sampl
collect
one
day
day
defervesc
specif
either
method
sensit
elisa
method
saliva
sensit
approxim
rtpcr
use
buccal
cell
saliva
specimen
howev
combin
rtpcr
result
type
oral
specimen
gave
sensit
result
summaris
tabl
conclus
collect
oral
specimen
less
invas
may
accept
certain
situat
singl
acut
specimen
adequ
diagnosi
rtpcr
specimen
howev
collect
late
cours
ill
affect
sensit
rtpcr
earlier
specimen
may
give
better
yield
studi
paediatr
patient
need
assess
valu
method
primari
dengu
infect
object
aim
studi
assess
proport
seroposit
hantavirus
among
healthi
blood
donor
method
volunt
donor
recruit
institut
transfus
medicin
repres
demograph
situat
tyrol
regard
gender
resid
sera
test
igg
commerci
avail
elisa
posit
sampl
confirm
commerci
avail
dot
blot
also
use
identif
serovar
set
studi
area
compris
north
tyrol
austria
north
main
ridg
alp
south
tyrol
itali
east
tyrol
austria
south
main
ridg
alp
south
tyrol
belong
catchment
area
etsch
river
drain
adriat
northand
east
tyrol
part
catchment
area
danub
drain
black
sea
result
none
sampl
italian
part
studi
area
yield
posit
result
wherein
donor
austrian
part
turn
seroposit
two
patient
posit
hantaan
patient
posit
puumala
one
patient
posit
dobrava
one
patient
antibodi
hantaan
dobrava
one
patient
report
extens
travel
abroad
conclus
evid
found
occurr
hantavirus
austrian
part
region
cover
catchment
area
danub
italian
part
studi
area
cover
catchment
area
etsch
river
seroposit
hantavirus
differ
hydrogeograph
area
object
canin
coronaviru
ccov
envelop
singlestrand
rna
viru
belong
group
coronavirus
within
famili
coronavirida
two
differ
ccov
genotyp
recognis
design
ccov
type
type
ii
basi
genet
related
felin
coronavirus
fcov
type
type
ii
respect
ccov
usual
respons
mild
selflimit
infect
restrict
enter
tract
report
molecular
characteris
pantrop
variant
ccov
caus
fatal
diseas
pup
method
ccov
type
ii
strain
isol
outbreak
fatal
diseas
affect
seven
dog
hous
pet
shop
apulia
region
itali
characteris
fever
lethargi
inappet
vomit
haemorrhag
diarrhoea
neurolog
sign
sever
lesion
parenchymat
organ
tissu
ccov
antigen
detect
immunoistochemistri
ccov
type
ii
rna
identifi
genotypespecif
realtim
rtpcr
end
genom
strain
determin
amplif
seven
partial
overlap
fragment
pcramplifi
product
subject
direct
sequenc
obtain
nucleotid
nt
sequenc
assembl
analys
use
bioedit
softwar
packag
ncbi
embl
analysi
tool
genbank
access
number
assign
sequenc
fragment
infer
amino
acid
sequenc
aa
compar
analog
protein
avail
onlin
databas
result
structur
protein
e
n
strain
display
high
degre
aa
ident
cognat
orf
ccov
type
ii
although
protein
show
highest
ident
type
ii
fcov
nonstructur
protein
nsp
length
known
ccov
shorter
expect
due
presenc
delet
posit
frame
shift
sequenc
downstream
delet
introduc
earli
stop
codon
conclus
associ
strain
sever
fatal
diseas
dog
togeth
viru
isol
organ
remark
lesion
strongli
suggest
viru
chang
tropism
acquir
abil
spread
enter
tract
intern
organ
sequenc
analysi
viral
genom
strike
chang
truncat
form
role
delet
determin
pathobiolog
chang
deserv
indepth
investig
object
perform
surveil
studi
sar
coronaviru
sarscov
like
viru
noncag
wild
anim
wild
hong
kong
special
administr
region
hksar
method
summer
spring
bat
rodent
monkey
locat
hksar
captur
nasopharyng
anal
swab
blood
sampl
collect
test
sarscovlik
viru
rna
rtpcr
use
conserv
primer
target
fragment
rnadepend
rna
polymeras
pol
gene
complet
genom
sarscovlik
viru
bat
batsarscov
sequenc
use
rna
extract
three
anal
swab
three
bat
templat
phylogenet
tree
construct
perform
use
neighborjoin
method
growtre
use
jukescantor
correct
predict
signal
peptid
cleavag
site
perform
use
signalp
transmembran
domain
use
tmpred
tmhmm
potenti
nglycosyl
site
use
scanprosit
protein
famili
analysi
use
pfam
interproscan
antibodi
detect
use
recombin
batsarscov
nucleocapsid
protein
enzym
immunoassay
neutral
assay
human
sarscov
result
identifi
coronaviru
close
relat
sarscov
batsarscov
anal
swab
wild
chines
horsesho
bat
rtpcr
sequenc
analysi
three
batsarscov
genom
sampl
collect
differ
date
show
batsarscov
close
relat
sarscov
human
civet
phylogenet
analysi
show
batsarscov
form
distinct
cluster
sarscov
group
coronavirus
distantli
relat
known
group
coronavirus
differ
batsarscov
sarscov
genom
observ
spike
gene
orf
orf
region
variat
also
observ
human
civet
sarscov
genom
addit
presenc
insert
orf
batsarscov
genom
human
sarscov
genom
suggest
common
ancestor
civet
sarscov
antibodi
recombin
batsarscov
nucleocapsid
protein
detect
chines
horsesho
bat
use
enzym
immunoassay
neutral
antibodi
human
sarscov
also
detect
lower
viral
load
conclus
data
support
exist
sarscovlik
viru
chines
horsesho
bat
hksar
norovirus
genet
heterogen
form
least
genotyp
within
genogroup
gi
gii
giii
giv
gv
base
capsid
gene
human
nov
caus
estim
million
case
ill
annual
unit
state
alon
nonbacteri
epidem
gastroenter
worldwid
porcin
caliciviru
found
genet
similar
human
gii
nov
sapovirus
caliciviru
rna
detect
low
frequenc
rtpcr
adult
fatten
pig
close
genet
relationship
human
porcin
nov
rais
public
health
concern
regard
potenti
zoonot
transmiss
potenti
sourc
new
epidem
human
strain
method
total
faecal
sampl
nurs
wean
piglet
enter
collect
porcin
herd
itali
addit
sampl
includ
analysi
collect
rotaviru
rv
surveil
studi
test
posit
rv
electron
microscopi
rtpcr
viral
rna
extract
guanidin
thiocyanateglass
milk
method
elimin
enzym
inhibitor
primer
pair
target
outer
capsid
protein
use
rv
detect
degener
version
primer
pair
use
nv
detect
target
conserv
region
rnapolymeras
result
nov
rna
detect
screen
sampl
rv
detect
sampl
mix
infect
novrv
found
sampl
screen
rv
posit
sampl
allow
detect
mix
infect
nov
conclus
previou
investig
nov
detect
normal
slaughter
pig
japan
pool
pig
faecal
sampl
fatten
pig
netherland
healthi
adult
finish
pig
unit
state
interestingli
studi
high
rate
posit
nov
found
nurs
wean
piglet
diarrhoea
find
may
suggest
higher
frequenc
infect
nov
young
pig
associ
nov
infect
occurr
enter
diseas
altogeth
find
demonstr
nov
common
porcin
herd
itali
provid
new
insight
ecolog
nov
detect
caliciviru
genom
calv
use
primer
mahzounieh
zahraeisalehi
e
moghtadaei
khorasgani
shahrekord
tehran
ir
calicivirus
may
caus
wide
spectrum
diseas
anim
import
etiolog
agent
viral
gastroenter
human
member
famili
calicivirida
small
nonenvelop
virus
nm
diamet
possess
singl
strand
poli
adenyl
rna
genom
calicivirus
isol
mink
dog
cattl
nonhuman
primat
norwalklik
virus
nlv
common
caus
acut
nonbacteri
gastroenter
human
cattl
may
reservoir
nlv
although
never
bovin
nlv
found
human
studi
tri
detect
enter
calicivirus
genom
faecal
sampl
dairi
cattl
herd
shahrekord
area
use
revers
transcriptas
polymeras
chain
reaction
rtpcr
assay
specif
nlv
found
human
primer
use
pcr
amplif
ni
amplifi
product
detect
genogroup
ii
srsv
rna
fecal
materi
result
show
nine
specimen
posit
find
suggest
caliciviru
infect
endem
dairi
herd
shahrekord
iran
may
import
role
calf
diarrhea
object
reovirus
nonenvelop
dsrna
virus
human
mammalian
three
distinct
serotyp
exist
whose
prototyp
strain
lang
jone
dear
although
reovirus
isol
enter
respiratori
tract
diseas
clearli
associ
reoviru
infect
human
potenti
associ
extrahepat
biliari
atresia
myocard
neurolog
cutan
diseas
requir
investig
reovirus
ubiquit
scarc
speciesspecif
reoviru
identif
usual
base
electron
microscopi
gel
electrophoresi
reoviru
incid
seem
low
human
mammalian
studi
investig
presenc
reovirus
dog
mean
molecular
method
method
one
hundr
ninetytwo
rectal
sampl
dog
diarrhoea
ocular
swab
nasal
swab
oropharyng
swab
dog
ocularnas
discharg
subject
rtpcr
assay
target
conserv
region
viral
genom
segment
primer
posit
sampl
characteris
polyacrylamid
gel
electrophoresi
page
serotypespecif
rtpcr
assay
target
segment
sequenc
analysi
increas
sensit
nest
pcr
use
primer
perform
sampl
test
rtpcr
neg
result
faecal
swab
found
posit
rtpcr
product
bp
use
serotypespecif
rtpcr
assay
andor
sequenc
analysi
two
strain
characteris
type
one
type
page
viral
dsrna
confirm
genet
characteris
unexpectedli
secondround
pcr
faecal
sampl
ocular
swab
nasal
swab
yield
bp
product
oropharyng
swab
posit
conclus
data
suggest
wider
distribut
reovirus
dog
previous
thought
even
reoviru
infect
detect
nest
pcr
abil
reovirus
induc
diseas
dog
alon
synerg
pathogen
still
unclear
sinc
attempt
reproduc
specif
diseas
germfre
dog
given
contradictori
result
due
poor
speciesspecif
reovirus
may
easili
transmit
anim
human
viceversa
studi
requir
understand
reoviru
ecolog
potenti
zoonot
impact
object
parvoviru
member
famili
parvovirida
basi
genet
distanc
evolutionari
relationship
human
parvovirus
divid
three
genotyp
genotyp
correspond
isol
genotyp
ii
lalirel
isol
genotyp
iii
isol
parvoviru
caus
common
exanthemat
diseas
childhood
adult
age
arthropathi
hydrop
fetali
variou
haematolog
disord
myocard
data
preval
viru
slovenian
popul
consequ
also
lack
inform
genotyp
parvoviru
involv
patient
suffer
infect
method
gather
inform
genet
variant
viru
present
slovenia
extract
dna
serum
sampl
sent
serolog
diagnost
parvoviru
infect
posit
specif
igm
period
januari
june
nearli
half
patient
children
young
adult
year
region
parvoviru
amplifi
nest
pcr
primer
pcr
product
directli
sequenc
result
studi
show
dna
parvoviru
present
sampl
test
posit
specif
igm
antibodi
first
round
pcr
reaction
sampl
posit
second
reaction
sampl
posit
altogeth
uniqu
genotyp
variant
parvoviru
identifi
cluster
genotyp
group
isol
distinct
genet
variant
differ
sequenc
deposit
gene
bank
major
sequenc
obtain
viru
epidem
repres
singl
variant
genotyp
gene
bank
acc
also
found
differ
genet
variant
parvoviru
circul
ident
genotyp
variant
gene
bank
acc
studi
abl
identifi
variant
rare
genotyp
lali
conclus
parvoviru
dna
success
amplifi
igm
posit
serum
sampl
patient
genotyp
parvoviru
domin
infect
parvoviru
slovenia
object
great
britain
free
anim
brucellosi
sinc
european
commiss
decis
main
sourc
infect
uk
resid
contact
infect
materi
foreign
countri
object
studi
type
human
sampl
receiv
uk
sinc
use
variabl
number
tandem
repeat
vntr
molecular
type
confirm
result
obtain
classic
type
relat
result
suspect
sourc
infect
method
classic
type
tradit
use
base
phenotyp
attribut
strain
biovar
vntr
type
recent
develop
molecular
method
base
short
repeat
contain
dna
amplifi
give
band
pattern
specif
strain
result
result
found
use
method
consist
result
show
geograph
differ
consist
observ
strain
genotyp
distribut
found
anim
brucellosi
conclus
patient
histori
gather
possibl
give
inform
recent
travel
along
result
found
classic
type
confirm
vntr
type
draw
pictur
sourc
infect
result
illustr
potenti
vntr
type
tool
aid
convent
approach
epidemiolog
traceback
presenc
suitabl
comprehens
databas
strain
genotyp
could
help
identifi
sourc
infect
brucella
isol
human
estubberfield
surrey
uk
object
brucellosi
zoonot
diseas
usual
associ
cattl
sheep
goat
pig
human
infect
attribut
b
melitensi
b
abortu
b
sui
b
cani
b
mari
although
uk
offici
bucellosi
free
number
human
case
due
travel
occup
submit
laboratori
diagnosi
definit
diagnosi
brucella
bacteriolog
cultur
microbi
test
classic
type
howev
requir
skill
personnel
result
subject
number
molecular
test
develop
assist
diagnosi
rapidli
case
strain
level
less
subject
molecular
techniqu
prove
use
identif
brucella
isol
speci
case
stain
level
reli
variabl
number
locat
mobil
genet
element
found
brucella
isol
method
brucella
isol
human
test
genom
dna
extract
digest
use
restrict
endonucleas
electrophores
southern
blot
perform
hybridis
diglabel
probe
result
number
brucella
copi
rang
brucella
melitensi
remain
commonli
acquir
brucella
speci
travel
occup
infect
includ
b
abortu
isol
cattl
farmer
b
sui
associ
pig
butcher
two
marin
brucella
strain
isol
origin
occup
perspect
laboratori
worker
natur
set
unknown
sourc
unusu
pattern
observ
uniqu
one
new
pattern
observ
isol
origin
east
african
countri
conclus
although
diagnosi
brucella
speci
strain
level
essenti
treatment
human
brucellosi
use
epidemiolog
studi
abl
identifi
three
biovar
b
melitensi
mani
techniqu
offer
capabl
may
use
test
epidemiolog
studi
method
remain
import
diagnost
tool
brucella
identif
rapid
diagnosi
brucellar
epididymoorch
realtim
pcr
assay
urin
sampl
object
studi
diagnost
yield
realtim
pcr
assay
urin
sampl
rapid
diagnosi
brucellar
epididymoorch
comparison
convent
microbiolog
techniqu
method
ten
consecut
patient
brucellar
epididymoorch
includ
studi
diagnosi
brucellosi
establish
accord
one
follow
criteria
first
isol
brucella
spp
blood
bodi
fluid
tissu
sampl
second
presenc
compat
clinic
pictur
togeth
demonstr
specif
antibodi
signific
titer
seroconvers
epididymoorch
diagnos
patient
scrotal
enlarg
swell
pain
due
causesfor
dna
amplif
use
sybr
green
lightcyclerbas
realtim
pcr
assay
assay
amplifi
bp
sequenc
gene
code
synthesi
immunogenet
membran
protein
pair
nucleotid
primer
tgg
ctc
ggt
tgc
caa
tat
caa
cgc
gct
tgc
ctt
tca
ggt
ctg
use
amplif
process
dna
amplic
perform
melt
curv
analysi
verifi
specif
pcr
product
order
studi
specif
techniqu
sampl
patient
brucellosi
pair
equal
number
sampl
control
urinari
tract
infect
e
coli
four
case
k
pneumonia
two
case
p
mirabili
two
case
c
freundii
p
aeruginosa
one
result
mean
age
year
rang
durat
symptom
prior
diagnosi
day
rang
b
melitensi
isol
blood
cultur
nine
case
wright
seroagglutin
neg
inconclus
case
brucella
isol
urin
one
case
wherea
realtim
pcr
assay
urin
posit
nine
case
result
avail
four
hour
wherea
mean
time
avail
final
blood
cultur
result
day
rang
day
realtim
pcr
neg
control
sampl
patient
urinari
tract
infect
conclus
sybr
green
lightcyclerbas
realtim
pcr
assay
urin
sampl
highli
sensit
specif
easi
perform
could
provid
clinician
result
five
hour
techniqu
could
practic
use
tool
rapid
diagnosi
genitourinari
complic
human
brucellosi
object
although
unit
kingdom
remain
brucellosisfre
new
case
human
brucellosi
report
year
accord
world
health
organis
uk
resid
return
worldwid
travel
may
encount
exposur
contact
infect
anim
anim
product
dairi
produc
meat
phenotyp
characteris
classic
method
remain
definit
diagnosi
though
requir
skill
personnel
limit
increas
rang
molecular
techniqu
aid
rapid
detect
characteris
brucella
speci
biovar
may
signific
epidemiolog
studi
method
studi
brucella
refer
field
strain
mainli
human
isol
differ
geograph
locat
analys
divers
gene
encod
outer
membran
protein
omp
pcr
product
three
gene
digest
seven
restrict
enzym
analys
polymorph
result
reoccur
uniqu
pattern
profil
seen
human
isol
observ
origin
european
countri
beyond
grow
databas
strain
type
give
recent
overview
brucella
infect
human
mani
countri
conclus
molecular
type
method
may
advantag
classic
type
concern
brucella
melitensi
common
brucella
infect
human
characteris
human
brucella
isol
may
use
epidemiolog
studi
varieti
purpos
object
studi
demonstr
rapid
detect
speciat
campylobact
jejuni
campylobact
coli
isol
directli
enrich
broth
use
taqman
assay
singl
nucleotid
polymorph
analysi
mapa
posit
strain
use
rapid
identif
c
jejuni
clonal
complex
method
thermotoler
campylobact
speci
initi
confirm
cultur
accord
modifi
draft
iso
method
water
sampl
filter
mm
pore
size
nylon
membran
filter
transfer
select
enrich
preston
broth
improv
recoveri
therefor
detect
campylobact
cell
present
dna
extract
directli
enrich
broth
cultur
realtim
detect
c
jejuni
c
coli
use
taqman
sampl
map
posit
characteris
singl
nucleotid
polymorph
profil
rapid
recognit
c
jejuni
clonal
complex
result
environment
sampl
confirm
cultur
also
map
posit
taqman
snp
profil
mapa
posit
isol
identifi
clonal
complex
predominantli
contain
isol
human
diseas
chicken
conclus
studi
demonstr
feasibl
rapid
detect
identif
c
jejuni
c
coli
follow
short
enrich
incub
use
taqman
assay
rapid
turnaround
time
h
per
batch
sampl
achiev
snp
profil
offer
import
epidemiolog
group
strain
level
enabl
accur
phylogenet
valid
strain
identif
c
jejuni
may
import
host
associ
trace
sourc
infect
consequ
improv
public
health
respons
object
campylobact
jejuni
c
coli
recogn
common
caus
acut
bacteri
gastroenter
human
c
jejuni
predomin
speci
develop
countri
hippur
hydrolysi
test
wide
use
differenti
c
jejuni
campylobact
speci
c
jejuni
isol
fail
hydrolyz
hippur
laboratori
condit
molecular
method
repres
altern
phenotypebas
method
test
two
multiplex
pcr
assay
speci
identif
human
campylobact
strain
compar
result
hippur
hydrolysi
test
method
campylobact
strain
isol
patient
test
hippur
hydrolysi
rosco
diagnost
tablet
hippurateneg
hippurateposit
strain
select
two
multiplex
pcr
assay
one
pcrmethod
base
distinct
ceuegen
c
jejuni
c
coli
pcrmethod
detect
gene
five
major
clinic
relev
campylobact
speci
hipo
c
jejuni
glya
c
coli
c
lari
c
upsaliensi
c
fetu
subsp
fetu
rrna
gene
campylobact
spp
intern
valid
control
result
c
jejuni
hipo
gene
detect
hippurateposit
strain
hippurateneg
strain
c
coli
glya
detect
hippurateneg
strain
one
hippurateneg
strain
c
fetu
subsp
fetu
detect
speciesspecif
gene
detect
strain
ceuebas
pcr
assay
c
jejuni
ceue
detect
hippurateposit
hippurateneg
strain
c
coli
ceue
detect
hippurateneg
strain
conclus
hippurateposit
strain
identifi
c
jejuni
hippurateneg
strain
identifi
c
coli
wherea
identifi
c
jejuni
one
strain
c
fetu
subsp
fetu
result
two
pcr
assay
concord
although
strain
could
identifi
ceuebas
pcr
assay
result
suggest
molecular
speci
identif
perform
hippurateneg
strain
hippur
hydrolysi
test
accur
speci
identif
multiplexpcr
quick
easi
perform
use
pcr
assay
simultan
detect
five
campylobact
speci
also
diminish
need
phenotyp
test
phenotyp
type
cryptosporidium
speci
isol
children
kuwait
role
uniqu
transmiss
j
iqbal
p
hira
safat
kw
background
cryptosporidiosi
recogn
worldwid
signific
caus
diarrhoeal
diseas
adult
children
especi
children
less
year
age
object
cryptosporidium
spp
isol
young
children
kuwait
character
molecular
level
understand
transmiss
infect
studi
approv
ethic
committe
faculti
medicin
kuwait
methodolog
period
year
faecal
specimen
kuwaiti
children
persist
diarrhoea
found
posit
cryptosporidium
spp
microscopi
genotyp
subtyp
small
subunit
rrnabas
pcrrestrict
fragment
length
polymorph
analysi
inform
consent
taken
individu
includ
studi
result
median
age
infect
children
year
major
infect
occur
cooler
month
januaryapril
indic
mark
season
variat
children
cryptosporidiosi
cryptosporidium
infect
sociodemograph
inform
reveal
particular
mode
transmiss
infect
genotyp
organ
isol
show
ninetytwo
children
c
parvum
c
homini
c
parvum
c
homini
altogeth
subtyp
c
parvum
c
homini
observ
object
intracellular
respiratori
pathogen
chlamydophila
pneumonia
cp
might
involv
pathogenesi
atherosclerosi
sever
studi
demonstr
serolog
associ
cp
cardiovascular
diseas
dna
bacteria
found
variou
atheromat
vessel
infect
respiratori
tract
cp
believ
dissemin
system
within
alveolar
macrophag
preval
cp
within
peripher
blood
mononuclear
cell
pbmc
studi
shown
higher
patient
suffer
cardiovascular
diseas
control
patient
investig
presenc
cp
dna
aortic
heart
valv
pmbc
patient
men
women
mean
age
year
undergo
aortic
valv
replac
aortic
stenosi
also
presenc
cp
mrna
investig
sclerot
aortic
heart
valv
marker
viabl
bacteria
method
dna
extract
aortic
valv
biopsi
pbmc
use
qiaamp
dna
mini
kit
qiagen
mrna
dna
extract
anoth
piec
biopsi
use
trizol
invitrogen
realtim
pcr
direct
chlamydia
momp
gene
use
detect
cpspecif
dna
mrna
patient
sera
test
cpspecif
igm
igg
iga
antibodi
microimmunofluoresc
techniqu
result
cp
dna
found
aortic
heart
valv
patient
pbmc
patient
one
patient
cp
dna
found
pbmc
heart
valv
patient
cpspecif
igm
antibodi
patient
pcrposit
cp
dna
aortic
heart
valv
igg
iga
patient
pcrneg
aortic
heart
valv
igg
iga
cpspecif
mrna
aortic
heart
valv
present
poster
conclus
cpspecif
dna
found
sclerot
aortic
heart
valv
patient
undergo
aortic
valv
replac
confirm
previou
investig
support
role
cp
pathogenesi
aortic
valv
sclerosi
preval
cp
pbmc
compar
report
healthi
blood
donor
lower
record
patient
suffer
cardiovascular
diseas
bacteria
involv
pathogenesi
aortic
sclerosi
like
spread
aortic
valv
long
patient
need
surgeri
stenot
valv
introduct
diarrhoea
one
common
caus
morbid
mortal
among
young
children
develop
countri
diarrheagen
e
coli
strain
includ
sever
emerg
pathogen
worldwid
public
health
six
import
categori
enteroaggrig
e
coli
eaec
entropathogen
e
coli
epec
enterotoxigen
e
coli
etec
enterohemorrahg
e
coli
ehec
entroinvas
eiec
shigatoxinproduc
e
coli
stec
studi
investig
role
differ
diarrheagen
e
coli
iranian
children
acut
diarrhoea
molecular
method
antibiot
suscept
isol
strain
method
april
januari
one
thousand
eighti
five
children
acut
diarrhoea
tehran
hospit
enrol
studi
fecal
sampl
cultur
macconkey
convent
bacteri
pathogen
sorbitol
macconkey
agar
non
sorbitol
ferment
phenotyp
incub
c
primari
stool
cultur
subject
six
differ
pcr
reaction
target
gene
heatlabil
enterotoxin
lt
produc
gene
heatstabl
enterotoxin
st
produc
gene
eae
gene
plasmid
kirbi
bauer
disc
diffus
method
use
antibiogram
isol
strain
differ
diarrheagen
e
coli
differ
antibiot
result
two
hundr
seventi
one
diarrheagen
e
coli
strain
detect
stec
preval
frequenc
strain
etec
eaec
epec
respect
stec
isol
strain
gene
strain
gene
eae
gene
found
stec
strain
test
strain
resist
ampicllin
cefalotin
streptomycin
conclus
studi
stec
frequent
associ
diarrhoea
strong
associ
use
antibiot
colon
antibiot
resist
e
coli
suggest
major
role
select
resist
strain
use
antibiot
exist
unknown
intestin
adher
factor
suggest
isol
stec
strain
lack
eae
gene
still
associ
bloodi
diarrhoea
hemolyt
uream
syndrom
hu
sinc
specif
treatment
urgent
need
effect
prevent
measur
base
detail
understand
epidemiolog
stec
infect
identif
shiga
toxinproduc
escherichia
coli
raw
beef
use
dna
hybrid
digoxigeninlabel
probe
multiplex
pcr
weiner
j
osek
pulawi
pl
shiga
toxinproduc
escherichia
coli
stec
import
caus
bloodi
diarrhoea
haemorrhag
coliti
haemolyt
urem
syndrom
thrombot
thrombocytopen
purpura
transmiss
stec
occur
consumpt
contamin
food
especi
meat
dairi
product
water
object
develop
threestep
procedur
base
two
multiplex
pcr
dna
hybrid
digoxigeninlabel
probe
identif
stec
raw
beef
method
beef
sampl
inocul
differ
number
e
coli
cell
incub
tsb
medium
h
cultur
transfer
tsb
mitomycin
c
incub
anoth
h
result
cultur
use
sourc
dna
templat
establish
identifi
shiga
toxin
gene
conserv
sequenc
posit
cultur
sampl
subject
dna
hybrid
diglabel
probe
follow
cultur
dilut
inocul
onto
agar
plate
supplement
tergitol
incub
h
nylon
membran
put
agar
plate
care
remov
incub
denatur
neutralis
equilibr
solut
follow
incub
stxspecif
diglabel
probe
antidig
conjug
final
develop
enzym
substrat
bcip
nbt
dark
spot
visibl
membran
compar
respect
bacteri
coloni
origin
agar
plate
correspond
bacteri
coloni
isol
character
use
test
allow
amplif
shiga
toxin
type
shiga
toxin
type
e
coli
gene
antigen
intern
control
amplif
e
coli
rrna
gene
also
includ
mpcr
test
result
first
mpcr
result
two
amplif
product
bp
stx
bp
rrna
gene
posit
meat
sampl
test
dna
probe
posit
coloni
character
second
test
gener
amplicon
either
bp
bp
bp
bp
bp
rrna
specif
procedur
confirm
test
e
coli
hand
nonstec
bacteria
sensit
method
estim
cfug
meat
conclus
obtain
result
demonstr
high
specif
procedur
develop
possibl
use
identif
shiga
toxinproduc
e
coli
raw
beef
correl
virul
pattern
phylogenet
group
extend
spectrum
betalactamas
gene
escherichia
coli
strain
isol
blood
cultur
damian
c
usein
tatuchitoiu
ciontea
jardan
palad
bucharest
ro
e
coli
heterogen
speci
consist
commens
pathogen
strain
caus
broad
spectrum
human
diseas
includ
extra
intestin
enter
infectionsth
strain
isol
invas
infect
document
carrier
larg
number
genet
structur
code
virul
well
resist
antimicrobi
agent
aim
studi
evalu
virul
strain
comparison
presenc
esbl
gene
distribut
among
differ
phylogenet
group
total
e
coli
strain
isol
blood
cultur
hospitalis
patient
adult
children
screen
virul
factorsencod
gene
pap
sfafoc
afa
hli
cnf
aer
fimh
gene
encod
resist
extend
spectrum
betalactam
antibiot
bla
shv
bla
tem
gene
appurten
one
main
four
phylogenet
group
base
presenc
absenc
marker
chua
yjaa
three
strain
neg
virul
gene
includ
phylogenet
group
ten
strain
posit
five
six
virul
gene
identifi
group
matter
phylogenet
group
remain
strain
possess
least
one
virul
gene
strain
pcr
posit
seven
virul
gene
target
among
strain
posit
doubl
disk
test
strain
exhibit
bla
shv
bla
tem
gene
strain
bla
tem
gene
restrict
pst
dde
sequenc
amplicon
perform
order
identifi
type
esbl
gene
express
product
take
account
link
phylogenet
group
virul
obtain
good
correl
bacterem
e
coli
strain
analys
relationship
product
esbl
isol
shigatoxin
produc
escherichia
coli
meat
sampl
phenotyp
genotyp
characteris
isol
strain
f
baghbaniarani
f
jafari
mr
zali
salmanzadehahrabi
tehran
ir
object
shigatoxin
produc
escherichia
coli
stec
emerg
foodborn
pathogen
worldwid
public
health
import
bacterium
report
etiolog
agent
mani
outbreak
sporad
case
definit
divers
antimicrobi
suscept
stec
may
help
manag
sporad
case
outbreak
studi
differ
countri
show
food
item
mayb
contamin
pathogen
present
studi
carri
determin
frequenc
contamin
meat
sampl
stec
collect
tehran
well
defin
genotyp
serotyp
antibiogram
suscept
pattern
molecular
divers
isol
bacteria
method
juli
june
beef
sampl
collect
differ
part
tehran
gram
sampl
enrich
ec
broth
subcultur
macconkey
agar
dna
extract
loop
full
bacteria
taken
primari
first
streak
area
macconkey
agar
subject
three
differ
pcr
reaction
target
eae
gene
much
coloni
requir
test
find
coloni
respons
posit
result
first
pcr
antibiogram
suscept
pattern
isol
strain
determin
standard
disk
diffus
method
antimicrobi
agent
use
studi
isol
serotyp
slide
agglutin
test
use
standard
antisera
mast
group
subtyp
strain
done
rapdpcr
result
among
sampl
sampl
posit
genotyp
follow
eae
eae
eae
eae
among
posit
sampl
strain
isol
accord
antibiot
suscept
test
isol
resist
erythromycin
e
oleandomycin
ol
sensit
imipenem
gentamicin
g
norofloxazin
nx
enterofloxazin
ex
ciprofloxazin
cf
ceftazidim
ca
otyp
htype
frequenc
serotyp
analysi
isol
rapdpcr
yield
pattern
conclus
result
show
contamin
meat
sampl
stec
lifethreaten
health
problem
combin
analysi
antibiogram
suscept
pattern
serotyp
rapdpcr
pattern
aid
survey
characterist
stec
strain
factor
affect
conjug
transfer
plasmid
enterococcu
faecali
alqurashi
dammam
sa
object
factor
known
influenc
plasmid
transfer
studi
use
conjug
plasmid
encod
erythromycin
resist
enterococcu
faecali
method
donor
strain
streptococcu
agalactia
group
b
resist
rifampicin
fusid
acid
non
hemolyt
blactamaseneg
contain
broad
host
rang
plasmid
confer
resist
erythromycin
chloramphenicol
recipi
enterococcu
faecali
strain
group
result
transfer
occur
agar
filter
broth
cultur
rel
high
densiti
bacteriaml
transfer
frequenc
larg
unaffect
wide
rang
temperatur
ph
medium
rang
ph
littl
effect
transfer
frequenc
log
phase
cultur
donor
recipi
ratio
requir
optim
plasmid
transfer
conclus
factor
modifi
transfer
effici
conjug
plasmid
mate
media
solid
liquid
environ
mate
time
mate
temperatur
select
temperatur
growth
temperatur
donor
recipi
prior
mate
ph
cultur
age
donorrecipi
cell
ratio
obtain
better
understand
plasmid
transfer
process
help
understand
role
may
dissemin
resist
among
streptococc
enterococc
popul
enterococcu
faecium
bloodcultur
isol
collect
fiveyear
period
h
sullivan
b
lund
stockholm
se
background
enterococcu
faecali
enterococcu
faecium
last
year
becom
signific
nosocomi
problem
could
due
enterococcu
hardi
natur
combin
intrins
acquir
antibiot
resist
sinc
individu
harbour
enterococci
normal
intestin
microflora
discuss
regard
origin
isol
last
ten
year
isol
ratio
e
faecali
e
faecium
shift
could
increas
antibiot
resist
among
infecti
e
faecium
isol
compar
infecti
e
faecali
one
possibl
increas
also
depend
upon
differ
virul
gene
enterococc
surfac
protein
esp
hyaluronidas
variant
gene
hylefm
e
faecali
antigen
variant
efafm
object
object
studi
determin
presenc
frequenc
seven
differ
enterococc
virul
gene
infecti
isol
object
see
number
virul
gene
isol
vari
increas
time
method
total
strain
isol
bacteraemia
patient
year
karolinska
univers
hospit
hudding
use
isol
screen
seven
differ
virul
gene
use
multiplex
pcr
seven
virul
gene
aggreg
substanc
asa
cytolysin
cyt
collagen
bind
protein
ace
e
faecali
antigen
variant
efafm
enterococc
surfac
protein
esp
gelatinas
gel
hyaluronidas
hyl
result
accord
result
half
isol
espposit
preval
virul
gene
asa
efafm
gel
hyl
detect
low
frequenc
conclus
seem
like
esp
gene
domin
virul
gene
e
faecium
isol
occurr
virul
trait
isol
indic
potenti
caus
infect
potenti
among
enterococc
popul
data
investig
support
hypothes
enterococci
caus
infect
hospit
patient
probabl
nosocomi
origin
rather
endogen
object
abil
l
monocytogen
toler
alkalin
stress
particular
import
pathogen
often
expos
stress
food
process
environ
clean
alkalin
deterg
mildli
alkalin
ph
valu
prevail
within
engulf
phagolysosom
studi
aim
investig
alkalin
toler
respons
altr
listeria
monocytogen
use
dna
microarray
technolog
knowledg
alkalineinduc
stress
respons
use
understand
pathogen
toler
alkalin
stress
method
transcript
profil
l
monocytogen
carri
min
high
ph
order
captur
earli
intermedi
prolong
express
respons
alkalin
stress
use
oligo
array
pathogen
function
genom
resourc
centr
verifi
microarray
result
regul
ph
stress
respons
gene
confirm
real
time
quantit
polymeras
chain
reaction
rtpcr
result
gene
upregul
gene
open
read
frame
repres
array
regul
least
fold
upon
alkalin
shock
mani
repress
gene
encod
enzym
involv
biosynthesi
amino
acid
nucleotid
coenzym
indic
metabol
adjust
cell
high
ph
notabl
strongest
alkalineinduc
gene
involv
membran
transport
system
conclus
analysi
data
reveal
cell
sens
respond
alkalin
stress
extens
program
chang
gene
express
interestingli
strong
correl
altr
virul
gene
express
comparison
variou
microarray
data
alreadi
literatur
reveal
similar
respons
alkalin
stress
transcript
respons
stress
osmot
shock
engin
improv
listeri
stress
toler
twist
r
sleator
c
hill
cork
ie
object
engin
listeria
monocytogen
strain
significantli
improv
abil
toler
stress
encount
extern
environ
gastrointestin
transit
thu
improv
listeria
efficaci
potenti
vaccin
drug
deliveri
platform
method
result
use
direct
evolut
approach
base
random
mutagenesi
strategi
involv
e
coli
mutat
strain
gener
mutant
variant
listeri
betl
gene
design
betl
encod
secondari
betain
uptak
system
mutant
betl
promot
dramat
increas
resist
number
biolog
relev
stress
express
varieti
differ
surrog
host
use
luciferas
lux
report
system
combin
ivi
imag
system
xenogen
corpor
alameda
ca
track
betl
express
real
time
vitro
variou
environment
stress
vivo
anim
model
infect
case
strain
express
betl
demonstr
mark
improv
express
wild
type
betl
term
gene
express
bacteri
growth
sequenc
analysi
mutat
gene
reveal
singl
nucleotid
delet
spacer
region
promot
element
upstream
betl
code
region
delet
presum
introduc
conform
twist
put
promot
therebi
increas
transcript
output
furthermor
betl
mutat
appear
counter
heretofor
unreport
twist
cell
morpholog
observ
use
scan
electron
microscopi
l
monocytogen
grown
elev
osmolar
conclus
possibl
select
improv
gene
requir
bacteri
stress
surviv
insid
outsid
host
mutat
gene
system
may
ultim
use
construct
physiolog
robust
bacteri
base
vaccin
drug
deliveri
platform
ar
samarbafzadeh
tajbakhsh
sm
moosavian
ahwaz
ir
introduct
peptic
ulcer
follow
infect
stomach
h
pylori
common
diseas
accur
rapid
detect
bacteria
lead
implement
appropri
treatment
recoveri
research
undertaken
evalu
sensiv
specif
fluoresc
insitu
hybrid
fish
detect
h
pylori
patient
suffer
dyspepsia
method
purpos
one
hundr
gastric
biopsi
sampl
taken
antrum
corpu
stomach
endoscopi
test
fish
compar
convent
cultur
method
complement
biochem
test
result
fish
detect
h
pylori
clinic
sampl
convent
method
detect
sampl
sensiv
specif
fish
detect
h
pylori
calcul
respect
conclus
find
studi
suggest
fish
highli
suitabl
rapid
method
diagnosi
h
pylori
especi
sampl
taken
antrum
corpu
stomach
techniqu
potenti
appli
routin
detect
bacterium
clinic
sampl
object
numer
studi
demonstr
h
pylori
ubiquit
approxim
world
popul
infect
organ
gastroduoden
diseas
associ
h
pylori
infect
manifest
princip
adult
howev
usual
chilhood
infect
acquir
possibil
mucos
humor
respons
time
may
determin
least
part
cours
natur
infect
studi
describ
preval
h
pylori
oral
carriag
children
resid
bari
south
itali
use
pcr
method
method
evalu
perform
children
age
rang
year
primari
school
district
local
health
unit
bari
itali
ausl
school
class
select
use
cluster
sampl
method
standard
questionnair
use
verifi
socioeconom
standard
hygien
histori
previou
gastrointestin
disord
standard
fullmouth
examin
made
detect
periodont
diseas
dental
plaqu
saliva
collect
children
place
pb
transport
laboratori
h
pylori
infect
statu
check
pcr
method
dna
extract
oral
sampl
boil
method
evalu
presenc
h
pylori
caga
urea
gene
use
commerci
kit
ab
analitica
padova
result
total
children
femal
male
partecip
studi
presenc
gene
code
caga
found
children
gene
urea
detect
bacteria
detect
saliva
supragingiv
subgingiv
plaqu
suggest
site
may
consid
reservoir
h
pylori
ureasiposit
patient
statist
signific
relationship
nt
wash
hand
frequent
presenc
urea
gene
conclus
current
knowledg
impli
acquisit
h
pylori
seem
occur
predominantli
childhood
acquir
infect
persist
lifelong
infect
subject
report
worldwid
level
h
pylori
infect
preval
children
vari
increas
low
socioeconom
educ
level
age
result
studi
suggest
oral
carriag
h
pylori
may
play
role
transmiss
infect
hand
may
instrument
transmiss
role
helicobact
pylori
otiti
media
effus
yilmaz
ceylan
akyon
ozcakir
b
gursel
ankara
tr
object
otiti
media
effus
ome
common
diseas
childhood
pathogenesi
still
remain
unsettl
pepsinogen
pepsin
shown
middl
ear
fluid
patient
ome
indic
gastric
juic
could
reach
far
middl
ear
gastric
juic
could
enter
middl
ear
helicobact
pylori
common
inhabit
gastric
juic
mucosa
would
also
expect
found
middl
ear
patient
ome
object
studi
evalu
possibl
role
helicobact
pylori
pathogenesi
otiti
media
effus
method
studi
group
consist
children
undergo
bilater
ventil
tube
insert
adenoidectomi
tonsillectomi
diagnosi
ome
adenoid
hypertrophi
chronic
tonsil
control
group
consist
children
undergo
adenoidectomi
tonsillectomi
diagnosi
adenoid
hypertrophi
chronic
tonsil
studi
group
middl
ear
fluid
aspir
small
biopsi
taken
promontorium
mucosa
control
group
myringotomi
done
small
biopsi
taken
promontorium
mucosa
group
mm
deep
tissu
specimen
obtain
tonsil
adenoid
specimen
taken
patient
cultur
nestedpcr
perform
show
helicobact
pylori
result
middl
ear
fluid
cultur
posit
h
pylori
patient
mucosa
cultur
posit
patient
control
group
middl
ear
mucosa
cultur
alway
neg
cultur
pcr
result
combin
togeth
middl
ear
posit
h
pylori
patient
studi
group
patient
control
group
differ
statist
signific
h
pylori
presenc
tonsillar
adenoid
tissu
cultur
pcr
also
significantli
frequent
studi
group
compar
control
group
conclus
studi
first
grow
h
pylori
middl
ear
ome
significantli
increas
colon
h
pylori
middl
ear
tonsillar
adenoid
tissu
patient
ome
indic
bacteria
reach
middl
ear
gastroesophag
reflux
might
involv
pathogenesi
ome
ome
case
resist
medic
treatment
may
meaning
evalu
patient
gastroesophag
reflux
h
pylori
distribut
serineaspart
repeat
proteinencod
sdr
gene
among
nasal
carriag
invas
staphylococcu
aureu
strain
object
studi
design
examin
distribut
sdr
gene
among
nasal
carriag
invas
staphylococcu
aureu
strain
well
methicillinsensit
aureu
mssa
methicillinresist
aureu
mrsa
method
presenc
absenc
sdr
gene
use
dna
aureu
strain
determin
novel
triplex
pcr
procedur
twotail
fisher
exact
test
use
analys
distribut
sdr
gene
among
aureu
strain
origin
differ
host
p
valu
less
consid
statist
signific
differ
result
sdr
locu
found
investig
aureu
strain
although
strain
contain
sdrc
gene
sdrd
sdre
sdrc
sdrd
sdregen
profil
exclus
mssa
strain
fisher
exact
test
p
found
strain
collect
bone
infect
p
also
found
strong
associ
presenc
sdrd
gene
mrsa
strain
p
conclus
find
suggest
mssa
strain
newli
uncov
sdrc
sdrd
sdregen
profil
substanti
decreas
potenti
establish
bone
infect
sequenc
lukspv
lukfpv
methicillinsensit
methicillinresist
staphylococcu
aureu
divers
genet
background
swedish
counti
c
berglund
b
derquist
rebro
se
object
communityaquir
methicillinresist
staphylococcu
aureu
camrsa
report
carri
loci
pantonvalentin
leukocidin
pvl
high
frequenc
aim
studi
describ
variat
within
pvl
gene
lukspv
lukfpv
methicillinsensit
methicillinresist
aureu
divers
genet
background
method
twelv
pvlposit
aureu
characteris
multilocu
sequenc
type
mlst
mrsa
also
staphylococc
cassett
chromosom
mec
sccmec
type
ten
isol
rebro
counti
sweden
oligonucleotid
primer
design
yield
product
size
bp
includ
lukspv
lukfpv
flank
region
pcr
amplif
cyclic
sequenc
perform
sever
set
primer
overlap
sequenc
strand
separ
abi
prism
genet
analyz
appli
biosystem
nucleotid
sequenc
analys
use
abi
prism
autoassembl
tm
dna
sequenc
assembl
softwar
compar
use
bioedit
result
analysi
mlst
differenti
pvlposit
camrsa
six
differ
sequenc
type
either
sccmec
type
iv
iv
c
v
unknown
type
six
addit
st
new
detect
among
pvlposit
methicillinsensit
aureu
sequenc
lukspv
lukfpv
reveal
eight
point
mutat
among
isol
twelv
differ
origin
five
substitut
occur
lukspv
three
lukfpv
one
substitut
nonsynonym
histidin
fi
arginin
conclus
pvlgene
well
conserv
despit
differ
genet
origin
isol
analys
pvl
extracellular
product
gene
subject
select
forc
therebi
diversifi
slowli
addit
nonsynonym
mutat
might
result
nonfunct
toxin
first
case
staphylococcu
pseudintermediu
human
isol
icd
lead
l
van
hoovel
vankeerberghen
k
van
vaerenbergh
boel
h
de
beenhouw
aalst
introduct
staphylococcu
pseudintermediu
recent
describ
new
coagulaseposit
speci
anim
devries
et
al
pathogen
signific
novel
speci
remain
unclear
knowledg
human
infect
due
pseudintermediu
report
date
present
first
isol
pseudintermediu
human
import
clinic
signific
patient
method
old
male
patient
refer
centr
ischem
cardiomyopathi
ventricl
tachycardia
reciev
implant
cardioverterdefibril
icd
januari
august
present
complaint
migrat
icd
devic
clinic
examin
reveal
perfor
icd
pocket
infect
suspect
confirm
presenc
pu
pocket
infect
icd
complet
remov
sever
sampl
ventricular
lead
pu
tissu
sampl
pocket
sent
culturebacteria
obtain
routin
cultur
characteris
phenotyp
identif
pastorex
staphplu
biorad
api
staph
phoenix
bd
molecular
analysi
pcr
perform
target
nucleas
nuc
coagulas
coag
gene
aureu
addit
sequenc
rrna
gene
perform
analys
use
blast
result
staphylococci
ident
phenotyp
appear
isol
icd
sampl
lead
pu
coloni
betahemolyt
sheep
blood
agar
dnase
coagulas
posit
clump
factor
mannitol
pastorex
neg
biochem
identif
api
staph
phoenix
gave
presumpt
identif
aureu
confid
valu
respect
pcr
nuc
coag
gene
neg
rrna
gene
sequenc
result
identif
pseudintermediu
base
sequenc
similar
previou
report
sequenc
devries
et
al
conclus
case
report
describ
first
identif
pseudintermediu
signific
pathogen
human
growth
characterist
commerci
identif
system
misidentifi
organ
aureu
confront
inconsist
phenotyp
identif
pattern
clinic
lab
consid
use
rrna
gene
sequenc
final
confirm
characteris
staphylococcu
aureu
isol
recov
dairi
sheep
farm
agr
group
adher
slime
resist
antibiot
e
vautor
sabah
g
mancini
pepin
h
carsentidellamonica
sophiaantipoli
nice
fr
object
purpos
studi
investig
staphylococcu
aureu
natur
isol
associ
dairi
sheep
mastiti
epidemiolog
key
featur
agr
group
adher
slime
product
antibiot
resist
method
aureu
isol
n
recov
field
studi
southeast
franc
subclin
mastiti
clinic
mastiti
environ
dairi
sheep
farm
total
thirteen
dairi
sheep
farm
produc
chees
manufactur
raw
ewe
milk
involv
agr
group
determin
multiplex
realtim
pcr
evalu
adher
slime
product
assess
method
previous
describ
christensen
et
al
suscept
pattern
antibiot
determin
use
discdiffus
method
muellerhinton
agar
plate
oxacillin
suscept
test
perform
isol
other
antibiot
suscept
studi
isol
recov
subclin
mastiti
repres
major
sourc
chees
contamin
result
isol
belong
agr
group
regardless
clinic
find
adher
strongli
adher
maxim
adher
biofilm
produc
slime
produc
moder
strong
produc
isol
n
seven
suscept
antibiot
test
two
isol
recov
subclin
mastiti
resist
oxacillin
partli
resist
ampicillin
penicil
five
isol
found
partli
resist
erythromycin
n
cefoperazon
penicil
n
erythromycin
n
neomycin
n
resist
enrofloxaxin
partli
resist
ampicillin
penicillin
n
conclus
aureu
isol
recov
sheep
mastiti
southeast
franc
mainli
relat
agr
group
suggest
role
agrregul
protein
persist
bacteria
sheep
udder
biofilm
slime
product
may
also
import
aspect
intracellular
surviv
aureu
could
promot
develop
persist
intramammari
infect
final
ewe
milk
appear
repres
sourc
resist
aureu
special
methicillin
oxacillin
resist
aureu
mrsa
human
health
detect
virul
gene
staphylococu
aureu
isol
dairi
sheep
goat
cow
mastiti
use
singledy
dna
microarray
e
vautor
v
magnon
g
rio
pepin
p
barbri
sophiaantipoli
fr
object
staphylococcu
aureu
common
caus
mastiti
dairi
farm
anim
although
mani
put
virul
factor
identifi
aureu
genom
kuroda
et
al
differ
pathogen
potenti
natur
occur
isol
remain
larg
unaddress
rel
import
host
tissu
factor
versu
bacteri
virul
determin
diseas
pathogenesi
well
known
wide
accept
bacteri
factor
includ
toxin
cell
wallassoci
adhes
secret
exoprotein
involv
process
studi
use
singledy
dna
microarray
assay
investig
presenc
absenc
put
virul
gene
aureu
isol
recov
case
ovin
caprin
bovin
mastiti
method
mastiti
aureu
isol
sheep
n
goat
n
cow
n
dna
microarray
array
spot
long
oligonucleotid
repres
known
virul
gene
new
candid
identifi
mu
genom
human
strain
aureu
genom
gene
spot
four
time
dna
extract
strain
label
fluoresc
use
bioprim
array
cgh
invitrogen
control
strain
known
genet
phenotyp
characterist
use
normal
data
result
major
virul
gene
detect
isol
eg
coa
ica
adbc
operon
htra
hysa
nuc
sbi
sdre
ssp
feob
fnb
sib
spa
ii
gene
detect
major
isol
eg
cna
edin
lukfpv
iii
gene
found
isol
depend
herd
eg
aur
absent
isol
dairi
sheep
farm
isol
whatev
speci
ig
bsap
caph
entk
eta
fnbb
hsd
lukd
found
gene
mainli
relat
speci
eg
agriii
comprehens
result
given
poster
conclus
present
studi
indic
preval
virul
gene
among
aureu
isol
recov
dairi
farm
speci
depend
gene
observ
suggest
common
occurr
hostadapt
tissueadapt
aureu
strain
particular
virul
gene
may
play
signific
role
taken
complementari
method
pcr
orand
southern
hybridis
singledy
dna
microarray
may
provid
power
tool
type
aureu
strain
epidemiolog
possibl
pathogenesi
studi
detect
dna
sequenc
distinguish
two
close
relat
genom
staphylococcu
aureu
subclin
versu
gangren
ewe
mastiti
strain
n
chevali
c
huard
r
thieri
e
vautor
sophiaantipoli
fr
object
staphylococcu
aureu
common
caus
mastiti
dairi
sheep
sever
mastiti
rang
subclin
gangren
form
subclin
mastiti
inflamm
readili
detect
clinic
wherea
gangren
form
acut
necrot
mastiti
find
genet
marker
virul
factor
present
gangren
strain
suppress
substract
hybridis
ssh
method
use
present
studi
compar
two
strain
aureu
respect
recov
subclin
gangren
mastiti
dairi
sheep
herd
method
ewe
held
investig
farm
subclin
strain
recov
januari
milk
ewe
gangren
strain
recov
decemb
primipar
dairi
sheep
subsequ
die
acut
mastiti
dna
extract
strain
first
compar
puls
field
gel
electrophoresi
pfge
ssh
perform
use
dna
subclin
strain
driver
describ
commerci
kit
clontech
pcrselect
bacteri
genom
substract
kit
result
use
pfge
four
band
differ
found
two
strain
two
dna
fragment
presum
specif
gangren
strain
detect
ssh
sequenc
bp
homolog
sulfid
quinon
reductas
contain
orf
pathogen
island
mrsa
strain
ii
bp
homolog
gene
code
bacteriophag
holin
contain
aureu
genom
control
pcr
test
use
primer
design
specif
gene
candid
confirm
present
aureu
gangren
strain
conclus
accord
tenov
et
al
band
differ
use
pfge
indic
strain
may
possibl
relat
genet
although
gene
classic
involv
virul
aureu
detect
present
studi
two
put
virul
factor
detect
sulfid
quinon
reductas
allow
aureu
growth
sulfid
found
anim
manur
holin
protein
break
intern
membran
aureu
releas
daughter
phage
suggest
mechan
horizont
gene
transfer
could
mediat
bacteriophag
could
explain
acquisit
virul
factor
antimicrobi
clinic
trial
outpati
treatment
acut
pyelonephr
pregnanc
week
randomis
control
trial
z
ahmadinejad
hantooshzadeh
tehran
ir
object
purpos
studi
compar
safeti
efficaci
outpati
inpati
treatment
acut
pyelonephr
pregnanc
method
random
control
clinic
trial
one
hundr
twenti
eight
gravida
past
week
gestat
admit
imam
khomeini
hospit
tehran
sahid
dr
bahonar
hospit
kerman
divid
random
block
outpati
inpati
therapi
receiv
two
dose
intramuscular
ceftriaxon
interv
hospit
discharg
reevalu
within
hour
remain
hospit
afebril
hour
patient
complet
cours
oral
cephalexin
perform
urin
cultur
admiss
day
therapi
result
two
group
similar
respect
age
pariti
temperatur
estim
gestat
age
initi
white
blood
cell
count
incid
bacteremia
signific
differ
two
group
clinic
improv
hour
bacteriuria
day
treatment
relaps
pyelonephr
requir
chang
antibiot
date
pregnanc
deliveri
preterm
labor
relaps
bacteriuria
preterm
labor
inpati
significantli
outpati
pv
respect
birth
weight
neonat
outpati
significantli
inpati
pv
conclus
outpati
antibiot
therapi
effect
safe
select
pregnant
women
pyelonephr
howev
studi
neonat
outcom
better
outpati
matern
outcom
inpati
experi
daptomycin
patient
renal
insuffici
investig
collect
demograph
diseas
state
clinic
microbiolog
data
outcom
defin
use
standard
definit
patient
nonevalu
outcom
exclud
core
data
divid
data
cohort
pt
creatinin
clearanc
crcl
mlmin
examin
result
pt
enrol
evalu
pt
outcom
either
crcl
mlmin
nml
n
crcl
mlmin
yet
requir
renal
replac
therapi
ri
n
distribut
male
femal
equal
group
ri
pt
older
yr
vs
p
group
differ
percent
come
commun
set
prior
start
dap
nml
ri
nml
frequent
histori
fracturesorthopaed
procedur
vs
p
haematolog
cancer
vs
p
ri
higher
rate
renal
diseas
vs
p
chf
vs
p
immunolog
inflammatori
diseas
vs
p
ri
higher
rate
skin
infect
vs
p
endocard
vs
p
infect
frequent
report
nml
ri
bacteremia
noncatheterrel
vs
bacteremia
catheterrel
vs
osteomyel
vs
foreign
bodyorthopaed
vs
p
methicillinresist
staphylococcu
aureu
common
pathogen
nml
ri
ri
higher
rate
coagulaseneg
staphylococci
vs
p
viridan
streptococci
vs
p
differ
percentag
receiv
antibiot
prior
dap
nml
ri
mean
dap
dose
durat
similar
nml
mgkg
ri
mgkg
frequent
dose
mgkg
nml
ri
ri
initi
dap
dose
frequent
recommend
q
h
mean
time
clinic
respons
similar
nml
ri
pt
nml
receiv
concomit
antibiot
dap
vs
p
clinic
success
cure
improv
rate
nml
ri
conclus
dap
show
favour
clinic
success
rate
pt
regardless
presenc
renal
insuffici
vitro
activ
second
line
antibiot
helicobact
pylori
infect
object
aim
studi
determin
vitro
activ
levofloxacin
ciprofloxacin
rifampicin
clinic
strain
h
pylori
materi
method
isol
h
pylori
biopsi
dyspept
patient
obtain
follow
standard
methodolog
vitro
activ
metronidazol
clarithromycin
levofloxacin
ciprofloxacin
rifampicin
determin
etest
use
sheep
blood
agar
incub
c
day
atmospher
mic
determin
point
complet
inhibit
growth
breakpoint
nccl
microorgan
consid
fluorquinolon
resist
mic
mg
l
rifampicin
consid
strain
suscept
mic
mg
l
studi
report
result
strain
resist
metronidazol
clarithromycin
rang
mgl
fi
levofloxacin
fi
ciprofloxacin
rifampicin
strain
suscept
rifampicin
resist
fluorquinolon
conclus
fluorquinolon
test
rifampicin
show
excel
vitro
activ
h
pylori
despit
high
resist
rate
metronidazol
clarithromycin
howev
vitro
suscept
test
done
use
clinic
practic
vibrio
antibodi
serum
breast
milk
sampl
parturi
women
calabar
nigeria
object
serum
breast
milk
sampl
parturi
women
serum
nonparturi
control
analys
preval
titr
vibrio
antibodi
method
v
cholera
agglutinin
vibriocid
antibodi
serum
sampl
analys
direct
agglutin
immun
bacteriolysi
techniqu
respect
use
well
microtitr
plate
protect
valu
breast
milk
evalu
haemagglutin
inhibit
rabbit
intestin
mucos
attach
v
cholera
cell
result
vibrio
agglutinin
detect
serum
sampl
parturi
nonparturi
subject
p
high
preval
rate
occur
among
parturi
control
subject
year
age
respect
cut
titr
evalu
vibrio
cholera
specif
bacteriocid
antibodi
activ
detect
sampl
parturi
control
respect
age
year
breast
milk
parturi
contain
vibrio
agglutinin
titr
rang
milk
sampl
subject
show
haemagglutin
inhibit
hi
activ
titr
p
hi
posit
milk
sampl
show
inhibit
v
cholera
adher
rabbit
intestin
mucosa
titr
p
reduct
cell
attach
conclus
studi
confirm
parturi
women
calabar
may
benefit
signific
serum
titr
v
cholera
antibodi
provid
immun
protect
babi
breast
milk
secret
moxifloxacin
vs
clarithromycin
treatment
communityacquir
pneumonia
associ
common
respiratori
pathogen
pool
analysi
object
streptococcu
pneumonia
haemophilu
influenza
pathogen
commonli
associ
communityacquir
pneumonia
cap
studi
compar
clinic
bacteriolog
efficaci
moxifloxacin
mxf
clarithromycin
clar
cap
patient
pathogen
patient
method
data
pool
three
doubleblind
multicent
phase
iii
trial
compar
oral
mxf
mg
qd
clar
mg
bid
day
patient
includ
mildtomoder
cap
clinic
bacteriolog
success
rate
identifi
pneumonia
h
influenza
isol
studi
data
efficacyvalid
popul
record
testofcur
toc
visit
day
posttherapi
result
patient
enter
microbiolog
evalu
infect
pneumonia
andor
h
influenza
document
patient
mxf
clar
patient
mix
infect
within
cohort
two
treatment
group
well
balanc
base
demographicbaselin
medic
characterist
male
mean
age
yr
smoker
recent
antimicrobi
therapi
clinic
success
bacteriolog
erad
rate
one
respons
per
patient
toc
present
tabl
conclus
cap
associ
pneumonia
h
influenza
trend
toward
greater
bacteri
erad
mxf
vs
clar
clinic
success
rate
significantli
higher
mxf
monotherapi
vs
clar
variabl
creatinin
clearanc
measur
inpati
communityacquir
pneumonia
r
grossman
choudhri
haverstock
mississauga
ca
west
us
object
moxifloxacin
levofloxacin
gatifloxacin
recommend
empir
therapi
patient
communityacquir
pneumonia
cap
levofloxacin
gatifloxacin
requir
doseadjust
renal
insuffici
dose
adjust
requir
moxifloxacin
studi
design
determin
frequenc
underli
variabl
renal
insuffici
patient
cap
method
pool
analysi
data
patient
mild
moder
sever
cap
enter
one
six
random
control
clinic
trial
undertaken
renal
function
calcul
creatinin
clearanc
crcl
assess
patient
prior
treatment
mxf
posttreat
result
baselin
crcl
level
pool
popul
patient
cap
mlmin
patient
mlmin
mlmin
patient
pretreat
crcl
measur
patient
lost
followup
post
treatment
valu
patient
cap
crcl
improv
baselin
mani
patient
posttreat
patient
experienc
worsen
renal
function
see
tabl
conclus
renal
function
crcl
highli
variabl
cap
patient
baselin
evid
renal
insuffici
renal
function
monitor
close
permit
appropri
dose
adjust
levofloxacin
gatifloxacin
use
patient
popul
moxifloxacin
may
better
empir
choic
set
requir
dose
adjust
patient
renal
insuffici
renal
failur
prospect
control
randomis
nonblind
compar
studi
efficaci
safeti
highdos
singl
daili
ceftriaxon
plu
ciprofloxacin
versu
thricedaili
ceftazidim
plu
amikacin
empir
therapi
febril
neutropen
patient
object
empir
antibiot
treatment
febril
neutropenia
well
establish
best
regimen
still
controversi
purpos
studi
evalu
efficaci
safeti
cost
highdos
singl
daili
ceftriaxon
plu
ciprofloxacin
versu
thrice
daili
ceftazidim
plu
amikacin
neutropen
febril
patient
patient
method
ninetyf
patient
febril
neutropenia
includ
prospect
control
random
nonblind
compar
studi
patient
randomli
assign
either
treatment
group
ceftriaxoneciprofloxacin
group
ceftazidim
amikacin
group
evalu
success
failur
accord
defin
criteria
daili
assess
made
patient
advers
event
record
result
overal
incid
document
infect
ceftriaxoneciprofloxacin
group
ceftazidimeamikacin
group
signific
differ
clinic
efficaci
group
p
end
therapi
ceftriaxoneciprofloxacin
group
overal
incid
resolut
improv
comparison
ceftazidimeamikacin
group
thirtynin
organ
isol
gramneg
gramposit
low
incid
advers
event
group
conclus
combin
high
dose
singl
daili
ceftriaxon
plu
ciprofloxacin
effect
standard
combin
thrice
daili
ceftazidim
plu
amikacn
signific
advers
event
either
group
object
past
studi
azithromycin
children
posttreat
pt
benefit
observ
day
recent
phase
trial
adult
singledos
zmax
least
effect
standard
compar
treatment
respiratori
tract
infect
rti
includ
cap
object
demonstr
pt
benefit
adult
popul
method
posthoc
analys
includ
respiratori
advers
event
burden
raeb
conduct
treat
popul
n
azm
compar
phase
studi
raeb
sum
durat
day
respiratori
advers
event
divid
total
number
observ
day
patient
normal
year
overal
per
studi
day
raeb
calcul
zmax
pool
compar
studi
combin
result
raeb
dayspati
year
azm
patient
vs
compar
patient
p
differ
raeb
consist
progress
favour
zmax
begin
day
achiev
statist
signific
day
upper
limit
ci
around
differ
zero
figur
faropenem
medoxomil
fm
oral
penem
potent
activ
streptococcu
pneumonia
haemophilu
influenza
integr
analysi
conduct
summar
efficaci
day
mg
bid
fm
compar
beta
lactam
manag
commun
acquir
pneumonia
cap
method
efficaci
determin
three
multicent
random
doubleblind
control
trial
rct
singl
uncontrol
studi
faropenem
medoxomil
compar
day
cefpodoxim
c
day
amoxicillinclavulan
ac
day
amoxicillin
analysi
allow
examin
treatment
effect
age
race
gender
studi
site
subgroup
result
total
subject
studi
studi
conduct
n
america
studi
europ
latin
america
israel
africa
n
american
vs
studi
includ
subject
least
vs
least
year
age
patient
vs
outpati
hospit
subject
clinic
respons
fm
per
protocol
intentiontotreat
popul
noninferior
compar
studi
three
trial
combin
differ
found
treatment
effect
age
race
gender
countri
recoveri
etiolog
agent
initi
respiratori
blood
cultur
vari
case
studi
total
microbiolog
evalu
subject
pneumonia
erad
presum
erad
h
influenza
aureu
h
parainfluenza
catarrhali
fm
compar
recipi
respect
clinic
respons
pneumonia
bacterem
patient
fm
conclus
fm
efficaci
consist
across
studi
within
subgroup
noninferior
compar
efficaci
common
bacteri
pathogen
sever
form
bacterem
diseas
fm
good
option
treatment
cap
propionibacterium
acn
strain
isol
acn
vulgari
sever
infect
c
oprica
ce
nord
stockholm
se
propionibacterium
acn
member
resid
flora
skin
import
factor
involv
inflammatori
reaction
acn
patient
last
year
preval
differ
sever
infect
due
p
acn
increas
object
detect
preval
resist
p
acn
strain
isol
acn
patient
stockholm
differ
sever
infect
europ
identifi
mechan
resist
genet
divers
among
resist
strain
method
p
acn
strain
isol
acn
vulgari
sever
infect
test
clindamycin
erythromycin
linezolid
tetracyclin
pulsedfield
gel
electrophoresi
use
character
pcr
sequenc
gene
encod
domain
v
rrna
clindamycin
erythromycin
resist
strain
rrna
tetracyclin
resist
strain
perform
result
antibioticresist
strain
often
isol
antibiot
treat
patient
moder
sever
acn
area
nonantibiot
treat
acn
patient
individu
might
harbor
differ
pulsotyp
p
acn
variou
degre
resist
ii
among
clinic
isol
european
countri
found
resist
strain
tetracyclin
clindamycin
erythromycin
overal
southern
europ
higher
preval
erythromycinresist
strain
notic
southern
eastern
europ
higher
preval
resist
clindamycin
notic
high
genom
divers
geograph
spread
clone
relat
area
also
geograph
distant
countri
clindamycin
erythromycin
resist
p
acn
isol
found
member
singl
clone
spread
differ
geograph
countri
iii
p
acn
clindamycin
erythromycin
resist
strain
carri
one
describ
mutat
within
rrna
predominantli
isol
swedish
acn
patient
compar
strain
infect
fortyfour
per
cent
tetracyclin
resist
strain
found
carri
mutat
rrna
strain
isol
swedish
acn
patient
highli
resist
cluster
one
pulsotyp
conclus
surveil
preval
resist
p
acn
strain
associ
resist
mechan
import
due
rapid
variat
resist
pattern
acn
patient
sever
infect
antimicrobi
activ
unisepta
quick
deconex
solarsept
surfac
contamin
dental
instrument
dental
clinic
iran
f
shahcheraghi
tehran
ir
object
quaternari
ammonium
compound
qac
amphoter
surfact
wide
use
control
bacteri
growth
clinic
industri
invironmentunisepta
quick
deconex
solarsept
new
gener
qac
wide
use
adjunct
iran
hygin
dental
clinicsth
aim
present
studi
investig
clinic
effici
substanc
surfac
instrument
dental
clinic
materi
method
follow
bacteria
fungi
base
aoac
standard
usedpseudomona
aeruginosa
atcc
staphylococcu
aureu
atcc
bacillu
subtili
atcc
mycobacterium
bovi
atcc
wild
type
trichophyton
mentagraphit
p
aeruginosa
salmonella
typhimorium
common
fungi
iran
stock
solut
deconex
solarsept
borer
chemi
unisepta
quick
micro
unid
prepar
recommend
manufactur
concentr
bacteri
suspent
macfarland
result
report
base
decreas
cfu
coloni
form
unit
result
result
show
disinfect
bactericid
fungicid
activ
standard
p
aeruginosa
aureu
typhimurium
trichophyton
mentagraphit
number
bacteria
decreas
significantli
p
signific
differ
seen
b
subtili
wild
type
p
aeruginosa
bovi
conclus
result
confirm
qac
abl
steril
disinfect
medic
dental
instrument
use
lone
must
use
method
steril
surfac
dental
instrument
macrolid
longterm
treatment
patient
bronchiectasi
colonis
p
aeruginosa
background
certain
efficaci
macrolid
p
aeruginosa
describ
vitro
mainli
mechan
disrupt
quorum
sens
suppress
inflamm
aim
evalu
efficaci
macrolid
patient
bronchiectasi
colonis
p
aeruginosa
method
studi
prospect
includ
patient
bronchiectasi
p
aeruginosa
isol
sputum
stabl
state
subject
receiv
either
azithromycin
mg
daysweek
clarithromycin
mg
daili
long
term
complet
daili
diari
card
symptom
pef
valu
end
therapi
followup
period
year
result
patient
bronchiectasi
p
aeruginosa
evid
sputum
includ
men
mean
age
yr
patient
receiv
azithromycin
patient
clarithromycin
mean
durat
month
five
patient
discontinu
treatment
less
week
advers
event
end
therapi
patient
show
evid
p
aeruginosa
sputum
patient
still
ps
aeruginosa
sputum
improv
follow
paramet
could
observ
patient
sputum
volum
mlday
therapi
versu
mlday
therapi
p
pef
lmin
therapi
versu
lmin
therapi
p
number
exacerbationsyear
previou
year
versu
followup
year
p
conclus
studi
show
macrolid
may
effect
therapi
patient
bronchiectasi
colonis
p
aeruginosa
independ
microbi
erad
improv
clinic
symptom
reduct
exacerb
observ
patient
fungal
pathogen
haematoncolog
patient
suscept
new
old
antifung
drug
expand
popul
immunocompromis
host
infect
mani
establish
emerg
opportunist
fungi
pathogen
treat
empir
wherea
increas
number
speci
proper
treatment
start
mic
becom
avail
though
invas
aspergillosi
remain
principl
life
threaten
complic
haematoncolog
patient
hop
pathogen
ignor
select
resist
prophylaxi
increas
risk
treatment
failurein
order
understand
frequenc
rare
fungal
pathogen
select
emerg
resist
trust
fungi
hop
identifi
use
standard
mycolog
techniqu
mic
amphotericin
b
amb
flucytosin
fluconazol
fcz
itraconazol
itz
voriconazol
vcz
caspofungin
cfg
determin
use
nccl
method
specimen
process
respiratori
blood
oral
steril
bile
csf
drain
line
tissu
biopsi
nonsteril
site
yeast
account
filament
fungi
ff
repres
candida
sp
type
yeast
aspergillu
sp
type
ff
c
albican
repres
c
glabrata
c
krusei
fumigatu
aspergillu
sp
isol
mic
isol
amb
fcz
itz
vcz
cfg
mg
l
except
acremonium
sp
versicolor
terreu
scedosporium
apiospermum
isol
includ
isol
c
lusitania
sensit
amb
ff
one
isol
c
albican
yeast
resist
ff
rhodotorula
sp
c
albican
c
glabrata
c
krusei
resist
fcz
absidia
corymbifera
acremonium
sp
c
albican
c
glabrata
saccharomyc
cerevisia
resist
itz
vcz
corymbifera
acremonium
sp
c
albican
c
glabrata
c
krusei
c
tropicali
rhodotorula
sp
p
aecilomyc
variotii
mic
mgl
cfg
effect
concentr
mgl
corymbifera
fusarium
solani
geotrichum
capitatum
sporobolomyc
salmonicolor
acremonium
sp
c
parapsilosi
data
show
hop
expos
mani
differ
fungal
pathogen
resist
old
new
antifung
amb
still
drug
broader
spectrum
less
develop
resist
yeast
ff
faropenem
medoxomil
treatment
acut
bacteri
sinus
integr
analysi
kowalski
r
tosiello
r
echol
milford
us
background
faropenem
medoxomil
fm
oral
absorb
synthet
penem
antibacteri
agent
vitro
activ
communityacquir
respiratori
pathogen
method
efficaci
fm
subject
acut
bacteri
sinus
ab
evalu
phase
iii
trial
studi
conduct
n
america
studi
conduct
europ
israel
studi
conduct
us
argentina
prospect
random
doubleblind
activ
compar
trial
openlabel
sinu
tap
trial
dose
fm
mg
bid
studi
compar
cefuroxim
axetil
cfx
mg
bid
durat
fm
treatment
day
day
vs
cfx
day
fm
cfx
given
day
fm
administ
day
primari
efficaci
variabl
studi
clinic
respons
testofcur
toc
microbiolog
respons
toc
secondari
efficaci
variabl
sinu
punctur
endoscop
collect
sinu
punctur
aspir
noninferior
defin
differ
cure
rate
fm
minu
compar
lower
boundari
ci
greater
result
cure
rate
toc
shown
tabl
valid
per
protocol
vpp
intenttotreat
itt
popul
frequenc
isol
key
pathogen
rate
erad
sampl
obtain
endoscopicallyguid
swab
sampl
obtain
tap
consist
across
studi
erad
rate
pneumonia
h
influenza
catarrhali
vs
fm
vs
cfx
vs
fm
vs
cfx
vs
fm
vs
cfx
respect
conclus
fm
mg
bid
x
day
shown
noninferior
cfx
clinic
efficaci
two
prospect
doubleblind
compar
trial
third
openlabel
trial
demonstr
similar
efficaci
microbiolog
document
ab
caus
key
pathogen
longer
treatment
fm
provid
addit
efficaci
faropenem
medoxomil
treatment
acut
exacerb
chronic
bronchiti
integr
analysi
kowalski
r
tosiello
r
echol
milford
us
background
faropenem
medoxomil
fm
oral
absorb
synthet
penem
antibacteri
vitro
activ
communityacquir
respiratori
pathogen
method
efficaci
fm
subject
acut
exacerb
chronic
bronchiti
aecb
evalu
phase
iii
trial
studi
conduct
europ
israel
mexico
south
africa
studi
conduct
us
argentina
prospect
random
doubleblind
activ
compar
trial
dose
fm
mg
bid
day
studi
compar
clarithromycin
clr
mg
bid
day
azithromycin
azi
qd
day
mg
day
mg
primari
efficaci
variabl
clinic
respons
testofcur
toc
microbiolog
respons
toc
subject
baselin
pathogen
secondari
variabl
noninferior
defin
differ
cure
rate
fm
minu
compar
lower
boundari
ci
greater
result
cure
rate
shown
valid
per
protocol
vpp
intenttotreat
itt
modifi
itt
popul
itt
subject
met
inclusionexclus
criteria
individu
studi
pool
analys
popul
treatment
fm
less
effect
either
compar
treat
subject
subject
evalu
microbiolog
respons
erad
rate
microbiolog
evalu
popul
higher
clr
group
compar
fm
group
ci
contrast
erad
rate
similar
fm
azi
group
ci
data
pool
across
studi
respons
rate
similar
fm
combin
compar
group
ci
combin
eradicationpresum
erad
rate
pool
fm
compar
group
vs
respect
pneumonia
vs
respect
h
influenza
conclus
fm
shown
noninferior
either
azi
clr
clinic
efficaci
two
adequ
wellcontrol
trial
pool
analysi
strengthen
clinic
noninferior
conclus
differ
erad
rate
observ
studi
clr
support
studi
azi
integr
safeti
analysi
faropenem
medoxomil
result
subject
phase
iiiii
clinic
trial
r
echol
r
tosiello
milford
us
object
evalu
safeti
profil
faropenem
medoxomil
fm
novel
oral
penem
antibiot
method
subject
phase
ii
phase
iii
clinic
trial
receiv
fm
mg
bid
day
treatment
acut
bacteri
infect
random
control
trial
rct
includ
fm
compar
treat
subject
analys
conduct
identifi
possibl
dispar
advers
event
ae
report
base
type
infect
subject
age
gender
durat
treatment
v
geographi
na
eu
row
studi
design
open
label
v
rct
relationship
treatment
comparison
made
control
treatment
base
antibiot
class
blactam
v
individu
antibiot
treatment
result
fm
compar
favour
penicillin
cephalosporin
macrolid
fm
better
toler
tmpsmx
coamoxiclav
open
label
trial
higher
ae
report
v
rct
ae
report
na
row
eu
except
seriou
ae
death
row
eu
na
ae
fm
fm
underli
infect
influenc
ae
report
femal
gender
higher
ae
report
male
gender
fm
toler
equal
well
across
age
rang
although
death
sae
common
age
group
common
ae
relat
rct
diarrhoea
nausea
fungal
vaginosi
headach
gener
less
frequent
fm
control
rx
evid
neuro
cardio
toxic
identifi
laboratori
test
identifi
hepat
renal
hematopoiet
signal
conclus
faropenem
medoxomil
novel
oral
penem
antibiot
safeti
profil
expect
blactam
better
toler
coamoxiclav
approxim
onethird
gi
side
effect
efficaci
nonsurg
system
antibiot
treatment
regimen
smoke
nonsmok
patient
e
k
ivuken
p
naaber
saag
tartu
ee
periodont
chronic
infecti
diseas
lead
destruct
periodont
ligament
fibr
alveolar
bone
tooth
loss
object
studi
compar
longitudin
effect
combin
nonsurg
periodont
therapi
system
antibiot
smoke
nonsmok
ns
patient
method
total
patient
sever
gener
chronic
periodont
involv
studi
ns
respond
well
previou
mechan
periodont
treatment
clinic
examin
includ
record
visibl
plaqu
index
vpi
modifi
gingiv
index
mgi
bleed
probe
bop
suppur
probe
sup
probe
pocket
depth
pd
clinic
attach
level
cal
nonsurg
periodont
therapi
perform
within
week
clinic
paramet
record
baselin
week
first
mechan
treatment
month
combin
treatment
regular
checkup
visit
patient
respond
convent
periodont
therapi
microbiolog
analys
taken
combin
system
amoxicillin
mg
metronidazol
mg
day
prescrib
result
result
suggest
combin
system
antibiot
therapi
effect
case
sever
gener
chronic
periodont
vpi
bop
sup
cal
mgi
improv
significantli
treatment
ns
group
paramet
except
cal
improv
significantli
treatment
show
markedli
smaller
reduct
sup
mgi
calaft
instrument
periodont
pathogen
isol
patient
patient
infect
one
three
differ
pathogen
among
pathogen
prevotella
intermedianigrescen
patient
actinobacillu
actinomycetemcomitan
patient
domin
total
level
microbi
load
cfuml
well
spectrum
pathogen
ns
patient
remain
similar
conclus
despit
posit
treatment
effect
gener
insignific
improv
clinic
paramet
smoke
group
smoke
advers
effect
periodont
therapi
therefor
dentist
cooper
patient
counsel
smoke
cessat
achiev
better
result
treatment
periodont
object
laminin
ln
larg
multidomain
glycoprotein
extra
cellular
matrix
attract
much
attent
import
mani
cellular
function
includ
induct
cell
adhes
growth
promot
mediat
cell
commun
target
studi
find
whether
relat
level
serum
ln
inflammatori
activ
microbi
infect
patientsmethod
june
octob
immunocompet
adult
confirm
bacteri
infect
admit
hospit
pneumonia
pyelonephr
cholecyst
group
time
hospitalis
patient
noninfecti
caus
stroke
gastrointestin
bleed
anaemia
also
studi
group
level
serum
ln
crp
measur
day
admiss
group
level
ln
measur
use
enzym
immunoassay
kit
takara
laminin
eia
kit
healthi
volunt
use
determin
normal
limit
ngml
plasma
crp
concentr
assess
immunoturbidometr
method
use
randox
uk
kit
normal
valu
consid
result
mean
serum
ln
level
patient
group
much
higher
normal
limit
mean
crp
valu
mean
correspond
valu
group
ln
within
normal
limit
crp
statist
signific
differ
mean
ln
level
two
group
p
addit
statist
signific
correl
level
ln
crp
well
studi
serum
inflammatori
marker
patient
bacteri
infect
group
pearson
correl
coeffici
r
p
conclus
definit
ln
level
could
constitut
new
reliabl
simpl
direct
serum
marker
confirm
activ
bacteri
infect
addit
crp
level
normal
group
patient
without
infect
ln
lie
within
normal
limit
mayb
ln
even
specif
crp
studi
requir
futur
patient
includ
order
confirm
outcom
studi
perform
clinic
signific
direct
tube
coagulas
test
use
serum
separ
tube
rapid
identif
staphylococcu
aureu
blood
cultur
broth
kwa
lincasonato
p
sturm
nijmegen
nl
object
blood
cultur
import
diagnosi
seriou
infect
earli
administr
effect
antibiot
associ
improv
patient
outcom
perform
direct
tube
coagulas
dtc
use
serum
separ
tube
sst
rapid
identif
aureu
blood
cultur
broth
bcb
investig
clinic
signific
rapid
identif
assess
method
consecut
blood
cultur
gramposit
cocci
cluster
test
bcb
collect
sst
use
subculturev
unit
centrifug
supernat
discard
ml
rabbit
plasma
ad
remain
pellet
bacteria
coagul
evalu
hour
incub
overnight
incub
room
temperatur
parallel
direct
tube
coagulas
test
perform
use
salin
dilut
bcb
describ
previous
isol
identifi
standard
microbiolog
procedur
clinic
signific
measur
comparison
antimicrobi
prescript
base
gram
stain
result
direct
coagulas
result
cultur
result
result
period
bcb
patient
test
aureu
present
bcb
use
serum
separ
tube
method
salin
dilut
method
sensit
dtc
hour
incub
hour
respect
specif
method
rapid
identif
aureu
result
initi
n
streamlin
n
antimicrobi
therapi
patient
aureu
bacteremia
rapid
identif
coagulaseneg
staphylococci
result
chang
antimicrobi
therapi
patient
conclus
dtc
use
sst
bacteri
enrich
reliabl
rapid
cheap
easi
perform
method
identif
aureu
bcb
implement
test
improv
antimicrobi
therapi
evalu
result
spanish
seimc
extern
qualiti
control
program
diagnosi
enterococcu
faecali
klebsiella
pneumonia
infect
r
guna
jl
n
orta
c
gimeno
behalf
seimc
object
evalu
result
obtain
four
shipment
two
differ
strain
particip
seimc
extern
qualiti
control
program
eqcp
control
intend
analys
percentag
correct
speci
identif
abil
particip
detect
special
featur
control
strain
vanb
phenotyp
case
e
faecali
product
extend
spectrum
betalactamas
esbl
k
pneumonia
method
strain
microorgan
sent
two
differ
shipment
vanb
e
faecali
strain
sent
control
year
well
esblproduc
k
pneumonia
sent
averag
laboratori
result
obtain
compar
refer
laboratori
certifi
speci
identif
resist
featur
result
control
particip
identifi
correctli
e
faecali
glycopeptid
resist
pattern
enterococc
strain
particip
detect
vanb
phenotyp
respect
overal
k
pneumonia
strain
correctli
identifi
separ
control
particip
respect
interestingli
percentag
laboratori
detect
presenc
esbl
k
pneumonia
strain
sharpli
increas
overal
percentag
correct
speci
identif
high
two
microorgan
control
point
import
abil
spanish
clinic
laboratori
detect
special
resist
featur
strain
clearli
improv
along
studi
period
data
confirm
import
implement
continu
surveil
diagnost
train
clinic
laboratori
well
possibl
posit
intervent
seimc
extern
qualiti
control
program
improv
sinc
analysi
result
accompani
updat
review
subject
control
bonnetpierroz
resenterra
sion
ch
object
evalu
new
elisa
ridascreen
borrelia
igg
igm
antibodi
respons
patient
confirm
lyme
borreliosi
compar
result
vida
lyme
iggigm
inhous
immunoblot
b
garinii
igg
igm
earli
case
b
burgdorferi
sensu
stricto
b
afzelii
b
garinii
b
valaisiana
igg
late
case
method
elisa
ridascreen
borrelia
igg
igm
use
screen
sera
patient
clinic
confirm
erythema
migran
em
n
patient
confirm
neuroborreliosi
intrathec
antibodi
synthesi
n
evalu
igg
antibodi
borrelia
sera
patient
acrodermat
chronica
atrophican
aca
n
sera
synovi
fluid
patient
lyme
arthriti
n
also
evalu
igg
antibodi
patient
syphili
n
infecti
mononucleosi
n
screen
igg
igm
antibodi
borrelia
order
estim
specif
conclus
elisa
ridascreen
borrelia
igg
igm
shown
good
sensit
serolog
diagnosi
lyme
borreliosi
short
evalu
specif
igg
test
reveal
good
assay
fals
posit
reaction
wherea
igm
assay
expect
prompt
give
fals
posit
result
sera
patient
infecti
mononucleosi
far
equivoc
posit
test
confirm
immunoblot
necessari
incub
bactalert
blood
cultur
bottl
day
object
assess
incub
time
reduct
aerob
anaerob
bactalert
system
bottl
day
method
process
blood
cultur
set
detect
posit
blood
cultur
clinic
signific
retrospect
examin
detect
time
posit
bottl
assess
clinic
signific
bottl
posit
fourth
fifth
day
result
posit
blood
cultur
clinic
signific
detect
within
first
day
incub
posit
blood
cultur
detect
fourth
fifth
incub
day
recov
concurr
cultur
within
first
day
chart
review
conduct
patient
remain
isol
patient
posit
blood
cultur
chang
antimicrobi
therapi
base
upon
posit
blood
cultur
result
day
made
patient
empir
treatment
adequ
isol
microorgan
patient
gramposit
cocci
staphylococcu
spp
aureu
staphylococcu
aureu
streptococcu
viridan
streptococcu
pyogen
anaerob
enterobacteriacea
pseudomona
aeruginosa
campylobact
spp
candida
spp
cryptococcu
neoforman
brucella
spp
haemophilu
influenza
conclus
incub
bactalert
blood
cultur
bottl
day
would
repres
detect
loss
clinic
signific
isol
led
antimicrobi
therapi
chang
although
keep
employ
incub
routin
blood
cultur
could
reduc
incub
time
day
depend
current
instrument
capac
enzym
immunoassay
antidiphtheria
antibodi
practic
altern
vero
cell
assay
r
budd
e
harley
r
georg
efstrati
k
broughton
bradwel
birmingham
london
uk
introduct
extend
studi
result
antidiphtheria
toxoid
enzym
immunoassay
eia
specif
design
detect
higher
affin
antibodi
compar
vero
cell
assay
vca
method
result
serum
sampl
antibodi
concentr
rang
iuml
vca
respiratori
system
infecti
laboratori
rsil
assay
eia
bind
site
ltd
uk
sampl
rsil
select
basi
close
protect
level
assay
confirm
perform
eia
eia
calibr
nibsc
refer
materi
assay
measur
rang
iuml
result
compar
use
guidelin
iuml
minimum
protect
level
iuml
protect
rel
agreement
sensit
specif
first
sampl
respect
second
set
sampl
perform
combin
sampl
result
respect
roc
analysi
total
sampl
confirm
highest
sensit
specif
occur
cutoff
precis
iuml
elisa
assay
conclus
total
discrep
sampl
vca
eia
valu
iuml
therefor
suggest
possibl
establish
equivoc
zone
interpret
eia
result
test
part
gener
immun
statu
assess
grey
zone
requir
undertaken
determin
requir
immun
use
equivoc
zone
recommend
appli
criteria
eia
one
sampl
would
suggest
inappropri
immun
indic
vca
result
iuml
agreement
two
assay
signific
advantag
cost
speed
eas
use
potenti
autom
eia
could
therefor
consid
altern
vca
evalu
accuraci
limit
countabl
colonyform
unit
agar
plate
j
arbiqu
rendel
k
forward
halifax
ca
object
accur
coloni
count
essenti
compon
mani
microbiolog
research
project
clinic
laboratori
process
suggest
rang
accuraci
colonyform
unit
cfu
extend
standard
method
examin
water
wastewat
recommend
date
fail
adequ
address
numer
sourc
interand
intravari
without
detail
analysi
difficult
estim
sampl
size
number
replic
necessari
ensur
accur
result
purpos
studi
determin
valid
accuraci
limit
quantifi
cfu
agar
plate
method
escherichia
coli
atcc
staphylococcu
epidermidi
atcc
use
prepar
seri
four
organ
densiti
rang
approxim
cfu
three
differ
day
day
densiti
organ
plate
sba
viabl
organ
count
follow
incub
averag
margin
error
obtain
day
test
use
determin
reproduc
agar
plate
count
estim
optimum
number
replic
plate
sampl
size
requir
organ
concentr
result
margin
error
organ
greatest
suspens
yield
approxim
cfu
lowest
suspens
yield
cfu
nine
replic
plate
requir
suspens
epidermidi
yield
cfu
achiev
margin
error
obtain
replic
plate
concentr
yield
cfu
seven
replic
plate
requir
suspens
e
coli
yield
cfu
achiev
similar
margin
error
obtain
replic
plate
concentr
yield
cfu
replic
plate
concentr
yield
cfu
conclus
found
greater
concentr
cfu
fewer
replic
plate
necessari
reliabl
estim
organ
concentr
lower
organ
densiti
cfu
plate
necessari
reliabl
estim
cfu
contrari
recommend
describ
standard
method
examin
water
wastewat
cfu
reliabl
reproduc
greatest
accuraci
experi
conduct
assur
coloni
count
rang
direct
microscopi
valuabl
instrument
diagnosi
prognosi
periodont
diseas
object
appreci
composit
micro
flora
periodont
pocket
use
light
microscopi
compar
clinic
statu
introduct
gener
accept
periodont
diseas
occur
anaerob
gramneg
flora
increas
number
subsequ
decreas
facult
anaerob
gramposit
bacteria
word
switch
gramposit
gramneg
subgingiv
flora
patholog
signific
could
observ
use
direct
microscopi
materi
method
specimen
sampl
steril
paper
point
periodont
pocket
sampl
clinic
healthi
person
includ
studi
sampl
dilut
ml
salin
solut
calibr
loop
taken
aliquot
order
prepar
smear
microscop
examin
inocul
solid
media
columbia
sheep
blood
smear
gram
stain
cultur
plate
incub
anaerob
condit
h
air
h
result
sampl
patient
periodont
diseas
easili
notabl
high
number
gramneg
bacteria
direct
microscopi
associ
abund
growth
anaerob
condit
poor
growth
air
healthi
patient
gramneg
flora
almost
absent
gramposit
bacteria
high
number
correl
absenc
bacteri
growth
anaerobiosi
growth
airth
presenc
treponema
spp
direct
microscopi
associ
deep
bleed
periodont
pocket
day
proper
therapi
good
clinic
statu
well
correl
increas
number
gramposit
bacteria
conclus
use
dilut
sampl
microscop
examin
valu
method
increas
offer
import
inform
composit
subgingiv
good
correl
clinic
statu
microscop
find
recommend
easi
use
diagnost
method
dentistri
identif
speci
glycopeptid
resist
among
enterococc
isol
bd
phoenix
object
vancomycin
resist
enterococci
emerg
europ
necessit
fast
accur
identif
laboratori
attempt
evalu
perform
bd
phoenix
autom
microbiolog
system
bd
diagnost
system
spark
md
correct
identif
speci
glycopeptid
resist
comparison
gold
standard
diagnosi
pcr
use
larg
collect
clinic
strain
method
total
enterococc
isol
test
bd
phoenix
sytem
strain
isol
faecal
urin
pu
blood
sampl
bodi
site
cultur
multiplex
pcr
appli
use
differ
pair
primer
specif
identif
e
faecium
e
faecali
vana
vanb
vanc
vand
vang
vane
glycopeptid
resist
genotyp
suscept
glycopeptid
also
confirm
etest
ab
biodisk
solna
sweden
result
accord
pcr
e
faecium
includ
vanaposit
strain
e
faecali
includ
vanaposit
vanbposit
strain
e
cassgal
isol
two
strain
identifi
exclud
analysi
discrep
result
multiplex
pcr
phoenix
system
obtain
isol
similar
rate
amongst
faecal
rest
isol
common
discrep
misidentif
e
faecium
vana
strain
e
faecali
strain
e
cassgal
phoenix
two
e
faecali
strain
incorrectli
character
vancomycin
resist
two
e
faecium
strain
misidentifi
e
hira
ecassgal
respect
one
ecassgal
strain
report
e
faecium
resist
glycopeptid
thu
sensit
specif
identif
ecassgal
phoenix
strain
strain
respect
vana
strain
strain
recogn
system
conclus
studi
demonstr
new
identif
system
phoenix
similarli
autom
manual
system
present
problem
regard
correct
identif
enterococc
speci
glycopeptid
resist
specif
laboratori
awar
clinic
signific
isol
identifi
ecassgal
confirm
anoth
method
audit
sputum
requisit
practic
p
lal
balakrishnan
london
uk
object
analys
indic
rational
process
sputum
specimen
london
teach
hospit
method
sputum
sampl
receiv
includ
studi
data
obtain
patient
requisit
form
winpath
system
analys
per
object
result
total
specimen
receiv
period
hospit
inpati
gener
practition
total
sampl
receiv
hospitalin
patient
epitheli
cell
lpf
clinic
detail
mention
patient
alreadi
antibiot
repeat
specimen
within
one
week
sent
case
atyp
serolog
also
sent
hospitalin
patient
sampl
signific
isol
normal
respiratori
tract
flora
isol
other
report
gross
oral
contamin
growth
signific
growth
specimen
report
inappropri
specimen
two
day
old
leak
saliva
total
sampl
receiv
gp
patient
sampl
epitheli
cellslpf
clinic
detail
provid
sampl
sent
patient
antibiot
sampl
repeat
within
one
week
atyp
serolog
also
sent
conclus
less
onethird
specimen
yield
signific
pathogenadequ
clinic
detail
lack
onefifth
specimensnearli
onethird
specimen
repeat
within
one
week
without
clear
indicationabout
specimen
poor
qualityatyp
serolog
perform
outpati
compar
inpatientsthi
audit
bring
forth
fact
clinic
indic
sputa
sent
cultur
need
clearli
defin
educ
campaign
institut
amongst
relev
healthcar
profession
sputum
collect
techniqu
need
rigor
appli
goodqual
specimen
obtain
indic
perform
atyp
serolog
need
defin
reinforc
particularli
primari
care
new
approach
laboratori
diagnost
infecti
gastroenter
followup
object
order
optim
use
laboratori
facil
ensur
flexibl
relat
current
epidemiolog
new
approach
laboratori
diagnosi
infecti
gastroenter
appli
algorithm
decis
organ
test
defin
demograph
clinic
epidemiolog
inform
submit
laboratori
paperelectron
request
form
method
april
june
hospit
gener
practition
submit
request
form
follow
inform
togeth
stool
sampl
acut
persist
diarrhoea
durat
week
bloodi
stool
recent
histori
foreign
travel
patient
within
epidemiolog
set
nosocomi
infect
provis
data
mandatori
submit
electron
base
data
analys
perform
accord
algorithm
examin
salmonella
shigella
yersinia
campylobact
clostridium
difficil
done
cultur
verotoxin
produc
e
coli
vtec
enteropathogen
e
coli
epec
enterotoxigen
e
coli
etec
enteroinvas
e
coli
eiec
identifi
pcr
virul
gene
serotyp
rota
adenoviru
detect
antigen
test
parasit
microscopi
result
total
examin
sampl
patient
pathogen
isol
patient
case
clinicalepidemiolog
data
miss
patient
diarrhoea
week
campylobact
salmonella
etec
giardia
eiec
vtec
patient
diarrhoea
week
campylobact
giardia
epec
vtec
patient
histori
foreign
travel
campylobact
etec
salmonella
giardia
patient
bloodi
stool
campylobact
salmonella
vtec
patient
year
campylobact
epec
giardia
vtec
salmonella
etec
conclus
campylobact
common
bacteri
pathogen
group
rotaviru
common
pathogen
children
year
new
approach
number
advantag
relev
microbiolog
analysi
collect
data
defin
patient
group
flexibl
regard
adapt
current
epidemiolog
knowledg
increas
use
electron
submiss
request
form
optim
approach
use
object
small
coloni
variant
scv
emerg
infecti
diseas
problem
present
natur
occur
slowgrow
subpopul
staphylococcu
aureu
character
tini
coloni
solid
media
studi
scv
recov
patient
persist
infect
hamper
due
frequent
unstabl
phenotyp
particular
scv
easili
distinguish
normal
phenotyp
broth
media
revers
scv
normal
phenotyp
traceabl
method
set
isogen
aureu
isol
compris
normal
ii
scv
phenotyp
isogen
isol
normal
phenotyp
recov
clinic
specimen
well
iii
correspond
mutant
mimick
scv
phenotyp
knockout
hemb
iv
complement
mutant
use
investig
feasibl
fouriertransform
infrar
ftir
spectroscopi
trace
express
phenotyp
broth
media
respect
isol
cultur
solid
media
serv
control
addit
isol
genotyp
pulsedfield
gel
electrophoresi
spa
type
result
use
firstderiv
infrar
spectra
calcul
spectral
distanc
hierarch
cluster
base
spectral
inform
three
differ
spectral
rang
result
dendrogram
show
clear
discrimin
staphylococc
phenotyp
distinct
cluster
compris
clinic
mutant
scv
phenotyp
one
hand
normal
phenotyp
isol
normal
phenotyp
complement
mutant
hand
found
thu
scv
differ
clonal
lineag
gave
spectra
similar
one
anoth
normal
growth
parent
ftir
also
shown
abl
trace
switch
phenotyp
broth
medium
supplement
conclus
ftir
spectroscopi
allow
rapid
reproduc
clear
discrimin
differ
phenotyp
aureu
fluid
media
diagnost
research
purpos
contrast
genotyp
approach
ftir
staphylococc
fingerprint
reliabl
type
purpos
isol
exhibit
phenotyp
futur
studi
techniqu
may
also
provid
approach
trace
scv
phenotyp
infect
tissu
object
trigger
receptor
express
myeloid
recent
discov
cell
surfac
molecul
whose
express
phagocyt
regul
exposur
bacteria
fungi
solubl
form
measur
variou
bodi
fluid
studi
whether
cerebrospin
fluid
csf
could
serv
biomark
presenc
outcom
patient
bacteri
mening
method
retrospect
studi
diagnost
accuraci
use
elisa
determin
level
csf
adult
bacteri
mening
confirm
csf
cultur
particip
prospect
dutch
mening
cohort
studi
patient
viral
mening
confirm
polymeras
chain
reaction
csf
healthi
control
subject
underw
lumbar
punctur
exclud
diagnosi
subarachnoid
haemorrhag
mannwhitney
u
test
chisquar
test
use
identifi
differ
group
receiveroperatingcharacterist
curv
roc
construct
illustr
variou
cutoff
csf
level
differenti
presenc
absenc
bacteri
mening
diagnost
accuraci
quantifi
confid
interv
ci
result
level
csf
higher
patient
bacteri
mening
compar
viral
mening
median
pgml
rang
pgml
versu
pgml
rang
pgml
p
control
pgml
rang
pgml
p
fig
patient
viral
mening
control
similar
csf
level
area
roc
curv
discrimin
patient
without
bacteri
mening
ci
p
cutoff
level
pgml
yield
sensit
ci
specif
ci
patient
bacteri
mening
csf
level
associ
mortal
survivor
versu
nonsurvivor
median
pgml
rang
pgml
versu
pgml
rang
pgml
p
conclus
measur
csf
may
valuabl
new
approach
accur
diagnos
bacteri
mening
identifi
patient
high
risk
advers
outcom
therefor
prospect
studi
biomark
bacteri
mening
need
systemat
review
rapid
diagnost
test
enterohaemorrhag
e
coli
abubakar
l
irvin
l
shepston
schelenz
c
aldu
p
hunter
norwich
uk
object
varieti
rapid
test
detect
enterohaemorrhag
escherichia
coli
ehec
recent
emerg
cultur
sorbitol
macconkey
smac
agar
biochem
identif
easi
use
inexpens
slow
lack
sensit
detect
non
serotyp
studi
sought
determin
accuraci
rapid
serolog
polymeras
chain
reaction
pcr
assay
evalu
detect
ehec
serotyp
compar
cultur
method
systemat
review
metaanalysi
articl
identifi
via
search
electron
databas
hand
search
select
journal
contact
expert
commerci
test
manufactur
major
need
exclud
due
low
qualiti
lack
accuraci
data
sensit
specif
method
calcul
use
full
biochem
identif
refer
standard
twentyon
studi
met
inclus
criteria
use
pcr
method
use
serolog
assay
base
cultur
summari
receiv
oper
curv
sroc
construct
data
area
curv
auc
calcul
use
trapezium
rule
result
serolog
test
individu
sensit
rang
specif
rang
pcr
test
individu
sensit
rang
specif
rang
addit
analysi
compar
smac
agar
cultur
toxin
detect
method
show
poor
sensit
compar
pcr
serolog
test
rang
yet
specif
good
studi
consid
result
suggest
molecular
serolog
test
may
potenti
role
detect
ehec
infect
whilst
littl
differ
effect
techniqu
faster
improv
sensit
compar
tradit
cultur
method
fast
reliabl
diagnosi
could
lead
inform
treatment
choic
improv
outbreak
control
measur
howev
given
substanti
extra
cost
assay
assess
econom
feasibl
necessari
prior
use
everyday
practic
antibodi
bordetella
pertussi
detect
slow
agglutin
test
elisa
two
agerel
group
vaccin
peopl
suspect
acut
pertussi
compar
studi
object
aim
present
studi
describ
differ
result
two
test
use
detect
antibodi
bordetella
pertussi
slow
agglutin
elisa
two
agerel
group
patient
suffer
respiratori
infect
peopl
undergon
vaccin
b
pertussi
method
pair
sera
obtain
two
agerel
group
patient
age
year
n
age
year
n
suffer
acut
respiratori
infect
test
first
group
compris
children
vaccin
earlier
one
year
test
second
group
determin
longer
interv
vaccin
test
criterion
posit
slow
agglutin
base
quadrupl
increasedecreas
titer
specif
antibodi
criterion
serodiagnosi
ill
patient
test
elisa
iga
igg
igm
virotech
period
posit
result
class
immunoglobulin
evalu
posit
elisa
differ
result
obtain
two
test
assess
insid
group
result
found
respect
concord
posit
respect
concord
neg
result
test
first
respect
second
group
found
follow
discrep
frame
non
equal
result
agglutin
positiveelisa
neg
sera
present
respect
person
agglutin
negativeelisa
posit
sampl
present
respect
person
conclus
frequenc
serolog
confirm
infect
base
result
slow
agglutin
higher
group
peopl
older
six
interpret
result
younger
group
limit
influenc
actual
vaccin
elisa
evalu
describ
show
extrem
high
frequenc
posit
group
thu
use
diagnost
acut
infect
seem
low
studi
continu
ass
relationship
posit
result
detect
slow
agglutin
posit
one
detect
elisa
separ
class
specif
immunglobulin
accuraci
microscan
walkaway
system
identifi
coagulaseneg
staphylococci
b
ruiz
l
santand
es
object
determin
reliabl
identif
coagulaseneg
staphylococci
con
microscan
walkaway
wa
dade
behr
system
speci
level
probabl
obtain
consid
refer
result
molecular
identif
method
one
hundr
sixtyeight
isol
con
clinic
sampl
octob
may
identif
wa
system
atcc
type
strain
evalu
bacteria
identifi
wa
system
use
po
combo
panel
absenc
coagulas
determin
latex
assay
pastorex
staphplu
biorad
refer
identif
establish
sequenc
rrna
identif
wa
rrna
disagre
definit
identif
defin
sequenc
soda
tuf
gene
previous
describ
drancourt
et
al
jcm
heiken
el
al
jcm
identif
sequenc
rrna
soda
tuf
compar
genebank
homolog
valu
consid
reliabl
result
type
strain
correctli
identifi
rrna
sequenc
name
atcc
among
clinic
isol
molecular
method
identifi
follow
speci
number
homini
haemolyticu
saprophyticu
epidermidi
lugdunensi
schleiferi
capiti
simulan
pasteuri
warneri
intermediu
equorum
wa
system
correctli
identifi
atcc
strain
pasteuri
includ
wa
databas
correspond
atcc
strain
misidentifi
warneri
one
hundr
fiftyseven
clinic
isol
correctli
identifi
wa
five
haemolyticu
identifi
wa
auriculari
simulan
warneri
error
correspond
two
pasteuri
misidentifi
warneri
one
epidermidi
homini
one
lugdunensi
schleiferi
one
homini
haemolyticu
one
equorum
cohnii
isol
saprophyticu
schleiferi
capiti
simulan
warneri
intermediu
correctli
identifi
wa
system
conclus
microscan
walkaway
reliabl
identifi
con
speci
level
probabl
obtain
pasteuri
incorpor
wa
databas
order
improv
perform
object
aim
studi
analys
result
profici
test
obtain
polish
microbiolog
laboratori
particip
polmicro
haemophilu
influenza
import
pathogen
caus
varieti
communityacquir
respiratori
tract
infect
acut
otiti
media
purul
mening
two
mechan
ampicillin
amp
resist
organ
describ
one
mediat
product
betalactamas
ampresist
strain
term
betalactamaseproduc
ampresist
blpar
second
mechan
involv
develop
alter
penicillinbind
protein
pbp
decreas
affin
amp
betalectam
agent
strain
resist
mechan
mediat
pbp
alter
term
betalactamasenonproduc
ampresist
blnar
h
influenza
method
four
hundr
seventi
eight
laboratori
particip
part
scheme
particip
laboratori
receiv
haemophilu
influenza
betalactamas
neg
ampicillinresist
strain
blnar
laboratori
ask
provid
identif
speci
level
suscept
result
interpret
result
correct
identif
speci
level
strain
report
laboratori
lab
involv
thirteen
laboratori
report
analys
strain
haemophilu
parainfluenza
three
hundr
nineti
eight
laboratori
correctli
detect
mechan
resist
betalactam
three
laboratori
incorrectli
report
organ
betalactamas
produc
greatest
dispers
inhibit
zone
observ
suscept
h
influenza
ampicillin
amoxicillinclavulan
acid
clarithromycin
conclus
laboratori
correctli
identifi
interpret
betalactamasenonproduc
ampresist
blnar
h
influenza
strain
purpos
methodsth
architect
syphili
tp
assay
chemiluminesc
eia
employ
three
recombin
antigen
treponema
pallidum
solid
phase
antihuman
igm
igg
conjug
evalu
assay
comparison
convent
eia
diess
enzywel
syphili
screen
recombin
unselect
routin
serum
sampl
repositori
specimen
result
specif
igg
igm
rapid
plasma
reagin
rpr
assay
alreadi
known
instanc
immunoblot
ib
innoliatm
syphili
score
innogenet
employ
discord
specimen
confirmatori
assay
precis
robust
architect
assay
also
evaluatedresultson
routin
sampl
volunt
blood
donor
outpati
concord
architect
eia
high
sampl
posit
neg
one
discord
posit
architect
neg
eia
confirm
ib
specif
architect
assay
confid
limit
repositori
sampl
assay
belong
three
group
biolog
fals
posit
subject
neg
architect
true
posit
posit
architect
significantli
stronger
signal
averag
sco
vs
igm
posit
sampl
also
posit
rpr
sampl
posit
rpr
neg
eia
igg
neg
architect
well
igm
two
specimen
strongli
posit
architect
posit
also
specif
igm
three
specif
band
innolia
suggest
pattern
recent
infect
reproduc
architect
assay
good
cv
replic
week
assay
neg
posit
control
intern
control
final
sco
distribut
neg
specimen
confirm
robust
assay
mean
median
standard
deviat
mean
cutoff
valu
percentil
sco
valu
autom
assay
antitreponema
pallidum
antibodi
architect
system
excel
sensit
good
specif
analyt
perform
coupl
elev
throughput
minim
sampl
handl
make
method
firstchoic
option
syphili
screen
diagnosi
medium
larg
volum
laboratori
object
quantit
urin
cultur
gold
standard
defin
diagnosi
urinari
tract
infect
uti
allow
identif
uropathogen
speci
howev
method
time
consum
expens
approxim
urin
cultur
neg
high
cost
unnecessari
test
thu
evalu
use
two
autom
analys
uti
screen
quickli
identifi
neg
sampl
prompt
report
clinician
improv
qualiti
patient
care
allow
laboratori
direct
effort
posit
sampl
method
midstream
urin
sampl
submit
microbiolog
examin
analys
convent
urin
cultur
plate
mcconkey
agar
trypticas
soy
agar
bile
esculin
azid
sysmex
sysmex
japan
coral
uti
screen
coral
biotechnolog
ca
usa
autom
analys
uti
defin
posit
follow
one
two
strain
bacteria
least
ufcml
cultur
plate
bacterial
wbcll
andor
rlu
valu
grater
calibr
valu
coral
two
strain
bacteria
found
cultur
classifi
contamin
result
diagnost
perform
sysmex
coral
uti
screen
shown
tabl
sensit
neg
predict
valu
confirm
sysmex
coral
uti
screen
excel
screen
uti
evalu
decid
use
sysmex
coral
uti
screen
routin
workflow
uti
screen
result
analys
sent
softwar
system
labfin
dasit
itali
connect
li
result
lower
cutoff
valu
uti
exclud
directli
report
physician
posit
result
submit
microbiolog
cultur
report
within
hour
depend
neg
posit
bacteri
growth
experi
evalu
sampl
mean
sampl
immedi
report
within
hour
posit
sampl
confirm
cultur
report
within
hour
confirm
report
within
hour
comparison
blood
bone
marrow
cultur
posit
rate
diagnosi
brucellosi
object
brucellosi
common
diseas
seen
worldwid
well
countri
diagnosi
brucellosi
made
certainli
brucella
recov
blood
bone
marrow
studi
aim
compar
blood
bone
marrow
cultur
posit
rate
patient
brucellosi
method
studi
perform
infecti
diseas
clinic
microbiolog
depart
ankara
research
train
hospit
diagnosi
brucellosi
made
histori
physic
find
serolog
find
isol
organ
number
patient
brucellosi
includ
studi
blood
bone
marrow
sampl
taken
patient
admiss
cultur
use
bactec
system
result
blood
cultur
posit
brucellosi
bone
marrow
cultur
posit
differ
posit
rate
found
statist
signific
p
isol
ratio
blood
cultur
among
acut
case
among
subacut
case
brucella
isol
blood
detect
chronic
case
isol
rate
microorgan
bone
marrow
acut
subacut
chronic
case
respect
among
patient
histori
medic
therapi
brucellosi
admiss
treat
inadequ
case
organ
isol
blood
bone
marrowin
case
high
standard
tube
agglutin
titer
rate
posit
also
high
blood
bone
marrow
cultur
howev
compar
low
standard
tube
agglutin
titer
differ
statist
significantth
mean
grow
time
posit
cultur
day
bone
marrow
day
blood
cultur
differ
mean
grow
time
two
cultur
type
found
statist
signific
ttest
p
conclus
premed
subacut
especi
chronic
phase
decreas
possibl
isol
microorgan
blood
cultur
therefor
suggest
take
bone
marrow
cultur
kind
patient
traumat
process
serolog
find
blood
sera
patient
yersiniatrigg
arthriti
e
golkocheva
r
stoilov
h
najdenski
sofia
bg
object
immunoblot
analysi
iga
igg
antibodi
respons
blood
sera
patient
yersinia
trigger
reactiv
arthriti
undifferenti
arthriti
made
patient
method
serum
sampl
obtain
patient
admit
clinic
rheumatolog
medic
univers
sofia
bulgaria
suspicion
yersinia
trigger
reactiv
arthriti
base
diagnost
criteria
total
blood
serum
sampl
analys
immunoblot
analysi
specif
antigensyop
yersinia
outermembran
protein
enterocolitica
cultiv
c
calcium
restrict
mm
ca
larg
amount
yop
secret
medium
protein
separ
result
immunoblot
analysi
iga
igg
antibodi
respons
yop
blood
sera
patient
arthralgia
polyarthropathi
carri
yersinia
enterocolitica
serotyp
use
sourc
yop
seven
strong
band
molecular
weight
kdayop
kdayopn
kdayopd
kda
vag
kdayopb
kdayopm
kdayoph
visual
immunoblot
assay
optim
concentr
antigen
establish
analyt
electrophoresi
blood
sera
patient
yersinia
trigger
reactiv
arthriti
igg
antibodi
detect
yoph
yopm
yopb
yopd
yopn
yope
iga
antibodi
establish
yopm
yopb
yopd
yopn
yope
sera
patient
rheumat
diseas
neg
presenc
antiyersinia
iga
antibodi
two
posit
igg
yopd
antibodi
two
class
detect
sera
sampl
healthi
peopl
conclus
yop
born
virul
plasmid
mean
clearli
associ
virul
properti
pathogen
strain
moreov
yop
restrict
singl
serotyp
made
specif
antigen
diagnosi
differ
yersinia
infect
convent
techniqu
cultur
demonstr
serum
agglutinin
prove
insuffici
demonstr
invas
chronic
yersiniosi
contrast
determin
specif
serum
iga
igg
antibodi
immunoblot
analysi
antigen
detect
detect
antiyop
igg
iga
antibodi
immunoblot
use
diagnosi
yersinia
trigger
arthriti
acknowledg
work
sponsor
natoreintegr
grant
object
evalu
identif
suscept
result
use
suspens
obtain
directli
posit
blood
cultur
method
period
august
octob
select
posit
cultur
grown
bact
alert
sa
sn
bottl
gramneg
bacilli
first
cultur
posit
patient
includ
inocul
ml
fluid
posit
bottl
serum
separ
tube
bd
vacutain
system
plymouth
unit
kingdom
centrifug
x
g
minut
supernat
care
aspir
use
cotton
swab
bacteria
remov
top
separ
layer
suspend
salin
solut
get
mcfarland
suspens
process
accord
standard
inocul
procedur
gn
vitek
card
posit
bactalert
bottl
also
sub
cultur
overnight
incub
sever
coloni
use
make
mcfarland
suspens
salin
suspens
process
accord
standard
vitek
inocul
procedur
gn
card
result
identif
total
gramneg
bacillu
posit
blood
cultur
investig
fifti
strain
correctli
identifi
speci
level
four
strain
identifi
two
strain
misidentifi
antimicrobi
suscept
test
mic
determin
isol
method
unidentifi
strain
exclud
overal
mic
agreement
direct
standard
inocul
individu
antimicrobi
agent
score
overal
minor
error
rate
overal
major
error
rate
overal
major
error
rate
highest
rate
mic
agreement
amikacin
norfloxacin
meropenem
gentamicin
ofloxacin
conclus
direct
method
posit
bact
alert
cultur
total
replac
approv
method
identif
suscept
case
provid
earlier
inform
allow
better
patient
manag
also
reduc
cost
patient
care
investig
listeria
monocytogen
antibodi
matern
cord
sera
agglutin
test
e
us
cengiz
gelisen
ankara
tr
object
listeria
monocytogen
gramposit
food
born
pathogen
respons
listeriosi
human
infect
mortal
rate
could
caus
sever
mothertochild
infect
seriou
pathogen
pregnanc
could
treat
diagnos
routin
screen
test
suscept
listeriosi
pregnanc
therefor
investig
differ
l
monocytogen
serotyp
antibodi
diagnosi
listeriosi
matern
sera
agglutin
test
spontan
abort
prematur
labour
stillbirth
group
obstetr
patolog
group
ii
previou
pregnanc
cord
blood
also
obtain
deliveri
test
method
sera
test
antigen
formul
serotyp
antigen
prepar
method
osebold
larsen
et
bacteri
suspens
trypsin
min
prevent
crossreact
contamin
sera
dilut
doubl
serial
salin
follow
addit
equal
volum
antigen
posit
titr
greater
equal
chosen
posit
test
result
maxim
sensit
specif
result
case
ingest
raw
milk
diari
product
readytoeat
food
develop
nonspecif
febril
ill
nfi
pregnanc
group
found
posit
develop
nfi
group
ii
posit
develop
nfi
agglutin
titr
one
ore
serotyp
cord
blood
sera
group
found
neg
wherea
two
group
ii
posit
posit
matern
sera
serotyp
evalu
transmiss
antibodi
mother
foetu
group
frequent
serotyp
group
ii
respect
newborn
show
symptom
sign
listeri
foetomatern
infect
conclus
women
encount
antigen
l
monocytogen
period
life
time
year
age
produc
antibodi
pathogen
relationship
nfi
posit
titr
diseas
recogn
possibl
treat
mother
allow
birth
healthi
infant
propos
less
time
consum
easi
perform
agglutin
test
routin
screen
test
suscept
listeriosi
pregnanc
prevent
bad
pregnanc
outcom
object
evalu
perform
real
time
pcr
assay
fluorogen
targetspecif
probe
mrsaidi
geneohm
scienc
mrsa
detect
directli
mucocutan
swab
hospit
patient
method
clinic
swab
sampl
median
sampl
per
patient
nare
n
skin
n
prospect
collect
mrsa
screen
patient
admit
teach
hospit
swab
inocul
onto
select
mrsa
agar
mrsaid
buffer
extract
solut
idimrsa
pcr
assay
enrich
broth
bhi
nacl
bhi
broth
subcultur
onto
mrsaid
agar
select
agar
incub
h
c
examin
daili
suspect
coloni
identifi
coagulas
test
oxacillin
resist
test
cefoxitin
disk
diffus
accord
clsi
recommend
pcr
assay
perform
accord
manufactur
instruct
pcr
result
compar
phenotyp
identif
test
result
case
discord
result
assay
repeat
result
first
test
consid
calcul
test
perform
result
mrsa
detect
cultur
specimen
patient
sensit
specif
pcr
compar
cultur
respect
posit
predict
valu
neg
predict
valu
respect
sensit
pcr
higher
nasal
swab
swab
site
p
pcr
assay
detect
mrsa
patient
pcr
assay
provid
result
versu
hour
convent
method
conclus
hospit
idmrsa
pcr
assay
detect
mrsa
carrier
less
hour
perform
multipl
specimen
assay
appear
sensit
test
nasal
swab
clinic
specimen
prospect
studi
need
evalu
impact
assay
rapid
implement
infect
control
procedur
global
cost
benefit
purpos
studi
establish
rapid
sensit
realtim
polymeras
chain
reaction
pcr
method
detect
methicillinresist
staphylococcu
aureu
mrsa
blood
cultur
bottl
result
use
broadspectrum
antibiot
whole
world
outbreak
mrsa
infect
seen
sever
nosocomi
infect
mrsa
bacteraemia
sepsi
may
lead
multipl
organ
failur
high
mortal
hospit
although
standard
method
took
least
hour
identifi
mrsa
blood
cultur
method
presenc
meca
nuc
gene
specif
methicillin
resist
aureu
determin
realtim
pcr
method
within
hour
blood
cultur
signal
posit
nineteen
aureu
coagulas
neg
staphylococci
posit
blood
cultur
bottl
studi
retrospect
detect
aureu
methicillin
resist
staphylococci
identifi
classic
method
mic
oxacillin
determin
etest
ab
biodisk
muellerhinton
agar
supplement
nacl
realtim
pcr
perform
posit
blood
cultur
sampl
aureu
methicillin
resist
determin
nineteen
aureu
determin
correctli
realtim
pcr
method
fortyfour
methicillin
resist
methicillin
sensit
staphylococci
detect
etest
use
realtim
pcr
method
meca
gene
detect
staphylococci
except
compar
etest
realtim
pcr
method
gave
sensit
specif
posit
neg
predict
valu
posit
neg
test
respect
agreement
two
method
high
discrep
result
among
strain
test
detect
mrsa
bacteraemia
methicillin
resist
realtim
pcr
definit
use
reduc
mortal
morbid
type
infect
conclus
method
mani
sensit
specif
detect
mrsa
bacteraemia
clinic
benefici
prevent
unnecessari
antibiot
use
determin
appropri
antibiot
treatment
mrsa
infect
pcr
detect
class
b
c
betalactamas
environment
clinic
aeromona
strain
foss
c
giraudmorin
f
la
louz
nice
fr
object
aeromona
spp
strain
waterborn
opportunist
pathogen
abl
produc
differ
type
betalactamas
class
b
c
determin
betalactamas
content
easi
phenotyp
method
develop
pcr
tool
studi
divers
distribut
class
b
c
betalactamas
set
repres
clinic
environment
aeromona
speci
method
total
refer
environment
clinic
strain
test
identif
realiz
convent
test
gyrb
sequenc
analysi
betalactam
antibiot
suscept
determin
diffus
agar
micro
broth
dilut
method
three
set
specif
primer
defin
pcr
amplif
intern
region
class
b
betalactamas
bp
size
class
c
betalactamas
bp
class
betalactamas
bp
pcr
product
sequenc
result
class
pcr
posit
strain
except
trota
ticarcillin
suscept
speci
strain
class
c
pcr
posit
cephalothin
resist
strain
mic
mgl
strain
includ
hydrophila
cavia
phenospeci
class
b
pcr
posit
strain
hydrophila
veronii
phenospeci
includ
three
imipenem
suscept
strain
mic
mgl
betalactamas
type
distribut
speci
relat
particularli
use
better
character
environment
speci
bestiarum
popoffii
allosaccharophila
partial
betalactamas
gene
sequenc
analysi
allow
phylogen
studi
cephalosporinas
gene
environment
speci
probabl
progenitor
ampc
plasmid
betalactamas
conclus
pcr
specif
primer
good
method
detect
class
b
c
betalactamas
aeromona
speci
betalactamas
type
distribut
sequenc
analysi
phylogeni
larg
speci
relat
could
help
molecular
diagnost
taxonom
purpos
object
aim
studi
develop
conveni
dna
extract
method
optimis
pcr
reaction
order
detect
enterotoxin
b
produc
aureu
strain
directli
milk
method
appli
chemic
extract
method
bacteri
dna
milk
sampl
artifici
inocul
aureu
pcr
base
method
use
detect
seb
gene
code
enterotoxin
b
nuc
gene
code
termonucleas
protocol
multiplex
pcr
develop
optim
sensit
reaction
check
determin
minimum
number
organismsaeml
detect
multiplex
pcr
singl
pcr
reaction
amplif
specif
seb
gene
verifi
amplicon
digest
restrict
endonucleas
result
specif
band
gene
multiplex
pcr
detect
sampl
contain
dna
quantiti
correspond
organismsaeml
reaction
amplicon
nuc
gene
visibl
littl
dna
concentr
correspond
organismsaeml
sensit
singl
pcr
reaction
similar
multiplex
pcr
reaction
conclus
appli
dna
extract
method
allow
us
obtain
good
qualiti
dna
use
direct
milk
extract
multiplex
pcr
reaction
simpl
rapid
reliabl
method
detect
enterotoxin
b
produc
aureu
strain
milk
object
detect
resist
fluoroquinolon
acinetobact
baumannii
strain
pcrrflp
assay
method
thirti
baumannii
clinic
isol
obtain
differ
specimen
bronchial
aspir
bloodcultur
cathet
etc
mic
minim
inhibitori
concentr
ofloxacin
determin
agar
dilut
follow
standard
methodologya
pcrrflp
method
use
one
primer
pair
amplif
bp
fragment
relat
gyra
gene
codifi
subun
dnagyras
use
one
restrict
enzym
hinf
develop
studi
resist
ofloxacin
differ
baumannii
strain
baumannii
strain
resist
fluoroquinolon
mutat
posit
ser
dnagyras
detect
decreas
affin
antimicrobi
agarosa
gel
use
determin
dna
pattern
fragment
bp
bp
mutat
fragment
bp
ser
leu
mutat
present
result
relationship
pcrrflp
pattern
mic
ofloxacin
shown
tabl
result
pcrrflp
analysi
strain
agreement
result
mic
one
isol
suscept
ofloxacin
agar
dilut
mic
mgl
wherea
pcrrflp
isol
seem
resist
present
mutat
gyra
gene
two
isol
intermedi
mic
mgl
show
mutat
gyra
genotyp
studi
pcrrflp
prove
ofloxacin
resist
baumannii
strain
show
punctual
mutat
gyra
gene
posit
insid
sequenc
gene
evalu
rapid
amplificationdetect
assay
identif
vancomycinresist
enterococci
j
fuller
l
turnbul
shokopl
b
lui
l
rosmu
r
renni
edmonton
ca
object
routin
identif
vancomycinresist
enterococci
vre
clinic
laboratori
often
yield
lengthi
turnaroundtim
may
imped
infect
control
effort
particularli
outbreak
situat
search
improv
vre
test
evalu
genotyp
enterococcu
assay
hain
lifesci
germani
provid
speci
van
gene
identif
vre
compar
result
convent
method
method
forti
clinic
enterococc
strain
isol
vrescreen
agar
media
select
studi
lactococcu
pediococcu
use
neg
control
convent
test
involv
basic
cultur
identif
test
etest
suscept
test
vancomycin
teichoplanin
pcr
vana
b
c
gene
genotyp
enterococcu
assay
involv
multiplex
dna
amplif
revers
hybrid
amplifi
product
immobil
dna
stripblot
contain
probe
e
faecium
e
faecali
e
casseliflavu
e
gallinarum
vana
vanb
genotyp
enterococcu
assay
produc
correct
speci
van
gene
identif
vre
isol
includ
e
faecali
vanb
e
faecium
vana
e
faecium
vanb
e
gallinarum
e
gallinarum
e
casseliflavu
minor
discrep
e
casseliflavu
hybrid
weakli
probe
addit
expect
probe
cost
per
specimen
compar
test
method
howev
genotyp
enterococcu
assay
could
complet
within
normal
work
day
contrast
convent
test
requir
minimum
two
day
point
isol
vancomycinscreen
media
conclus
preliminari
evalu
genotyp
enterococcu
amplificationdetect
assay
provid
vre
speci
van
genotyp
identif
rapid
costeffect
manner
superior
convent
cultur
method
although
studi
requir
kit
may
clinic
util
vre
outbreak
applic
minim
sequenc
qualiti
valu
prevent
misidentif
blashv
type
singl
bacteri
isol
carri
differ
shv
extendedspectrum
betalactamas
gene
background
detect
extend
spectrum
betalactamas
esbl
gene
pcr
sequenc
analysi
gold
standard
detect
shvtype
beta
lactamas
usual
qualiti
valu
sequenc
analys
report
studi
esbl
epidemiolog
three
strain
default
sequenc
assembl
show
shv
gene
show
low
qualiti
valu
certain
posit
individu
sequenc
trace
investig
reason
lower
valu
method
shv
gene
amplifi
pcr
three
isol
escherichia
coli
enterobact
cloaca
pseudomona
aeruginosa
individu
sequenc
trace
analys
comput
program
phred
codon
code
pcr
product
ligat
vector
transform
e
coli
sequenc
analysi
perform
eight
individu
clone
transform
result
visual
inspect
low
qualiti
posit
sequenc
trace
show
signal
two
differ
nucleotid
three
posit
shv
sequenc
posit
g
posit
g
posit
polymorph
posit
lead
aminoacid
substitut
four
differ
combin
would
give
shv
type
doubl
signal
suggest
two
blashv
allel
amplifi
pcr
amplicon
clone
e
coli
sequenc
individu
clone
two
combin
three
polymorph
present
two
combin
correspond
respect
conclus
isol
three
differ
speci
two
differ
shv
gene
present
ii
genotyp
detect
default
sequenc
assembl
paramet
may
lead
misidentif
number
type
shv
gene
carri
singl
strain
iii
care
interpret
sequenc
data
shv
gene
includ
analysi
low
qualiti
posit
may
improv
understand
epidemiolog
evolut
esbl
gene
antimicrobi
suscept
epidemiolog
analysi
salmonella
typhimurium
human
isol
slovakia
phage
type
pulsedfield
gel
electrophoresi
v
l
bratislava
sk
object
salmonella
typhimurium
common
caus
salmonellosi
among
human
anim
mani
countri
last
decad
incid
multidrugresist
typhimurium
infect
appear
pose
particular
health
risk
object
studi
analysi
antibiot
suscept
phage
type
pulsedfield
gel
electrophoresi
pfge
typhimurium
human
isol
method
total
strain
isol
analys
suscept
isol
ten
antibiot
evalu
disk
diffus
method
phage
type
identifi
accord
anderson
et
al
nation
refer
center
phage
type
salmonella
pfge
use
resolv
xbai
macro
restrict
fragment
strain
result
human
isol
resist
two
antibiot
sixtythre
isol
show
classic
resist
profil
ampicillin
chloramphenicol
streptomycin
sulfonamid
tetracyclin
acssut
among
resist
type
one
strain
isol
encompass
phage
type
major
isol
found
definit
phage
type
repres
isol
phage
type
mainli
nine
pulsotyp
subpulsotyp
obtain
use
xbai
restrict
enzym
pattern
subtyp
predomin
major
pulsotyp
repres
isol
also
found
among
isol
conclus
result
indic
spread
differ
clone
multidrugresist
typhimurium
slovakia
predomin
one
clone
repres
mainli
isol
phage
type
well
pfge
may
offer
improv
level
discrimin
epidemiolog
investig
typhimurium
human
strain
novel
revers
hybridis
assay
identifi
ctxm
genotyp
cephalosporinresist
isol
uk
india
valid
assay
result
dna
sequenc
method
isol
collect
enterobacteriacea
resist
extendedspectrum
cephalosporin
isol
london
southeast
england
isol
known
carri
phylogenet
group
blactxm
precis
genotyp
determin
isol
collect
enterobacteriacea
resist
extendedspectrum
cephalosporin
isol
aligarh
north
india
resist
determin
investig
previous
novel
multiplex
pcr
use
amplifi
blactxm
revers
hybridis
carri
use
biotinyl
pcr
amplicon
sequencespecif
oligonucleotid
design
identifi
member
ctxm
phylogenet
group
hybridis
result
valid
dna
sequenc
repres
isol
collect
result
london
se
england
isol
known
carri
group
blactxm
gave
consist
profil
correspond
gave
profil
correspond
indian
isol
blactxm
gene
belong
group
gave
hybridis
profil
correspond
rare
variant
suggest
enzym
present
like
confirm
dna
sequenc
conclus
first
report
applic
novel
revers
hybridis
assay
analysi
larg
number
cephalosporinresist
enterobacteriacea
result
valid
dna
sequenc
assay
cheap
conveni
enabl
reason
throughput
provid
result
within
one
day
use
place
dna
sequenc
believ
valuabl
monitor
preval
genotyp
blactxm
gene
enterobacteriacea
detect
mexa
mexx
efflux
gene
p
aeruginosa
correl
qcrtpcr
realtim
pcr
object
efflux
system
rare
identifi
clinic
microbiolog
laboratori
yet
express
transport
mexaboprm
mexxyoprm
like
caus
antibiot
multiand
crossresist
pseudomona
aeruginosa
lead
potenti
clinic
treatment
failur
induc
charact
previous
develop
valid
refer
strain
qcrtpcr
method
quantifi
mexa
mexx
express
level
eccmid
present
studi
develop
realtimepcr
assay
present
correl
method
use
control
strain
clinic
isol
method
express
level
mexa
mexx
measur
techniqu
refer
strain
express
one
efflux
mechan
mexa
mexx
ii
clinic
isol
comparison
wildtyp
strain
basal
mexa
mexx
express
level
result
realtim
pcr
show
interday
reproduc
triplic
strain
among
clinic
strain
express
mexa
mexx
tabl
show
mean
level
overexpress
mexa
mexx
comparison
wild
type
strain
set
detect
realtim
pcr
strain
ii
ratio
valu
observ
qcrtpcr
correspond
transport
conclus
qcrtpcr
realtimepcr
potenti
use
clinic
laboratori
sensit
rapid
diagnost
tool
quantifi
express
level
mexa
mexx
p
aeruginosa
combin
phenotyp
character
approach
may
help
better
understand
resist
mechan
epidemiolog
resist
difficulttotreat
nosocomi
pathogen
molecular
detect
penicillin
resist
streptococcu
pneumomia
ng
rizk
na
abo
khadr
sm
abdel
salam
nm
gamil
hassan
alexandria
eg
object
aim
studi
detect
penicillin
resist
streptococcu
pneumonia
use
seminest
polymeras
chain
reaction
pcr
compar
minimum
inhibitori
concentr
mic
penicillin
g
method
fifti
clinic
isol
streptococcu
pneumonia
isol
patient
admit
alexandria
main
univers
hospit
egypt
recov
sputum
strain
throat
swab
strain
pleural
effus
strain
two
speciesspecif
primer
amplifi
bp
region
penicillinbind
gene
use
pneumococc
detect
two
resist
primer
use
bind
alter
area
gene
togeth
stream
primer
amplifi
dna
sequenc
bp
bp
isol
penicillin
mic
object
lipopolysaccharidebind
protein
lbp
acut
phase
protein
produc
liver
object
studi
evalu
lbp
marker
sever
prognosi
patient
bacteraemia
method
adult
patient
communityacquir
bacteraemia
includ
prospect
manner
daili
blood
sampl
lbp
perform
patient
classifi
accord
system
inflammatori
respons
syndrom
sir
criteria
demograph
data
comorbid
microbiolog
aaetiolog
routin
biochem
paramet
focu
infect
sever
score
mortal
day
record
lbp
level
analys
plasma
sampl
chemiluminesc
immunometr
assay
result
median
age
yr
mortal
rate
day
patient
bacteraemia
without
sir
patient
sepsi
patient
sever
sepsi
lbp
concentr
present
median
rang
lgml
patient
without
sir
patient
sepsi
lgml
patient
sever
sepsi
p
lbp
level
correl
level
rs
creactiv
protein
rs
leukocyt
rs
neutrophil
rs
p
lbp
predict
outcom
patient
bacteraemia
conclus
lbp
level
increas
sever
sepsi
patient
bacteraemia
lbp
correl
creactiv
protein
leukocyt
neutrophil
lbp
predict
outcom
patient
small
cohort
pyrosequenc
gene
discrimin
type
ii
iii
toxoplasma
gondii
clinic
sampl
b
edvinsson
b
behalf
esgt
object
infect
toxoplasma
gondii
immunocompromis
transplant
recipi
rare
often
fatal
increas
knowledg
signific
genotyp
parasit
infect
method
suitabl
routin
use
need
develop
pyrosequenc
rapid
sequencingbysynthesi
method
perform
realtim
develop
detect
short
nucleotid
polymorph
snp
suitabl
molecular
genotyp
microorgan
present
pyrosequenc
assay
rapid
reliabl
discrimin
toxoplasma
gondii
type
ii
iii
clinic
sampl
method
twentytwo
isol
gondii
use
pyrosequenc
analysi
gene
realtim
pcr
perform
use
lightcycl
instrument
amplifi
bp
fragment
gene
pyrosequenc
analysi
two
differ
snp
contain
within
bp
fragment
amplifi
product
preform
identifi
gondii
type
detect
nucleotid
g
respect
posit
type
ii
g
g
type
iii
test
assay
clinic
context
blood
sampl
lung
tissu
immunocompromis
patient
analys
result
detect
limit
assay
parasit
genom
sampl
reproduc
r
calcul
r
nrn
nr
number
isol
assign
type
repeat
test
n
number
isol
test
r
determin
use
three
independ
run
suggest
clearli
interpret
result
littl
variat
typeablil
assay
calcul
ntn
nt
number
typeabl
strain
n
number
isol
test
determin
use
three
independ
run
includ
four
atyp
isol
suggest
assay
discrimin
correctli
three
main
genotyp
gondii
detect
atyp
strain
analysi
clinic
sampl
reveal
type
ii
gondii
blood
sampl
lung
tissu
conclus
preced
realtim
pcr
pyrosequenc
rapid
process
high
reproduc
throughput
make
good
candid
routin
use
method
howev
detect
atyp
recombin
strain
one
gene
may
analys
purpos
acknowledg
particular
want
thank
marielaur
pelloux
provis
gondii
isol
virul
gene
escherichia
coli
isol
calv
shahrekord
area
iran
shiga
toxinproduc
escherichia
coli
stec
strain
also
call
verotoxinproduc
e
coli
vtec
strain
repres
import
recent
emerg
group
foodborn
pathogen
around
world
member
group
major
caus
gastroenter
may
complic
hemorrhag
coliti
hc
hemolyt
urem
syndrom
hu
main
caus
acut
renal
failur
children
domest
rumin
mainli
cattl
sheep
goat
implic
princip
reservoir
transmiss
occur
consumpt
undercook
meat
unpasteur
dairi
product
veget
water
contamin
fece
carrier
stec
strain
found
part
normal
intestin
flora
animalsw
studi
preval
shiga
toxinproduc
escherichia
coli
stec
stool
specimen
calv
diarrhoea
gastrointestin
alter
dairi
cattl
farm
shahrekord
citi
central
iran
virul
gene
eae
intimin
hli
enterohemolysin
st
lt
detect
multiplex
pcr
method
stec
strain
detect
e
coli
case
investig
stec
isol
case
wherea
stec
strain
isol
anim
stec
strain
frequent
recov
enteropathogen
bacteria
pcr
show
isol
carri
st
gene
none
isol
carri
ehxa
eae
lt
labil
toxin
gene
result
suggest
stec
strain
signific
caus
calf
infect
area
confirm
infect
caus
stec
strain
common
caus
isol
high
preval
stec
strain
strain
also
found
human
patient
investig
associ
seriou
complic
strongli
support
util
protocol
detect
serotyp
stec
spanish
clinic
microbiolog
laboratori
object
shiga
toxin
ab
holotoxin
includ
one
enzymat
activ
subunit
associ
noncoval
five
ident
receptor
bind
b
subunit
subunit
caus
differ
signal
pathway
differ
cell
assess
effect
singl
subunit
specif
clone
express
singl
subunit
design
periplasm
express
yield
nativ
holotoxin
pentam
method
use
bacteri
strain
pcr
amplif
shiga
toxin
gene
subunit
amplifi
specif
primer
amplifi
gene
clone
pbad
express
vector
express
clone
gene
induc
optim
differ
concentr
arabinos
express
protein
assess
sdspage
detect
elisa
western
blot
express
recombin
holotoxin
b
subunit
purifi
assess
biolog
activ
cell
cell
cytotox
shown
express
holotoxin
moreov
inhibit
observ
b
subunit
antibodi
result
e
coli
clone
express
recombin
shiga
toxin
recombin
shiga
toxin
b
subunit
establish
releas
toxin
periplasm
space
express
toxin
examin
sdspage
visual
two
subunit
whole
structur
express
subunit
check
nativ
gel
activ
structur
express
periplasm
space
extract
polymyxin
b
biolog
activ
construct
recombin
shiga
toxin
show
vero
cell
cytotox
inhibit
vitro
protein
synthesi
conclus
studi
shown
b
subunit
assembl
secret
periplasm
space
pentam
homolog
leader
sequenc
need
although
biolog
activ
holotoxin
secret
periplasm
space
presenc
homolog
leader
sequenc
gene
essenti
subunit
use
studi
cell
cytotox
also
vector
antigen
present
immunotherapeut
approach
characteris
gramposit
anaerob
cocci
biochem
test
partial
rrna
sequenc
bryk
kanervonordstrom
hyvonen
e
kononen
helsinki
fi
object
gramposit
anaerob
cocci
common
find
variou
infect
difficult
identifi
clinic
microbiolog
laboratori
identif
base
phenotyp
test
recent
year
group
organ
tradit
known
peptostreptococci
encount
sever
taxonom
chang
aim
present
studi
compar
character
made
select
key
phenotyp
test
partial
sequenc
rrna
gene
method
fiftynin
clinic
isol
sent
laboratori
gramposit
anaerob
cocci
examin
coloni
cell
morpholog
biochem
character
use
spot
catalas
indol
reaction
enzym
reaction
individu
diagnost
tablet
rosco
sodium
polyanethol
sulphat
suscept
glucos
ferment
determin
metabol
end
product
addit
commerci
identif
test
kit
rapid
id
pattern
perform
sequenc
rrna
gene
clinic
isol
refer
strain
compris
bp
sequenc
obtain
compar
genbank
databas
use
multisequ
advanc
blast
comparison
softwar
nation
center
biotechnolog
inform
result
biochem
characterist
isol
consist
peptostreptococcu
anaerobiu
n
peptostreptococcu
micromona
micro
n
finegoldia
magna
n
peptoniphilu
asaccharolyticu
n
peptoniphilu
sp
n
anaerococcu
sp
n
wherea
isol
remain
unidentifi
gramposit
anaerob
cocci
biochem
identif
correl
obtain
partial
rrna
sequenc
isol
genu
level
isol
speci
level
agreement
biochem
sequencebas
identif
p
micro
f
magna
isol
biochem
identifi
p
asaccharolyticu
isol
identifi
peptoniphilu
harei
remain
peptoniphilu
sp
sequenc
accord
sequenc
data
unidentifi
isol
peptoniphilu
ivorii
conclus
isol
human
infect
prove
f
magna
rel
good
agreement
identif
obtain
use
biochem
test
partial
rrna
sequenc
object
molecular
method
identif
infecti
agent
patient
clinic
infecti
diseas
increasingli
use
especi
case
antibiot
given
prior
sampl
fastidi
bacteria
difficult
grow
aaetiolog
infect
infecti
arthriti
seriou
diseas
identif
etiolog
agent
mandatori
optim
antibiot
treatment
well
indic
primari
focu
joint
self
method
present
prospect
studi
synovi
fluid
taken
patient
elucid
affect
joint
sent
clinic
microbiolog
laboratori
copenhagen
area
denmark
examin
convent
cultur
phenotyp
test
molecular
method
pcrsequenc
ribosom
gene
convent
method
includ
gramstain
microscopi
aerob
anaerob
cultur
identif
pcrsequenc
includ
dna
extract
pcr
assay
produc
bp
fragment
rdna
sequenc
dna
strand
amplicon
sequenc
data
edit
blast
search
ncbi
databas
done
result
overal
microorgan
identifi
synovi
fluid
synovi
fluid
nine
patient
bacteria
identifi
either
method
staphylococcu
aureu
n
streptococcu
pneumonia
n
streptococcu
dysgalactia
n
citrobact
freundii
n
six
synovi
fluid
cultur
posit
four
six
specimen
coagulas
neg
staphylococci
isol
three
synovi
fluid
microorgan
identifi
pcr
two
synovi
fluid
pcr
identifi
one
microorgan
wherea
cultur
result
two
isol
conclus
present
studi
indic
signific
contribut
molecular
method
pcrsequenc
ribosom
gene
recogn
identif
microorgan
foci
normal
consid
steril
like
synovi
fluid
continu
suspicion
infect
arthriti
despit
neg
cultur
result
use
molecular
diagnost
direct
detect
cardiobacterium
homini
broadrang
rrna
pcr
sequenc
serum
patient
infect
endocard
e
malli
klapsa
vasdeki
morava
pitsitaki
e
petinaki
maniati
larissa
gr
object
describ
detect
cardiobacterium
homini
directli
serum
patient
infect
endocard
employ
broadrang
rrna
pcr
follow
sequenc
method
seri
blood
cultur
taken
patient
start
empir
treatment
addit
ml
whole
blood
collect
rubber
seal
pyrogenfre
tube
direct
detect
bacteri
dna
bacteri
dna
detect
broad
rang
pcr
reaction
sequenc
process
allow
identif
bacteria
speci
result
cardiobacterium
homini
identifi
caus
agent
infect
endocard
two
day
serum
collect
blood
cultur
simultan
obtain
serum
sampl
remain
neg
day
routin
incub
howev
prolong
incub
twelv
day
gram
neg
bacterium
isol
aerob
bottl
identifi
c
homini
speci
usual
phenotyp
studi
catalas
oxidas
reaction
indol
nitrat
etc
timeconsum
conclus
knowledg
first
report
direct
detect
c
homini
serum
use
molecular
method
emphas
need
establish
method
especi
infect
caus
fastidi
organ
identif
danger
bacteri
pathogen
ribosom
rna
gene
sequenc
analysi
w
ruppitsch
stoeger
indra
schmid
k
grif
c
schabereitergurtn
hirschl
f
allerberg
vienna
assess
use
partial
rrna
sequenc
analysi
identif
danger
bacteri
pathogen
total
isol
compris
bacillu
anthraci
brucella
melitensi
biovar
melitensi
sui
abortu
bovi
burkholderia
mallei
burkholderia
pseudomallei
francisella
tularensi
yersinia
pesti
genusrel
unrel
control
strain
sequenc
analys
use
genbank
databas
blast
nation
institut
health
usa
databas
version
appli
biosystem
foster
citi
usa
ribosom
databas
projectii
databas
rdpii
releas
updat
michigan
state
univers
usa
ribosom
differenti
medic
microorgan
databas
ridom
univers
wuerzburg
germani
genu
level
isol
identifi
use
genbank
rdpii
microseq
older
microseq
databas
identifi
test
sampl
correctli
genu
level
ridom
databas
includ
sequenc
data
test
speci
even
genu
level
ridom
databas
none
seem
least
current
close
rel
avail
genbank
rdpii
identifi
danger
pathogen
correctli
microseq
v
databas
identifi
four
six
speci
danger
pathogen
speci
level
none
danger
pathogen
correctli
identifi
use
microseq
ridom
previous
note
variou
author
import
reason
failur
databas
identifi
bacterium
lack
rrna
gene
sequenc
particular
bacterium
databas
rather
misidentif
poor
sequenc
qualiti
one
must
also
awar
follow
bacteri
speci
subspeci
rrna
gene
sequenc
make
differenti
sequenc
analysi
imposs
b
anthraci
b
cereu
pesti
pseudotuberculosi
brucella
subspeci
francisella
tularensi
ssp
holarctica
mediasiatica
addit
rrna
gene
analysi
complementari
method
essenti
discrimin
bacteria
speci
subspeci
level
identif
nontubercul
mycobacteria
sequenc
analysi
ribosom
rna
heatshock
protein
rna
polymeras
betasubunit
gene
shin
jh
yoon
ec
kim
seoul
kr
object
diagnosi
diseas
caus
nontubercul
mycobacteria
ntm
difficult
ntm
preval
environ
soil
water
fastidi
properti
studi
investig
distribut
pattern
ntm
clinic
isol
identif
speci
level
method
among
presumpt
ntm
clinic
isol
cultur
third
referr
hospit
seoul
south
korea
neg
probe
hybrid
method
mycobacterium
tuberculosi
complex
select
coloni
cultur
twice
patient
total
isol
studi
distribut
ntm
includ
isol
recruit
speci
identif
direct
sequenc
rrna
rpob
gene
segment
also
identifi
presumpt
ntm
isol
identif
rate
sequenc
rrna
rpob
respect
rpob
gene
effici
rrna
identif
ntm
sequenc
conclus
ntm
consid
caus
organ
clinic
diseas
even
countri
intermedi
burden
tuberculosi
accur
identif
method
direct
sequenc
adapt
clinic
laboratori
evalu
genotyp
mtbdr
assay
simultan
detect
resist
rifampicin
isoniazid
mycobacterium
tuberculosi
clinic
strain
f
brossier
c
truffotpernot
n
veziri
v
jarlier
w
sougakoff
pari
fr
object
rapid
determin
drug
resist
mycobacterium
tuberculosi
import
challeng
ensur
rapid
effect
chemotherapi
genotyp
mtbdr
test
commerci
avail
dna
strip
assay
enabl
molecular
genet
identif
tuberculosi
complex
resist
rifampicin
rifr
isoniazid
inhr
detect
commonli
found
mutat
gene
rpob
katg
report
evalu
genotyp
mtbdr
assay
set
clinic
isol
tuberculosi
method
clinic
isol
collect
franc
year
period
includ
studi
rifr
inhr
also
rifr
suscept
drug
suscept
test
carri
standard
proport
method
mutat
involv
rifr
inhr
rpob
katg
inha
promot
region
character
dna
sequenc
result
genotyp
mtbdr
assay
identifi
rifr
strain
harbour
mutat
rpob
gene
show
mutat
tyr
mutat
inhr
strain
harbour
mutat
katg
identifi
genotyp
mtbdr
assay
strain
display
high
level
inhr
among
inhr
strain
show
katg
mutat
level
region
differ
show
low
level
inhr
one
harbour
delet
katg
high
level
inhr
mutat
also
detect
strip
final
among
remain
inhr
strain
detect
mtbdr
assay
character
mutat
posit
promot
region
mabainha
regulon
low
level
inhr
mutat
inha
low
level
resist
mutat
conclus
mtbdr
assay
readili
includ
routin
laboratori
workflow
identifi
strain
resist
rif
inh
respect
interestingli
inhr
strain
show
high
level
resist
inhr
strain
low
level
resist
detect
mtbdr
assay
indic
complementari
test
necessari
detect
tuberculosi
strain
low
level
resist
inh
variat
streptococc
rdna
detect
pyrosequenc
p
huovinen
j
jalava
turku
fi
origin
aim
studi
identifi
alphahaemolyt
streptococc
isol
speci
level
pyrosequenc
region
rdna
compar
result
sequenc
type
strain
determin
earlier
howev
isol
could
unambigu
identifi
due
sequenc
variat
detect
alphahaemolyt
isol
materi
method
invas
pneumonia
isol
n
alphahaemolyt
streptococc
blood
cultur
isol
n
alphahaemolyt
streptococc
isol
normal
pharyng
microbiota
n
six
elderli
person
analys
pyrosequenc
region
result
vari
degre
genet
variat
found
differ
type
streptococc
isol
pneumococc
isol
sequenc
variat
detect
isol
contain
sequenc
specif
pneumonia
region
also
sequenc
alphahaemolyt
blood
cultur
isol
well
agreement
sequenc
streptococc
type
strain
howev
isol
could
unambigu
identifi
contain
sequenc
belong
differ
speci
region
consequ
five
isol
could
unequivoc
identifi
gallolyticu
n
anginosu
n
miti
n
sanguini
n
commens
streptococci
contain
numer
sequenc
ident
type
sequenc
could
found
also
sequenc
ident
type
strain
found
similarli
blood
cultur
isol
result
enabl
identif
four
isol
miti
n
parasanguini
n
salivariu
vestibulari
n
moreov
pyrogram
three
blood
cultur
isol
ten
pharyng
isol
indic
heterogen
rdna
allel
one
pyrogram
region
present
figur
interestingli
four
eight
differ
nonheterogen
sequenc
combin
blood
cultur
isol
also
present
among
pharyng
isol
result
studi
indic
variat
commens
streptococci
greater
streptococc
type
strain
pathogen
isol
presenc
ident
sequenc
combin
among
blood
cultur
pharyng
isol
support
assumpt
potenti
pathogen
isol
present
normal
microbiota
evalu
partial
rrna
gene
sequenc
identif
clinic
isol
nocardia
speci
del
rosal
e
cercenado
p
e
bouza
madrid
es
new
speci
nocardia
describ
convent
identif
base
biochem
characterist
pcrrestrict
enzym
analysi
frequent
unabl
distinguish
partial
sequenc
rrna
gene
proven
use
identif
bacteria
object
evalu
util
rrna
gene
pcr
sequenc
identif
clinic
isol
nocardia
sp
compar
convent
method
pcrrflp
method
clinic
isol
nocardia
sp
character
biochem
reaction
disk
diffus
suscept
test
molecular
identif
perform
pcrrflp
pcr
rrna
gene
follow
sequenc
sequenc
obtain
compar
includ
genebank
align
similar
higher
consid
comparison
sequenc
nocardia
isol
deposit
genebank
well
character
phenotyp
perform
use
clustal
x
softwar
result
distribut
speci
pcrrflp
n
asteroid
vi
n
farcinica
n
nova
n
asteroid
n
otitidiscaviarum
n
asteroid
iv
partial
sequenc
analysi
rrna
reveal
great
heterogen
isol
n
asteroid
vi
follow
n
cyriacigeorgica
isol
n
abscessu
isol
n
carnea
isol
isol
genebank
sequenc
found
similar
n
farcinica
isol
sequenc
show
similar
deposit
genebank
n
nova
n
asteroid
n
otitidiscaviarum
also
show
sequenc
heterogen
three
n
nova
isol
match
recent
describ
n
veterana
n
nova
n
asteroid
isol
identifi
n
abscessu
n
beijingensi
n
otitidiscaviarum
identifi
properli
isol
n
asteroid
iv
identifi
n
transvalensi
conclus
sequenc
rrna
gene
use
rapid
molecular
tool
identif
nocardia
clinic
isol
method
could
provid
accur
result
convent
one
use
routin
laboratori
sequenc
analysi
rrna
enabl
us
recogn
great
divers
new
speci
among
nocardia
isol
sever
speci
would
gone
unnot
use
nonsequencingbas
method
antibacteri
suscept
studiesiii
anaerob
bacteraemia
due
fusobacterium
necrophorum
clostiridium
cadaveri
case
report
panopoul
e
alepopoul
e
chrisafid
tsaroucha
c
simopoulo
kartali
alexandroupoli
gr
introduct
anaerob
bacteremia
uncommon
account
bacteremia
associ
high
mortal
rate
strongli
independ
associ
underli
liver
diseas
case
report
yearold
man
present
hospit
fever
rigor
histori
cancer
extrahepat
biliari
tree
found
incident
oper
treatment
echinococc
cyst
liver
physic
examin
reveal
high
fever
c
tachycardia
blood
test
show
follow
result
hb
grdl
wbc
ul
plt
ul
tprot
coloni
type
subcultur
blood
agar
plate
incub
aerob
anaerob
aerotoler
test
hour
incub
two
organ
grew
anaerob
condit
identifi
api
system
biomerieuxfr
fusobacterium
necrophorum
clostiridium
cadaveri
patient
treatment
start
metronidazol
amikacin
ceftriaxon
follow
metronidazol
imipenem
discharg
week
good
condit
conclus
although
anaerob
bacteremia
rare
valu
perform
separ
anaerob
blood
cultur
earli
recognit
anaerob
bacteremia
administr
appropri
antimicrobi
therapi
play
major
role
prevent
mortal
especi
patient
underli
diseas
fluoroquinolon
resist
among
enterobacteriacea
strain
isol
urinari
tract
infect
v
skandamiepitropaki
p
fostira
tsiringa
xanthaki
k
zampitha
toutouza
athen
gr
object
studi
frequenc
antibiot
suscept
quinolon
resist
bacteri
stain
isol
patient
communityaquir
bacteriuria
compar
urinari
pathogen
hospit
patient
method
period
octob
octob
total
bacteri
strain
isol
urin
sampl
submit
cultur
hospit
laboratori
commun
hospit
patient
urinari
tract
infect
symptom
cultur
bacteri
identif
obtain
convent
method
antibiot
suscept
test
done
kirbybau
disk
diffus
method
accord
nccl
criteria
result
bactrial
strain
studi
escherichia
coli
klebsiella
pneumonia
proteu
mirabili
found
quinolon
resist
percentag
quinolon
resist
hospit
patient
hp
commun
patient
cp
quinolon
resist
e
coli
hp
cp
k
pneumonia
hp
cp
p
mirabili
hp
cp
suscept
pattern
quinolon
resist
isol
antimicrobi
agent
hospit
patient
commun
patient
respect
follow
e
coli
ampicillin
amoxicillinclavulan
amc
piperacillintazobactam
tzp
cefuroxim
cxm
trimethoprimsulfamethoxazol
sxt
ceftazidim
caz
cefepim
fep
gentamicin
gm
k
pneumonia
amc
tzp
cxm
sxt
caz
fep
gm
p
mirabili
amc
tzp
cxm
sxt
caz
fep
gm
seven
strain
k
pneumonia
carbapenem
resist
metallobeta
lactamas
produc
conclus
high
resist
rate
fluoroquinolon
observ
uropathogen
bacteria
isol
hospit
patient
also
patient
communityacquir
urinari
tract
infect
greec
increas
resist
rate
rest
antibiot
agent
make
treatment
urinari
tract
infect
difficult
problem
suscept
pseudomona
aeruginosa
isol
mystic
programm
carbapenem
meropenem
imipenem
pj
turner
macclesfield
uk
object
meropenem
yearli
suscept
test
inform
collect
programm
mystic
initi
order
track
suscept
organ
centr
prescrib
meropenem
poster
seek
examin
suscept
pseudomona
aeruginosa
isol
period
carbapenem
meropenem
imipenem
particular
record
suscept
imipenemresist
isol
meropenem
vice
versa
method
pseudomona
aeruginosa
isol
speciat
method
current
use
particip
centr
minimum
inhibitori
concentr
meropenem
imipenem
determin
use
refer
method
describ
clsi
result
total
isol
pseudomona
aeruginosa
test
global
suscept
meropenem
breakpoint
mgl
imipenem
global
suscept
two
carbapenem
remain
stabl
period
howev
imipenemresist
isol
examin
n
prove
suscept
meropenem
convers
meropenemresist
isol
prove
suscept
imipenem
similar
pattern
seen
isol
separ
global
region
usa
imipenemresist
isol
suscept
meropenemusa
meropenem
result
bacteroid
fragili
group
bafg
account
isol
fusobacterium
spp
gram
neg
bacilli
ognb
clostridia
clo
nonsporeform
gramposit
bacilli
nsfgpb
cocci
betalactamas
bl
detect
isol
bl
strain
belong
bafg
ognb
ncclsrecommend
breakpoint
isol
suscept
tzp
mtz
chl
mem
amc
fox
ctt
cli
pen
respect
ncclsbreakpoint
anaerob
avail
mxf
lzd
tig
mic
mic
mxf
mgl
lzd
mgl
tig
mgl
comparison
similar
survey
conduct
suscept
bafg
clindamycin
decreas
bafg
b
fragili
nonb
fragili
suscept
amc
studi
suscept
group
respect
isol
except
bafg
clo
suscept
mem
isol
suscept
chl
suscept
mtz
remain
stabl
high
group
except
nsfgpb
mtz
activ
mere
isol
conclus
tzp
mem
mtz
remain
potent
antimicrobi
agent
treatment
anaerob
infect
although
still
rare
resist
organ
detect
therefor
suscept
test
anaerob
isol
indic
sever
infect
confirm
appropri
antimicrobi
therapi
monitor
background
suscept
necessari
guid
empir
treatment
compar
vitro
activ
levofloxacin
escherichia
coli
isol
acut
pyelonephr
franc
cj
soussi
c
lascol
c
dibsmahi
multicent
group
studi
object
object
studi
evalu
vitro
activ
levofloxacin
lvx
compar
antibiot
escherichia
coli
strain
isol
acut
pyelonephr
women
consult
emerg
room
french
hospit
method
mic
lvx
ofloxacin
ofx
ciprofloxacin
cip
nalidix
acid
nal
amoxicillinclavulan
acid
amc
ceftriaxon
cro
cefixim
cfm
amikacin
gentamicin
gm
cotrimoxazol
sxt
determin
agar
dilut
accord
eucast
breakpoint
approv
recommend
de
lantibiogramm
de
la
de
microbiologi
qualiti
control
perform
e
coli
strain
atcc
result
total
strain
collect
strain
isol
urinari
sampl
blood
cultur
two
specimen
mic
mgl
rang
mic
percentag
suscept
present
follow
tabl
concern
fluoroquinolon
lvx
onetwo
dilut
lower
ofx
twoon
dilut
higher
cip
antibiot
higher
percentag
suscept
observ
cro
lower
percentag
suscept
observ
amc
sxt
conclus
levofloxacin
exhibit
good
vitro
activ
e
coli
strain
isol
acut
pyelonephr
suscept
strain
vitro
activ
doubl
tripl
combin
colistin
imipenem
rifampicin
linezolid
epidem
strain
multidrugresist
acinetobact
baumannii
produc
oxa
carbapenamas
dw
wareham
dc
bean
london
uk
object
baumannii
emerg
import
caus
nosocomi
infect
critic
ill
patient
worldwid
uk
three
strain
particular
exhibit
multidrug
resist
produc
oxa
carbapenamas
respons
ongo
outbreak
treatment
option
infect
organ
limit
colistin
tigecyclin
retain
signific
activ
vitro
anim
model
vitro
studi
use
multiresist
strain
suggest
drug
combin
colistin
may
effect
assess
activ
colistin
combin
includ
imipenem
rifampicin
linezolid
epidem
strain
recent
uk
outbreak
method
isol
baumannii
exhibit
resist
carbapenem
recov
patient
bart
london
nh
isol
refer
health
protect
agenc
confirm
belong
clone
produc
oxa
carbapenemas
activ
polymyxin
imipenem
rifampicin
linezolid
alon
doubl
tripl
combin
determin
use
standard
chequerboard
assay
increas
concentr
drug
x
axi
drug
axi
drug
three
multipl
replic
plate
incub
hour
well
examin
growth
mic
determin
combin
synergi
agent
defin
fix
inhibitori
concentr
index
fici
result
isol
test
belong
clone
clone
south
east
clone
confir
hpa
colistin
activ
agent
alon
mic
mgl
imipenem
mic
vari
mgl
activ
combin
colistin
plu
rifampicin
fici
colistin
rifampicin
imipenem
fici
synergi
seen
colistin
combin
imipenem
alon
linezolid
combin
colistin
fici
imipenem
fici
synergist
therapeut
unobtain
linezolid
concentr
mgl
conclus
multidrug
resist
strain
baumannii
uk
produc
oxa
carbapenemas
remain
suscept
polymyxin
vitro
polymyxin
exert
effect
bacteri
cell
wall
theoret
assist
antibiot
reach
respect
target
seem
logic
choic
inclus
combin
therapi
shown
rifampicin
synergist
polymyxin
isol
vitro
may
effect
treat
sever
baumannii
infect
man
compar
vitro
evalu
resist
develop
exposur
teicoplanin
vancomycin
linezolid
quinupristin
dalfopristin
staphylococcu
spp
enterococcu
spp
mssa
mrse
msse
e
faecium
e
faecali
strain
determin
agar
plate
contain
antibiot
clsi
resist
breakpoint
peak
blood
concentr
incub
h
coloni
count
compar
inoculum
calcul
frequenc
mutat
coloni
grown
plate
contain
antibiot
sampl
determin
mic
valu
result
frequenc
mutat
less
test
antibiot
peak
blood
concentr
result
obtain
breakpoint
concentr
drug
use
conclus
onestep
vitro
studi
demonstr
abil
teicoplanin
vancomycin
linezolid
quinupristin
dalfopristin
prevent
growth
resist
mutant
staphylococci
enterococci
thu
suggest
occurr
mutat
event
lead
resist
bacteria
expos
blood
concentr
drug
order
establish
develop
resist
vitro
serial
exposur
antibiot
simul
differ
vivo
concentr
studi
need
progress
multi
step
induct
resist
vitro
activ
antimicrobi
agent
legionella
obtain
hotel
water
system
turkey
object
aim
studi
evalu
vitro
activ
colistin
endem
panresist
acinetobact
baumannii
includ
resist
imipenem
isol
year
period
univers
hospit
method
imipenemresist
acinetobact
spp
isol
collect
januari
octob
varieti
clinic
specimen
differ
patient
attend
distinct
ward
univers
teach
hospit
isol
identifi
sequenc
rrna
gene
mic
colistin
determin
agar
dilut
method
accord
nccl
suscept
breakpoint
mgl
pfge
apai
restrict
enzym
perform
result
baumannii
isol
suscept
colistin
colistin
resist
mic
mgl
observ
isol
isol
mic
mgl
isol
mic
mgl
recov
differ
patient
distinct
ward
among
imipenemand
colistinresist
isol
distinct
pfge
pattern
identifi
clone
b
c
resist
almost
betalactam
includ
carbapenem
variabl
suscept
aztreonam
amikacin
tobramycin
common
featur
clone
isol
belong
clone
b
show
resist
imipenem
amoxicillin
associ
clavulan
acid
amc
ureidopenicillin
associ
suscept
ceftazidim
variabl
behaviour
meropenem
cefepim
cefpirom
aztreonam
suscept
profil
aminoglycosid
variabl
differ
clone
suscept
netilmicin
minocyclin
clone
c
resist
imipenem
amoxicillin
amc
piperacillin
piperacillin
tazobactam
ticarcillin
ticarcillin
clavulan
acid
remain
suscept
meropenem
aztreonam
cefpirom
ceftazidim
cefepim
conclus
colistin
one
effect
drug
avail
multidrugresist
acinetobact
infect
show
vitro
activ
major
acinetobact
spp
strain
isol
within
sampl
hospit
observ
baumannii
resist
recent
reintroduc
colistin
seem
like
first
chapter
novel
repeatedli
told
sever
antibiot
emerg
highlevel
gentamicin
resist
clinic
enterococc
isol
companion
anim
portug
object
character
vitro
gentamicin
suscept
among
enterococci
caus
infect
cat
dog
order
evalu
impact
highlevel
gentamicin
resist
small
anim
therapeut
method
sampl
collect
veterinari
teach
hospit
faculti
veterinari
medicin
veterinari
privat
practic
lisbon
area
januari
novemb
total
enterococci
isol
dog
cat
urinari
tract
infect
uti
otiti
externa
oe
pioderma
bbl
crystal
gram
posit
id
system
use
identif
speci
level
minim
inhibitori
concentr
mic
determin
microdilut
method
accord
nccl
bifunt
enzym
gene
confer
highlevel
gentamicin
resist
hlgr
detect
use
pcr
result
enterococcu
faecali
predomin
isol
n
follow
frequenc
enterococcu
faecium
n
mic
cumul
data
analysi
show
valu
lg
ml
lgml
six
hlgr
clinic
enterococc
isol
detect
mic
rang
lgml
four
enterococci
isol
uti
oe
four
phenotyp
highlevel
gentamicin
resist
isol
carri
aac
ieaph
ia
gene
conclus
import
enterococc
infect
small
anim
clinic
sampl
increas
last
year
mic
cumul
data
point
lowlevel
gentamicin
resist
among
clinic
enterococci
isol
veterinari
origin
emerg
highlevel
isol
previous
detect
fact
compromis
cellwal
activ
agent
ampicillin
vancomicin
aminoglicosid
vivo
synergi
aac
ieaph
ia
gene
carriag
concern
express
confer
resist
also
tobramicin
netilmicin
amikacin
kanamicin
find
critic
import
may
direct
impact
therapeut
decis
manag
companion
anim
infect
enterococci
furthermor
transfer
resist
gene
resist
strain
anim
ownerscaretak
direct
contact
concern
probabl
refer
result
interpret
criteria
use
accord
nccl
studi
period
penicillin
resist
strain
pneumonia
note
follow
sputum
csf
other
cefuroxim
resist
sputum
csfregard
suscept
ofx
penicillin
resist
pneumonia
strain
sputum
ta
reveal
penicillin
resist
strain
come
sputum
ta
show
resist
follow
em
sxt
strain
isol
other
em
sxtno
resist
strain
va
found
conclus
percentag
penicillin
resist
pneumonia
isol
lower
respiratori
tract
middl
ear
fluid
eye
fluid
sinu
markedli
higher
isol
blood
csf
effici
drug
penicillin
resist
pneumococci
cefuroxim
ofloxacin
result
romania
also
underlin
previou
observ
regard
higher
emerg
rate
resist
pneumonia
worldwid
penicillin
resist
streptococcu
agalactia
object
streptococcu
agalactia
becom
recogn
caus
seriou
ill
newborn
pregnant
women
adult
chronic
medic
condit
heavi
colon
genit
tract
streptococcu
agalactia
also
increas
risk
woman
deliv
preterm
lowbirthweight
infant
earlyonset
infect
occur
day
age
associ
much
lower
fatal
first
describ
incid
final
decreas
use
prevent
antibiot
childbirth
increas
among
women
risk
penicillin
ampicillin
remain
drug
choic
intrapartum
antibiot
prophylaxi
streptococcu
agalactia
colon
pregnant
women
erythromycin
clindamycin
drug
choic
women
seriou
penicillin
allergi
colon
streptococcu
agalactia
object
studi
estim
insorg
penicillin
resist
among
streptococcu
agalactia
method
streptococcu
agalactia
test
penicillin
agar
dilut
method
accord
clinic
laboratori
standard
institut
clsi
breakpoint
resist
recommend
clsi
antimicrobi
agent
obtain
manufactur
laboratori
grade
powder
result
discuss
four
hundr
seven
clinic
isol
analys
streptococcu
agalactia
result
resist
penicillin
case
result
borderlinesth
present
find
indic
probabl
evolut
agalactia
toward
penicillin
resist
find
suggest
need
continu
nation
intern
surveil
program
provid
time
data
evolut
incid
penicillin
resist
pathogen
ciprofloxacin
suscept
common
isol
bacteri
conuct
conclus
accord
averag
numer
conclud
isol
strain
highli
suscept
ciprofloxacin
applic
conuctivi
saccu
especi
import
cure
conuctivi
infect
resist
strain
like
pseudomona
aeruginosa
success
cure
bacteria
chronic
conuct
adequ
use
therapi
accord
antibiogram
antimicrobi
resist
pattern
acinetobact
baumannii
clinic
isol
gt
tsilika
vp
pliatsika
mt
tsivitanid
ds
sofian
thessaloniki
gr
object
baumannii
nosocomi
pathogen
commonli
isol
critic
ill
immunocompromis
patient
aim
present
studi
evalu
antimicrobi
resist
baumannii
strain
isol
tertiari
care
hospit
througout
threeyear
period
method
total
baumannii
strain
select
januari
decemb
specimen
obtain
inpati
hospit
intens
care
unit
icu
pediatr
intens
care
unit
picu
depart
hospitalth
identif
antimicrobi
suscept
test
perform
use
vitek
autom
system
biomerieux
franc
conclus
emerg
rapid
spread
multidrug
resist
baumannii
isol
great
concern
worldwideimipenem
one
potent
agent
treatment
infect
caus
multiresist
strainsth
increas
preval
imipenem
resist
limit
therapeut
option
lead
outbreak
carbapenem
resist
strain
tigecyclin
vivo
studi
object
antibacteri
agent
disrupt
ecolog
balanc
normal
human
microflora
disturb
may
lead
emerg
antibiot
resist
andor
infect
potenti
pathogen
bacteria
tigecyclin
member
new
class
antibiot
glycylcyclin
shown
potent
expand
broadspectrum
activ
gramposit
gramneg
aerob
anaerob
bacteria
aim
studi
investig
ecolog
effect
tigecyclin
normal
oropharyng
intestin
microflora
healthi
subject
method
thirteen
white
subject
women
men
age
year
receiv
mg
tigecyclin
morn
day
intraven
iv
infus
follow
dose
tigecyclin
given
everi
hour
infus
day
one
subject
withdrawn
day
advers
event
serum
saliva
faecal
sampl
collect
administr
microbiolog
cultiv
assay
tigecyclin
new
colon
bacteria
test
suscept
resist
mgl
investig
period
result
serum
concentr
day
hour
dose
mgl
mean
valu
mgl
median
valu
mgl
sd
mgl
faecal
concentr
day
mgkg
mean
valu
mgkg
median
valu
mgkg
sd
mgl
saliva
concentr
gener
low
highest
mean
valu
mgl
median
valu
mgl
day
hour
dose
minor
effect
oropharyng
microflora
observ
number
enterococci
escherichia
coli
intestin
microflora
reduc
day
enterobacteria
yeast
increas
mark
reduct
lactobacilli
bifidobacteria
impact
bacteroid
clostridium
difficil
strain
isol
two
klebsiella
strain
enterobact
strain
resist
tigecyclin
found
conclus
tigecyclin
minor
effect
oropharyng
microflora
tigecyclin
effect
intestin
microflora
due
spectrum
antibacteri
activ
intestin
concentr
object
examin
report
use
tigecyclin
wyeth
treatment
multidrug
resist
acinetobact
mdra
cultur
posit
sepsi
patient
requir
mutiorgan
support
method
patient
manag
within
liver
intens
care
unit
physiolog
data
collect
prospect
enter
onto
specialist
databas
patient
receiv
standard
intens
care
manag
antibiot
antifung
therapi
administ
indic
microbiolog
cultur
system
inflammatori
respons
sir
featur
initi
blood
cultur
vascular
line
peripher
drain
fluid
cultur
broncoalveolar
lavag
bal
screen
swab
undertaken
weekli
sampl
sent
cultur
laparotomi
mdra
posit
cultur
blood
bal
drain
fluid
sampl
taken
laparotomi
context
sir
result
initi
tigecyclin
treatment
result
patient
receiv
tigecyclin
treatment
mdra
infect
underli
diseas
state
necrot
pancreat
post
hepatectomi
polytrauma
postiv
intraabdomin
cultur
acut
acut
chronic
liver
failur
mdra
ive
bronchoalveolar
lavag
blood
cultur
post
liver
transplant
patient
necrotis
pancreat
one
recurr
small
bowel
perfor
retroperiton
haemorrhag
posit
blood
cultur
posit
intraabdomin
tissueclot
mean
time
admiss
treatment
mdra
day
mean
durat
treatment
day
rang
mean
apach
ii
score
initi
therapi
rang
patient
surviv
intens
care
discharg
hospit
discharg
microbiolog
clearanc
mdra
observ
case
achiev
microbiolog
clearanc
caus
death
intraabdomin
haemorrhag
recalcitr
organ
failur
recurr
small
bowel
perfor
vasopressor
resist
shock
patient
one
remain
cultur
posit
intraabdomin
sepsi
despit
full
treatment
small
bowel
perfor
drug
well
toler
side
effect
hypercalcaemia
observ
patient
mean
correct
calcium
mmoll
rang
case
resolv
drug
discontinu
conclus
tigecyclin
appear
efficaci
agent
treatment
deep
seat
mdra
infect
object
nausea
n
vomit
v
report
tigecyclin
new
glycylcyclin
expand
broad
spectrum
activ
exposurerespons
relationship
patient
covari
predict
first
n
v
occurr
evalu
patient
complic
intraabdomin
infect
ciai
method
data
patient
ciai
trial
one
phase
two
phase
receiv
mg
load
dose
mg
everi
hour
pool
analysi
n
v
definit
possibl
probabl
relat
tigecyclin
report
start
infus
hour
last
dose
includ
individu
exposur
measur
cmax
calcul
use
previous
develop
popul
pk
model
logist
regress
use
evalu
predictor
first
n
v
occurr
covari
includ
age
weight
sex
region
treatment
baselin
n
v
result
dataset
includ
patient
pk
mean
sd
age
weight
year
kg
patient
men
enrol
north
america
europ
latin
america
respect
baselin
nausea
vomit
report
overal
n
v
occur
patient
receiv
tigecyclin
howev
first
n
v
event
mild
natur
women
n
v
men
n
v
lower
europ
region
cmax
predict
final
nausea
model
includ
weight
sex
region
baselin
nausea
interact
weightregion
predictor
first
nausea
occurr
p
respect
object
hospitalis
communityacquir
pneumonia
cap
associ
substanti
morbid
health
resourc
utilis
evalu
predictor
prolong
hospit
length
stay
lo
treatment
durat
method
conduct
retrospect
analysi
data
doubleblind
randomis
multicentr
clinic
studi
compar
efficaci
safeti
tigecyclin
levofloxacin
treatment
patient
cap
requir
hospitalis
patient
stratifi
fine
pneumonia
sever
index
randomli
assign
receiv
tigecyclin
levofloxacin
via
iv
administr
least
day
treatment
durat
hospit
discharg
base
physician
assess
sign
symptom
infect
patient
condit
use
cox
proport
hazard
model
stepwis
select
identifi
statist
signific
predictor
p
treatment
durat
hospit
lo
result
among
patient
cap
clinic
intenttotreat
popul
complet
hospitalis
data
mean
age
year
rang
patient
age
year
diabet
chronic
obstruct
pulmonari
diseas
congest
heart
failur
lead
comorbid
patient
smoker
characteris
alcohol
abus
median
fine
pneumonia
sever
index
score
patient
score
signific
differ
group
treatment
durat
lo
conclus
tigecyclin
firstinclass
glycylcyclin
associ
treatment
durat
lo
similar
levofloxacin
adjust
sever
identifi
risk
factor
tigecyclin
effect
treat
patient
intraabdomin
skinskin
structur
infect
bacteraemia
ej
ellisgross
r
maroko
collegevil
us
object
treatment
bacteraemia
potenti
fatal
complic
infect
origin
bodi
site
complic
increas
resist
tigecyclin
firstinclass
glycylcyclin
expand
spectrum
activ
gramposit
gramneg
anaerob
atyp
bacteria
includ
resist
strain
tigecyclin
safe
effect
treat
complic
skin
skin
structur
csssi
intraabdomin
infect
ciai
analysi
examin
tigecyclin
clinic
trial
experi
patient
ciai
csssi
bacteraemia
presenc
bacteria
blood
baselin
object
treatment
complic
intraabdomin
infect
ciai
challeng
due
divers
bacteriolog
bacteri
resist
efficaci
safeti
tigecyclin
tgc
firstinclass
glycylcyclin
approv
mexico
brazil
peru
colombia
usa
treat
ciai
complic
skin
skin
structur
infect
compar
imipenemcilastatin
imici
adult
hospitalis
patient
ciai
two
doubleblind
phase
multin
trial
analysi
evalu
tgc
efficaci
safeti
european
region
integr
result
two
trial
method
one
studi
conduct
centr
countri
studi
conduct
centr
countri
patient
stratifi
diseas
sever
apach
ii
score
vs
randomli
assign
iv
tgc
mg
load
mg
iv
imici
mg
day
clinic
respons
testofcur
toc
day
therapi
microbiolog
evalu
microbiolog
modifi
intenttotreat
mmitt
coprimari
efficaci
endpoint
curefailur
respons
determin
safeti
assess
physic
examin
laboratori
result
advers
event
ae
report
result
european
analysi
patient
mitt
receiv
dose
mmitt
tgc
imici
tgc
imici
treatment
group
balanc
respect
demograph
patient
mostli
white
men
mean
age
year
clinic
cure
rate
toc
tgc
vs
imici
ci
test
noninferior
p
clinic
cure
rate
mmitt
tgc
vs
imici
ci
test
noninferior
p
commonli
report
treatment
emerg
ae
teae
mitt
tgc
imici
nausea
p
vomit
p
imici
group
significantli
higher
teae
fever
imici
vs
tgc
p
hyperglycaemia
imici
vs
tgc
p
dyspnoea
imici
vs
tgc
p
tgc
significantli
higher
amylas
increas
tgc
vs
imici
p
bun
increas
tgc
vs
imici
p
conclus
similar
overal
integr
analysi
two
phase
trail
european
analysi
tgc
safe
effect
treatment
hospitalis
patient
ciai
comparison
imici
tigecyclin
safe
effect
treatment
complic
skin
skin
structur
infect
european
experi
two
doubleblind
phase
comparison
studi
vancomycinaztreonam
r
maroko
n
dartoi
sarkozi
j
goodrich
ej
ellisgross
behalf
tigecyclin
studi
group
object
tigecyclin
tgc
firstinclass
expand
spectrum
glycylcyclin
approv
mexico
brazil
peru
colombia
usa
treat
complic
skin
skin
structur
infect
csssi
complic
intraabdomin
infect
two
phase
randomis
doubleblind
studi
conduct
hospitalis
men
women
csssi
determin
tgc
safeti
efficaci
compar
vancomycinaztreonam
va
object
analysi
evalu
efficaci
safeti
seen
european
popul
integr
analysi
phase
trial
method
one
studi
conduct
centr
countri
studi
conduct
centr
countri
patient
randomli
assign
receiv
either
tgc
mg
follow
mg
iv
twice
daili
vancomycin
g
iv
twice
daili
plu
aztreonam
g
iv
twice
daili
day
clinic
respons
testofcur
toc
day
therapi
clinic
evalu
ce
clinic
modifi
intenttotreat
cmitt
popul
coprimari
efficaci
endpoint
curefailur
respons
determin
secondari
object
includ
determin
vitro
suscept
tgc
rang
bacteria
caus
csssi
microbiolog
efficaci
safeti
assess
physic
examin
laboratori
result
advers
event
ae
report
result
european
analysi
patient
compris
mitt
receiv
dose
studi
drug
compris
ce
tgc
vaci
compris
cmitt
tgc
va
ci
treatment
group
balanc
respect
demograph
patient
mostli
white
men
mean
age
year
european
region
clinic
respons
tgc
va
testofcur
similar
cmitt
versu
differ
tgcva
ci
similar
result
note
ce
popul
tgc
cure
va
cure
differ
tgcva
ci
commonli
report
treatment
emerg
ae
teae
mitt
tgc
va
nausea
p
vomit
p
va
group
significantli
higher
teae
sgpt
increas
va
vs
tgc
p
rash
va
vs
tgc
p
conclus
european
analysi
integr
phase
worldwid
clinic
studi
tgc
monotherapi
safe
efficaci
combin
va
treatment
patient
csssi
safeti
toler
tigecyclin
r
maroko
n
dartoi
g
rose
ej
ellisgross
collegevil
us
pari
fr
object
tigecyclin
tgc
glycylcyclin
firstinclass
extend
broadspectrum
iv
antibiot
demonstr
clinic
activ
patient
complic
intraabdomin
infect
ciai
complic
skin
skinstructur
infect
csssi
safeti
tigecyclin
evalu
four
phase
iii
trial
method
total
hospit
patient
trial
pool
evalu
safeti
analysi
ciai
trial
patient
receiv
tgc
mg
q
hr
follow
load
dose
imipenem
mg
cilastin
mg
q
hr
csssi
studi
treat
either
tgc
doseschedul
vancomycin
gm
without
aztreonam
gm
q
hr
result
frequent
report
advers
event
ae
tgctreat
group
nausea
n
vomit
v
incid
n
v
approxim
gener
mild
moder
sever
infectionrel
seriou
ae
slightli
frequent
tgc
versu
compar
vs
discontinu
due
treatmentemerg
ae
includ
nv
occur
similar
rate
tgc
compar
vs
six
patient
treat
tgc
present
intestin
perfor
develop
sepsissept
shock
compar
imipenemcilastatin
higher
baselin
apach
ii
score
tgc
group
relationship
treatment
could
determin
overal
efficaci
analysi
subject
perfor
intestin
balanc
two
group
overal
efficaci
statist
differ
clinic
signific
renal
hepat
cardiac
qtc
bone
marrow
cn
toxic
note
tgc
conclus
tgc
appear
safe
toler
patient
ciai
csssi
nv
gener
mild
moder
sever
selflimit
result
increas
overal
drug
discontinu
appear
clinic
signific
renal
hepat
cardiac
bone
marrow
neurolog
toxic
relat
tgc
treatment
allcaus
mortal
rate
statist
differ
treat
tgc
compar
demonstr
efficaci
favour
toxic
profil
make
tgc
good
monotherapi
option
select
seriou
infect
tigecyclin
effect
imipenemcilastatin
treatment
complic
intraabdomin
infect
experi
india
object
due
divers
bacteriolog
bacteri
resist
treatment
complic
intraabdomin
infect
ciai
challeng
doubleblind
phase
multin
trial
efficaci
tigecyclin
firstinclass
glycylcyclin
compar
imipenemcilastatin
imici
hospitalis
patient
ciai
subanalysi
evalu
tigecyclin
safeti
efficaci
investig
site
india
method
patient
stratifi
diseas
sever
apach
ii
score
vs
randomli
assign
iv
tigecyclin
mg
load
mg
iv
imici
adjust
bodi
weight
mg
kg
day
clinic
respons
testofcur
toc
day
therapi
microbiolog
evalu
microbiolog
modifi
intenttotreat
mmitt
popul
coprimari
efficaci
endpoint
curefailur
respons
determin
safeti
evalu
includ
vital
sign
laboratori
test
record
advers
event
ae
result
india
patient
receiv
least
dose
mitt
tigecyclin
imici
patient
clinic
evalu
ce
mmitt
treatment
group
balanc
respect
demographicbaselin
medic
characterist
primari
diagnos
mitt
complic
append
gastricduoden
perfor
perfor
intestin
cholecyst
periton
intraabdomin
abscess
cure
rate
toc
india
tigecyclin
imi
ci
consist
overal
result
tigecyclin
vs
imici
ci
noninferior
p
india
mmitt
cure
rate
toc
tigecyclin
imici
similar
overal
mmitt
result
tigecyclin
vs
imici
ci
noninferior
p
noninferior
tigecyclin
among
india
patient
could
statist
demonstr
insuffici
sampl
size
howev
magnitud
respons
studi
drug
patient
treat
india
compar
overal
patient
india
treatment
ae
similar
significantli
higher
incid
dyspnoea
tigecyclin
vs
imici
p
conclus
efficaci
result
india
consist
find
overal
studi
result
centr
suggest
tigecyclin
noninferior
compar
treat
ciai
nosocomi
infect
control
environ
viral
infect
bacteri
flora
contamin
blood
pressur
cuff
use
hospit
ward
n
walker
r
gupta
j
cheesbrough
preston
uk
blood
pressur
cuff
plausbil
vehicl
transmiss
nosocomi
infect
patient
despit
studi
examin
level
bacteri
contamin
test
presenc
common
nosocomi
pathogen
surfac
swab
cuff
current
use
hospit
ward
use
steril
glove
dispos
templat
measur
cm
place
onto
cuff
moisten
steril
swab
rub
onto
defin
area
minut
transport
ml
buffer
medium
sampl
ml
buffer
plate
onto
differ
media
includ
nonselect
agar
medium
total
viabl
count
tvc
select
media
aureu
mrsa
c
difficil
coliform
vancomycin
resist
enterococci
vre
bacteri
growth
recov
cuff
pathogen
organ
isol
cuff
mssa
mrsa
c
difficil
remain
three
cuff
grew
one
pathogen
organ
mssa
mrsa
c
difficil
one
mssa
c
difficil
cuff
colifrom
vre
isol
cuff
rang
total
viabl
count
recov
per
cm
area
cuff
vari
cfu
cuff
highest
count
tend
pathogen
present
mssa
c
difficil
isol
cuff
sampl
mrsa
actual
import
potenti
rout
transmiss
nosocomi
pathogen
remain
unclear
dismiss
impract
decontamin
blood
pressur
cuff
patient
suggest
singl
patient
use
cuff
barrier
cuff
skin
would
viabl
option
busi
gener
ward
needlestick
sharp
injuri
health
care
personnel
newli
found
tertiari
hospit
prospect
studi
falaga
karydi
g
georgoulia
p
hatzopoul
nikita
kostogiann
athen
gr
object
needlestick
sharp
injuri
health
care
worker
major
caus
anxieti
may
expos
suscept
employe
risk
infecti
diseas
howev
incid
injuri
examin
newli
found
hospit
prevent
programm
take
place
method
prospect
studi
needlestick
sharp
injuri
employe
newli
found
tertiari
hospit
athen
greec
vaccin
program
hepat
b
viru
well
educ
activ
avoid
injuri
take
place
serolog
studi
hepat
b
c
viru
well
human
immunodefici
viru
hiv
perform
injur
employe
sourc
patient
known
result
sixtyeight
needlestick
sharp
injuri
splash
report
studi
period
nurs
housekeep
technician
ambul
worker
overal
incid
percutan
injuri
splash
per
employmentyear
ftey
wherea
incid
percutan
injuri
alon
per
ftey
higher
incid
injuri
note
first
second
half
studi
period
versu
p
sourc
patient
found
posit
hepat
c
hiv
use
hightitr
immunoglobulin
adjust
incid
injuri
higher
first
second
half
studi
period
vs
p
conclus
although
adjust
possibl
confound
data
show
educ
vaccin
prevent
program
needlestick
sharp
injuri
led
statist
signific
decreas
incid
injuri
use
hightitr
immunoglobulin
epidemiolog
occup
needlestick
sharp
injuri
among
healthcarework
turkey
hosoglu
behalf
occup
infect
studi
group
turkey
background
health
care
worker
hcw
frequent
expos
danger
infecti
agent
needl
stick
sharp
injuri
nssi
occup
effort
turkey
hepat
b
c
virus
caus
essenti
threat
hcw
preval
rate
respect
crosssect
countrywid
survey
studi
perform
epidemiolog
nssi
among
hcw
hospit
citi
throughout
countri
data
relat
epidemiolog
nssi
collect
use
standard
questionnair
result
total
hcw
complet
questionnair
form
nurs
lead
group
person
join
studi
follow
doctor
person
andlaboratori
technician
total
declar
occup
exposur
nssi
last
month
relat
job
needl
stick
injuri
report
splash
eye
sharp
injuri
injuri
hepat
posit
report
case
object
assess
microbiolog
statu
reprocess
singleus
devic
intervent
cardiolog
test
bioburden
steril
pyrogen
load
method
total
amount
electrophysiolog
nonlumen
cathet
ep
collect
first
clinic
use
patient
devic
contamin
bacteria
spike
human
blood
underw
four
differ
presteril
protocol
includ
chlorin
polyphenol
enzymat
agent
treat
sampl
assay
cultur
quantit
method
cqm
bactericid
properti
electron
microscopi
em
biolog
residu
ep
test
steril
repetit
simulatedus
bacteria
spike
blood
regener
enzymat
chlorin
treatment
ga
plasma
steril
obtain
sampl
respect
reprocess
time
devic
cultur
day
trypticas
soy
broth
pyrogen
statu
ep
monitor
clinic
use
decontaminationclean
treatment
complet
reprocess
lal
test
result
highresolut
em
cqm
confirm
superior
properti
chlorin
releas
agent
ad
enzymat
deterg
devic
treatment
steril
hypochlor
acid
base
protocol
biocid
log
cfu
reduct
polyphenol
log
cfu
reduct
steril
test
show
posit
sampl
inocul
strain
fourth
cycl
reprocess
cathet
show
growth
inocul
strain
bacillu
subtili
sampl
five
cycl
six
cycl
respect
everi
reprocess
devic
nonpyrogen
eucathet
addit
test
conduct
invitro
spike
cathet
show
pyrogen
load
eudevic
reduc
less
eudevic
conclus
reprocess
procedur
follow
adopt
regener
protocol
abl
satisfi
fundament
microbiolog
requir
five
invitro
reus
steril
test
show
devic
steril
guarante
five
reus
presteril
treatment
includ
enzymat
solut
chlorin
reveal
high
clean
properti
effect
bioburden
reduct
storag
interv
among
reprocess
step
longer
hour
avoid
order
limit
contamin
pyrogen
load
technic
consider
suggest
consid
introduct
reprocess
procedur
hospit
consider
workload
room
disinfect
hospit
set
use
akacid
plu
c
kratzer
tobud
w
graning
buxbaum
georgopoulo
vienna
object
akacid
plu
novel
polymer
guanidin
broad
antimicrobi
activ
also
multiresist
bacteri
strain
use
present
studi
room
disinfect
method
disinfect
close
room
experiment
contamin
antibioticsuscept
multiresist
staphylococcu
aureu
mrsa
pseudomona
aeruginosa
escherichia
coli
perform
use
akacid
plu
concentr
minut
bacteri
suspens
distribut
stainless
steel
plate
place
test
control
room
recoveri
test
bacteria
determinedbefor
nebul
minut
begin
hour
end
room
disinfect
modifi
simpl
swabrins
techniqu
detect
mrsa
isol
unit
surfac
sampl
collect
direct
swab
enrich
cultur
result
swabrins
method
demonstr
doseand
timedepend
effect
akacid
plu
erad
aureu
e
coli
p
aeruginosa
stainless
steel
plate
nebul
akacid
plu
success
elimin
hospit
pathogen
min
contact
time
mrsa
still
detect
use
akacid
plu
akacid
plu
achiev
reduct
cfu
aureu
p
aeruginosa
abl
erad
e
coli
observ
time
result
suggest
nebul
akacid
plu
concentr
potent
substanc
erad
pathogen
organ
hospit
set
studi
antivir
efficaci
citrofresh
flavonoid
base
organ
acid
complex
sanit
z
nack
northgeelong
au
object
determin
antivir
efficaci
organ
sanit
envelop
nonenvelop
virus
use
carrier
base
method
seek
registr
citrofresh
australia
eu
hospit
grade
antivir
sanit
method
studi
perform
accord
american
societi
test
materi
astm
design
e
recommend
australian
therapeut
good
administr
tga
determin
efficaci
disinfect
intend
use
inanim
environment
surfac
test
citrofresh
dilut
standard
hard
water
three
differ
concentr
adher
cell
line
mdck
four
replic
five
differ
virus
includ
porcin
parvoviru
nonenvelop
high
resist
sanit
human
nonenvelop
high
resist
sanit
human
nonenvelop
moder
resist
sanit
human
influenza
type
viru
envelop
moder
resist
sanit
human
herp
simplex
viru
type
envelop
low
resist
sanit
prior
viral
test
acut
toxic
assay
carri
determin
adher
cell
viabil
citrofresh
result
cell
line
exhibit
viabil
exposur
three
concentr
herp
simplex
type
human
influenza
type
human
exhibit
signific
viral
log
reduct
concentr
citrofresh
follow
human
porcin
parvoviru
reduct
concentr
reduct
viabl
viru
load
exhibit
minut
exposur
time
citrofresh
mean
timedepend
activ
citrofresh
clearli
exhibit
concentr
ph
depend
viral
load
reduct
activ
influenza
type
human
adenoviru
human
herp
simplex
type
viru
reduct
viral
titr
porcin
parvoviru
human
probabl
ph
depend
ph
citrofresh
conclus
investig
show
citrofresh
effect
disinfect
environment
surfac
elimin
envelop
nonenvelop
virus
suffici
achiev
minimum
reduct
complet
viral
inactiv
prerequisit
registr
rapid
environment
recontamin
intens
care
unit
decontamin
hydrogen
peroxid
vapour
object
evalu
effect
hydrogen
peroxid
vapour
hpv
reduc
level
total
bacteri
methicillin
resist
staphylococcu
aureu
mrsa
environment
contamin
intens
care
unit
icu
establish
rate
environment
recontamin
method
studi
took
place
bed
open
plan
icu
environment
screen
site
bed
space
bed
workstat
monitor
examin
use
broth
enrich
detect
mrsa
addit
total
bacteri
count
determin
bed
workstat
use
rodac
plate
environment
screen
carri
monthli
month
preced
usag
hpv
increas
weekli
week
prior
usag
addit
sampl
carri
immedi
patient
discharg
icu
follow
subsequ
termin
clean
immedi
hpv
use
readmiss
patient
sampl
carri
h
h
weekli
period
week
patient
screen
mrsa
admiss
weekli
result
sampl
environ
prior
usag
hpv
reveal
contamin
environ
mrsa
occas
mrsa
colonis
patient
present
occas
discharg
patient
termin
clean
environ
mrsa
isol
environment
site
use
hpv
mrsa
isol
environment
site
upon
immedi
sampl
h
patient
readmit
includ
patient
known
colonis
mrsa
mrsa
isol
site
site
cluster
around
colonis
patient
widespread
across
icu
week
post
hpv
usag
mrsa
isol
everi
week
mean
total
bacteri
count
prior
use
hpv
cm
underneath
bed
cm
workstat
reduc
hpv
cm
cm
respect
patient
readmiss
count
cm
underneath
bed
cm
workstat
h
return
prehpv
level
cm
cm
site
respect
week
conclus
hydrogen
peroxid
vapour
effect
elimin
bacteria
environ
rapid
rate
recontamin
environ
suggest
use
hpv
effect
mean
maintain
low
level
environment
contamin
open
plan
icu
object
nosocomi
infect
seriou
danger
commun
acquir
infect
sinc
high
rate
morbid
mortal
well
increas
cost
therapi
recent
mani
precaut
taken
prevent
infect
one
applic
cover
floor
ward
clinic
intens
care
unit
oper
room
hospit
vinyl
floor
materi
believ
clean
easili
effect
studi
aim
determin
durat
surviv
staphylococcu
aureu
enterococcu
feacali
escherichia
coli
pseudomona
aeruginosa
common
encount
nosocomi
infect
agent
surfac
floor
materi
vinyl
floor
ceram
lamin
wood
galvan
sheet
room
temperatur
method
four
kind
floor
materi
prepar
approxim
cm
coupon
steril
separ
bacteri
suspens
equal
mc
farland
turbid
swap
surfac
floor
materi
steril
cotton
swab
contamin
test
materi
put
steril
petri
dish
cover
kept
room
temperatur
without
subject
direct
sunlight
third
day
cultur
sampl
taken
surfac
materi
steril
cotton
swap
soak
steril
salin
streak
blood
agar
surfac
cultur
procedur
repeat
everi
day
growth
detect
case
three
consequ
neg
cultur
result
obtain
cultur
end
result
overal
result
studi
present
tabl
conclus
among
four
floor
materi
galvanis
sheet
seem
unsuit
one
bacteria
surviv
long
period
word
materi
prefer
lamin
wood
cover
bench
laboratori
tabl
floor
floor
vinyl
floor
materi
better
ceram
cover
complet
cmv
proteinsresult
cmv
seroposit
transplant
recipi
significantli
highten
specif
cell
frequenc
compar
seroneg
individu
patient
withevid
cmv
antigenemia
dnaemia
could
discrimin
base
cmvand
donorreact
cell
serum
creatinin
howev
recipi
seroposit
graft
low
respons
show
tendenc
toward
frequent
cmv
infect
cmv
diseas
observ
individu
detect
cell
respons
third
present
domin
respons
interestingli
cell
correl
invers
earli
posttx
donorreact
cell
frequenc
week
posttx
importantli
cell
frequenc
correl
invers
serum
creatinin
month
sever
time
posttx
patient
without
acut
reject
even
pretranspl
specif
cell
correl
invers
month
creatinin
conclus
data
suggest
subclin
control
cmv
infect
specif
cell
subsequ
less
graft
injuri
cmvinduc
alloimmun
univers
precaut
knowledg
attitud
practic
healthcar
worker
regard
hiv
hepat
b
c
v
gupta
bhoi
goel
p
aggarw
new
delhi
object
increas
incid
hiv
hepat
b
hbv
hepat
c
hcv
patient
expos
healthcar
profession
acquir
infect
occup
exposur
studi
knowledg
attitud
practic
healthcar
worker
regard
hiv
hbv
hcv
risk
occup
transmiss
diseas
method
interview
survey
conduct
among
health
care
worker
hcw
use
standardis
questionnair
compris
item
english
local
languag
suitabl
expert
emerg
ward
tertiari
care
teach
hospit
develop
nation
data
analysi
bivari
multivari
analysi
done
use
spss
version
result
respons
rate
hcw
particip
studi
mean
age
year
femal
studi
popul
compris
doctor
nurs
lab
technician
support
staff
respond
adequ
knowledg
caus
usual
transmiss
symptom
aid
poor
knowledg
hbv
hcv
respect
inadequ
knowledg
also
reveal
infecti
bodyfluid
disinfect
equip
pregnanc
hcw
suscept
factor
post
exposur
prophylaxi
compar
infect
hiv
hepat
hcw
becam
anxiou
treat
patient
poor
complianc
univers
precaut
notic
high
complianc
report
wear
mask
wear
glove
doctor
like
suffer
needlestick
injuri
p
occup
exposur
found
high
poor
declar
rate
guidelin
adher
influenc
profess
p
avail
adequaci
protect
equip
work
experi
hcw
p
respond
urg
interact
inform
session
conclus
result
studi
reveal
fair
level
knowledg
hivaid
hepat
b
c
gener
adequ
concern
among
hcw
incongru
perceiv
knowledg
report
practic
suggest
need
interact
awar
cours
univers
precaut
educ
programm
need
consid
attitud
conjunct
empir
knowledg
object
seropreval
hepat
hav
antibodi
known
low
young
adult
korea
recent
seventeen
case
hepat
report
healthcar
worker
hcw
icu
univers
hospit
may
juli
perform
surveil
determin
molecular
identif
outbreak
method
check
hav
igm
patient
sicu
elev
astalt
retrospect
screen
astalt
level
nurs
doctor
contact
suspici
index
case
determin
exist
outbreak
molecular
subtyp
hav
blood
hcw
determin
provid
data
epidemiolog
studi
determin
index
case
transmiss
rout
intervent
control
outbreak
plan
result
seventeen
hcw
includ
nurs
doctor
year
old
suffer
acut
hav
week
period
possibl
transmiss
hav
fecalor
rout
bedridden
patient
diarrhea
expos
hcw
seventeen
hcw
identifi
posit
antihav
igm
eight
hcw
posit
hav
rna
analysi
region
isol
show
genotyp
five
strain
cocircul
other
conclus
occurr
hav
outbreak
highlight
import
standard
precaut
hospit
hav
vaccin
consid
young
agedhcw
genotyp
identif
blood
would
use
epidemiolog
studi
suspici
hav
outbreak
hospit
manag
norovirusassoci
gastroenter
outbreak
two
psychiatr
ward
buehl
u
arnold
magdeburg
de
object
report
norovirusassoci
outbreak
gastroenter
close
psychiatr
gerontopsychiatr
ward
decemb
februari
time
patient
healthcar
worker
hcw
affect
introduct
result
hygien
measur
base
publish
guidelin
psychiatr
ward
describ
method
effect
adapt
measur
implement
stop
outbreak
prevent
spread
diseas
area
hospit
isol
cohort
psychiatr
patient
exclud
therapeut
reason
regular
hand
disinfect
patient
room
imposs
high
risk
abus
follow
measur
introduc
use
gown
mask
glove
hcw
care
infect
patientsfrequ
hand
disinfect
alcoholbas
disinfect
hcw
use
pocket
bottl
recommend
person
enter
station
use
gown
glove
mask
disinfect
hand
frequent
distribut
handout
describ
measur
hand
disinfect
patient
use
toilet
take
meal
distribut
disinfect
hcw
increas
frequenc
routin
surfac
disinfect
time
daili
instead
routin
clean
daili
routin
disinfect
door
handl
handrail
washbasin
fit
light
switch
time
shift
avoid
patient
transfer
via
hospit
visitor
restrict
outbreak
time
daili
evalu
recommend
measur
adapt
current
situat
exclus
affect
staff
ward
h
symptom
free
result
hygien
measur
explain
local
hcw
daili
meet
fulli
accept
sever
staff
shortag
fifth
week
outbreak
new
case
gastroenter
hcw
newli
infect
patient
restrict
applic
adapt
guidelin
special
ward
outbreak
stop
within
week
conclus
case
norovirusbas
gastroenter
outbreak
close
psychiatr
ward
hygien
measur
adapt
concret
situat
necessari
especi
case
complianc
guidelin
increas
daili
meet
daili
evalu
recommend
staff
shortag
outbreak
forc
strict
complianc
recommend
measur
region
spread
antibiot
resist
method
perform
surveil
patient
healthcar
stuff
icu
environ
regist
infect
ab
period
day
one
interv
period
month
period
year
rectal
oropharyng
swab
tracheal
aspir
patient
handswab
stuff
sampl
environ
taken
weekli
identif
ab
perform
use
vitek
ii
system
suscept
test
kirbybau
mic
method
dna
fingerprint
obtain
puls
field
gel
electrophoresi
pfge
result
period
patient
men
women
patient
men
women
patient
men
women
hospit
icu
respect
ab
isol
sampl
period
period
total
ab
isol
specimen
period
among
patient
carri
ab
infect
respect
infect
observ
studi
period
sepsi
urinari
tract
infect
pneumonia
mening
thrombophleb
isol
ab
strain
multiresist
antimicrobi
agent
molecular
analysi
isol
strain
pfge
distinguish
follow
type
subtyp
b
period
c
e
f
g
h
j
period
b
h
k
l
period
infect
caus
mainli
type
type
isol
environ
hand
icu
stuff
conclus
high
rate
colon
infect
icu
patient
multiresist
clone
ab
persist
clone
baumannii
appear
b
type
period
disappear
period
despit
applic
hygien
measur
indic
need
strict
reinforc
infect
control
icu
transmiss
via
hand
stuff
patient
becom
import
contributor
factor
patient
colon
andor
infect
object
antibiot
resist
mechan
group
streptococci
ga
vari
accord
nation
studi
period
investig
antibiot
resist
mechan
macrolid
resist
strain
isol
korean
children
compar
previou
result
method
throat
cultur
taken
elementari
school
children
jinju
korea
octob
decemb
isol
ga
antibiot
suscept
test
erythromycin
em
clindamycin
cc
tetracyclin
tc
perform
disk
diffus
method
macrolid
resist
phenotyp
genotyp
well
emm
genotyp
studi
result
isol
rate
ga
resist
rate
em
cc
tc
respect
dramat
decreas
area
preval
common
type
cmlsb
imlsb
observ
respect
compar
strain
cmlsb
imlsb
ermb
gene
one
phenotyp
posit
mefa
gene
conclus
resist
rate
em
cc
dramat
decreas
compar
past
educ
public
physician
decreas
consumpt
antibiot
acquisit
immun
resist
strain
chang
preval
emm
type
could
consid
explain
reason
decreas
antibiot
resist
although
antibiot
resist
rate
decreas
cmlsb
type
high
mic
preval
suggest
treatment
failur
children
carri
resist
strain
jinju
korea
analysi
skin
soft
tissu
infect
european
medic
centr
report
sentri
antimicrobi
surveil
program
g
moet
p
strabala
h
sader
fritsch
r
jone
north
liberti
us
object
analys
skin
soft
tissu
infect
ssti
wound
infect
hospit
patient
sentri
program
pathogen
preval
resist
r
variat
european
eu
medic
centr
year
year
program
also
includ
north
america
na
latin
america
la
year
except
method
consecut
isol
pathogenssit
collect
centr
per
year
vari
number
site
year
eu
eu
eu
eu
eu
eu
eu
suscept
test
determin
clsi
formerli
nccl
broth
microdilut
method
interpret
current
breakpoint
result
tabl
year
total
ssti
pathogen
see
tabl
sa
predomin
pathogen
eu
rang
ssti
isol
top
preval
organ
account
isol
year
psa
ec
rank
second
third
respect
combin
enc
ent
rank
fourth
fifth
total
isol
compar
america
mrsa
vre
isol
lower
occurr
rate
eu
rate
monitor
contin
ctzr
psa
cipror
ec
ctzr
ent
ampc
vre
increas
eu
year
conclus
pathogen
preval
ssti
eu
consist
monitor
year
although
sa
mrsa
appear
increas
eu
world
leader
key
r
marker
compar
america
howev
r
rate
evolv
suggest
continu
need
surveil
program
regular
interv
detect
mobil
genet
r
element
object
carbapenem
play
import
role
therapi
pseudomona
aeruginosa
infect
aim
studi
character
molecular
alter
respons
chang
suscept
toward
carbapenem
multiresist
p
aeruginosa
strain
germani
method
multiresist
p
aeruginosa
strain
cystic
fibrosi
non
cystic
fibrosi
patient
collect
german
hospit
strain
show
reduc
suscept
intermedi
resist
din
guidelin
imipenem
piperacillin
ciprofloxacin
gentamicin
clonal
test
use
pfge
pcr
screen
vim
imp
carri
effluxpump
overexpress
detect
use
effluxpump
inhibitor
epi
test
oprd
strain
posit
result
epi
test
effluxpump
repressorgen
mexr
nfxb
sequenc
result
pfge
pattern
reveal
clonal
relationship
among
multiresist
strain
neither
vim
imp
detect
genoand
phenotyp
found
depict
tabl
defect
oprd
gene
caus
prematur
stopcodon
frameshift
found
strain
among
mutat
mexr
nfxb
show
highest
mic
found
rang
mgl
imipenem
meropenem
respect
addit
defect
mexr
gene
intact
nfxb
gene
also
modif
mexr
nfxb
show
nfxb
addit
alter
strain
alter
oprd
mexr
proven
conclus
predomin
mechan
carbapenem
resist
multiresist
p
aeruginosa
strain
germani
loss
oprd
accessori
overexpress
mexaboprm
due
modif
mexr
result
significantli
elev
mic
meropenem
moreov
addit
overexpress
mexcdoprj
lower
mic
imipenem
strain
modif
mexr
elev
mic
imipenem
indic
reduc
express
oprd
accompani
overexpress
mexefoprn
confer
nfxctype
mutant
object
mart
studi
monitor
antimicrobi
resist
trend
ongo
global
antimicrobi
surveil
program
focus
clinic
isol
intraabdomin
infect
iai
aim
subanalysi
assess
antimicrobi
suscept
pattern
among
gramneg
bacilli
differ
region
world
method
total
major
medic
centr
north
america
latin
america
europ
middl
eastafrica
asia
pacif
test
vitro
activ
antimicrobi
agent
commonli
use
treat
iai
consecut
uniqu
aerob
facult
gramneg
bacilli
iai
use
microdilut
techniqu
accord
clsi
guidelin
breakpoint
result
enterobacteriacea
recov
nonenterobacteriacea
recov
patient
studi
worldwid
constitut
total
isol
respect
e
coli
n
klebsiella
spp
n
commonli
isol
enterobacteriacea
pseudomona
spp
n
acinetobact
spp
n
commonli
isol
nonenterobacteriacea
isol
asiapacif
latin
america
gener
resist
enterobacteriacea
nonenterobacteriacea
recov
hour
hospit
suscept
isol
report
conclus
studi
enterobacteriacea
predomin
intraabdomin
isol
recov
h
h
hospit
carbapenem
overal
activ
agent
enterobacteriacea
worldwid
resist
rate
vari
among
geograph
region
asiapacif
latin
america
region
gener
resist
characteris
streptogramin
resist
gene
among
enterococcu
faecium
isol
austrian
anim
husbandri
eisner
g
gorkiewicz
g
feierl
f
dieber
e
marth
j
fer
graz
object
streptogramin
virginiamycin
wide
use
growth
promot
anim
husbandri
european
union
ban
concern
evolv
crossresist
streptogramin
quinupristindalfopristin
use
human
medicin
aim
present
studi
investig
preval
streptogramin
resist
gene
enterococcu
faecium
recov
anim
faecal
specimen
collect
southeast
austria
method
analys
e
faecium
isol
cattl
n
pig
n
poultri
n
presenc
streptogramin
resist
gene
use
select
enterococc
broth
isol
speci
identif
done
basi
gram
stain
catalas
pyrrolidonyl
arylamidas
activ
motil
lancefield
group
antigen
type
strep
apitest
detect
resist
gene
vat
e
vat
erm
b
done
pcr
result
erm
b
gene
encod
macrolid
lincosamin
streptogramin
b
mlsb
resist
found
e
faecium
isol
recov
pig
cattl
none
isol
anim
carri
gene
code
streptogramin
resist
contrari
e
faecium
isol
broiler
specimen
contain
vat
e
gene
one
isol
contain
vat
gene
isol
also
contain
erm
b
gene
conclus
data
indic
use
meanwhil
ban
antimicrobi
feed
addit
virginiamycin
creat
reservoir
streptograminresist
e
faecium
southeast
austrian
poultri
characteris
macrolideresist
streptococcu
pneumonia
isol
russia
object
streptococcu
pneumonia
spn
resist
macrolid
antibiot
continu
major
concern
aim
present
studi
analys
phenotyp
genotyp
characterist
macrolid
resist
spn
isol
method
eighti
one
macrolid
resist
spn
isol
collect
moscow
moscow
suscept
test
perform
accord
clsi
guidelin
macrolid
resist
phenotyp
character
tripledisk
diffus
test
use
erythromycin
clindamycin
rokitamycin
disk
detect
gene
code
resist
macrolid
done
rtpcr
sequenc
qrdr
mutat
perform
levofloxacin
resist
spn
isol
select
isol
analys
mlst
result
tripledisk
test
isol
assign
phenotyp
carri
mefa
gene
one
neg
twenti
eight
isol
cmlsbphenotyp
carri
ermb
mefa
gene
two
isol
ermb
detect
one
isol
neg
gene
imclsb
phenotyp
demonstr
isol
ermb
mefa
gene
detect
ermb
three
isol
nt
demonstr
blunt
zone
inhibit
around
rokitamycin
disk
associ
resist
penicillin
g
tetracyclin
chloramphenicol
cotrimoxazol
observ
spn
isol
respect
nine
multidrug
resist
isol
harbour
mefa
ermb
gene
subject
mlst
among
one
isol
found
share
allel
profil
st
clone
four
isol
singleallel
variant
st
four
isol
new
allel
profil
detect
three
isol
resist
levofloxacin
mic
mgl
two
levofloxacin
mic
mgl
singleallel
variant
substitut
detect
gyra
parc
pare
respect
substitut
detect
parc
pare
one
isol
new
allel
profil
conclus
high
preval
macrolid
resist
spn
harbor
ermb
mefa
gene
observ
moscow
macrolid
resist
associ
resist
group
antibacteri
multidrug
resist
isol
highli
relat
intern
dissemin
multiresist
clone
strain
fluoroquinolon
resist
moscow
singl
locu
variant
clone
occurr
tet
w
gene
clostridium
difficil
clinic
isol
p
mastrantonio
f
barbanti
p
spigaglia
rome
object
investig
presenc
tet
w
tetracyclin
resist
gene
recent
identifi
anaerob
commens
bacteria
anim
human
c
difficil
clinic
isol
method
sever
c
difficil
clinic
isol
differ
italian
hospit
analys
presenc
tet
w
gene
pcr
assay
primer
use
design
tet
w
sequenc
avail
genbank
pcr
fragment
obtain
amplif
sequenc
tet
w
dna
flank
region
also
examin
set
pcr
construct
sequenc
conjug
transposon
butyrivibrio
fibrisolven
element
carri
tet
w
partial
character
far
tet
w
posit
isol
also
examin
tet
gene
presenc
int
tndx
marker
element
respect
element
character
pcr
design
enteroccu
faecali
sequenc
tetracyclin
mic
valu
determin
etest
method
tetracyclin
resist
gene
transfer
evalu
filter
mate
experi
use
c
difficil
strain
recipi
result
tet
w
gene
found
one
isol
c
difficil
also
posit
tet
gene
isol
resist
tetracyclin
mic
mgl
sequenc
analysi
tet
w
pcr
fragment
bp
show
gene
ident
gene
found
clostridium
spp
strain
mitsuokella
multacida
butyrivibrio
fibrisolven
amplif
obtain
primer
design
indic
presenc
differ
genet
support
tet
w
c
difficil
tet
gene
c
difficil
carri
element
show
nucleotid
sequenc
mutat
region
contain
orf
compar
element
e
faecali
conjug
transfer
tet
w
observ
wherea
tet
gene
transfer
recipi
strain
c
difficil
transconjug
resist
tetracyclin
mic
mgl
conclus
result
obtain
studi
demonstr
first
time
presenc
tet
w
gene
clinic
isol
c
difficil
provid
evid
spread
resist
determin
among
gastrointestin
bacteria
macrolid
resist
determin
preval
readili
select
viridan
group
streptococci
among
healthi
norwegian
adult
background
norway
low
preval
antimicrobialresist
bacteria
includ
macrolid
resist
mr
respiratori
tract
pathogen
observ
increas
macrolid
consumpt
norway
lack
knowledg
reservoir
macrolid
resist
determin
among
viridan
group
streptococci
vg
pharyng
flora
object
examin
occurr
select
persist
macrolid
resist
determin
vg
pharyng
flora
healthi
norwegian
adult
treatment
azithromycin
method
throat
sampl
collect
day
treatment
day
month
day
healthi
volunt
sampl
plate
directli
lawn
pdmii
agar
plate
defibrin
blood
erythromycin
etest
strip
photo
use
quantit
comparison
morpholog
differ
coloni
erythromycin
etest
mic
specimen
collect
n
day
n
day
n
total
repres
mr
vgsisol
select
studi
mic
erythromycin
tetracyclin
penicillin
determin
etest
ii
pcr
erm
b
erm
tr
mef
ae
subsequ
sequencetyp
mef
speci
identif
perform
soda
sequenc
result
total
person
carri
low
number
mr
vg
specimen
signific
higher
number
mr
strain
specimen
specimen
carri
low
number
mr
resembl
reduc
suscept
penicillin
observ
isol
tetracyclin
resist
found
mainli
erm
b
posit
strain
mef
ae
posit
domin
erm
b
specimen
sequenc
type
reveal
mef
e
n
mef
n
soda
sequenc
miti
n
orali
n
parasanguini
n
salivariu
n
sanguini
n
conclus
pool
vg
carri
macrolid
resist
determin
normal
pharyng
flora
healthi
adult
readili
select
azithromycin
exposur
mef
e
erm
b
preval
resist
gene
coresist
tetracyclin
frequent
observ
resembl
find
norwegian
clinic
isol
pneumonia
vg
may
provid
pool
resist
bacteria
may
transfer
resist
determin
pathogen
organ
relationship
genotyp
phenotyp
type
pfge
type
among
macrolideresist
streptococcu
pyogen
strain
isol
czech
republ
v
p
l
pragu
cz
object
determin
relationship
phenotyp
genotyp
method
among
erythromycinresist
pyogen
strain
method
total
clinic
isol
pyogen
resist
erythromycin
collect
microbiolog
laboratori
erythromycin
suscept
test
disk
diffus
method
strain
inhibit
zone
mm
around
erythromycin
disk
lg
sent
nation
refer
laboratori
antibiot
nrl
presenc
mlsb
resist
gene
ermtr
ermb
mefa
test
pcr
serotyp
determin
randomli
select
repres
phenotyp
n
pfge
type
determin
strain
year
n
result
rate
preval
phenotyp
constitut
mlsb
resist
year
respect
major
preval
type
among
analys
strain
serotyp
gene
ermb
frequent
result
pcr
method
highli
congruent
observ
phenotyp
resist
pfge
pattern
strain
constitut
mlsb
resist
highli
ident
conclus
phenotyp
constitut
induc
resist
mlsb
antibiot
found
ermtr
ermb
mefa
gene
detect
among
analys
strain
serotyp
identifi
mainli
preval
collect
major
strain
harbour
serotyp
constitut
resist
macrolid
studi
show
close
relationship
among
genotyp
type
specif
resistotyp
phenotyp
pfge
type
object
sinc
recognit
transfer
clindamycin
tetracyclin
resist
bacteroid
undertaken
us
nation
survey
suscept
b
fragili
group
analys
emerg
resist
trend
sinc
speci
routin
test
suscept
hospit
clinic
laboratori
method
agar
dilut
mic
determin
isol
b
fragili
relat
speci
geograph
divers
center
us
antibiot
includ
carbapenem
blactamblactamas
inhibitor
quinolon
tetracyclin
clindamycin
metronidazol
chloramphenicol
glycylcyclin
linezolid
isol
ident
confirm
api
result
analysi
resist
trend
show
decreas
geometr
mean
mic
geomic
imipenem
mcgml
mcgml
p
meropenem
mcgml
p
bacteroid
speci
ertapenem
geomic
remain
unchang
mcg
ml
blactamas
inhibitor
piperacillintazobactam
geomic
declin
mcgml
mcgml
p
ampicillinsulbactam
geomic
chang
isol
resist
carbapenem
blactamas
inhibitor
combin
clindamycin
resist
increas
especi
b
fragili
b
ovatu
b
thetaiotaomicron
p
among
quinolon
resist
bacteroid
moxifloxacin
increas
geomic
went
mcgml
mcgml
p
b
fragili
remain
sensit
bacteroid
speci
moxifloxacin
although
approxim
stain
mic
mcgml
tigecyclin
suscept
test
year
chang
first
confirm
metronidazoleresist
isol
mic
mcgml
obtain
us
note
none
note
conclus
improv
suscept
bacteroid
speci
carbapenem
blactamas
inhibitor
combin
unexplain
signific
clindamycin
resist
continu
increas
especi
b
fragili
moxifloxacin
suscept
non
fragili
speci
show
major
strain
resist
first
metronidazol
resist
isol
report
us
sinc
resist
trend
associ
speci
differenti
within
speci
extrem
import
sinc
may
impact
choic
antimicrobi
agent
treatment
infect
caus
group
anaerob
observ
durat
nasopharyng
carriag
penicillinresist
pneumococci
relat
age
serogroup
p
geli
l
gberg
h
ringberg
e
meland
lipsitch
k
ekdahl
solna
lund
stockholm
se
boston
us
background
object
knowledg
durat
pneumococc
carriag
vari
age
serogroup
essenti
understand
immun
carriag
aris
throughout
cours
life
design
appropri
model
effect
vaccin
public
health
initi
aim
reduc
pneumococc
transmiss
commun
use
data
ongo
swedish
intervent
project
durat
nasopharyng
carriag
penicillinresist
pneumococci
mic
pcg
mgl
stratifi
serogroup
age
carrier
estim
method
mean
durat
correspond
confid
interv
estim
fit
gamma
distribut
observ
durat
carriag
serogroup
age
stratum
result
mean
durat
carriag
case
day
ci
children
age
year
carri
prp
significantli
longer
period
day
ci
compar
older
individu
day
ci
also
differ
within
group
case
age
year
durat
carriag
becam
significantli
shorter
year
older
case
serogroup
carri
significantli
shorter
period
compar
serogroup
serogroup
also
significantli
shorter
carriag
durat
compar
serogroup
case
year
case
year
older
signific
differ
carriag
durat
differ
age
serogroup
could
note
conclus
even
though
estim
cover
correct
censor
carriag
durat
therefor
yield
estim
total
length
carriag
result
highlight
import
take
serogroup
age
explor
molecular
basi
differ
phenotyp
salmonella
enteritidi
type
phage
n
delapp
morri
cormican
galway
ie
object
salmonella
enteritidi
phage
tie
scheme
laboratori
enter
pathogen
health
protect
agenc
uk
wide
use
method
subtyp
import
pathogen
method
rapid
highli
discriminatori
interpret
result
subject
type
phage
central
method
well
characteris
complet
sequenc
data
avail
salmonella
typhimurium
podoviru
phage
method
type
phage
propag
enteritidi
phage
visualis
electron
microscopi
phage
dna
extract
digest
hindiii
consensu
pcr
primer
design
base
sequenc
typhimurium
phage
addit
primer
design
base
sequenc
enterititidi
type
phage
siphoviru
amplif
sequenc
dna
probe
hybridis
variou
phage
gene
perform
use
standard
techniqu
result
em
type
phage
compris
podovirida
phage
siphovirida
phage
myovirida
phage
digest
hindiii
subdivid
morphotyp
group
podovirida
contain
gene
homolog
siphovirida
contain
gene
homolog
sequenc
enteritidi
type
phage
sequenc
variat
detect
podoviru
siphoviru
gene
howev
case
phage
differ
phenotyp
differ
detect
hindiii
digest
pattern
partial
sequenc
conclus
enteritidi
type
phage
set
compris
distinct
phage
morphotyp
instanc
distinct
phage
contribut
differenti
enteritidi
phage
type
dna
sequenc
variat
detect
variat
phage
type
reaction
may
part
due
epigenet
differ
type
phage
eg
due
methyl
phage
dna
salmonella
enteritidi
type
phage
biolog
could
provid
model
develop
approach
phage
therapi
tularemia
zoonot
bacteri
diseas
caus
agent
francisella
tularensi
spread
human
direct
contact
infect
rodent
inhal
ingest
contamin
water
arthropod
bite
endem
region
outbreak
occur
frequent
wherea
nearbi
rural
part
may
complet
free
present
two
case
tularemia
non
endem
region
turkey
case
year
old
femal
patient
refer
tertiari
hospit
due
swollen
neck
month
admiss
beta
lactam
antibiot
prescrib
tonsilopharyngitidi
complaint
continu
admit
hospit
suffer
fever
sore
throat
neck
pain
palpabl
painful
cervic
lymphadenopathi
suppur
leukocytosi
elev
c
reactiv
protein
predomin
screen
lymphadenopathi
detect
elsewher
examin
cytomegaloviru
epstein
barr
viru
brucellosi
neg
fine
needl
aspir
neck
neg
consid
malign
cultur
neg
routin
bacteriolog
examin
microagglutin
test
tularemia
posit
decid
treat
gentamycin
day
treatment
cervic
lymphadenopathi
becam
small
leukocyt
count
c
reactiv
protein
level
reach
normal
rang
case
year
old
femal
patient
refer
univers
hospit
due
cervic
lymphadenopathi
fever
sore
throat
admiss
beta
lactam
antibiot
prescrib
week
appar
benefit
detect
palpabl
fistul
cervic
lymphdenopathi
drainag
examin
microscop
cultur
bacteria
mycobacteria
fungi
routin
cultur
microorgan
grown
fine
needl
aspir
done
report
suppur
granulamat
lympaden
examin
tularemia
cat
scratch
diseas
microaggltun
test
tularemia
posit
streptomycin
given
day
excis
lymphadenopathi
done
complic
recurr
occur
result
patient
appli
us
non
endem
differ
region
turkey
known
insect
bite
histori
diagnos
serolog
test
conclus
differenti
diagnosi
tonsillopharyngitidi
tularemia
also
must
consid
non
endem
region
tularaemia
present
tonsillopharyng
cervic
lymphaden
two
case
report
b
kandemir
erayman
bitirgen
e
turk
ariba
ac
inkaya
guler
konya
tr
tularemia
zoonot
diseas
caus
francisella
tularensi
francisella
tularensi
transmit
human
direct
contact
ingest
infect
anim
tissu
bite
infect
arthropod
consumpt
contamin
food
water
inhal
aerosol
bacteria
report
describ
two
case
oropharyng
tularemia
present
tonsillopharyng
cervic
lymphaden
case
year
old
woman
multipl
cervic
lymphaden
admit
clinic
complaint
start
month
ago
sign
symptom
tonsillopharyng
receiv
non
specif
treatment
ampicillinsulbactam
ten
day
later
cervic
lymph
node
appear
diagnosi
made
serolog
antimicrobi
therapi
streptomycin
g
im
given
fourteen
day
patient
recov
complet
case
ii
year
old
girl
multipl
cervic
lymphaden
admit
hospit
complaint
start
month
ago
throat
ach
multipl
cervic
lymphaden
appear
admit
patient
clinic
diagnos
tularemia
antimicrobi
therapi
streptomycin
g
imdoxycycilin
mg
given
four
week
clinic
respons
achiev
patient
admit
hospit
surgic
drainag
perform
treatment
tularemia
prolong
patient
final
recov
end
nine
week
therapi
conclud
earli
diagnosi
treatment
tularemia
import
patient
may
benefit
surgic
drainag
prolong
therapi
case
nonclostridi
crepit
cellul
due
escherichia
coli
c
ayaz
ulug
mk
celen
mf
geyik
hosoglu
diyarbakir
tr
object
condit
caus
ga
form
bacteria
involv
skin
either
extens
deeper
structur
origin
infect
abdomin
wound
perian
diseas
oper
incis
becom
secondarili
infect
track
gasform
organ
deeper
site
infect
may
also
present
crepit
cellul
without
break
skin
diabet
like
acquir
infect
especi
lower
extremit
among
bacteria
isol
anaerob
organ
bacteriod
anaerob
streptococci
coliform
bacteria
especi
escherichia
coli
klebsiella
reason
report
case
nonclostridi
crepit
cellul
due
escherichia
coli
case
year
old
man
previous
healthi
come
fever
pain
oedema
erythema
crepit
limit
movement
right
lower
extrem
histori
complaint
week
ago
perian
abscess
develop
time
draing
spontan
day
later
complaint
compris
day
durat
physic
examin
temperatur
puls
rate
minut
respiratori
rate
blood
pressur
mmhg
laboratori
evalu
show
haemoglobin
gdl
leucocyt
count
neutrophil
serum
electrolyt
renal
liver
function
test
within
normal
limit
c
reactiv
protein
elev
mgdl
esr
mmh
escherichia
coli
isol
wound
blood
cultur
treat
initi
ampicilinsulbactam
gday
requir
attempt
even
optim
surgic
medic
therapi
die
third
day
treatment
septic
shock
conclus
onset
gener
gradual
usual
mild
local
pain
system
toxic
allow
clinic
differenti
fulmin
clostridi
myonecrosi
surgic
approach
aggress
tailor
specif
underli
caus
infect
antibiot
therapi
direct
mix
aerobicanaerob
flora
cultur
report
avail
case
iliopsoa
abscess
due
pseudomona
aeruginosa
object
pyogen
psoa
abscess
rare
lifethreaten
infect
result
primari
suppur
secondari
spread
infect
adjac
structur
primari
iliopsoa
abscess
occur
probabl
result
hematogen
spread
infecti
process
occult
sourc
bodi
primari
iliopsoa
abscess
occur
diabetu
mellitu
intraven
drug
abus
aid
renal
failur
immunosupress
ultrasound
diagnost
case
comput
tomographi
done
definit
diagnosi
consid
gold
standard
stapylococcu
aureu
caus
organ
patient
primari
iliopsoa
abscess
pyogen
psoa
abscess
caus
pseudomona
aeruginosa
uncommon
reason
report
case
case
previous
well
year
old
woman
present
month
histori
right
loin
groin
pain
limp
limit
hip
movement
fever
nausea
diabetu
mellitu
patient
year
physic
examin
temperatur
puls
rate
respiratori
rate
blood
pressur
mmhg
examin
respiratori
system
cardiovascular
system
abdomen
found
normal
laboratori
investig
reveal
total
leucocyt
count
polymorph
c
reactiv
protein
elev
mgdl
esr
mmh
serum
electrolyt
renal
liver
function
test
within
normal
limit
serum
glucos
level
elev
mgdl
blood
cultur
steril
abscess
cultur
yield
pseudomona
aeruginosa
taken
surgeri
treat
imipenem
g
day
amicasin
gday
requir
surgic
drainag
treat
follow
day
discharg
end
treatment
conclus
patient
treatment
involv
use
appropri
antibiot
along
drainag
abscess
adequ
knowledg
caus
organ
guid
initi
choic
antibiot
depend
result
abscess
fluid
cultur
sensit
adjust
made
percutan
drainag
surgic
drainag
may
done
conclus
earli
recognit
empir
antimicrobi
coverag
aggress
drainag
debriment
indic
patient
cervic
lymphaden
diabet
woman
f
azap
h
erdi
sanli
l
ankara
kirikkal
tr
object
rhodococcu
equi
infect
commonli
seen
immunocompromis
patient
exposur
domest
anim
hors
pig
may
play
role
case
two
third
r
equi
infect
immunocompromis
report
hiv
infect
patient
rest
divid
transplant
recipi
immunosupress
medic
kind
immunosupress
clinic
pictur
present
pulmonari
infect
patient
report
rare
case
cervic
lymphaden
diabet
women
due
r
equi
case
sixtyyearold
diabet
woman
admit
complaint
fever
right
cervic
erythemat
swell
tender
warmth
physic
examin
inflamm
begin
right
submandibular
region
descend
upper
chest
detect
tender
mass
cm
palpat
right
cervic
region
ampicillinsulbactam
gday
given
empric
week
improv
ct
scan
neck
show
conglomer
lymphadenopathi
extend
submandibular
area
supraclaviculari
region
cm
size
mass
began
fluctuat
cc
abscess
materi
drain
surgic
gram
stain
purul
materi
show
polymorphonuclear
leukocyt
pleomorph
gram
posit
coccobacilli
cultur
materi
grew
r
equi
therapi
chang
teicoplanin
ciprofloxacin
combin
surgic
care
wound
antisept
perform
month
intreven
medic
therapi
chang
oral
rout
roxythromycin
ciprofloxacin
continu
month
complet
resolut
conclus
increas
awar
improv
laboratori
techniqu
help
earli
diagnosi
rhodococc
infect
time
diagnosi
import
microorgan
usual
resist
penicillin
g
oxacillin
ampicillin
carbenicillin
cefazolin
use
least
one
antibiot
intracellular
activ
necessari
treatment
r
equi
infect
empir
two
drug
regimen
erythromycin
rifampin
andor
ciprofloxacin
recommend
object
analys
featur
spondylodisc
sd
clinic
present
commonest
diagnost
method
kind
treatment
appli
accord
differ
group
studi
method
retrospect
descript
studi
take
place
amongst
patient
diagnos
sd
till
case
studi
presenc
underli
diseas
primari
infecti
sourc
prior
month
way
symptom
start
locat
diagnost
method
treatment
evolut
compar
differ
aetiolog
result
patient
sd
pyogen
sd
spontan
sd
sd
spinal
surgeri
patient
tubercul
sd
men
year
mean
patient
postop
sd
youngest
mean
p
underli
diseas
found
patient
mainli
postop
sd
case
p
episod
previou
bacteremia
infecti
sourc
found
respect
patient
spontan
pyogen
sd
significantli
higher
surgic
sd
bacteremia
infecti
sourc
p
common
present
symptom
back
pain
neurolog
deficit
frank
fever
occur
case
frequent
spontan
sd
postop
sd
tubercul
sd
p
leukocytosi
found
patient
postop
sd
present
lowest
level
esr
p
aureu
frequent
bacteria
isol
pyogen
spontan
sd
coagulas
neg
staphylococci
surgic
sd
lumbosacr
local
detect
spontan
pyogen
sd
postop
sd
tubercul
sd
predomin
dorsolumbar
region
paravertebr
abscess
format
observ
pyogen
sd
tubercul
sd
p
surgic
treatment
requir
tubercul
sd
pyogen
sd
p
outcom
patient
spontan
sd
wors
sequela
patient
surgic
sd
tubercul
sd
p
conclus
spontan
sd
frequent
occur
mainli
patient
suffer
underli
diseas
nearli
patient
pain
accompani
fever
lumbar
zone
frequent
locat
major
patient
complet
resolut
symptom
medic
treatment
background
ethiopathogenesi
cn
abscess
includ
broad
spectrum
pathogen
predispos
condit
polymicrobi
flora
quit
frequent
event
capnocytophaga
spp
includ
fastidi
gramneg
organ
usual
underestim
common
clinic
practic
poorli
test
vitro
antimicrobi
suscept
surprisingli
also
agent
usual
activ
gramposit
pathogen
demonstr
efficaci
capnocytophaga
spp
ie
erythromycin
rifampin
tetracyclin
cotrimoxazol
chloramphenicol
glycopeptid
usual
respons
anecdot
episod
cn
infect
mening
brain
abscess
subdur
empyema
method
result
fourth
case
report
capnocytophaga
spp
brain
abscess
herewith
report
probabl
origin
recent
cat
bite
mandibular
granuloma
suspect
due
lack
clinic
neuroradiolog
respons
neurosurg
debrid
associ
therapi
includ
imipenem
amikacin
clindamycin
fluconazol
empir
administr
linezolid
mgday
attempt
rapidli
favor
clinic
microbiolog
neuroradiolog
respons
achiev
notwithstand
identif
capnocytophaga
spp
sole
microorgan
yield
purul
drainag
cn
abscess
patient
multipl
risk
factor
recent
surgeri
expect
suffer
polymicrobi
cn
infect
due
favour
cn
penetr
dual
mode
administr
iv
oral
linezolid
may
repres
altern
option
event
cn
diseas
born
numer
risk
factor
suspect
polymicrobi
origin
especi
lack
respons
first
therapeut
attempt
concern
manag
cn
abscess
role
microorgan
unpredict
sensit
profil
remain
concern
chemotherapi
direct
also
potenti
multiresist
organ
consid
also
relev
limit
given
often
poor
cn
penetr
activ
glycopeptid
agent
limit
compar
linezolid
aetiolog
antimicrobi
resist
profil
purul
mening
studi
carri
hospit
infecti
diseas
algier
object
bacteri
mening
seriou
clinic
medicoleg
consequ
manag
incorrect
mening
protocol
recent
publish
british
infect
societymening
research
foundat
wide
dissemin
institut
local
guidelin
also
avail
hospit
intranet
emerg
depart
acut
medic
admiss
ward
studi
investig
level
understand
mening
knowledg
guidelin
medic
staff
differ
grade
work
emerg
depart
acut
medic
admiss
unit
larg
teach
emerg
hospit
method
medic
staff
interview
face
face
ask
seri
question
manag
mening
result
store
databas
respons
analys
result
gener
knowledg
mening
variabl
although
knew
bacteri
mening
notifi
diseas
knew
procedur
inform
health
protect
agenc
would
notifi
viral
mening
respond
awar
guidelin
could
view
hospit
intranet
correctli
identifi
indic
caution
lumbar
punctur
although
major
recognis
need
urgent
administr
antibiot
would
omit
antibiot
assess
lumbar
punctur
result
awar
need
consid
ad
ampicillin
cover
listeria
patient
year
age
uncertainti
manag
patient
penicillin
resist
conclus
although
protocol
guidelin
mening
produc
easili
access
major
medic
staff
uncertain
access
utilis
inform
level
knowledg
expertis
manag
mening
amongst
medic
staff
work
e
acut
medic
unit
poor
need
educ
improv
patient
manag
guidelin
valu
dissemin
frontlin
medic
staff
object
aim
studi
evalu
preval
penicillin
resist
multidrug
resist
pneumococci
isol
streptococcu
pneumonia
mening
method
retrospect
studi
carri
clinic
record
januari
octob
among
csf
sampl
pneumococc
ethiolog
confirm
posit
cultur
latex
agglutin
antibiot
suscept
test
perform
disk
diffus
method
accord
nccl
standard
isol
pneumococci
oxacillin
zone
side
mm
suscept
mic
microgml
penicillin
mm
mic
determin
e
test
result
isol
patient
found
penicillinresist
prp
multidrug
resistantand
penicillin
suscept
resist
drug
abrupt
onset
diseas
found
prp
patient
nonprp
one
chest
x
ray
pulmonari
determin
found
prp
patient
nonprp
one
sixtysix
per
cent
prp
patient
nonprp
one
prior
hospit
non
prp
patient
posit
blood
cultur
antibiot
switch
made
case
prp
isol
case
non
prp
one
overal
rate
mortal
prp
patient
nonprp
one
conclus
nonprp
isol
preval
ethiolog
pneumonia
mening
non
prp
strain
develop
drug
resist
prp
strain
multi
drug
resist
prp
meningit
evolv
hospitalrel
patholog
abrupt
onset
frequent
associ
pulmonari
determin
higher
mortal
rate
background
although
vaccin
strategi
shift
age
distribut
mening
older
age
group
studi
specif
examin
bacteri
mening
older
adult
method
octob
april
prospect
includ
episod
communityacquir
bacteri
mening
confirm
cultur
cerebrospin
fluid
occur
patient
age
year
dichotom
cohort
respect
age
patient
age
year
defin
older
adult
patient
age
year
younger
adult
predictor
unfavour
outcom
defin
score
glasgow
outcom
scale
determin
logist
regress
test
statist
interact
age
group
potenti
prognost
factor
ad
multipl
interact
term
model
mannwhitney
u
test
chisquar
test
use
identifi
differ
group
result
episod
occur
older
adult
episod
younger
adult
streptococcu
pneumonia
common
pathogen
older
adult
mening
younger
adult
caus
neisseria
meningitidi
pneumonia
episod
respect
older
adult
like
present
classic
triad
bacteri
mening
fever
neck
stiff
alter
mental
statu
younger
adult
versu
p
prognost
valu
independ
risk
factor
unfavour
outcom
similar
age
group
older
adult
complic
clinic
cours
result
higher
mortal
rate
younger
adult
versu
p
sepsi
common
caus
death
age
group
older
adult
versu
younger
adult
fig
wherea
older
adult
tend
die
often
due
cardiorespiratori
failur
versu
p
younger
adult
often
die
due
brain
herniat
versu
p
conclus
bacteri
mening
older
adult
associ
high
morbid
mortal
rate
elderli
patient
often
present
classic
symptom
pneumonia
common
pathogen
within
age
group
wherea
older
adult
often
die
due
cardiorespiratori
failur
younger
adult
often
die
due
brain
herniat
incid
serogroup
penicillin
suscept
neisseria
meningitidi
isol
object
aim
studi
analys
serogroup
incid
penicillin
suscept
n
meningitidi
spanish
epidem
outbreak
year
public
health
servic
decid
massiv
vaccin
sanitari
area
galicia
northwest
spain
inhabit
autum
inclus
vaccin
n
meningitidi
serogroup
c
vaccin
programm
method
retrospect
studi
case
meningococc
diseas
confirm
cultur
andor
pcr
health
care
area
santiago
de
compostela
galicia
result
period
identifi
meningococc
diseas
episod
microbiolog
diagnosi
b
c
respect
serogroup
c
isol
serogroup
incid
almost
b
c
increas
b
serogroup
case
detect
frecuent
phenotyp
c
serogroup
period
increas
penicillin
suscept
observ
b
serogroup
isol
suscept
c
serogroup
conclus
b
serogroup
frecuent
isol
period
except
year
strain
caus
epidem
outbreak
isol
sinc
health
care
area
serotyp
isol
first
time
sinc
uniqu
serotyp
isol
c
serogroup
incid
rate
c
serogroup
chang
decreas
caus
drop
incid
rate
youngest
group
year
year
incid
rate
b
serogroup
year
modifi
fouryear
retrospect
analysi
infect
endocard
belgian
univers
hospit
n
de
visscher
b
delaer
b
krug
glupczynski
yvoir
object
establish
epidemiolog
infect
endocard
ie
determin
prognost
factor
advers
outcom
patient
admit
univers
hospit
cardiovascular
surgeri
depart
method
clinic
laboratori
featur
consecut
adult
patient
definit
diagnosi
ie
duke
criteria
evalu
retrospect
two
infecti
diseas
physician
basi
clinic
data
chart
microbiolog
laboratori
result
patient
men
women
present
definit
diagnosi
ie
mean
age
yr
case
nativ
valv
endocard
nve
prosthet
valv
endocard
pve
patient
nve
underli
valvular
abnorm
bicuspidi
mitral
prolapsu
regurgit
other
ten
case
pve
lateonset
episod
year
surgeri
global
mortal
pt
includ
patient
still
antibiot
therapi
higher
mortal
rate
observ
pve
nve
overal
pt
underw
surgeri
mean
day
follow
admiss
valvular
replac
contraind
pt
critic
statu
andor
major
comorbid
distribut
isol
pathogen
streptococci
case
includ
case
bovi
aureu
case
includ
mrsa
enterococci
case
miscellan
case
affect
valv
aortic
mitral
tricuspid
aortic
mitral
mitral
tricuspid
aortic
mitral
tricuspid
high
mortal
rate
observ
aureu
ie
especi
subgroup
patient
pve
pt
mortal
rate
patient
ie
episod
caus
streptococci
amount
pt
clinic
microbiolog
infect
volum
supplement
relat
n
previou
surgeri
n
relat
urinari
digest
tract
procedur
patient
illeg
substanc
abus
frequent
predispos
acquir
cardiac
condit
nativ
valv
endocard
degen
valvular
diseas
twelv
percentag
n
prior
ie
frequent
predispos
congenit
cardiac
condit
bicuspid
aortic
valv
n
n
predispos
heart
diseas
discern
caus
microorgan
includ
staphylococci
n
aureu
n
con
n
streptococci
n
viridan
n
bovi
n
enterococci
n
pathogen
n
cultur
neg
ie
report
n
communityacquir
nosocomi
ie
aureu
frequent
caus
agent
twentythre
percentag
methicillinresist
aureu
viridan
ie
mainli
communityacquir
enterococc
ie
nearli
equal
distribut
commun
nosocomi
origin
conclus
compar
older
seri
observ
high
proport
nosocomi
ie
prosthet
valv
ie
aureu
e
faecali
preval
caus
microorgan
enterococci
nearli
equal
distribut
commun
nosocomi
origin
suggest
nosocomi
enterococcemia
ad
major
criterion
propos
aureu
role
aminoglycosid
combin
betalactam
treatment
bacteri
endocard
metaanalysi
compar
trial
falaga
matthaiou
p
papastamataki
blizioti
athen
gr
object
addit
aminoglycosid
betalactam
treatment
patient
infect
endocard
support
mainli
data
laboratori
anim
studi
sought
review
evid
avail
compar
clinic
trial
regard
role
aminoglycosid
combin
betalactam
treatment
bacteri
endocard
due
gramposit
cocci
method
studi
metaanalysi
retriev
search
pubm
databas
refer
relev
articl
includ
studi
trial
provid
compar
data
regard
effect
treatment
andor
mortal
patient
receiv
monotherapi
betalactam
betalactamaminoglycosid
combin
therapi
two
independ
review
perform
literatur
search
studi
select
extract
data
relev
studi
publish
english
period
result
clinic
trial
compar
betalactam
monotherapi
betalactamaminoglycosid
combin
therapi
treatment
enterococc
endocard
found
perform
metaanalysi
avail
compar
trial
random
control
trial
compar
prospect
trial
includ
patient
bacteri
endocard
nativ
valv
due
staphylococcu
aureu
studi
streptococcu
viridan
studi
statist
signific
differ
compar
arm
regard
mortal
ci
treatment
success
ci
treatment
success
without
surgeri
relaps
endocard
nephrotox
less
common
betalactam
monotherapi
arm
compar
betalactamaminoglycosid
combin
therapi
ci
p
conclus
limit
evid
avail
prospect
compar
studi
offer
support
addit
aminoglycosid
betalactam
treatment
patient
endocard
due
gramposit
cocci
larg
multicent
random
control
trial
may
necessari
reach
definit
conclus
issu
outpati
antimicrobi
therapi
infect
endocard
singlecentr
experi
object
evalu
characterist
outcom
infect
endocard
ie
patient
includ
outpati
antimicrobi
therapi
opat
program
method
januari
may
patient
receiv
opat
therapi
ie
prospect
evalu
inclus
opat
program
requir
clinic
stabil
agreement
patient
activ
drug
addict
contraind
inclus
antibiot
treatment
administ
bolu
oncedaili
antibiot
regimen
use
caddlegaci
tm
plu
deltec
inc
st
paul
usa
portabl
infus
system
either
continu
intermittentprogram
bolu
infus
result
includ
patient
male
mean
age
year
old
sd
year
diagnost
ie
definit
case
patholog
diagnosi
probabl
possibl
mostli
case
communityacquir
ie
mitral
valv
ie
frequent
anatom
site
involv
follow
aortic
nativevalv
ie
repres
major
case
prostheticvalv
pacemak
lead
ie
viridan
group
streptococci
frequent
isol
patient
case
bovi
ie
eleven
patient
aureu
ie
time
diagnosi
patient
valv
ruptur
patient
periannular
abscess
total
patient
requir
surgic
intervent
ie
valvular
replac
associ
aortic
graft
pacemak
extract
aortic
graft
major
patient
receiv
outpati
monotherapi
frequent
antibiot
use
ceftriaxon
case
follow
cloxacillin
gentamycin
vancomycin
teicoplanin
ampicillin
antibiot
patient
vascular
access
perifericallyinsert
venou
central
cathet
use
portabl
infus
system
twelv
patient
complic
opat
requir
hospit
readmiss
could
return
opat
program
three
patient
fatal
outcom
death
admiss
relat
ie
complic
mean
durat
opat
day
per
patient
global
suppos
day
hospit
admiss
save
conclus
opat
ie
good
therapeut
option
ie
stabl
patient
procedur
repres
consider
amount
hospit
admiss
save
improv
also
patient
wellb
must
take
account
treatment
diseas
object
botul
neuroparalyt
ill
caus
toxin
produc
clostridium
botulinum
food
born
botul
potenti
lethal
neuroparalyt
diseas
caus
ingest
preform
toxin
clinic
ill
characteris
cranial
nerv
paralysi
follow
descend
flaccid
muscl
paralysi
articl
report
case
seri
includ
famili
group
type
e
botul
ingest
iranian
tradit
soup
method
januari
patient
famili
group
develop
clinic
manifest
botul
hour
follow
ingest
tradit
soup
main
clinic
present
sever
weak
case
lethargi
case
sign
symptom
blur
vision
fix
dilat
pupil
diplopia
dri
mouth
decreas
gag
reflex
base
clinic
find
patient
receiv
monoval
antitoxin
b
c
stool
gastric
fluid
serum
sampl
sent
toxicolog
evalu
use
standard
mous
bioassay
result
type
e
toxin
detect
stool
serum
sampl
one
patient
patient
recov
discharg
one
week
admiss
conclus
studi
confirm
prompt
administr
antitoxin
prevent
progress
diseas
base
clinic
judgment
also
may
life
save
case
seri
studi
observ
short
incub
period
hour
type
e
botul
outbreak
group
g
streptococc
pharyng
among
hospit
personnel
consid
foodborn
n
karabib
gurbuz
erta
karahan
e
aykut
arca
zc
karahan
teke
ankara
tr
introduct
foodborn
outbreak
streptococc
pharyng
rel
rare
report
group
streptococci
main
caus
agent
epidem
caus
group
g
streptococci
publish
describ
outbreak
group
g
streptococc
pharyng
occur
among
staff
teach
hospit
ankarath
outbreak
explos
outbreak
pharyng
occur
mainli
among
staff
work
certain
depart
ie
intens
care
unit
oper
room
rkiy
ksek
ihtisa
teach
hospit
januari
method
total
cater
firm
personel
throat
cultur
evalu
day
bh
strain
isol
first
second
day
respect
presumpt
identif
nbacitracin
trimethoprimsulfametoxazol
disk
diffus
test
show
strain
nongroup
strain
group
streptococci
definit
group
streptococcu
group
kit
avipathstrep
omega
strain
found
lancefield
group
strain
found
group
streptococci
ga
one
ga
strain
isol
cater
staff
first
day
two
isol
two
health
care
personnel
second
day
outbreak
cater
firm
personel
found
posit
group
g
streptococci
bh
test
found
sensit
penicillin
g
erythromycin
agar
disc
diffus
method
conclus
configur
epidem
curv
suggest
common
sourc
exposur
sinc
respiratori
spread
streptococci
rapid
fashion
would
highli
unlik
posit
throat
cultur
staff
cater
firm
provid
food
servic
hospit
work
depart
outbreak
occur
consid
outbreak
might
foodborn
prompt
treatment
penicillin
ill
personnel
holiday
come
consequ
januari
termin
outbreak
strain
cryopreserv
type
studiesw
type
strain
puls
field
gel
electophoresi
pfge
digest
smai
restrict
endonucleas
initi
result
show
strain
origin
outbreak
acut
gastroenter
air
forc
base
western
greec
e
jelastopulu
constantinidi
kolokotroni
venieri
g
komnin
c
bantia
patra
andravida
gr
object
septemb
oper
train
day
air
forc
base
western
greec
soldier
staff
experienc
outbreak
acut
gastroenter
purpos
studi
determin
caus
outbreak
develop
control
measur
method
follow
assess
descript
epidemiolog
casecontrol
analyt
approach
util
randomli
select
case
control
patient
complet
questionnair
pertain
presenc
sever
gastrointestin
disturb
date
time
symptom
onset
consumpt
food
item
serv
base
impli
train
day
adequ
questionnair
administ
control
odd
ratio
calcul
statist
signific
determin
use
test
sampl
food
item
collect
bacteriolog
examin
result
overal
attack
rate
least
among
approxim
attende
outbreak
start
abruptli
late
afternoon
septemb
peak
midnight
end
hour
later
interview
analysi
establish
lunch
beef
macaroni
tomato
sauc
grate
chees
consum
sever
hour
prior
onset
symptom
affect
militari
personnel
like
sourc
outbreak
strong
statist
associ
one
subject
eat
lunch
among
symptom
promin
wateri
diarrhoea
abdomin
pain
rel
indic
vomit
nausea
mean
incub
period
h
bacteriolog
examin
staphylococcu
aureu
detect
sampl
raw
beef
two
sampl
grate
chees
restchees
lunch
unopen
packag
conclus
short
incub
period
abrupt
onset
symptomatolog
short
selflimit
natur
ill
suggest
gastroenter
caus
enterotoxinproduc
bacterium
aureu
consid
like
caus
although
mortal
longerterm
morbid
uncommon
food
poison
caus
enterotoxinproduc
bacteria
outbreak
highlight
capac
caus
short
term
moderatelysever
ill
young
healthi
popul
underscor
need
proper
food
handl
practic
reinforc
import
appropri
microbiolog
specimen
collect
case
well
public
health
import
time
notif
outbreak
occurr
characteris
antimicrobi
resist
pattern
staphylococcu
aureu
strain
isol
dairi
product
southern
itali
g
la
salandra
e
goffredo
c
pedarra
mc
nardella
parisi
dambrosio
nc
quaglia
gv
celano
g
normanno
foggia
valenzano
object
ingest
food
contamin
enterotoxin
se
synthes
staphylococcu
aureu
respons
one
common
foodborn
diseas
staphylococc
food
poisoningsfp
sinc
aureu
often
involv
case
subclin
mastiti
rumin
milk
may
result
contamin
infact
dairi
product
frequent
relat
case
sfp
expeci
area
character
high
level
consumpt
product
consequ
activ
microbiolog
surveil
need
order
control
risk
sfp
allow
improv
public
health
standard
aureu
also
show
larg
antimicrobi
resist
pattern
work
report
result
survey
conduct
occurr
aureu
dairi
product
apulia
region
southern
itali
furthermor
isol
strain
character
order
determin
abil
synthes
se
evalu
antimicrobi
resist
pattern
method
sampl
dairi
product
milk
chees
mozzarella
chees
ricotta
chees
analys
detect
aureu
isol
strain
test
detect
se
use
revers
passiv
latex
agglutin
test
sea
sed
submit
pcr
detect
enta
entb
entc
entd
ent
gene
furthermor
strain
test
suscept
ampicillin
tetracyclin
gentamicin
eritromycin
enrofloxacin
cotrimoxazol
teicoplanin
vancomycin
agar
diffus
method
result
sampl
analys
result
contamin
aureu
among
recogn
enterotoxigen
strain
sampl
milk
sampl
mozzarella
chees
sampl
chees
ovin
milk
sampl
chees
strain
test
one
per
posit
sampl
show
antimicrobi
resist
properti
none
resist
teicoplanin
vancomicin
conclus
result
obtain
survey
show
milk
dairi
product
southern
itali
frequent
contamin
enterotoxigen
strain
aureu
highlight
need
implement
strict
hygien
control
measur
along
food
chain
order
decreas
risk
spf
furthermor
presenc
antimicrobialresist
strain
aureu
food
may
consid
sourc
communityacquir
infect
direct
risk
transfer
antimicrobialresist
intestin
human
microflora
object
infect
account
onethird
case
fever
unknown
origin
fuo
remain
major
diagnost
challeng
recent
fdg
positron
emiss
tomographi
pet
enter
field
clinic
infecti
diseas
fdg
accumul
tissu
high
rate
glycolysi
present
malign
cell
activ
leukocyt
aim
prospect
multicentr
studi
valid
use
fdgpet
part
structur
diagnost
protocol
gener
patient
popul
fuo
method
decemb
juli
patient
fuo
defin
accord
revis
petersdorf
criteria
recruit
one
univers
hospit
five
commun
hospit
structur
diagnost
protocol
use
fdgpet
perform
certain
obligatori
laboratori
test
chest
xray
abdomin
ultrasound
final
clinic
diagnosi
use
comparison
fdgpet
result
result
final
diagnosi
establish
patient
infect
malign
noninfecti
inflammatori
disord
miscellan
caus
total
number
fdgpetscan
help
posit
predict
valu
fdgpet
neg
predict
valu
fdgpet
help
patient
diagnos
infect
except
one
case
pyelonephr
contribut
fdgpet
final
diagnosi
differ
significantli
univers
hospit
commun
hospit
fdgpet
help
patient
normal
erythrocyt
sediment
rate
esr
creactiv
protein
crp
conclus
addit
appar
valu
fdgpet
diagnos
differ
infecti
diseas
describ
sever
case
seri
fdgpet
valuabl
imag
techniqu
part
diagnost
protocol
gener
patient
popul
fuo
rais
esr
crp
base
previou
studi
compar
label
leukocyt
scintigraphi
fdgpet
patient
fuo
result
favour
characterist
fdgpet
convent
scintigraph
techniqu
may
replac
fdgpet
institut
pet
avail
emerg
clindamycinresist
streptococcu
pyogen
caus
cellul
